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PBS	 phosphate-buffered	saline	
PCR		 polymerase	chain	reaction	
PFA	 paraformaldehyde	
RNA		 ribonucleic	acid	
rpm		 revolutions	per	minute	
RT	 room	temperature	
s	 seconds	
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Abstract	
	 x	
Abstract	
A	significant	amount	of	the	mammalian	genome	previously	found	to	not	code	for	proteins	and	
considered	‘junk’,	is	actually	pervasively	transcribed	and	specifies	a	dynamic	network	of	regulatory	
RNAs,	the	most	abundant	of	which	are	long	non-coding	RNAs	(lncRNAs).	lncRNAs	are	critical	players	
in	many	biological	processes	including	epigenetic,	transcriptional	and	post-transcriptional	control	as	
well	as	protein	metabolism.	Many	exhibit	cell-type	or	developmentally	specific	expression	patterns	
and	are	associated	with	human	disease.	Interestingly,	the	majority	of	single	nucleotide	
polymorphisms	(SNPs)	identified	through	genome	wide	association	studies	(GWAS)	map	to	non-
coding	regions	of	the	genome,	which	could	potentially	affect	ncRNAs,	given	that	~80%	of	the	
human	genome	is	transcribed.	
Here,	we	show	that	the	key	cardiac	transcriptional	regulator,	Nkx2-5,	is,	in	humans	and	
mouse,	surrounded	by	two	previously	uncharacterised,	long	cardiac	transcripts,	which	we	named	
NkxDS	and	NkxUS.	In	humans,	NKX2-5	mutations	are	commonly	associated	with	congenital	heart	
disease	and	a	variety	of	specific	cardiac	malformations.	Several	lncRNAs	have	also	been	identified	
to	be	crucial	for	cardiac	function	as	well	as	cardiac	lineage	commitment.	At	least	100	lncRNAs	have	
been	found	to	be	cardiac	specific,	however,	for	most,	their	functional	mechanisms,	especially	in	
vivo,	remain	unknown.	This	work	aimed	to	characterise	the	two	novel	transcripts	in	order	to	explain	
whether	NkxUS	and	NkxDS	regulate	Nkx2-5	itself	or	other	processes	important	for	heart	function,	
development	and/or	disease.	
This	work	shows	that	both	mouse	transcripts	are	nuclear	and	cardiac-enriched,	expressed	in	
the	heart	throughout	development	and	are	also	expressed	specifically	in	the	human	heart.	NkxDS	is	
a	novel	long	isoform	of	Nkx2-5	as	it	contains	the	Nkx2-5	protein-coding	sequence.	Therefore,	Nkx2-
5	may	have	a	protein-coding	function	as	well	as	a	non-coding	role	within	the	nucleus.	In	contrast,	
NkxUS	is	an	independent	transcript	to	Nkx2-5.	Downregulation	of	mouse	NkxUS	expression	in	the	
HL-1	cardiac	cell	line	displayed	an	upregulation	of	transcripts	involved	in	cardiac	contraction	and	
conduction.	Moreover,	NkxUS	interacting	partners	included	proteins	localising	to	the	nucleus	and	
mitochondria,	which	are	involved	in	metabolism	and	in	the	regulation	of	transcription.	
Interestingly,	a	GWAS	SNP	associated	with	an	increased	resting	heart	rate	lies	within	and	disrupts	a	
600nt	RNA	structure	conserved	between	mouse	and	human	NkxUS.	Analysis	of	mice	harboring	a	
partial	deletion	of	this	structure,	generated	by	CRISPR/Cas9	technology,	revealed	no	developmental	
defects,	nor	did	the	deleted	structure	have	any	effect	on	Nkx2-5	expression.	However,	remarkably,	
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a	similar	phenotype	as	described	for	humans	harboring	the	GWAS	SNP	was	observed,	with	
homozygous	mice	exhibiting	an	increased	resting	heart	rate.	The	phenotype	was	shown	to	result	
from	an	elevated	pacemaker	activity,	most	likely	due	to	enhanced	signaling	through	the	cAMP	
pathway	caused	possibly	by	an	upregulation	of	ion	channels.		
In	conclusion,	this	work	has	discovered	NkxDS	as	a	new	isoform	of	the	master	cardiac	
transcription	factor	Nkx2-5	and	has	shown	that	a	conserved	RNA	structure	within	NkxUS	plays	an	
important	role	in	the	regulation	of	resting	heart	rate.	These	results	provide	new	insights	into	the	
functional	importance	of	lncRNA	secondary	structures	and	their	involvement	in	GWAS	SNPs	
associated	traits	and	diseases.	
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Zusammenfassung	
Ein	erheblicher	Teil	des	Säugetiergenoms,	von	dem	zuvor	festgestellt	wurde,	dass	er	nicht	für	
Proteine	kodiert	und	deshalb	als	"Müll"	bezeichnet	wurde,	wird	tatsächlich	größtenteils	
transkribiert	und	bezeichnet	ein	dynamisches	Netzwerk	von	regulatorischen	RNAs,	von	denen	lange	
nicht-kodierende	RNAs	(lncRNAs)	die	am	weitverbreitetsten	sind.	LncRNAs	spielen	bei	vielen	
biologischen	Prozessen	eine	entscheidende	Rolle,	wie	zum	Beispiel	bei	der	Kontrolle	von	
epigenetischen,	transkriptionellen	und	posttranskriptionellen	Vorgängen	sowie	des	
Proteinstoffwechsels.	Viele	weisen	zellart-	oder	entwicklungsspezifische	Expressionsmuster	auf	und	
sind	mit	menschlichen	Erkrankungen	assoziiert.	Interessanterweise	befindet	sich	die	Mehrheit	der	
durch	genomweite	Assoziationsstudien	(GWAS)	identifizierten	Einzelnukleotid-polymorphismen	
(SNPs)	in	nicht-kodierenden	Regionen	des	Genoms.	Diese	SNPs	könnten	daher	möglicherweise	
ncRNAs	beeinflussen,	da	etwa	80%	des	menschlichen	Genoms	transkribiert	wird.	
Mit	dieser	Arbeit	zeigen	wir,	dass	der	wichtige	kardiale	Transkriptionsfaktor,	Nkx2-5,	bei	
Mensch	und	Maus	von	zwei	zuvor	nicht	charakterisierten	langen	herzspezifischen	Transkripten	
umgeben	ist,	die	wir	als	NkxDS	und	NkxUS	bezeichnet	haben.	Beim	Menschen	sind	NKX2-5	
Mutationen	häufig	mit	angeborenen	Herzerkrankungen	und	einer	Vielzahl	spezifischer	
Herzfehlbildungen	verbunden.	Es	wurde	festgestellt,	dass	mehrere	lncRNAs	für	die	Herzfunktion	
sowie	die	Herzentwicklung	eine	wichtige	Rolle	spielen.	Mindestens	100	IncRNAs	sind	herzspezifisch,	
jedoch	sind	die	Funktionsmechanismen,	besondere	in	vivo,	für	die	Meisten	noch	unbekannt.	Diese	
Arbeit	zielte	darauf	ab,	die	beiden	neuen	Transkripte	zu	charakterisieren,	um	herauszufinden,	ob	
NkxUS	und	NkxDS	Nkx2-5	selbst	oder	andere	Prozesse,	die	für	die	Herzfunktion,	die	
Herzentwicklung	oder	Krankheiten	eine	wichtige	Rolle	spielen,	regulieren.	
Diese	Arbeit	zeigt,	dass	beide	Maus	Transkripte	im	Zellkern	und	im	Herzen	angereichert	
sind,	während	der	gesamten	Entwicklung	im	Herzen	und	auch	im	menschlichen	Herzen	spezifisch	
exprimiert	sind.	NkxDS	ist	eine	neue	lange	Isoform	von	Nkx2-5,	da	es	die	Protein-kodierende	
Sequenz	von	Nkx2-5	enthält.	Daher	könnte	Nkx2-5	eine	Protein-kodierende	sowie	eine	nicht-
kodierende	Rolle	innerhalb	des	Zellkerns	ausführen.	Im	Gegensatz	dazu	ist	NkxUS	ein	unabhängiges	
Transkript	zu	Nkx2-5.	Die	Verminderung	der	NkxUS	Expression	in	der	Maus	HL-1	Herzzelllinie	führte	
zu	einer	erhöhten	Expression	von	Transkripten,	die	an	der	Herzkontraktion	und	-leitung	beteiligt	
sind.	Darüber	hinaus	interagiert	NkxUS	mit	Proteinen,	die	im	Zellkern	und	in	den	Mitochondrien	
vorhanden	und	am	Metabolismus	und	an	der	Regulation	der	Transkription	beteiligt	sind.	
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Interessanterweise	liegt	ein	GWAS-SNP,	der	mit	einer	erhöhten	Ruheherzfrequenz	assoziiert	ist,	
innerhalb	einer	600-nt	RNA	Struktur,	die	zwischen	Maus	und	menschlichem	NkxUS	konserviert	ist.	
Die	Analyse	von	Mäusen,	welche	durch	die	CRISPR/Cas9-Technologie	erzeugt	wurde	und	Teile	
dieser	Struktur	fehlen,	zeigte	keine	Entwicklungsdefekte	und	keine	Änderung	in	der	Expression	von	
Nkx2-5.	Bemerkenswerterweise	wurde	jedoch	ein	ähnlicher	Phänotyp	wie	für	Menschen,	die	den	
GWAS	SNP	enthalten,	beobachtet,	da	homozygote	Mäuse	eine	erhöhte	Ruheherzfrequenz	
aufwiesen.	Es	konnte	gezeigt	werden,	dass	der	Phänotyp	aus	einer	erhöhten	Schrittmacheraktivität	
resultiert,	höchstwahrscheinlich	aufgrund	einer	verstärkten	Signalisierung	des	cAMP-Signalwegs,	
möglicherweise	durch	eine	erhöhte	Expression	von	Ionenkanälen.	
Zusammenfassend	hat	diese	Arbeit	NkxDS	als	eine	neue	Isoform	des	Transkriptionfaktors	Nkx2-
5	entdeckt	und	gezeigt,	dass	eine	konservierte	RNA	Struktur	in	NkxUS	eine	wichtige	Rolle	bei	der	
Regulierung	der	Ruheherzfrequenz	spielt.	Diese	Ergebnisse	liefern	neue	Einblicke	in	die	funktionale	
Bedeutung	von	lncRNA	Sekundärstrukturen	und	ihre	Auswirkungen	auf	GWAS-SNPs,	die	mit	
Erkrankungen	assoziiert	sind.	
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1.1 The	heart	and	its	physiology	 	
The	heart	is	the	first	organ	to	form	and	function	in	the	vertebrate	embryo	[1].	It	is	a	highly	modified	
muscular	pump,	regulating	and	maintaining	homeostasis	by	distributing	oxygenated	blood	
throughout	the	body.	Blood	is	not	only	essential	for	providing	oxygen	but	also	nutrients	to	all	
tissues	of	the	body	and	removing	unwanted	metabolic	waste.	Without	a	functioning	heart,	the	
organism	will	die	within	minutes.			
	
	
1.1.1 Adult	heart	anatomy	
Anatomically,	the	human	heart	consists	of	a	left	and	right	side,	each	with	an	atria	and	ventricle,	
four	chambers	in	total	[2-4]	(Figure	1A).	The	right	atrium	receives	oxygen-poor	blood	from	the	
systemic	veins	and	pumps	it	to	the	right	ventricle,	which	in	turn	distributes	the	blood	to	the	lungs	
via	the	pulmonary	arteries	(Figure	1A).	Oxygen-rich	blood	from	the	lungs	is	received	by	the	left	
atrium,	then	pumped	into	the	left	ventricle	and	via	the	aorta	to	the	body’s	tissues.	To	prevent	
blood	regurgitation,	the	chambers	are	separated	from	each	other	and	the	great	vessels	by	valves.	
Atria	and	ventricles	are	separated	by	tricuspid	(on	the	left)	and	mitral	valve	(on	the	right),	which	
prevent	back	flow	of	blood	during	ventricular	contraction.	Ventricles	and	great	vessels	are	
separated	by	the	pulmonary	(on	the	right)	and	aortic	valve	(on	the	left),	which	prevent	
regurgitation	after	ventricular	contraction	[5].		
	
	
1.1.2 The	cardiac	cycle	
One	cardiac	cycle	describes	the	event	of	one	heart	beat	beginning	with	the	atria	contracting	and	
ending	with	the	relaxation	of	the	ventricles	[6].	It	has	two	phases,	diastole	and	systole.	Diastole	is	
the	phase	of	relaxation	during	which	the	chambers	relax	and	refill	with	blood,	while	systole	is	the	
phase	of	contraction	and	blood	ejection	out	of	the	chambers.	Both	atria	and	ventricles	undergo	
systole	and	diastole.	The	atrioventricular	valves	between	the	atria	and	ventricles	are	open	in	atrial	
diastole	and	systole	ensuring	that	blood	can	flow	into	the	ventricles.	During	ventricular	systole,	the	
atrioventricular	valves	close	and	the	aortic	and	pulmonary	valves	open	to	allow	blood	flow	into	the	
aorta	and	pulmonary	artery,	respectively.	At	this	point	no	blood	enters	the	ventricles,	only	the	
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atria.	The	cardiac	cycle	begins	with	atrial	systole,	then	ventricular	systole,	atrial	diastole	and	ends	
with	ventricular	diastole	until	the	cycle	repeats	itself.	
	
	
1.1.3 Layers	of	the	heart	
The	cardiac	chamber	wall	is	divided	into	three	layers,	the	endocardium,	myocardium	and	
epicardium	[5]	(Figure	1B).	The	endocardium	forms	the	endothelial	lining	of	the	heart	and	is	the	
innermost	and	thinnest	layer.	It	has	a	smooth	surface,	which	prevents	blood	from	adhering	to	the	
walls	and	therefore	prevents	potential	damage	of	the	heart	and	formation	of	blood	clots.	The	
myocardium	is	the	middle	and	thickest	layer.	It	consists	mostly	of	cardiomyocytes,	the	cardiac	
muscle	cells,	which	are	able	to	contract.	The	epicardium	is	the	mesothelium	forming	the	outermost	
layer.	It	functions	as	a	protective	layer	against	infections	and	tumor	propagation	and	provides	
lubrication	for	frictionless	movement	of	the	heart.	
The	thickness	of	the	myocardium	varies	across	the	chambers.	Atrial	myocardium	is	thinner	
than	that	of	the	ventricles	as	less	force	is	needed	to	pump	blood	into	the	neighboring	chamber	
compared	to	distant	organs.	Additionally,	the	myocardium	is	thicker	in	the	left	than	right	ventricle	
as	it	has	to	generate	more	power	to	distribute	blood	throughout	the	body.	 	
In	numbers,	the	heart	consists	of	about	30%	cardiomyocytes	[7].	Of	the	non-cardiomyocyte	
fraction,	endothelial	cells	account	for	about	64%,	resident	mesenchymal	cells	including	fibroblast	
for	about	27%	and	leukocytes	for	9%	[7].	Inter-cellular	crosstalk	between	these	cell	types	and	layers	
is	essential	not	only	during	cardiac	development	but	also	for	normal	heart	function.	Small	
molecules,	peptides	and	proteins	for	example	can	be	secreted	from	endothelial	cells	and	affect	
contractility	of	the	myocardium	or	even	induce	an	increase	in	cardiomyocyte	cell	size	[8,	9].	
Introduction	
	 4	
	
Figure	1	The	adult	mammalian	heart.	A)	Structure	of	the	adult	heart.	B)	The	three	layers	of	the	
chamber	walls.	
	
	
1.1.4 Cardiac	conduction	system	
The	beating	of	the	heart	provides	the	powerful	force	required	for	pumping	blood	throughout	the	
body	and	depends	upon	the	proper	activation	and	recovery	of	electrical	excitation	of	the	chamber	
myocardium,	which	is	regulated	by	the	cardiac	conduction	system.	The	cardiac	conduction	system	
consists	of	five	elements,	the	sinoatrial	node	(SAN),	the	atrioventricular	node	(AVN),	the	bundles	of	
His,	the	bundle	branches	and	the	Purkinje	fibres	[10].	Electrical	excitation	is	mediated	by	different	
ion	currents	across	the	plasma	membrane	that	result	in	action	potentials,	which	are	then	
propagated	from	cell	to	cell	via	gap	junctions	[11,	12].	The	heartbeat	is	initiated	by	electrical	
impulses	in	the	SAN,	the	pacemaker	of	the	heart,	which	lies	at	the	junction	of	the	right	atrium	and	
superior	vena	cava	[13,	14].	The	SAN	is	a	heterogeneous	population	of	cells	consisting	of	mostly	
pacemaker	cells,	which	are	specialised	cardiomyocytes,	but	also	of	non-pacemaker	cells	like	
endothelial	cells,	fibroblasts	and	atrial	myocytes	[13,	15].	Adult	pacemaker	cells	originate	from	and	
resemble	embryonic	cardiomyocytes	by	having	a	weaker	contractile	force	and	the	ability	to	
depolarise	spontaneously	[16,	17].	They	are	characterised	by	lacking	a	true	resting	membrane	
potential	and	being	able	to	generate	an	action	potential	without	external	stimuli.	Action	potentials	
generated	in	the	SAN	are	propagated	to	the	atria	causing	atrial	contraction.	From	the	atria	the	
impulse	is	conducted	to	the	AVN,	which	is	located	in	the	interatrial	septum,	a	wall	of	tissue	
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separating	both	atria	[10].	The	AVN	delays	the	stimuli	briefly	giving	the	atria	enough	time	to	fully	
empty	its	blood	into	the	ventricles.	The	valves	close	and	the	atria	refill	with	blood.	From	the	AVN	
the	signal	is	propagated	to	the	bundles	of	His	and	then	via	its	left	and	right	branches	to	the	Purkinje	
fibre	network	on	each	side	of	the	heart	to	activate	the	ventricular	cardiomyocytes	causing	
ventricular	contraction	[10].		
Dysfunction	in	any	of	the	five	elements	can	lead	to	increased,	decreased	or	irregular	heart	
rates	(cardiac	arrhythmia)	[18].	
The	propagation	of	action	potentials	can	be	visualised	using	an	electrocardiogram	(ECG),	in	
which	the	P	wave	represents	atrial	depolarisation,	the	P-R	interval	the	time	it	takes	for	the	impulse	
to	reach	the	ventricles	through	the	AVN,	the	QRS-complex	the	ventricular	depolarisation	and	the	T-
wave	ventricular	repolarisation	(Figure	2).	
	
Figure	2	Schematic	of	an	ECG	of	a	human	heart	in	normal	sinus	rhythm.	The	P-wave	illustrates	
atrial	contraction,	the	PR-interval	reflects	atrial	and	atrioventricular	nodal	conduction,	the	QRS-
complex	represents	ventricular	contraction	and	the	T-wave	depicts	ventricular	recovery.	
	
	
1.1.4.1 The	mechanism	of	sinoatrial	node	automaticity	
A	normal	healthy	human	heart	beats	on	average	about	42	Million	times	per	year,	all	due	to	the	
unique	ability	of	the	SAN	to	spontaneously	depolarise	and	to	generate	regular	action	potentials	to	
stimulate	contraction.		
The	SAN	action	potentials	are	distinct	from	other	cardiomyocytes	and	can	be	divided	into	
three	phases	(Figure	3A	and	B).	The	action	potentials	start	with	Phase	4,	the	hyperpolarisation	
phase,	in	which	the	SAN	specific	hyperpolarisation-activated	cyclic	nucleotide-gated	potassium	
(HCN)	channels	are	activated	by	hyperpolarisation	and	conduct	a	slow,	inward	depolarising	sodium	
P
Q
R
S
T
QRS- complex
PR- 
interval
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current	(Figure	3A)	[19,	20].	This	current	is	often	also	referred	to	as	the	“funny	current”,	as	it	has	
several	unusual	features	such	as	activation	by	hyperpolarisation	rather	than	depolarisation,	
permeability	to	both	sodium	and	potassium	and	modulation	by	cyclic	adenosine	monophosphate	
(cAMP)	[21].	Once	a	certain	threshold	is	reached,	low	voltage	gated	T-Type	calcium	channels	open	
followed	by	the	high	voltage	gated	L-Type	calcium	channels	causing	further	depolarisation	(Phase	0,	
depolarisation	phase,	Figure	3A)	[22-25].	After	a	delay	the	potassium	channels	open,	allowing	efflux	
of	potassium	ions,	which	causes	repolarisation	of	the	cell	(Phase	3,	repolarisation	phase,	Figure	3A)	
[26].	Once	the	cell	is	completely	repolarised,	the	cycle	repeats	itself	spontaneously	without	a	rest.		
Action	potentials	of	cardiomyocytes	are	quite	different	in	that	they	have	a	true	resting	
potential,	a	rapid	depolarisation	phase,	a	plateau	phase	and	do	not	spontaneously	depolarise	
(Figure	3B).	Cardiomyocytes	have	to	be	activated	by	action	potentials	from	adjacent	cells	to	reach	
the	threshold	for	calcium	channel	activation.	
The	mechanism	of	spontaneous	depolarisation	of	SAN	cells	is	mediated	by	two	oscillators,	
the	membrane	and	calcium	clocks,	which	work	in	concert	with	each	other	(Figure	3C)	[27-29].	The	
membrane	clock	resides	in	the	plasma	membrane	and	as	mentioned	above	generates	
depolarisation	mainly	through	the	pacemaker	current	via	HCN	channels	and	also	the	voltage	gated	
T-	and	L-Type	calcium	channels	(Figure	3C).	The	calcium	clock	initiates	spontaneous	depolarisation	
by	a	rhythmic	calcium	release	from	the	sarcoplasmic	reticulum	(SR),	the	main	intracellular	calcium	
store,	mediated	by	the	ryraonide	receptor	(RYR)	(Figure	3C)	[30,	31].	This	calcium	release	activates	
the	sodium	calcium	exchanger	(NCX)	in	the	plasma	membrane,	which	exchanges	three	sodium	ions	
for	one	calcium	ion	leading	to	depolarisation	of	the	cell	(Figure	3C)		[30,	32].	Upon	reaching	the	
threshold	to	activate	the	voltage	gated	calcium	channels,	both	clocks	are	in	synchrony.	After	
excitation,	relaxation	is	facilitated	by	cytosolic	calcium	removal	mainly	via	calcium	uptake	back	into	
the	SR	by	the	sarcoplasmic/endoplasmic	reticulum	calcium	ATPase	(SERCA)	(Figure	3C)	[28].	
Moreover,	this	uptake	refills	the	calcium	store	and	primes	the	cell	for	the	next	cycle	[28].	
Although	action	potentials	are	spontaneously	generated	by	SAN	cells,	the	rate	of	this	
activity	can	be	modulated	by	external	factors	such	as	the	autonomic	nervous	system	and	drugs	
through	β-adrenergic	and	muscarinic	stimulation,	which	modulates	the	activity	of	cAMP-dependent	
protein	kinases	that	phosphorylate	the	illustrated	channels	in	Figure	3C,	except	NCX		[33-35].		
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Figure	3	Sinoatrial	node	automaticity.	A)	Action	potential	from	SAN	cells.	Phase	4	is	the	
hyperpolarisation	phase,	Phase	0	the	depolarisation	and	Phase	3	the	repolarisation	phase.	In	Phase	
4,	HCN	channels	are	activated	by	hyperpolarisation	upon	reaching	a	membrane	potential	of	~-60	
mV.	These	channels	conduct	a	slow,	inward	depolarising	sodium	current.	Upon	reaching	a	threshold	
value	of	~-50	mV	T-type	calcium	channels	open	followed	by	the	L-type	calcium	channel	at	~-40mV	
further	depolarising	the	cell	(Phase	0).	Repolarisation	occurs	when	potassium	channels	open	and	
calcium	channels	close	(Phase	3).	B)	The	cardiomyocyte	action	potential	is	quite	different	to	SAN	
action	potentials	as	they	have	a	true	resting	potential	(Phase	4),	which	stays	constant	at	~-90	mV,	
depolarise	much	more	rapidly	(Phase	0)	and	exhibit	an	initial	repolarisation	phase	(Phase	1)	and	a	
plateau	phase	(Phase	2),	which	SAN	cells	do	not	possess.	Further,	these	cells	do	not	spontaneously	
depolarise	and	have	to	be	activated	by	an	action	potential	from	an	adjacent	cell.	C)	The	mechanism	
of	SAN	automaticity	is	provided	by	the	membrane	(HCN	channels,	L-type	and	T-type	calcium	
channels)	and	the	calcium	(RYR,	NCX,	L-type	calcium	channel	and	SERCA)	clocks.	HCN	channels	are	
activated	by	hyperpolarisation	and	conduct	an	inward	sodium	current,	which	slowly	depolarises	the	
cell	and	upon	reaching	a	threshold	value	activates	the	L-type	and	T-type	calcium	channels	leading	
to	further	depolarisation.	The	calcium	clock	facilitates	spontaneous	depolarisation	via	calcium	
release	from	the	SR	through	RYR,	which	activates	NCX.	NCX	exchanges	one	sodium	for	three	
calcium	further	depolarising	the	cell.	Upon	reaching	the	threshold	value	L-type	calcium	channels	
open	and	both	clocks	are	in	synchrony.	Calcium	is	taken	up	into	the	SR	by	SERCA	to	prepare	the	cell	
for	the	next	depolarisation.	
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1.1.5 Adult	heart	disease	
Cardiovascular	disease	(CVD)	is	the	world’s	leading	cause	of	death	and	disability	and	includes	
diseases	affecting	the	heart	or	blood	vessels.	Globally,	about	17.9	Million	people	die	yearly	from	
CVD	representing	31%	of	all	deaths	(source	WHO).		
The	most	common	types	of	adult	cardiovascular	disease	are	stroke,	heart	failure	and	
coronary	artery	disease	with	heart	attack	and	stroke	accounting	for	about	85%	of	CVD	deaths	
worldwide	(source	WHO).	Smoking,	obesity,	increased	age,	diabetes,	high	cholesterol,	
hypertension,	higher	resting	heart	rate,	physical	inactivity	and	a	family	history	of	cardiovascular	
disease	are	well	known	risk	factors	for	CVD.	A	few	risk	factors	can	be	reduced	by	adopting	a	healthy	
lifestyle	including	a	healthy	diet,	increasing	physical	activity,	loosing	weight	and	stopping	smoking.	
However,	given	the	high	incidence	of	CVD,	it	is	still	surprising	how	little	is	known	about	the	
underlying	causes.	
	
	
1.1.5.1 Types	of	adult	heart	disease	
There	are	several	types	of	CVD	which	involve	the	adult	heart	including	heart	failure,	myocardial	
infarction,	cardiomyopathy	and	cardiac	arrhythmias.	
In	heart	failure,	the	pumping	efficiency	of	the	heart	is	decreased,	thus	it	can	no	longer	meet	
the	body’s	requirement	for	blood	supply	and	the	organs	as	well	as	heart	muscle	do	not	get	enough	
oxygen	to	work	effectively	[36].		
Myocardial	infarction	(MI),	commonly	known	as	heart	attack,	occurs	due	to	blockage	of	a	
coronary	artery	[37].	Coronary	arteries	supply	the	myocardium	with	oxygen-rich	blood	needed	to	
meet	its	high	metabolic	demand.	A	decrease	in	oxygen	supply	causes	death	of	cardiomyocytes	and	
other	cell	types	and	ultimately	results	in	the	loss	of	functional	myocardium	[37].	In	response	to	MI,	
the	heart	undergoes	remodelling	to	try	and	adapt	to	the	changes.	Cardiac	remodelling	includes	scar	
formation,	infarct	expansion,	ventricular	wall	thinning	and	chamber	dilatation,	resulting	eventually	
in	reduced	cardiac	function	and	heart	failure	[38].	
Cardiomyopathy	refers	to	diseases	affecting	the	myocardium,	which	causes	enlargement	
and	stiffness,	leading	to	decreased	contractility,	thus	inadequate	pumping	of	the	heart	[39,	40].	It	is	
a	group	of	conditions	that	alter	the	structure	of	the	myocardium,	leading	to	severe	cardiac	
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dysfunction	and	heart	failure.	Some	are	inherited	while	others	are	the	result	of	viral	infections	or	
heart	attacks	[40-44].		
Cardiac	arrhythmias	are	caused	by	disrupted	electrical	signaling	in	the	heart,	leading	to	an	
abnormal	heart	beat	[18,	45].	The	heart	is	either	beating	too	fast	(tachycardia),	too	slow	
(bradycardia)	or	irregular	(fibrillation)	independent	of	exercise	or	stress	[18].	The	underlying	
mechanism	responsible	for	cardiac	arrhythmias	can	either	be	due	to	abnormalities	in	impulse	
conduction	or	formation	in	the	SAN	[46].	For	example,	sinus	tachycardia	is	described	as	an	elevated	
resting	heart	rate	with	no	or	minimal	physical	activity	and	results	from	either	enhanced	pacemaker	
automaticity,	disordered	autonomic	nervous	system	activation	or	both	[18,	46].	An	elevated	resting	
heart	rate	increases	the	oxygen	demand	and	metabolic	load	on	the	heart	and	is	associated	with	an	
increased	risk	for	cardiovascular	disease	and	all-cause	mortality	independent	of	blood	pressure	and	
physical	fitness	[47,	48].	Bradycardia	results	from	a	decreased	intrinsic	SAN	function	or	a	block	in	
conduction,	most	commonly	within	the	AV	node	or	the	His-Purkinje	system	[46].	Furthermore,	
disruption	of	the	SAN	membrane	clock	can	result	in	heart	rates	alternating	between	high	and	low,	
termed	tachycardia	–	bradycardia	syndrome	[18,	49].	An	irregular	heart	rate	can	also	occur	due	to	
premature	depolarisation	before	full	repolarisation	or	delayed	after-depolarisation	[18].	Both	of	
which	can	occur	under	conditions	of	intracellular	calcium	overload,	which	can	be	caused	by	random	
and	spontaneous	calcium	release	from	the	sarcoplasmic	reticulum,	which	in	turn	results	in	
depolarisation	of	the	cell	[18,	46].		
	
	
1.2 Heart	development	
The	human	heart	begins	to	develop	at	conception,	starts	beating	after	about	three	weeks	as	a	
linear	tube	and	is	completely	formed	by	8	weeks	into	pregnancy.	Cardiac	development	into	a	four	
chambered	heart	is	a	highly	complex	and	dynamic	process	involving	the	migration	and	integration	
of	several	cell	lineages	(Figure	4)	[50].	Briefly,	the	heart	is	formed	from	two	progenitor	cell	
populations,	termed	the	first	and	second	heart	field,	which	exhibit	different	behaviors	and	lineage	
fates	[51-53].	Embryonic	development	of	the	heart	can	be	divided	into	four	major	phases:	Cardiac	
crescent	formation,	formation	of	the	linear	heart	tube,	cardiac	looping	and	chamber	specification,	
and	chamber	septation	and	maturation.	
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During	gastrulation,	cardiac	progenitors	derived	from	paired	regions	of	the	lateral	mesoderm	
extend	across	the	midline	to	form	the	cardiac	crescent	or	first	heart	field	[1,	51,	53]	(Figure	4A	and	
B).	Next,	the	progenitor	cells	move	ventrally	to	form	the	linear	heart	tube,	which	consists	of	an	
inner	endothelial	and	outer	myocardial	layer	and	is	able	to	beat	continuously	(Figure	4C)	[50,	51,	
54].	Progenitor	cells	from	the	second	heart	field,	derived	from	pharyngeal	and	splanchnic	
mesoderm,	contribute	progressively	to	both	poles	of	the	elongating	linear	heart	tube,	while	it	
undergoes	a	process	termed	cardiac	looping	[51,	55].	The	cells	from	the	second	heart	field	were	
shown	to	contribute	to	the	outflow	tract,	right	ventricle	and	both	atria,	while	those	of	the	first	
heart	field	contribute	to	the	left	ventricle	and	both	atria	[1,	52,	55].	During	cardiac	looping,	the	
heart	tube	lengthens	and	folds	to	the	right	into	an	S-shaped	form,	which	shows	distinct	anatomical	
features	for	ventricular	and	atrial	components	as	well	as	the	outflow	tract	(Figure	4D)	[51].	With	
ongoing	looping	morphogenesis,	the	chambers	and	major	vessels	are	placed	in	their	correct	
alignment	with	the	future	atria	and	outflow	tract	being	positioned	above	the	future	ventricle	and	
the	myocardium	further	expands	with	the	chambers	becoming	more	distinct	[51].	Further,	
endocardial	cushions	form	at	the	outflow	tract,	which	later	give	rise	to	the	different	valves.	During	
the	next	phase,	atria	and	ventricles	are	separated	into	left	and	right	by	septa	formation	and	the	
outflow	tract	is	transformed	into	the	ascending	aorta	and	the	pulmonary	trunk	[56].	During	further	
growth	and	differentiation,	the	cardiac	conduction	system	and	coronary	circulation	are	established	
to	give	rise	to	the	adult	four-chambered	heart	(Figure	4E).	
	
Figure	4	The	embryonic	development	of	the	heart.	Schematic	representing	mouse	heart	
development	with	staging	in	days	of	embryonic	development	(E)	including	the	first	cardiac	
progenitors	which	migrate	over	the	midline	(A)	to	form	the	cardiac	crescent	and	first	heart	field	(B),	
second	heart	field	formation	at	the	cardiac	crescent	stage	(B),	the	formation	of	the	linear	heart	
tube	(C),	which	undergoes	cardiac	looping	(D),	followed	by	septation	and	maturation	of	the	heart	
(E).	Arrows	indicate	the	direction	of	movement.	ML=	midline,	HF=	head	folds,	FHF=	first	heart	field,	
SHF=	second	heart	field.		
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1.2.1 Congenital	heart	disease	(CHD)	
The	development	of	the	heart	is	a	complex	and	complicated	process,	requiring	tight	and	accurate	
regulation	of	related	genes	over	time	and	space	as	described	above.	If	one	of	these	crucial	steps	
does	not	happen	at	the	right	time,	the	heart	does	not	develop	properly	leading	to	congenital	heart	
disease	(CHD).	CHD	is	defined	as	a	defect	in	the	structure	of	the	newborn’s	heart	and	is	worldwide	
the	most	common	birth	defect,	affecting	up	to	1%	of	newborns.	CHD	can	affect	the	walls	between	
the	atria	or	ventricle,	the	valves,	blood	vessels,	or	the	chambers	themselves	[57].	While	some	
defects	cause	no	or	few	symptoms,	others	need	treatments	directly	after	birth	including	in	the	
most	severe	cases	multiple	surgeries.	Others	are	lethal	even	before	birth.	Many	different	types	of	
CHD	exist,	likely	arising	due	to	defects	in	the	early	stages	of	heart	development	[50,	58].	The	cause	
of	disease	is	largely	still	unknown;	therefore	it	is	important	to	understand	the	genetic	and	
developmental	pathways	that	shape	the	heart	[50,	58].	
	
	
1.2.1.1 Types	of	CHD	
The	many	different	types	of	CHD	can	be	grouped	based	on	anatomic	and	physiologic	features.		
The	most	common	types	are	septal	defects,	in	which	the	wall	between	the	atria	or	ventricles	
fails	to	close	completely	during	development	[59].	These	defects	allow	blood	flow	between	the	
right	and	left	chambers,	thereby	reducing	cardiac	function.	Depending	on	the	size	of	the	lesion,	the	
defects	can	cause	mild	to	severe	outcomes.		
One	of	the	most	serious	defects	is	hypoplasia	of	the	heart,	in	which	one	of	the	chambers	
and/or	aorta	are	severely	underdeveloped	and	not	able	to	pump	blood	efficiently	[60].	
Other	defects	can	be	group	together	based	on	a	blocked	or	narrowed	vein,	artery	or	valve	
leading	to	an	increased	resistance	for	the	heart	in	order	to	pump	blood	to	the	body’s	tissue,	which	
may	cause	hypertension	and	cardiac	hypertrophy.	
Further,	cyanotic	defects	are	a	group	of	CHD’s,	in	which	newborns	exhibit	bluish	skin	due	to	
lack	of	oxygen.	Several	birth	defects	can	result	in	cyanotic	defects	including	abnormalities	in	any	of	
the	large	blood	vessels,	which	lead	to	or	from	the	heart,	or	the	valves	[59].	Classically	this	type	of	
CHD	is	not	due	to	a	single	abnormality,	rather	a	combination	of	defects	which	results	in	
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deoxygenated	blood	bypassing	the	lungs	and	entering	the	aorta.	The	most	common	cyanotic	defect	
is	tetralogy	of	Fallot	which	is	due	to	a	combination	of	four	defects	[61]:		
• a	ventricular	defect	
• an	overriding	aorta,	meaning	that	the	aorta	is	localised	directly	over	the	ventricular	septal	
defect,	thus	allowing	deoxygenated	blood	to	enter	the	left	ventricle	and	be	pumped	
throughout	the	body		
• pulmonary	stenosis,	in	which	the	pulmonary	artery	is	constricted	thus	decreasing	the	
amount	of	blood	going	to	the	lungs	and	increasing	the	resistance	to	blood	flow,	which	leads	
to	fourth	defect		
• right	ventricular	hypertrophy,	in	which	the	myocardium	of	the	right	ventricle	is	abnormally	
thick		
	
	
1.3 Cardiac	gene	regulatory	networks	
A	gene	regulatory	network	(GRN)	consists	of	a	set	of	“controller”	and	“responder”	genes	spread	
across	the	genome,	which	interact	with	each	other	to	coordinate	and	regulate	cellular	functions	
important	for	development,	differentiation	and	environmental	adaptation.	
	
	
1.3.1 Transcription	factors	
Development	and	function	of	the	mammalian	heart	are	regulated	by	complex	gene	networks	that	
orchestrate	morphogenesis,	physiology	and	adaptation	[50,	58,	62,	63].		
The	network	includes	several	evolutionary	conserved	core	transcription	factors,	also	referred	to	as	
kernels	(Figure	5).	The	most	critical	kernels	include	NK2	Homeobox	5	(NKX2-5),	myocyte	enhancer	
factor	2c	(MEF2c),	Heart	and	Neural	Crest	Derivatives	Expressed	1/2	(HAND1/2),	T-box	5/20	
(TBX5/20),	Insulin	Gene	Enhancer	Protein	(ISL1),	Serum	Response	Factor	(SRF)	and	zinc-finger	
transcription	factor	GATA4/6	(Figure	5)	[62,	63].	All	of	these	are	expressed	in	the	cardiac	
progenitors	and	differentiating	cells	[62].	Components	of	the	network	physically	interact	and	
function	synergistically	with	one	another	and	with	an	array	of	other	transcription	factors	to	control	
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cardiogenesis	[62,	63].	Not	surprisingly,	disruption	of	the	network	has	catastrophic	consequences	
for	development	with	mutations	in	at	least	25	transcription	factors	identified	in	CHD	patients	[64].		
Understanding	and	determination	of	the	components	of	the	cardiac	GRN	and	its	subcircuits,	
as	well	as	regulators	of	these	core	transcription	factors	could	give	further	insight	into	heart	
development	and	thus	the	underlying	cause	of	heart	disease.	
A	summary	of	the	network	is	shown	in	Figure	5. 
	
	
Figure	5	Simplified	cardiac	gene	regulatory	network	of	the	core	transcription	factors	involved	in	
vertebrate	heart	development	(from	[65]).	NKX2-5	sits	at	the	center	of	the	network	interacting	
with	several	other	kernels.	
	
	
1.3.2 The	transcription	factor	NKX2-5		
One	of	the	key	transcriptional	regulators	of	the	heart	and	earliest	known	marker	of	vertebrate	
cardiac	lineage	is	the	homeodomain	transcription	factor	NKX2-5	[66-68].	The	abbreviation	NK	refers	
to	Nirenberg	and	Kim,	the	researches	that	identified	this	class	of	homeodomain	containing	proteins	
in	Drosophila	[69].	Originally	identified	as	tinman,	a	gene	essential	for	heart	and	visceral	muscle	
development	in	Drosophila,	Nkx2-5	is	highly	conserved	and	expressed	in	cardiac	precursor	cells	
from	Drosophila	to	humans	[68,	70].		
NKX2-5	is	a	central	player	of	the	cardiac	GRN	and	known	to	regulate	a	number	of	other	
genes	involved	in	this	network.	In	the	mouse,	NKX2-5	is	expressed	in	the	forming	myocardium	from	
E7.0	onwards,	is	expressed	in	both	heart	fields	and	its	expression	in	the	heart	is	maintained	
throughout	development	[68,	71].	Expression	was	also	detected	in	the	developing	foregut,	spleen,	
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tongue,	thyroid	and	stomach	[68].	After	birth,	NKX2-5	continues	to	be	expressed	in	the	heart,	
however,	with	much	lower	expression.	In	mouse,	targeted	disruptions	of	NKX2-5	have	catastrophic	
outcomes	for	development,	with	early	embryonic	lethality	by	E10.5	due	to	the	absence	of	cardiac	
looping,	abnormal	chamber	formation	and	growth	retardation	[72-74].	Heterozygous	and	
conditional	Nkx2-5	mouse	models	show	milder	abnormalities	leading	to	septal	defects,	conduction	
disorders	and	a	propensity	for	lethal	arrhythmias	[74-77].	In	summary,	studies	in	mice	have	shown	
that	Nkx2-5	is	important	for	the	formation	and	maintenance	of	chamber	myocardium	as	well	as	the	
cardiac	conduction	system	[72,	73,	78-80].	Based	on	its	essential	role	in	cardiac	development	it	
does	not	come	as	a	surprise	that	mutations	within	NKX2-5	are	associated	with	a	collection	of	
congenital	heart	disorders.	In	humans,	about	40	mutations	within	NKX2-5	were	linked	to	structural	
malformations	as	well	as	conduction,	alignment	and	compaction	defects	of	the	heart,	most	
commonly	atrial	and	ventricular	septal	defects	and	atrioventricular	conduction	block	as	well	as	
tetralogy	of	Fallot	[76,	81-83].		
 
	
1.3.2.1 Transcriptional	regulation	of	Nkx2-5		
The	NKX2-5	gene	in	mouse	as	well	as	humans	consists	of	two	main	exons.	Studies	in	the	mouse	
identified	a	complex	regulatory	region	of	about	27kb	surrounding	NKX2-5,	consisting	of	two	
additional	upstream	exons,	termed	exon	1a	and	1b,	as	well	as	a	variety	of	independent	enhancer	
and	negative	regulatory	elements	which	drive	Nkx2-5	expression	in	different	tissues	and	
compartments	of	the	heart	(Figure	6)	[73,	84-87].	Several	alternative	Nkx2-5	isoforms	exist	with	
exon	1a	and	1b	also	being	able	to	be	spliced	to	Nkx2-5	coding	region	[84,	88].	So	far,	nine	activating	
and	three	inhibitory	elements	were	identified	providing	tissue	specificity	by	driving	Nkx2-5	
expression	in	cardiac	and	non-cardiac	tissue,	but	none	alone	could	account	for	the	complete	Nkx2-5	
expression	pattern	[85].		
In	total,	seven	activating	regions	were	identified	which	recapitulate	Nkx2-5	expression	in	
cardiac	tissues	(Figure	6).	Activating	region	1	(AR1)	drives	early	Nkx2-5	expression	in	cardiac	
progenitor	cells	throughout	heart	development	until	the	chambers	form	after	which	its	expression	
becomes	strictly	localised	to	the	right	ventricle	(Figure	6)	[87].	AR2	recapitulate	Nkx2-5	expression	
in	the	cardiac	crescent	and	linear	heart	tube,	and	later	becomes	restricted	to	the	outflow	tract	and	
right	ventricle	(Figure	6)	[86].	A	third	cardiac	enhancer	(AR3)	is	responsible	for	expression	in	the	
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outflow	tract	(Figure	6).	These	three	enhancers	can	be	repressed	by	inhibitory	regions	(IR),	which	
are	located	immediately	next	to	the	individual	enhancers	(Figure	6)	[84,	87].	Additional	enhancers	
drive	expression	in	both	ventricles	(AR4),	right	ventricle	(AR5)	and	both	atria	(Upstream	Homology	
[UH]	region	5)	[88,	89].	An	additional	upstream	enhancer	composed	of	clustered	repeats	of	Smad	
and	GATA	DNA	binding	sites,	termed	the	Gata-Smad-responsive	enhancer	(G-S),	recapitulates	
expression	in	the	cardiac	crescent	(Figure	6)	[90].		
Lastly,	enhancer	elements	for	non-cardiac	tissues	included	AR6,	which	is	responsible	for	
thyroid	expression,	AR7	for	expression	in	thyroid,	spleen,	stomach	and	pharynx	and	UH4	for	
expression	in	tongue	(Figure	6)	[88,	89].	
Further,	it	was	shown	that	transcription	factors	interact	with	some	of	these	enhancers	to	
participate	in	regulating	Nkx2-5	expression	[86,	89-91].	A	network	interference	model	predicted	
binding	of	the	transcription	factor	Tead1	(TEA	Domain	Transcription	Factor	1),	GATA4,	MSX2	(Msh	
Homeobox	2)	and	TGIF1	(TGFB	Induced	Factor	Homeobox)	to	AR2	and	EGR1	(Early	Growth	
Response	1)	and	SOX11	(SRY-related	HMG-box)	to	AR1	[86,	87,	91].		
In	summary,	Nkx2-5	is	a	tightly	regulated	gene	with	a	set	of	upstream	enhancers	directing	
Nkx2-5	expression	during	cardiac	progenitor	commitment	and	specification	and	another	set	driving	
expression	during	chamber	specification	and	septation	[89].		
 
	
Figure	6	Mouse	Nkx2-5	genomic	region	with	locations	of	regulatory	elements.	Diagram	showing	
Nkx2-5	with	its	upstream	exons,	enhancers	and	inhibitory	elements.	Cardiac	enhancers	are	
indicated	in	green	and	non-cardiac	in	yellow.	Inhibitory	regions	are	highlighted	in	black.	AR=	
activating	region,	G-S=	Gata-Smad-responsive	enhancer,	UH=	upstream	homology	region,	IR=	
inhibitory	region.	
	
	
1.3.3 Long	non-coding	RNAs	
Recent	years	showed	that	GRNs	are	not	only	controlled	by	transcription	factors	but	also	by	long	
non-coding	RNAs	(lncRNA).	Advances	and	widespread	application	of	high-throughput	sequencing	
methods	revealed	that	the	vast	majority	of	the	human	genome	does	not	code	for	genes	that	
G-SAR2 AR1 AR4 UH5AR3
AR7 AR6
Nkx2-5
10kb
UH4
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produce	proteins.	Only	around	2%	of	the	human	genome	actually	consists	of	protein-coding	genes.	
Prior	to	the	completion	of	the	human	genome	project,	it	was	assumed	that	human	complexity	was	
due	to	an	increased	number	of	protein-coding	genes.	However,	the	results	showed	that	humans	
have	a	similar	number	of	protein-coding	genes	to,	for	example,	nematode	worms,	suggesting	that	
the	number	of	protein-coding	genes	cannot	explain	human	complexity	[92,	93].	However,	the	
proportion	of	non-coding	DNA	was	shown	to	be	positively	correlated	with	increased	organismal	
complexity.	Humans	have	the	highest	amount	of	non-coding	DNA,	indicating	that	this	might	be	a	
more	accurate	measurement	of	complexity	[94,	95].	
About	80%	of	our	DNA	is	transcribed,	mostly	into	non-coding	RNAs	(ncRNAs),	which	do	not	
contain	a	defined	open	reading	frame	[96].	They	can	be	divided	into	short	and	long	ncRNAs	based	
on	their	transcript	size.	Short	ncRNAs	include	mainly	well-validated	classes	of	regulatory	RNAs	like	
microRNAs	(miRNAs),	which	will	not	be	further	discussed	in	this	thesis.		
Transcripts	with	a	length	greater	than	200	nucleotides	are	arbitrarily	defined	as	lncRNAs.	
LncRNAs	are	a	rapidly	growing	class	with	until	now	up	to	96,308	and	17,216	described	human	
lncRNA	genes	and	transcripts,	respectively	(Source:	NONCODE).	Until	recently	it	was	thought	that	
GRNs	were	comprised	exclusively	of	protein-coding	genes	mediating	control	of	the	genome	and	
that	disease	resulted	as	a	consequence	of	dysfunction	of	this	network.	However,	the	interest	in	
lncRNAs	has	produced	a	major	shift	in	our	understanding	of	gene	regulation	with	lncRNAs	playing	
critical	roles	within	GRNs	as	structural	and	regulatory	elements.	
	
	
1.3.3.1 Structure	
Intriguingly,	lncRNAs	share	many	processing	properties	with	protein-coding	RNAs	in	that	many	are	
transcribed	by	RNA	Polymerase	II	(or	III),	spliced,	have	a	5’cap	and	a	poly(A)	tail	[97,	98].	One	of	the	
only	differences	lies	within	the	absence	of	an	open	reading	frame	that	can	be	translated	[99].	
Examination	of	their	genomic	location	revealed	that	many	protein-coding	genes	are	in	fact	
surrounded	by	a	host	of	lncRNAs	transcripts	[100-108].	These	can	be	expressed	in	sense	or	
antisense	orientation	and	can	be	intronic,	overlapping	or	intergenic	relative	to	the	location	of	
nearby	protein-coding	genes	[109-111].	
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1.3.3.2 Localisation		
Many	lncRNAs	display	highly	specific	sub-cellular	localisation	patterns	providing	key	steps	towards	
elucidating	their	possible	regulatory	roles	[98,	112].	The	patterns	can	range	from	specifically	
nuclear,	exclusively	cytoplasmic	or	a	combination	of	both	[113].	A	major	fraction	of	lncRNAs	are	
retained	in	the	nucleus	with	some	localising	to	specific	sub-nuclear	organelles	[112].	NEAT1	
(Nuclear	enriched	abundant	transcript	1)	and	MALAT1	(Metastasis	Associated	Lung	
Adenocarcinoma	Transcript	1),	for	example,	localise	to	specific	nuclear	bodies,	the	paraspeckles	
and	nuclear	speckles,	respectively,	two	compartments	involved	in	splicing	[114,	115].	NEAT1	plays	
an	essential	role	in	paraspeckle	formation	and	maintenance,	while	MALAT1	is	required	for	optimal	
splicing	[114-116].	
	
	
1.3.3.3 Expression	
Analysis	of	lncRNAs	revealed	that	many	exhibit	exceptional	cell-type,	tissue	and	developmental	
specific	expression	patterns	[117-121].	One	major	concern	for	many	years	regarding	the	
functionality	of	lncRNAs	has	been	their	low	abundance	in	whole	tissue	RNA	sequencing	data.	
However,	the	emergence	of	single	cell	RNA	sequencing	revealed	that	rather	than	being	distributed	
at	low	expression	over	thousands	of	cells,	lncRNAs	expression	was	highly	precise	and	dynamic	[121-
123].	In	individual	cells,	lncRNAs	were	expressed	at	similar	levels	to	mRNAs,	whereas	in	pooled	cells	
expression	appeared	lower	[122,	123].	Therefore,	even	though	some	lncRNAs	exhibit	low	
expression	in	bulk	tissues,	they	may	still	play	essential	biological	roles	and	should	not	be	ignored.	
Further,	since	lncRNAs	may	not	produce	a	protein,	their	function	is	tied	to	the	specific	tissue	or	cell-
types	in	which	they	are	expressed.	Hence,	it	is	useful	to	determine	their	cellular	and	tissue	specific	
expression	as	a	first	step	towards	exploring	their	function.	
 
 
1.3.3.4 Conservation	
In	contrast	to	mRNAs,	most	lncRNAs	lack	or	have	low	sequence	conservation,	which	for	many	years	
stimulated	a	heated	debate	regarding	their	biological	relevance.	However,	non-conservation	agrees	
with	the	observation	that	lncRNAs	emerged	only	recently	in	evolution	and	that	the	sequence	of	
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lncRNAs	is	not	constrained	by	the	need	to	encode	amino	acids.	In	contrast	to	sequence	
conservation,	splice	sites,	promoters	or	chromatin	signatures	of	many	lncRNAs	have	been	found	to	
be	evolutionary	well	conserved	[124-127].	Further,	computational	approaches	identified	that	
secondary	structures	within	lncRNAs	are	often	conserved	in	vertebrates	[128-130].	These	
conserved	structures	frequently	show	overlap	in	expression	between	vertebrates	and/or	co-
localisation	with	binding	sites	for	the	same	RNA-binding	proteins,	indicating	that	knowledge	of	the	
nature	and	conservation	of	RNA	structures	might	imply	biological	relevance	and	give	insights	into	
their	functionality	and	mechanisms	of	action	[119,	128,	129].		
 
	
1.3.3.5 Function	
Unlike	miRNAs,	which	post-transcriptionally	regulate	gene	expression,	lncRNAs	have	more	diverse	
functions.	LncRNAs	can	form	specific	RNA-RNA,	RNA-DNA	and	RNA-protein	interactions	and	
thereby	can	regulate	genetic	output	at	almost	every	stage	of	a	gene’s	life	cycle,	from	epigenetic,	
transcriptional	and	post-transcriptional	control	to	protein	metabolism	[117,	131-135].	Over	the	past	
decade,	there	have	been	many	studies	linking	lncRNAs	with	a	variety	of	functions	within	cellular	
processes	including	regulation	of	chromatin	remodelling,	pre-mRNA	processing,	mRNA	stability	and	
splicing	as	well	as	protein	stability,	activity	or	localisation	[112,	136-140].	They	commonly	interact	
with	chromatin-modifying	proteins	including	the	repressive	PRC2	(polycomb	repressive	complex	2)	
and	the	activating	MLL/TrxG	(Mixed-Lineage	Leukemia/Trithorax	group)	complex	as	well	as	histone-
modifying	enzymes	and	transcription	factors	to	control	gene	expression	[97,	121,	134,	139,	141].	
LncRNAs	have	various	mechanisms	of	function.	They	may	act	as	a	guide	to	recruit	proteins	or	
enzymes	to	their	specific	site	of	action,	as	decoys	to	prevent	target	site	binding	or	even	as	modular	
scaffolds	to	aid	in	the	assembly	of	relevant	complexes	(Table	1)	[142,	143].	In	fact,	many	lncRNAs	
were	identified	to	directly	interact	with	either	PRC2	or	MLL/TrxG	to	inhibit	or	activate	target	gene	
expression	[144,	145].	Others	act	as	miRNA	sponges,	competing	for	binding	with	miRNA	targets,	
thus	trapping	the	miRNA	and	leading	to	the	activation	of	its	target	genes	instead	of	silencing	(Table	
1)	[146-149].	LncRNAs	can	act	in	cis	and/or	trans	and	thus	are	able	to	control	gene	expression	from	
neighbouring	to	very	distant	genomic	loci	[105,	150].	Additionally,	lncRNAs	can	indirectly	control	
expression	of	neighboring	genes	through	mechanisms	of	their	biogenesis	rather	than	the	lncRNA	
molecule	itself	[104].	When	terminating	the	transcription	start	site	of	the	cardiac	lncRNA	Uph	
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(Upperhand),	which	is	transcribed	from	a	divergent	promoter	shared	with	the	cardiac	transcription	
factor	Hand2,	Hand2	expression	was	lost	[104].	In	contrast,	knockdown	of	the	transcript	had	no	
effect	[104].	
Overall,	thousands	of	lncRNAs	still	remain	un-characterised	and	a	major	challenge	lies	in	
defining	their	function.	Regarding	the	heart,	several	lncRNAs	have	been	identified	to	be	involved	in	
the	regulation	of	cardiac	pathways	[101,	139,	148,	149,	151,	152].	Some	are	involved	in	metabolism	
and	cardiac	conduction,	others	altered	during	heart	development	as	well	as	disease	and	some	
showing	cardioprotective	properties	(Table	1)	[101,	102,	105,	151-156].	Considering	the	still	
unknown	function	of	thousands	of	lncRNAs,	many	more	are	likely	to	be	discovered	as	important	
regulators	of	heart	development	and/or	function	and	may	represent	an	additional	layer	of	
regulation	to	the	cardiac	transcription	factor	composed	GRN.	
	
	
1.3.3.5.1 Role	of	LncRNAs	in	heart	development 	
Analysis	of	the	transcriptome	of	embryonic	(E13.5)	and	adult	mouse	hearts,	revealed	hundreds	of	
differentially	expressed	lncRNAs	with	about	117	being	cardiac	enriched,	indicating	that	many	
lncRNAs	likely	exhibit	specific	functions	in	cardiac	development	[157].	Interestingly,	the	same	study	
compared	healthy	adult	with	hypertrophic	hearts	and	found	far	less	differentially	expressed	
lncRNAs	[157].	Another	RNA	sequencing	study	identified	1378	lncRNAs	expressed	in	E8.25	hearts	
with	about	200	being	specifically	expressed	in	the	heart	at	this	stage	[158].		
Examples	of	lncRNAs	altered	during	development	include	Braveheart,	Fendrr	(Fetal-lethal	
non-coding	developmental	regulatory	RNA),	ALIEN	and	CARMEN	(Cardiac	mesoderm	enhancer-
associated	noncoding	RNA),	all	of	which	are	expressed	in	cardiac	progenitor	cells	and,	except	ALIEN,	
found	to	interact	with	PRC2,	either	as	a	decoy	(Braveheart)	or	guide	(Fendrr)	(Table	1)	[102,	103,	
152,	154].	The	mechanisms	of	how	CARMEN	regulates	gene	expression	through	PRC2	remains	
unknown	[154].	Interestingly,	Fendrr	is	also	able	to	interact	with	the	activating	MLL/TrxG	complex	
[103].	Additionally,	Fendrr	is	one	of	the	very	few	lncRNAs	involved	in	heart	development	that	have	
been	functionally	interrogated	in	vivo	in	mice	[103].	Consistent	with	its	early	cardiac	expression,	
Fendrr	loss-of-function	resulted	in	disturbed	cardiac	morphogenesis	and	embryonic	lethality	at	
E13.75,	most	likely	due	to	myocardial	dysfunction	[103].	
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However,	most	of	the	lncRNAs	involved	cardiac	development	lack	in	vivo	proof	of	function	
and	were	mostly	studied	in	vitro	in	differentiated	stem	cells,	which	can	provide	important	insights	
into	their	function,	however,	has	to	be	interpreted	with	caution.		
	
	
1.3.3.5.2 Relevance	of	lncRNAs	in	cardiovascular	disease	
Besides	their	involvement	in	cardiac	development,	lncRNAs	are	also	important	regulators	of	
homeostasis	in	adult	hearts	and	their	disruption	is	linked	to	a	variety	of	human	cardiovascular	
diseases,	including	heart	attack,	heart	failure,	hypertension	and	cardiac	arrhythmias.	Annotation	of	
the	cardiac	transcriptome	after	cardiac	disease	identified	hundreds	of	deregulated	lncRNAs	and	
together	with	their	often	very	specific	expression,	they	have	great	potential	to	be	used	as	
biomarkers	for	cardiac	form	and	function	as	well	as	therapeutic	targets	in	the	future	[101,	139,	156,	
159].		
Deep	RNA	sequencing	of	failing	and	non-failing	human	heart	samples	before	and	after	
mechanical	support	with	an	assist	device	revealed	dynamic	regulation	of	myocardial	lncRNAs	[156].	
About	10%	of	the	lncRNAs,	deregulated	between	failing	and	non-failing	hearts,	showed	improved	
expression	after	mechanical	circulatory	support,	suggesting	that	lncRNAs	play	biochemical	roles	in	
reverse	remodeling	observed	with	mechanical	support	[156].	Further,	the	expression	profile	of	
lncRNAs	was	reported	to	be	more	predictive	than	the	profile	of	mRNAs	or	miRNAs	to	discriminate	
failing	from	non-failing	hearts,	indicating	an	important	pathophysiological	role	of	lncRNAs	in	the	
cardiovascular	system	[156].		
Examples	of	cardiovascular	disease	associated	lncRNAs	are	summarised	in	Table	1.	Some	
lncRNAs,	including	ANRIL	(Antisense	noncoding	RNA	in	the	INK4	locus)	and	MIAT	(Myocardial	
infarction	associated	transcript),	were	identified	in	genome-wide	association	studies	(GWAS),	in	
which	a	single	nucleotide	polymorphism	(SNP)	associated	with	an	increased	risk	for	coronary	artery	
disease	and	myocardial	infarction	was	identified	within	the	ANRIL	and	MIAT	locus,	respectively	
[108,	160].	In	fact,	an	increasing	number	of	the	trait-	and	disease-associated	GWAS	SNPs	map	to	
non-coding,	intergenic	regions	of	the	genome	with	many	found	to	be	within	transcriptionally	active	
regions,	suggesting	that	the	causative	SNPs	may	affect	ncRNA’s	expression	and/or	functions	and	
highlighting	their	potential	as	candidate	biomarkers	[161-165].		
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Of	note,	lncRNAs	may	also	be	cardioprotective.	During	cardiac	stress,	including	myocardial	
infarction	and	cardiac	hypertrophy,	Mhrt	(Myosin	heavy	chain	associated	RNA	transcript)	
expression	is	repressed	and	restoring	expression	was	reported	to	provide	cardioprotection	[153].		
Moreover,	lncRNAs	were	shown	to	predict	cardiac	disease	development	and	survival.	By	
analsying	plasma	samples	of	heart	failure	patients,	expression	of	the	mitochondrial	transcript	
LIPCAR	was	found	to	increase	significantly	during	the	process	of	cardiac	remodeling	after	
myocardial	infarction	and	during	chronic	heart	failure,	thus	LIPCAR	expression	levels	may	serve	as	a	
prognostic	marker	for	heart	failure	[106,	166].		
Taken	together,	the	highly	specific	expression	patterns	and	powerful	regulatory	functions	of	
lncRNAs	in	cardiac	disease	onset	and	progression	as	well	as	association	to	genetic	risk	factors	
supports	their	potential	as	biomarkers	for	diagnosis	and	prognosis	as	well	as	promising	targets	for	
new	therapeutic	approaches.	Several	tools	are	available	to	modulate	lncRNAs	to	either	inhibit	or	
overexpress	lncRNAs.	LncRNA	expression	can	be	reduced	during	disease	by	using	antisense-based	
approaches,	or	restored	by	reintroducing	its	activity	using	for	example	viral	delivery	[167,	168].	But	
also	here,	challenges	in	improving	delivery	and	reducing	toxicity	still	exist.	Furthermore,	the	field	of	
lncRNA	research	is	still	relatively	new	and	to	date	detailed	mechanism	of	function	is	only	described	
for	a	few	lncRNAs,	with	even	fewer	studies	providing	functional	validation	in	vivo.	Thereby,	
emphasising	the	need	for	detailed	characterisation	and	systematic	functional	testing	of	lncRNAs	to	
allow	the	development	of	highly	targeted	therapeutic	approaches,	which	would	provide	a	
considerable	benefit	to	human	healthcare.	
	
Table	1	Summary	of	functional	roles	and	mechanisms	of	known	cardiac	lncRNAs	
Name	 Role	 Mechanism	 References	
ALIEN	 Cardiac	development	 Unknown	 [152]	
Braveheart	 Cardiac	development	 Decoy	 [102]	
CARMEN	 Cardiac	development	&	homeostasis	 Unknown	 [154]	
Fendrr	 Cardiac	development	 Guide	 [103]	
ANRIL	
Genetic	risk	factor	for	coronary	artery	
disease	
Scaffold	 [160]	
MIAT	 Genetic	risk	factor	for	myocardial	infarction	 miRNA	sponge	
[107,	108,	
169]	
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TINCR	 Inhibits	cardiac	hypertrophy	 Guide	 [170]	
Mhrt	 Inhibits	cardiac	hypertrophy	 Decoy	 [153]	
CARL	 Inhibits	cardiac	apoptosis	 miRNA	sponge	 [148]	
CHRF	 Promotes	cardiac	hypertrophy	 miRNA	sponge	 [149]	
CHAST	 Promotes	cardiac	hypertrophy	 Unknown	 [171]	
LIPCAR	
Predicts	onset	and	survival	in	heart	failure	
patients	
Unknown	 [106]	
SENCR	 Promotes	smooth	muscle	cell	contraction	 Decoy	 [172]	
	
	
1.4 Discovery	of	two	novel	transcripts	surrounding	mouse	Nkx2-5	
In	mice,	as	well	as	in	humans,	Nkx2-5	is	an	isolated	protein-coding	gene,	having	no	neighbouring	
protein-coding	genes	located	50-70kb	up-	and	downstream.	However,	while	scanning	available	
ENCODE	RNA	data	of	adult	and	embryonic	mouse	hearts,	Dr.	Nicole	Schonrock	(previous	Harvey	
group	member,	Victor	Chang	Cardiac	Research	Institute,	Australia)	identified	the	area	surrounding	
Nkx2-5	to	be	very	transciptomically	rich.	Highly	expressed,	long	RNAs	were	expressed	directly	
downstream	as	well	as	on	the	opposite	strand	upstream	of	mouse	Nkx2-5	(Figure	7)	[96].	This	
expression	seems	to	be	heart	specific	as	it	was	not	found	in	ENCODE	transcriptome	data	of	any	
other	tissue	type	(Figure	7).	Based	on	their	genomic	location	relative	to	Nkx2-5,	the	transcripts	
were	termed	NkxDS	for	Nkx2-5	DOWNSTREAM	and	NkxUS	for	Nkx2-5	UPSTREAM.		
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Figure	7	Transcriptional	landscape	of	mouse	Nkx2-5.	Overview	of	the	genomic	location	of	Nkx2-5	
(in	gray)	and	ENCODE	transcriptome	data	on	different	mouse	tissues	showing	that	Nkx2-5	is	
surrounded	by	heart	specific	transcripts.	
	
	
1.5 Aim	of	this	thesis	
Nkx2-5	has	been	studied	for	about	two	decades	to	analyse	its	contribution	to	heart	development	
and	CHD.	However,	very	little	is	known	about	its	biochemical	function	and	regulation,	or	how	it	
participates	in	guiding	the	cardiac	GRN.	
Based	on	the	recently	discovered	cardiac	enriched	transcripts	and	their	close	proximity	to	
Nkx2-5,	we	hypothesised	that	NkxUS	and	NkxDS	are	either	involved	in	the	regulation	of	Nkx2-5	
itself	or	other	genes	important	for	heart	development	and/or	function.	The	aim	of	this	thesis	was	to	
characterise	NkxUS	and	NkxDS	to	determine	their	potential	role	within	the	cardiac	GRN.	
Specifically,	my	experimental	approaches	are	summarised	below	in	Table	2:	
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Table	2	Summary	of	thesis	aims	with	experimental	approach	and	objectives.	
Feature	Analysed	 Experimental	Approach	 Objective	
Structure	 Northern	blot	
5’	and	3’RACE	
FANTOM	CAGE	data	analysis	
Analysis	of	RNA	length		
Determination	of	RNA	boundaries	
Investigation	of	RNA	start		
Expression	 Real	Time-PCR	
In-situ	hybridisation	
Overall	tissue	specificity	
High	resolution	cardiac	sub-structure	analysis	
Localisation	 Cell-fractionation	
RNA-Fluorescent	In	Situ	
Hybridisation	(FISH)	
Sub-cellular	localisation	
Sub-nuclear	localisation	
Coding	Potential	 Polysome	profiling	
Open	reading	frame	analysis	
Translation	potential	
Coding	potential	prediction	
Conservation	 Real	Time-PCR		
In	silico	structural	analysis	
Expression	in	human	samples	
RNA	structure	conservation	
Relevance	in	
disease	
GWAS	association	 Identification	of	genetic	risk	factors	
Function	 Knockdown	in	cardiac	cells	
Chromatin	Isolation	by	RNA	
Purfication	(ChIRP)	
CRISPR	mouse	model	
Insights	into	biological	function	in	vitro	
Identification	DNA	and	protein	interacting	
partners	
Investigation	of	in	vivo	function		
	
Thereby,	this	work	provides	a	detailed	analysis	of	two	novel	transcripts	and	has	the	potential	to	
increase	our	understanding	of	Nkx2-5	genetic	regulation	as	well	as	deepen	our	knowledge	of	
lncRNA	function	and	regulatory	mechanisms	in	the	heart.	
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2.1 		Structure		
2.1.1 Mouse	NkxUS	and	NkxDS	are	long,	polyadenylated	transcripts	
Elucidating	the	structure,	including	length	and	RNA	boundaries,	of	the	cardiac	enriched	transcripts	
surrounding	Nkx2-5	was	the	first	aim	of	this	work	and	was	performed	by	Dr.	Nicole	Schonrock	
(former	Victor	Chang	Cardiac	Research	Institute,	Australia).	
To	identify	the	transcript	length,	northern	blotting	was	performed	on	5µg	and	10µg	of	adult	
mouse	heart	RNA	with	probes	for	Nkx2-5,	NkxDS	and	NkxUS	(Figure	8A).	The	blot	results	showed	
that	both	are	long	transcripts,	NkxDS	is	~11kb	in	length	and	NkxUS	~10kb	in	length.	Interestingly,	a	
~11kb	transcript	was	detected	with	both,	Nkx2-5	mRNA	and	NkxDS-specific	probes,	indicating	that	
NkxDS	possibly	contains	the	Nkx2-5	probe	sequence	and	that	probably	the	important	cardiac	
transcription	factor	Nkx2-5,	may	have	an	uncharacterised	long	isoform	(Figure	8A).	To	analyse	if	
NkxDS	and	Nkx2-5	share	the	same	transcription	start	site,	we	mapped	the	5’end	of	NkxDS	using	
FANTOM	Cap	Analysis	of	Gene	Expression	(CAGE)	[173,	174].	FANTOM	CAGE	is	a	catalogue	of	
5’ends	of	capped	transcripts	and	available	for	investigation	on	the	University	of	California,	Santa	
Cruz	(UCSC)	genome	browser	(Figure	8C)	[175].	The	FANTOM	CAGE	data	showed	one	prominent	
peak	at	the	annotated	Nkx2-5	start,	suggesting	that	Nkx2-5	and	NkxDS	share	a	similar	transcription	
start	site	(Figure	8C,	blue	CAGE	counts).	NkxDS	could	thus	have	been	generated	via	read-through	of	
the	Nkx2-5	primary	transcript.	We	performed	several	Real-Time	(RT)-PCRs	on	adult	mouse	heart	
tissue	with	different	set	of	primers,	six	forward	and	three	reverse	primers,	across	the	recognised	
Nkx2-5	mRNA	polyadenyation	site,	including	the	5’untranslated	region	(UTR)	and	both	exons	
(Figure	8B)	of	Nkx2-5.	As	a	control	for	genomic	DNA	contamination,	we	performed	each	RT-PCR	
with	two	cDNA	samples	(with	and	without	the	reverse	transcriptase	enzyme)	(Figure	8B).	The	RT-
PCR	results	showed	expression	for	all	the	tested	primer	pairs	and	only	for	those	using	the	cDNA	
samples	with	the	enzyme,	indicating	that	NkxDS	can	be	continuous	with	the	Nkx2-5	mRNA	and	can	
contain	both	exons	and	the	5’UTR	of	Nkx2-5	(Figure	8B).	The	exact	3’end	of	NkxDS	was	mapped	
using	3’rapid	amplification	of	cDNA	ends	(RACE)	with	a	Poly(dT)	primer,	additionally	also	identifying	
a	canonical	AAUAAA	polyadenylation	signal,	which	is	a	signal	for	RNA	polyadenylation	as	well	as	
transcription	termination	(Figure	8C)	[176].	This	long,	potentially	non-coding,	tail	may	contain	
miRNA	or	protein	binding	sites	that	could	regulate	Nkx2-5	mRNA	stability,	sub-cellular	localisation	
or	protein	translation.		
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NkxUS,	on	the	other	hand,	is	produced	several	kilobases	upstream	and	on	the	opposite	
strand	to	Nkx2-5.	To	identify	the	start	site	of	NkxUS,	5’RACE	was	performed	on	adult	mouse	heart	
RNA.	The	results	of	two	clones	revealed	that	NkxUS	is	comprised	of	two	exons,	one	short	one	
(157bp),	which	sits	very	close	to	the	second	longer	exon	(~10kb)	and	is	also	present	in	the	ENCODE	
heart	RNA	sequencing	data	(Figure	8C).	As	for	NkxDS,	the	exact	3’end	was	mapped	using	3’RACE,	
thus	also	revealing	a	canonical	polyadenylation	site	(AAUAAAA)	(Figure	8C).		
In	summary,	NkxUS	is	longer	than	200nt,	spliced	and	polyadenylated,	fulfilling	all	features	
defining	typical	lncRNAs	[99,	109].	With	respect	to	the	location	to	the	nearest	protein-coding	gene,	
Nkx2-5,	NkxUS	would	be	defined	as	an	intergenic	RNA	[177].	Moreover,	we	may	have	discovered	a	
potential	novel	isoform	of	Nkx2-5,	NkxDS.	
	
Figure	8	Mouse	NkxDS	and	NkxUS	are	long	transcripts.	A)	Northern	blot	using	specific	probes	
targeting	Nkx2-5,	NkxDS	and	NkxUS.	For	each	probe	5µg	and	10µg	of	adult	mouse	heart	RNA	was	
used.	The	locations	of	the	probes	are	indicated	in	the	lower	image.	B)	RT-PCR	on	mouse	heart	cDNA	
with	six	different	forward	primers	(F1-F6)	and	three	different	reverse	primers	(R1-3)	across	the	
proposed	Nkx2-5/NkxDS	boundary	suggests	that	NkxDS	is	continuous	with	Nkx2-5	mRNA	and	that	
NkxDS	can	contain	both	exons	and	the	5’UTR	of	Nkx2-5.	The	primer	locations	are	shown	in	the	
upper	image.	The	gel	showed	bands	for	all	RT-PCRs	and	only	for	the	samples	containing	reverse	
transcriptase	(+).	C)	Map	of	the	genomic	location	of	Nkx2-5	and	the	surrounding	transcripts,	NkxUS	
and	NkxDS,	showing	ENCODE	mouse	heart	RNA	sequencing	data	from	the	plus	(+)	and	minus	(-)	
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strand	and	FANTOM	CAGE	counts,	with	blue	indicating	counts	on	the	minus	strand	and	red	on	the	
plus	strand	(adapted	from	UCSC	browser	[178]).	
	
	
2.2 Expression		
2.2.1 Mouse	NkxUS	and	NkxDS	are	highly	enriched	in	cardiac	tissues	
Previously	characterised	lncRNAs	were	found	to	function	in	a	tissue-,	cell-type	or	developmental	
specific	manner	[98,	117,	119].	Therefore,	as	a	first	step	towards	exploring	the	potential	function	of	
NkxDS	and	NkxUS,	we	analysed	their	expression	levels	during	development	and	in	different	mouse	
tissues.	
RT-PCR	analysis	was	performed	on	12	adult	mouse	tissues	as	well	as	E9.5	heart	tissue	and	
HL-1	cells,	a	mouse	atrial	cardiomyocyte	cell	line,	with	primers	for	Nkx2-5,	NkxDS	and	NkxUS	(Figure	
9A)	[179].	Primers	for	Nkx2-5	measure	both	Nkx2-5	as	well	as	NkxDS	expression,	since	the	
transcripts	overlap	we	were	unable	to	design	Nkx2-5	specific	primers	(Figure	9A).	The	RT-PCR	
results	showed	that	all	transcripts	are	highly	enriched	in	adult	as	well	as	embryonic	cardiac	tissues	
(Figure	9A).	As	previously	shown,	Nkx2-5	is	mainly	expressed	in	the	heart,	both	embryonic	and	
adult,	but	additionally	showed	some	low-level	expression	in	spleen	and	tongue	[68].	NkxDS	
mimicked	Nkx2-5	mRNA	expression,	whereas	NkxUS	was	exclusively	expressed	in	cardiac	tissue	in	
adult	mice	(Figure	9A).	Relative	to	Nkx2-5,	NkxUS	and	NkxDS	were	more	lowly	expressed	in	HL-1	
cells	as	well	as	adult	mouse	heart,	which	is	a	common	feature	of	lncRNAs	(Figure	9B	and	C)	[97].		
In	situ	hybridisation	performed	by	Dr.	Gonzalo	del	Monte	Nieto	(Victor	Chang	Cardiac	
Research	Institute,	Australia)	on	embryonic	and	adult	mouse	tissues,	using	the	same	probes	as	used	
for	northern	blotting,	confirmed	the	RT-PCR	results	showing	that	both	transcripts	are	cardiac-
enriched	(Figure	9D-H).	Here	showing	data	of	sections	from	E8.5	(Figure	9D),	E17.0	(Figure	9E-G)	
and	adult	(Figure	9H).	However,	the	entire	experiment	was	performed	on	sections	from	embryos	at	
E8.5,	E9.5,	E10.5,	E17.0,	postnatal	day	10	and	adult	and	the	complete	Figure	can	be	found	in	
Appendix	I	(Figure	49).	The	results	showed	that	NkxUS	and	NkxDS	are	expressed	in	the	heart	
throughout	development	(Figure	9D-H).	NkxDS	and	Nkx2-5	share	a	similar	expression	pattern,	
whilst	the	expression	pattern	of	NkxUS	is	markedly	different.	From	E8.5	to	adulthood,	NkxDS	and	
Nkx2-5	are	cardiac	expressed	and	predominantly	localised	to	the	myocardium	(Figure	10D,	F	and	H,	
arrows).	In	contrast,	NkxUS	is	mainly	expressed	in	the	endocardium	and	to	a	lesser	extend	in	the	
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myocardium	(Figure	10D,	F	and	H,	arrowhead).	Furthermore,	NkxUS	was	not	confined	to	the	heart	
during	early	development	and	was	also	expressed	in	other	tissues	such	as	the	lungs	and	neural	tube	
(Figure	10G),	but	became	strictly	cardiac	after	birth	(Figure	9A).	Interestingly,	NkxUS	is	strongly	
expressed	in	the	endocardium	surrounding	the	valve	leaflets	at	E17.0	(Figure	9F,	arrow)	and	in	the	
sinoatrial	node	(Figure	9G,	inset),	whereas	no	expression	was	observed	for	NkxDS	and	Nkx2-5	in	
these	tissues	(Figure	9F,	arrowheads	and	9G).	However,	after	birth	and	in	adult	mice	all	three	
transcripts	are	expressed	in	the	valve	endocardium	(Appendix	Figure	49E3	and	F3).	Upon	close	
inspection,	NkxUS	and	NkxDS	showed	a	more	speckled,	potentially	nuclear	staining,	whilst	Nkx2-5	
displayed	a	more	diffuse,	potentially	cytoplasmic	staining	(Appendix	Figure	49D4).	
In	summary,	NkxUS	and	NkxDS	are	expressed	in	the	heart	throughout	development,	are	
cardiac	enriched	in	adult	mouse	tissues	and	predominately	expressed	in	distinct	layers	of	the	heart	
wall,	suggesting	that	both	transcripts	do	not	function	in	a	developmentally	specific	but	perhaps	in	a	
cell-	or	tissue	specific	manner.	
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Figure	9	Expression	in	mouse	tissues.	A)	RT-PCR	on	different	adult	mouse	tissues	as	well	as	E9.5	
mouse	heart	and	the	cardiac	cell	line	HL-1	showed	that	both	transcripts	are	highly	enriched	in	
cardiac	tissues.	Nkx2-5	and	NkxDS	share	a	similar	expression	pattern	with	low	expression	in	some	
non-cardiac	tissues	(spleen	and	tongue).	NkxUS	is	strictly	cardiac	enriched	in	adult	mouse	tissues.	
Data	presented	as	mean	±	SD,	n=3	B-C)	RT-PCR	on	HL-1	cells	(B)	and	adult	mouse	heart	(C)	showed	
that	NkxUS	and	NkxDS	are	relative	to	Nkx2-5	much	more	lowly	expressed.	Data	presented	as	mean	
±	SD,	n=3.	D-H)	Nkx2-5	(left	panels),	NkxDS	(middle	panels)	and	NkxUS	(right	panels)	expression	
pattern	by	in	situ	hybridisation	on	sections	from	embryos	at	E8.5	(D),	E17.0	(E-G)	and	adult	(H)	
showing	that	both	transcripts	are	expressed	in	the	heart	throughout	development.	Heart	(h),	
endocardium	(endo),	myocardium	(myo),	left	ventricle	(lv),	right	atrium	(ra),	left	atrium	(la),	right	
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ventricle	(rv),	left	ventricle	(lv),	atrioventricular	valve	(avv),	neural	tube	(nt),	lungs	(l),	sinoatrial	
node	(san).	
	
	
2.2.2 NkxUS	and	NkxDS	expression	in	differentiating	embryoid	bodies	is	similar	to	
Nkx2-5	
In	addition	to	their	development,	tissue-	and	cell-type	specificity,	lncRNAs	have	also	been	shown	to	
be	dynamically	regulated	during	differentiation	[180].	In	order	to	examine	this,	we	analysed	
expression	levels	of	NkxUS	and	NkxDS	in	a	differentiation	time	course	of	mouse	embryonic	stem	
cell	(mESC)	into	embryoid	bodies	(EBs).	mESCs	are	immortal	cells,	derived	from	the	inner	cell	mass	
of	a	blastocyst	during	gastrulation	and	are	able	to	differentiate	into	ecto-,	meso-	and	endoderm	in	
vitro	[181-183].	Using	conventional	EB	differentiation	protocols,	only	a	minor	proportion	of	mESCs	
spontaneously	differentiate	into	cardiomyocytes.	However,	the	addition	of	ascorbic	acid	was	shown	
to	enhance	cardiomyocyte	differentiation	[184].	mESCs	were	differentiated	into	EBs	enriched	for	
cardiomyocytes	by	Hananeh	Fonoudi	following	a	published	method	[185].	RNA	was	extracted	at	day	
0,	4,	7,	10,	14,	17,	21,	24	and	30	and	expression	levels	of	Nkx2-5,	NkxDS	and	NkxUS	were	analysed	
via	RT-PCR	using	the	same	primers	as	in	section	2.2.1.	Expression	was	normalised	and	analysed	
relative	to	day	7.	As	previously	observed,	Nkx2-5	expression	levels	followed	a	very	dynamic	and	
stage-specific	expression	pattern	with	low	expression	at	day	0	(undifferentiated	mESCs)	and	day	4	
(differentiating	mESCs),	highest	expression	at	day	7	and	then	a	drop	in	expression,	which	remained	
low	until	the	end	of	the	time	course	(Figure	10A)	[186].	NkxUS	and	NkxDS	shared	a	very	similar	
dynamic	expression	pattern	to	Nkx2-5	(Figure	10A).	This	was	consistent	with	previous	
cardiomyocyte	differentiation	studies,	which	identified	that	lncRNAs	are	significantly	correlated	in	
expression	with	their	neighboring	genes	compared	to	randomly	selected	ones	[186].	The	observed	
dynamic	and	stage-specific	expression	of	Nkx2-5	highlights	how	it	might	activate	specific	gene	
programs	or	pathways	in	a	time	dependent	manner	to	induce	cardiomyocyte	differentiation.	The	
fact	that	all	three	transcripts	are	expressed	at	the	same	stage	suggests	that	they	may	act	in	similar	
processes	during	cardiac	development.	Expression	analysis	of	NkxUS	and	NkxDS	at	day	7	relative	to	
Nkx2-5	showed,	as	before	for	whole	heart	and	HL-1	cells	(Figure	9	B	and	C),	a	much	lower	
expression	level	for	both	transcripts	(Figure	10B).		
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Figure	10	NkxUS	and	NkxDS	follow	the	expression	pattern	of	Nkx2-5	in	a	time	course	of	mouse	
embryonic	stem	cells	into	embryoid	bodies	enriched	for	cardiomyocytes.	A)	RT-PCR	on	different	
timepoints	of	the	time	course	measuring	Nkx2-5,	NkxDS	and	NkxUS	expression	relative	to	day	(d)	7	
showed	that	all	three	transcripts	are	expressed	at	the	same	timepoints.	B)	Expression	at	day	7	of	
NkxUS	and	NkxDS	relative	to	Nkx2-5	showed	that	NkxDS	and	NkxUS	are	around	80%	lower	
expressed	compared	to	Nkx2-5.	Data	presented	as	mean	±	SD,	n=3.	
	
	
2.2.3 NkxUS	and	NkxDS	are	expressed	in	purified	cardiomyocytes	at	different	
postnatal	stages	
To	test	for	cell-type	specific	expression	in	mature	cells,	we	interrogated	RNA	sequencing	data	from	
mouse	cardiomyocytes	at	different	postnatal	stages,	which	were	freshly	isolated	and	purified	by	
Prof.	Robert	Graham’s	group	(unpublished).		
Cardiomyocytes	were	harvested	at	four	different	time	points,	postnatal	(P)	days	2,	10,	13	
and	73.	Unlike	in	HL-1	cells,	whole	heart	and	the	mESC	timecourse	(Figure	9B,	C	and	10B),	Nkx2-5	
was	only	marginally	more	highly	expressed	than	NkxDS,	but	NkxDS	and	Nkx2-5	mRNA	were	more	
highly	expressed	than	NkxUS	(Figure	11).	This	was	perhaps	not	surprising	since	in	situ	hybridisation	
showed	that	NkxUS	is	predominantly	expressed	in	the	endocardium	(Figure	9D).	Interestingly,	the	
expression	dynamics	of	both	transcripts	is	similar	to	Nkx2-5,	with	a	decrease	in	expression	with	
ongoing	postnatal	development,	which	was	already	previously	described	for	Nkx2-5	[187].		
Analysis	of	expression	levels	in	cells	and	tissues	showed	that	both	transcripts	are	cardiac	
enriched,	expressed	in	the	heart	throughout	cardiac	development	and	that	NkxUS	is	to	some	
extend	also	expressed	in	adult	mouse	cardiomyocytes.	Both	RNAs	showed	a	similar	dynamic	
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developmental	expression	pattern	to	Nkx2-5,	indicating	that	all	three	transcripts	may	function	at	
similar	timepoints	and	potentially	in	related	cardiac	pathways.	
	
	
Figure	11	NkxUS	and	NkxDS	follow	the	expression	pattern	of	Nkx2-5	in	purified	cardiomyocytes.	
RNA	sequencing	data	of	purified	mouse	cardiomyocytes	harvested	at	different	postnatal	(P)	time	
points	obtained	from	the	Robert	Graham	group	(unpublished)	revealed	that	both	transcripts	exhibit	
lower	expression	with	ongoing	development	similar	to	Nkx2-5.	NkxDS	is	almost	as	abundant	as	
Nkx2-5	at	all	the	postnatal	stages,	whereas	NkxUS	is	much	more	lowly	expressed	in	purified	
cardiomyocytes	at	any	postnatal	stage.	Results	shown	in	transcripts	per	million;	n=1.	
	
	
2.3 Subcellular	localisation	
2.3.1 Both	transcripts	are	retained	in	the	nucleus	
Identification	of	the	subcellular	localisation	of	lncRNAs	can	give	significant	insight	into	their	
function,	as	nuclear	retained	lncRNAs	have	very	distinct	roles	from	cytoplasmic	enriched	lncRNAs	
[112,	113].		
Nuclear	and	cytoplasmic	HL-1	cell	fractionations	followed	by	RT-PCRs	were	performed	by	Dr.	
Nicole	Schonrock	with	NEAT1	as	a	control	for	nuclear	localisation	and	GAPDH	as	a	cytoplasm-
enriched	control.	The	fractionations	showed	enrichment	for	NkxDS	and	NkxUS	in	the	nucleus	
(Figure	12A),	whereas	Nkx2-5	was	slightly	enriched	in	the	cytoplasm	(Figure	12A).	Similar	to	GAPDH,	
Nkx2-5	showed	also	some	nuclear	expression	(Figure	12A),	potentially	due	to	Nkx2-5	primers	also	
measuring	NkxDS	expression,	which	was	mostly	nuclear	(Figure	12A).	
To	validate	the	nuclear	expression	of	NkxDS	and	NkxUS	and	gain	further	insights	into	their	
subnuclear	localisation,	we	performed	RNA-fluorescence	in	situ	hybridisation	(RNA-FISH)	with	
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probes	targeting	NkxDS,	NkxUS	and	NEAT1.	Using	RNA-FISH,	individual	RNA	molecules	can	be	
simultaneously	detected,	systematically	quantified	and	analysed	for	subcellular	localisation	
patterns.	A	set	of	48	oligonucleotide	probes,	each	20	bases	long,	with	a	Quasar	670	fluorescent	
label	and	a	different	sequence	to	cover	the	entire	transcript	were	designed	for	NkxUS	and	NkxDS.	
The	Nkx2-5	protein-coding	region	was	excluded	for	NkxDS	probe	design.	For	NEAT1	a	commercially	
available	probe	set	(Biosearch	Technologies	Inc.)	with	a	Quasar	570	fluorescent	label	was	used.	The	
probes	from	one	set	collectively	hybridise	to	the	same	target	RNA,	which	results	in	a	concentration	
of	fluorophores	at	a	single	location	producing	a	distinct	signal,	which	is	detectable	using	fluorescent	
microscopy	[113].		
For	the	experiment,	fixed	HL-1	and	C2C12	cells	were	used.	C2C12,	which	is	an	immortalised	
mouse	myoblast	cell	line,	was	used	as	a	non-cardiac	cell	line	and	served	as	a	negative	specificity	
control	since	NkxUS	and	NkxDS	are	not	expressed	in	these	cells	[188].	
RNA-FISH	results	showed	that	NkxUS	and	NkxDS	are	exclusively	expressed	in	the	nucleus	of	
cardiac	cells	(Figure	12B),	which	were	stained	with	DAPI.	Whilst	transcripts	appeared	to	occur	
throughout	the	nucleus,	some	cells	showed	one	to	three	brighter	foci	(Figure	12B),	which	could	
represent	transcription	start	sites	and	hence	accumulation	of	nascent	transcript.	Furthermore,	both	
transcripts	seem	to	be	excluded	from	the	nucleolus,	visible	as	DAPI-negative	“holes”	(Figure	12B).	
Since	NEAT1	localises	to	paraspeckles	and	is	expressed	in	most	cell	types,	it	localised	as	bright	
discrete	foci	in	cardiac	and	non-cardiac	cells	(Figure	12B)	[114,	189].	
Taken	together,	the	RNA-FISH	results	confirmed	the	results	from	the	cell	fractionation	and	in	
situ	hybridisation	experiments	showing	that	both	transcripts	are	retained	in	the	cell	nucleus.	
Furthermore,	neither	transcript	seemed	to	localise	exclusively	to	a	sub-nuclear	structure	as	signal	
was	observed	throughout	the	nucleus,	suggesting	that	its	biological	function	is	within	the	nucleus,	
but	most	likely	not	associated	with	specific	sub-nuclear	organelles.		
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Figure	12	NkxUS	and	NkxDS	localise	to	the	nucleus	in	cardiac	cells.	A)	Nuclear	and	cytoplasmic	
fractionation	of	HL-1	cells	showing	enrichment	of	NkxDS	and	NkxUS	in	the	nucleus.	Data	presented	
as	mean	±	SD,	n=3	B)	RNA-FISH	showed	exclusive	nuclear	localisation	with	no	specific	sub-nuclear	
localisation	for	NkxDS	or	NkxUS	in	cardiac	cells	(HL-1),	whereas	no	expression	was	observed	in	non-
cardiac	cells	(C2C12).	NEAT1	showed	sub-nuclear	localisation	in	both	cell	types.	DAPI	is	shown	in	
blue.	NkxUS	and	NkxDS	specific	probes	are	shown	in	red.	NEAT1	specific	probes	are	shown	in	green.	
Scale	bar	=	5μm.	
	
	
2.4 Coding	potential	of	NkxUS	and	NkxDS	
To	clarify	the	coding	potential	of	NkxUS	and	NkxDS,	we	used	both	experimental	and	computational	
approaches.	
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2.4.1 Polysome	gradient	profiling	resulted	in	minimal	association	of	NkxUS	and	
NkxDS	with	polysomes	
We	performed	an	RNA	polysome	gradient	profile	in	HL-1	cells,	in	collaboration	with	Prof.	Thomas	
Preiss	(Australian	National	University,	Australia).	A	polysome	gradient	can	give	insight	into	the	
degree	of	association	of	an	RNA	with	ribosomes	as	actively	translated	RNAs	are	generally	bound	by	
several	ribosomes	(polysomes)	[190].	To	obtain	the	polysome	profile	of	a	cell,	they	are	treated	with	
cycloheximide,	which	inhibits	translation	and	immobilises	the	ribosome	on	the	RNA,	hence	keeping	
them	attached	to	the	RNA.	Afterwards,	the	cell	lysate	is	layered	on	a	sucrose	gradient	to	separate	
RNAs	according	to	the	number	of	bound	ribosomes. Well-translated	RNAs	have	more	ribosomes	
bound	and	therefore	sediment	in	the	denser	(later)	fractions	of	the	gradient.	However,	there	is	a	
possibility	that	RNAs	which	sediment	in	the	denser	fractions	are	actually	not	bound	to	ribosomes	
but	merely	associate	with	other	protein	complexes.	Therefore,	in	a	second	experiment,	puromycin,	
which	detaches	ribosomes	from	RNAs,	was	added	to	the	cells.	Thus,	if	an	RNA	was	truly	bound	to	
polysomes	it	should	now	sediment	in	the	less	dense	fractions,	while	RNAs	which	were	bound	to	
other	proteins	should	still	sediment	in	the	denser	fractions.	 
In	the	experiment,	Nkx2-5	served	as	a	control	for	a	well-	translated	RNA.	In	normal	
(“cycloheximide-treated”)	HL-1	cells,	virtually	all	Nkx2-5	mRNA	sedimented	in	the	dense-polysome	
fraction	(Fraction	9)	as	expected	for	a	well-translated	mRNA	(Figure	13A).	With	puromycin	
treatment,	Nkx2-5	sedimented	in	Fractions	4-6,	which	suggests	that	Nkx2-5	does	indeed	associate	
with	polysomes	and	is	a	well-translated	mRNA	(Figure	13B).		
Like	Nkx2-5	mRNA,	NkxDS	sedimented	in	the	denser	fractions	(Figure	13A),	although	this	
persisted	after	puromycin	treatment	(Figure	13B),	suggesting	that	NkxDS	may	associate	with	a	non-
polysome	protein	complex	that	also	sediments	in	these	denser	fractions.		
The	majority	of	NkxUS	transcripts	sedimented	in	Fraction	2	in	both	normal-	and	puromycin-
treated	HL-1	cells	(Figure	13A	and	B),	suggesting	that,	consistent	with	their	nuclear	localisation,	the	
majority	of	NkxUS	RNAs	are	not	translated.	There	did	appear	to	be	a	minor	peak	in	Fractions	8-9	in	
both	conditions,	which	suggests	that	NkxUS	may	associate	with	another	non-polysomal	protein	
complex.	There	was	also	a	small	peak	appearing	in	Fractions	4-6	in	puromycin-treated	HL-1,	
indicating	that	a	minority	fraction	of	NkxUS	might	associate	with	polysomes.	However,	the	
puromycin	experiment	was	not	performed	in	replicates	and	thus	the	results	have	to	be	interpreted	
with	caution.		
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In	summary,	the	polysome	profiling	revealed	no	or	very	minimal	ribosome	association	of	
NkxUS.	The	minimal	presence	of	NkxUS	in	denser	polysome	fractions	may	represent	an	association	
of	NkxUS	with	other	ribosomal	associated	RNAs,	much	the	same	way	as	miRNAs	are	also	detected	
in	late	polysome	fractions	although	they	are	not	actually	translated	[191,	192].	Interestingly,	NkxDS	
and	Nkx2-5	behaved	similar	in	the	cycloheximide	but	different	in	the	puromycin	experiment,	which	
suggests	that	NkxDS	potentially	associates	with	a	non-polysomal	protein	complex	and	not	with	
polysomes	even	though	it	contains	the	Nkx2-5	coding	region.		
	
Figure	13	Polysome	gradient	profiling	showed	no	or	little	association	of	NkxUS	and	NkxDS	with	
ribosomes.	A)	Cycloheximide	treated	HL-1	cells,	in	which	the	RNA	is	kept	in	place	with	the	
polysomes,	showed	that	Nkx2-5	and	NkxDS	sediment	in	the	later	polysome	fraction	whereas	NkxUS	
sediments	in	the	early	ones,	indicating	that	NkxUS	does	not	associate	with	polysomes	but	NkxDS	
might.	Nkx2-5	was	as	expected	detected	in	the	late	fractions	as	it	is	a	well	translated	RNA	and	thus	
associates	with	polysomes.	Data	presented	as	mean	±	SD,	n=3	B)	Puromycin	treated	HL-1	cells,	in	
which	the	polysomes	are	detached	from	the	RNA,	showed	that	NkxDS	still	sediments	in	the	late	
fractions,	indicating	that	it	might	associate	with	a	non-polysomal	protein	complex	rather	than	
ribosomes.	Nkx2-5	sediments	as	expected	in	earlier	fractions	compared	to	A)	as	it	was	detached	
from	ribosomes.	NkxUS	still	sedimented	in	the	early	fractions	indicating	that	it	does	not	associate	
with	polysomes.	n=1.	
	
	
2.4.2 Open	reading	frame	analysis	revealed	no	coding	potential	for	the	NkxDS	tail	
and	NkxUS	
As	a	computational	approach,	we	determined	the	likelihood	of	open	reading	frames	(ORFs)	
contained	in	both	transcripts	encoding	proteins	using	freely	available	tools.	ORFs	are	defined	as	a	
stretch	of	codons	containing	no	stop	codon	and	thus	have	the	ability	to	be	translated.	Identification	
of	long	ORFs	may	indicate	protein-coding	potential	as	long	ORFs	are	thought	to	be	unlikely	to	occur	
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by	chance	in	lncRNAs.	ORF	analysis	of	mouse	NkxDS	and	NkxUS	was	performed	using	the	Coding-
Potential	Assessment	Tool	(CPAT),	which	evaluates	characteristic	features	of	coding	RNA	
sequences,	including	maximum	ORF	size,	codon	and	hexamer	usage	bias	as	well	as	dinucleotide	
usage	[193].	Since	the	majority	of	lncRNAs	lack	sequence	conservation,	this	method	is	based	on	an	
alignment-free	approach.	CPAT	calculates	four	features:		
• the	maximum	ORF	length	
• ORF	coverage,	which	is	the	ratio	of	ORF	to	transcript	length	(longer	RNAs	are	expected	to	
have	longer	ORFs	by	chance)	
• Fickett	score,	which	measures	the	combinatorial	effect	of	nucleotide	composition	and	
codon	usage	bias,	hence	to	which	degree	each	base	is	favored	in	one	codon	position	
compared	to	another	[194]	
• hexamer	score,	which	determines	the	relative	degree	of	hexamer	usage	bias	in	a	particular	
sequence	(positive	values	suggests	protein-coding)	
From	these	features	a	coding	probability	is	calculated.	
Analysis	of	NkxDS,	excluding	the	Nkx2-5	mRNA	sequence,	revealed	a	maximum	ORF	length	
of	306	nucleotides,	a	Fickett	score	of	0.6	and	negative	hexamer	score,	resulting	in	low	coding	
probability	(0.09),	indicating	that,	according	to	CPAT,	this	ORF	is	not	protein-coding.	By	comparison,	
when	using	the	Nkx2-5	mRNA	sequence,	we	get	a	Fickett	score	of	1.2,	a	positive	hexamer	score	
(0.5)	and	high	coding	probability	(0.99),	as	expected	for	a	protein-coding	sequence.	Analysis	of	
NkxUS,	revealed	a	maximum	ORF	length	of	294	nucleotides,	a	Fickett	score	of	0.8	and	negative	
hexamer	score	(-0.25),	resulting	in	low	coding	probability	(0.05).	Altogether,	according	to	CPAT,	the	
longest	ORFs	in	NkxUS	and	NkxDS	are	predicted	to	be	non-coding.		
However,	recent	studies	identified	a	novel	class	of	short	regulatory	polypeptides	(less	than	
100	amino	acids	in	length),	termed	micropeptides	[195-197].	Due	to	their	translation	from	small	
ORFs,	this	emerging	class	has	been	missed	in	conventional	genome	annotation.	There	is	increasing	
evidence	that	functionally	important	micropeptides	can	be	hidden	in	transcripts	annotated	as	
lncRNAs	[196,	198-200].	These	micropeptides	were	found	to	be	conserved	over	large	evolutionary	
distances	and	can	thereby	be	discovered	using	phylogenetic	conservation	analysis	[195,	201,	202].	
Based	on	the	idea	that	evolutionary	conservation	indicates	functionality,	a	study	identified	about	
100	small	ORFs	within	annotated	ncRNAs	or	untranslated	mRNA	regions,	which	show	strong	
conservation	and	are	indicated	to	be	translated	when	overlapping	with	ribosome	profiling	data	
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[202].	Once	potential	conserved	small	ORFs	are	detected,	other	techniques	can	help	to	provide	
evidence	for	the	translation	into	micropeptides,	such	as	ribosome	footprinting	and	mass	
spectrometry	[195].	Thus,	many	lncRNAs	might	have	been	mis-annotated	and/or	could	possess	
both	protein-coding	and	non-coding	functions	[97].	Using	CPAT,	several	smaller	ORFs	were	
identified	for	NkxDS	and	NkxUS,	which,	according	to	CPAT,	did	not	have	any	coding	potential.		
We	further	scanned	NkxDS	and	NkxUS	for	potential	ORFs	of	any	length	conserved	across	
multiple	species	using	PhyloCSF,	a	method	which	was	previously	used	to	identify	the	micropeptide	
DWORF		[199,	203].	The	phyloCSF	measures	codon	substitution	frequencies	(CSF)	and	compares	
nucleotide	sequence	alignments	across	multiple	species	to	analyse	the	likelihood	of	representing	a	
protein-coding	region.	If	the	alignment	is	likely	to	be	a	conserved	protein-coding	region	the	
phyloCSF	score	will	be	positive.	PhyloCSF	has	been	integrated	into	the	UCSC	browser	and	revealed	
negative,	non-coding	scores	for	mouse	NkxUS	and	NkxDS,	whereas	clear	positive,	protein-coding	
scores	were	observed	for	the	Nkx2-5	(Figure	14).	Regions	where	no	PhyloCSF	score	was	observed	
indicate	that	PhyloCSF	did	not	have	sufficient	statistical	power	to	calculate	an	accurate	score.		
Taken	together,	the	polysome	profiling	and	coding	potential	analysis	data	along	with	the	
exclusively	nuclear	localisation	suggests	that	both	transcripts	are	unlikely	to	be	translated.	At	this	
point,	no	further	experiments	were	undertaken	to	analyse	whether	any	of	the	smaller	ORFs	in	
NkxUS	or	NkxDS	encode	a	micropeptide.	
	
	
Figure	14	Coding	potential	of	mouse	NkxUS	and	NkxDS.	PhyloCSF	score	plot	for	the	region	
surrounding	Nkx2-5	as	seen	in	the	UCSC	genome	browser,	depicting	in	green	the	plus	(+)	strand	and	
in	red	the	minus	(-)	strand.	PhyloCSF	showed	a	positive	score	for	the	Nkx2-5	exons	and	negative	
scores	for	the	exons	of	NkxUS	and	NkxDS.	NkxUS	and	NkxDS	also	contained	regions	with	no	score,	
indicating	that	the	PhyloCSF	had	not	sufficient	statistical	power	to	calculate	a	meaningful	score.	
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2.5 Conservation	of	NkxUS	and	NkxDS	in	the	human	genome	
2.5.1 	Identification	of	similar	transcripts	in	humans	
To	determine	if	similar	transcripts	are	present	in	humans,	we	investigated	RNA-sequencing	from	
the	Roadmap	Epigenomics	Project	and	Genotype-Tissue	Expression	(GTEx)	data	on	human	heart	
[204,	205].	A	wealth	of	unannotated	transcripts	surrounding	NKX2-5	was	observed	in	these	
datasets	(Figure	15A).	Whilst	a	large	number	of	reads	map	to	the	highly	expressed	Nkx2-5	mRNA	
regions,	lower	abundant	reads	clearly	demarcate	transcripts	both	upstream	and	downstream	of	
NKX2-5	in	human	heart	(Figure	15A).	A	5.1kb	transcript	(BC033632)	has	been	annotated	
downstream	of	NKX2-5,	suggesting	conservation	of	functionality	with	NkxDS	[206].	Furthermore,	a	
scan	of	the	long	intergenic	ncRNA	(lincRNA)	Illumina	human	body	map	revealed	a	heart	specific	and	
spliced	4.4kb	long	transcript	(TCONS_00010558)	located	1.4kb	upstream	of	NKX2-5,	transcribed	
from	the	same	strand	(Figure	15A)	[207].		
	
Figure	15	Similar	transcripts	are	expressed	in	humans.	UCSC	browser	view	of	the	NKX2-5	locus	
showing	the	upstream	and	downstream	identified	transcripts	in	black.	Human	left	ventricle	(LV)	
RNA	sequencing	data,	showing	two	tracks,	in	which	thresholds	have	been	adjusted	to	visualise	
NkxUS	in	the	upper	track	and	Nkx2-5	in	the	lower	track,	and	left	atrial	(LA)	RNA	sequencing	data	
from	the	GTEx	project	is	shown	in	purple.	CAGE	read	counts	are	shown	underneath	the	GTEx	data,	
with	blue	indicating	CAGE	tags	for	the	(-)	strand.	Further,	Illumina	Body	map	RNA	sequencing	data	
is	illustrated	below	the	CAGE	read	counts	track	and	identified	a	heart	specific	lincRNA	upstream	of	
NKX2-5.	
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2.5.2 Human	and	mouse	NkxDS	and	NkxDS	are	not	conserved	on	sequence	level	
Unlike	NKX2-5,	the	sequence	conservation	of	the	NKXDS	alternative	spliced	3’UTR	and	NKXUS	
across	mammalian	species	is	very	low,	consistent	with	previous	findings	that	thousands	of	lncRNAs	
have	a	faster	evolutionary	turnover	and	are	therefore	often	species	specific	and	less	well	conserved	
than	protein-coding	genes	[208].	Pairwise	sequence	alignment	of	human	and	mouse	NkxUS	and	
NkxDS	using	the	freely	available	bioinformatic	tool	EMBOSS	identified	a	sequence	identity	of	30.3%	
and	42%	for	NkxUS	and	NkxDS,	respectively	[209].	Additionally,	mouse	NkxUS	is	expressed	in	the	
plus	direction	whereas	human	NkxUS	is	expressed	in	the	minus	direction	and	sits	much	closer	to	
NKX2-5	(Figure	15A).	NkxDS	did	not	change	position,	however,	seems	to	be	much	shorter	in	
humans	(Figure	15A).	
	
	
2.5.3 	NkxUS	is	conserved	between	mouse	and	human	on	structural	level	
In	contrast	to	sequence	conservation,	many	lncRNAs	were	shown	to	contain	highly	conserved	
secondary	structures,	which	in	turn	might	relate	to	their	function,	highlighting	the	importance	of	
lncRNA	structural	analysis	[143,	210].	Therefore,	structural	alignment	analysis	was	performed	by	Dr.	
Stefan	Seemann	(University	of	Copenhagen,	Denmark)	to	explore	if	common	signals	exists	between	
the	human	and	mouse	transcripts.	Foldalign	was	used	to	make	structural	alignments	of	the	human	
and	mouse	RNA	sequences,	which	were	compared	and	scanned	for	common	structural	domains	to	
determine	conservation	[211,	212].		
Three	highly	conserved	structural	alignments	with	a	p-value	<0.01	were	identified	to	be	
conserved	between	mouse	and	human	NkxUS,	shown	in	red	in	Figure	16A.	The	three	conserved	
alignments	in	human	NkxUS	map	to	the	same	region	in	mouse	NkxUS,	which	is	the	start	of	the	
second	exon	(Figure	16A	and	B).	Listed	in	Table	3	are	the	positions	of	the	alignments	in	human	and	
mouse	NkxUS	as	well	as	the	corresponding	p-values.	
No	significantly	conserved	structural	domains	were	identified	for	NkxDS,	when	excluding	the	
Nkx2-5	mRNA	sequence	(Figure	16C).		
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Figure	16	NkxUS	contains	an	RNA	structure	conserved	between	mice	and	humans.	A)	Location	of	
structural	alignments	for	NkxUS,	showing	mouse	NkxUS	on	the	X-axis	and	human	NkxUS	on	the	Y-
axis.	The	different	color	scheme	indicates	different	p-values:	red	–	p-value	<0.01;	green	–	p-value	
<0.1;	blue	p-value	<1.	B)	Schematic	showing	human	NKXUS	in	the	upper	and	mouse	NkxUS	in	the	
lower	panel.	Human	NKXUS	contains	three	conserved	structural	alignments	(Align1-3),	which	all	
map	to	the	start	of	the	second	exon	of	mouse	NkxUS.	C)	No	conserved	structural	alignments	were	
identified	for	NkxDS.	
	
Table	3	Structural	alignment	positions	
	 Nucleotide	position	 	
Alignment	number	 Mouse	NkxUS	 Human	NKXUS	 P-value	
1	 190-597	 178-588	 0.001	
2	 433-915	 3934-4417	 0.004	
3	 201-640	 2067-2506	 0.009	
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2.5.4 NkxUS	and	NkxDS	are	expressed	in	the	adult	human	heart	
Using	commercially	available	total	RNA	from	human	heart	(Clonetech),	we	validated	expression	of	
human	NkxUS	and	NkxDS.	RT-PCR	results	showed	that	both	transcripts	are	expressed,	with	NkxUS	
being	more	abundant	than	NkxDS	(Figure	17).	Relative	to	Nkx2-5,	NkxUS	and	NkxDS	are	much	more	
lowly	expressed,	as	already	seen	from	the	GTEx	RNA	sequencing	data	(Figure	15)	[205].	This	is	also	
similar	to	what	we	observed	in	the	mouse	data	(Figure	9C).	However,	unlike	in	mouse	whole	heart	
(Figure	9C),	NkxUS	in	human	heart	seems	to	be	more	highly	expressed	than	NkxDS	(Figure	17).	
	
Figure	17	NkxUS	and	NkxDS	are	expressed	in	total	RNA	from	human	heart.	RT-PCR	results	
displayed	in	log10	scale	showed	that	NkxUS	and	NkxDS	are	both	expressed	in	the	human	heart,	
although	much	lower	than	Nkx2-5.	NkxUS	in	human	heart	is	more	abundant	than	NkxDS.	Data	
presented	as	mean	±	SD	from	technical	replicates,	n=1.	
	
	
2.5.5 	NkxUS	and	NkxDS	show	similar	expression	dynamics	to	Nkx2-5	in	
differentiating	human	cardiomyocytes		
We	further	confirmed	expression	of	both	human	transcripts	in	a	differentiation	time	course	of	
human	induced	pluripotent	stem	cells	(iPSC)	into	cardiomyocytes.	The	differentiation	was	
performed	by	Hananeh	Fonoudi	following	a	published	protocol	[213].	RNA	was	extracted	every	fifth	
day	from	day	0	to	day	20	of	differentiation	and	expression	levels	of	Nkx2-5,	NkxDS	and	NkxUS	were	
analysed	using	RT-PCR.	
All	three	transcripts	were	expressed	in	the	time	course	(Figure	18).	Similar	to	the	mEB	time	
course	(Figure	10A),	human	NkxUS	and	NkxDS	transcript	levels	follow	Nkx2-5	expression	in	the	iPSC	
time	course	(Figure	18).	Expression	levels	peak	when	the	cells	start	beating	at	around	day	10,	
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followed	by	a	steep	decrease	from	day	15,	and	levels	continue	to	stay	low	until	day	20	(Figure	18).	
Since	expression	of	NkxUS,	NkxDS	and	Nkx2-5	were	observed	at	the	same	timepoints,	it	is	
reasonable	to	propose	that	the	transcripts	could	function	at	similar	stages	and	perhaps	perform	
related	functions.		
	In	summary,	it	was	confirmed	that	NkxUS	and	NkxDS,	despite	being	only	minimally	
conserved	at	the	sequence	level,	are	expressed	in	human	cardiac	tissue	and	both	transcripts	
showed	similar	expression	dynamics	in	both	human	and	mouse	pluripotent	stem	cell-derived	
cardiac	tissue.	Furthermore,	NkxUS	contains	an	RNA	structure	conserved	between	mice	and	
humans.	
	
	
Figure	18	NkxUS	and	NkxDS	are	expressed	in	human	cardiomyocytes	and	follow	Nkx2-5	
expression	in	a	differentiation	time	course	of	iPSCs	into	cardiomyocytes.	RT-PCR	for	Nkx2-5,	
NkxUS	and	NkxDS	using	RNA	taken	from	different	days	during	the	differentiation.	The	results	are	
presented	relative	to	day	10.	Data	presented	as	mean	±	SD,	n=3.	
	
	
2.5.6 	Human	NkxUS	consists	of	two	exons	
As	seen	from	the	Illumina	body	map	lincRNA	data,	human	NkxUS	seems	to	have	two	exons,	similar	
to	mouse	NkxUS.	To	confirm	the	exon-exon	junction,	we	performed	a	PCR	on	human	heart	cDNA	
using	primers	on	either	site	of	the	exon	junction	(Figure	19).	PCR	products	were	run	on	a	1%	
agarose	gel,	bands	were	excised	from	the	gel	and	after	DNA	extraction	cloned	into	pGEMTeasy.	
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DNA	sequencing	of	several	clones	confirmed	the	junction	with	the	exact	sequence	as	annotated	
from	the	Illumina	body	map	data	(Figure	19).	
	
Figure	19.	Human	NkxUS	consists	of	two	exons.	PCR	across	the	proposed	NkxUS	junction	showing	
in	gray	the	results	from	the	DNA-sequencing.	Red	arrows	indicate	positions	for	the	forward	(F)	and	
reverse	(R)	primers.	Prominent	CAGE	tags	for	the	(+)	strand	(blue)	line	up	with	the	approximate	
start	site	of	Nkx2-5	and	NkxUS.		
	
	
2.5.7 	Evidence	of	human	NkxUS	in	the	literature	
A	recent	study	generated	an	atlas	of	around	28.000	human	lncRNAs	with	their	accurate	start	sites	
[214].	The	study	integrated	CAGE	data	to	obtain	high-confidence	5’ends	of	thousands	of	lncRNAs	
across	major	human	tissues	and	cell-types.	Based	on	the	accurately	mapped	5’ends,	the	authors	
were	able	to	analyse	the	regulatory	regions	and	found	that	lncRNAs	are	more	conserved	than	
previously	thought.	The	study	identified	that	lncRNAs	implicated	in	a	specific	GWAS	traits	are	often	
expressed	in	the	specific	cell-type	or	tissue	relevant	to	the	trait	and	that	these	GWAS	lncRNAs	are	
often	conserved.	The	authors	generated	an	interactive	browser,	the	FANTOM	CAT	browser	
(http://fantom.gsc.riken.jp/cat/v1/#/)	allowing	viewing	of	the	genomic	location	of	identified	
lncRNA	genes.	Additionally,	the	study	integrated	data	of	gene	expression,	conservational	and	
genetic	studies.	In	total,	the	results	suggest	that	19,175	lncRNA	may	be	functional,	almost	as	many	
as	human	protein	coding	genes.		
Searching	for	NkxUS	and	NkxDS	only	revealed	annotation	for	NkxUS.	In	the	atlas,	NkxUS	is	described	
as	an	intergenic	lncRNA,	termed	CATG00000082047.1.	The	accurate	5’end	of	NkxUS	as	annotated	
by	FANTOM	CAT	differs	by	58bp	from	that	found	in	the	Illumina	body	map	with	FANTOM	CAT	
mapping	the	start	site	of	NkxUS	to	the	exact	position	of	the	strongest	and	most	proximal	CAGE	
signal.	The	study	also	searched	for	dynamically	expressed	lncRNAs.	25	sets	of	FANTOM5	
experiments,	which	were	either	differentiation	time	courses	or	paired	control	and	treatment	
experiments,	were	analysed	for	differential	expression	[215,	216].	When	a	lncRNA	was	significantly	
differentially	expressed	(FDR	<	0.05)	in	at	least	one	comparison,	it	was	defined	as	dynamically	
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regulated.	NkxUS	was	found	to	be	dynamically	regulated	during	differentiation	of	human	
embryonic	stem	cells	(ESC)	into	cardiomyocytes.	Compared	to	day	0,	NkxUS	was	significant	
upregulated	from	day	5	onwards	(FDR=	9.68E-23),	similar	to	what	we	observed	in	the	iPSC	time	
course	(Figure	18).	The	study	also	analysed	coding	potential	based	on	several	resources	(CPAT,	
RNACode,	phyloCSF,	RiboSeq)	and	found	a	maximal	ORF	length	of	258,	but	altogether	no	coding	
potential.		
Taken	together,	this	study	showed	similar	results	to	our	study	for	NkxUS,	in	that	it	is	
dynamically	expressed	during	cardiomyocyte	differentiation.	In	addition,	the	study	also	predicted	
human	NkxUS	to	be	non-coding.	
	
	
2.6 Relevance	in	disease	
2.6.1 Human	NKXUS	contains	a	GWAS	SNP	associated	with	an	increased	heart	rate	
As	mentioned	in	the	introduction,	many	trait-	and	disease-associated	SNPs	were	found	to	map	to	
intergenic	regions	[161].	Interestingly,	we	identified	a	GWAS	SNP	(rs6882776),	associated	with	an	
increased	heart	rate	and	increased	risk	of	atrial	fibrillation,	that	lies	within	one	of	the	conserved	
RNA	structures	of	human	NkxUS	(Figure	20)	[217].	The	SNP	overlaps	with	alignment	number	2	of	
the	structural	conservation	analysis	(Figure	16A,	B	and	Table	3),	which	lies	at	the	end	of	the	second	
exon	(Figure	20).	An	elevated	resting	heart	rate	is	associated	with	an	increased	risk	for	
cardiovascular	diseases	including	heart	failure,	hypertension	and	arrhythmia	as	well	as	all-cause	
mortality	[218-220].		
As	per	the	dbSNP	database,	rs6882776	is	a	common	SNP	in	the	total	population	with	58.2%	
of	individuals	having	a	G	allele	that	elevates	resting	heart	rate,	compared	to	individuals	with	an	A	at	
this	position.	In	the	GWAS	study,	~95%	of	the	participants	were	of	European	ancestry	with	
rs6882776	showing	an	effect	allele	frequency	(EAF)	of	68%,	meaning	that	68%	of	participants	have	
the	G	allele	(Table	4).	The	SNP	was	associated	with	an	increase	in	resting	heart	rate	by	0.301	beats	
per	minute	(bpm).	Whist	this	overall	effect	might	be	small,	the	same	study	showed	that	the	heart	
rate	of	individuals	harboring	a	combination	of	heart	rate	increasing	alleles	increased	by	up	to	
4.1bpm,	which	was	previously	shown	to	be	clinically	relevant	[217,	221].		
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The	heart	rate	increasing	allele	at	this	locus	was	further	associated	with	prolonged	PR	
duration	(+1.29ms)	and	reduced	QT	duration	(-0.49ms),	independent	of	heart	rate,	as	well	as	a	
reduced	QRS	duration	(-0.27ms)	(Table	4)	[217].		
In	addition,	two	independent	GWAS	studies	on	mostly	individuals	with	European	ancestry	
associated	this	SNP	with	an	increased	risk	of	atrial	fibrillation	with	an	odds	ratio	(OR)	of	1.11	and	
1.06	(P-value	=	4.41x10-8	and	3x10-14)	(Table	4)	[217,	222].	
	
Figure	20	A	GWAS	SNP	lies	within	the	conserved	structural	alignment	of	human	NkxUS.	GTEx	data	
of	human	LV	RNA	(purple)	showing	human	NkxUS	and	illustrating	the	position	of	the	GWAS	SNP,	
rs6882776,	in	dark	green	and	the	conserved	structure	in	light	green.	
	
	
Table	4	GWAS	study	details	for	rs6882776.	EAF=effect	allele	frequency	based	on	meta-analysis	of	
stages	1	and	2	combined,	β=	effect	size,	SE=	standard	error,	OR=odds	ratio,	CI=confidence	interval.	
		 Alelles	 		 Per-allele	change	in	heart	rate	 Stage	1	and	2	
SNP	 Effect		 Other	 EAF	 β		(bpm)	 SE		 #	people	 P-value	
rs6882776	 G	 A	 0.68	 0.301	 0.051	 158.807	 2.29	x	10-12	
QRS	duration	 QT	duration	
#	people	 β	(ms)		 SE	(ms)	 P-value	 #	people	 β	(ms)		 SE	(ms)	 P-value	
30.877	 -0.27	 0.09	 1.87	×	10−2		 60.768	 -0.49	 0.12	 2.27	×	10−5		
PR	duration	 Atrial	fibrillation	 	  
  
#	people	 β	(ms)		 SE	(ms)	 P-value	 OR	(95%	CI)	 P-value	 	  
18.484	 1.29	 0.27	 1.46	×	10−6		 1.110	(1.07–	1.15)		1.06	(1.05-1.08)	
4.41	×	10−6	
3	x	10	-14		 	  
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2.6.2 The	GWAS	SNP	is	predicted	to	totally	disrupt	the	conserved	secondary	
structure	of	NkxUS	
To	examined	if	the	SNP	has	an	impact	the	conserved	RNA	structure,	an	in	silico	analysis	using	
RNAsnp	was	performed	by	Dr.	Stefan	Seemann	(University	of	Copenhagen,	Denmark)	[223].	
RNAsnp	predicts	local	RNA	secondary	structural	changes	due	to	SNPs	based	on	base	pairing	
probabilities	[223].	The	results	generated	by	RNAsnp	can	be	visualised	in	a	dot	plot,	in	which	a	dot	
indicates	base	pairing	at	this	position	[223].	The	larger	the	dot,	the	higher	the	base	pairing	
probability	[223].	
Analysis	of	the	second	exon	of	human	NkxUS,	which	is	2393bp	in	length,	with	and	without	
the	SNP	using	RNAsnp	predicted	a	local	structure	change	in	the	region	1904	to	1964,	highlighted	in	
gray	background	(Figure	21A).	The	predicted	secondary	structural	change	maps	to	the	region	
surrounding	the	SNP,	which	lies	at	position	1934	(Figure	21B)	and	thus	also	affects	the	conserved	
RNA	structure,	which	spans	the	region	from	1902	to	2385.	Looking	at	the	dot	plot	of	the	magnified	
view	of	the	highlighted	gray	region	of	Figure	21A,	showed	a	clear	difference	in	base	pairing	
positions	for	wildtype	and	mutant	NkxUS	(Figure	21B).	Regions	with	high	base	pairing	probability	
for	wildtype	NkxUS	showed	in	some	regions	none	at	all	for	mutant	NkxUS,	indicating	a	total	
disruption	of	the	conserved	RNA	structure.	This	disruption	becomes	obvious	when	displaying	the	
minimum	free	energy	structures	in	a	planar	graphic	for	wildtype	(left)	and	mutant	NkxUS	(right)	
(Figure	21C).	The	colored	region	in	Figure	14C	indicates	the	local	structure	change	and	the	position	
of	the	SNP	is	highlighted	with	arrows	at	position	101.		
Taken	together,	the	disruptive	effect	of	the	GWAS	SNP	on	the	predicted	conserved	RNA	
structure	of	NkxUS	may	potentially	associate	this	structure	to	the	SNP	associated	phenotype.		
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Figure	21	The	SNP	totally	disrupts	the	conserved	RNA	structure	in	human	NkxUS.	A)	RNAsnp	
analysis	comparing	the	secondary	structure	of	the	second	exon	of	human	wildtype	(red)	and	
mutant	(rs6882776,	green)	NkxUS	revealed	a	structural	change	in	the	region	1904	to	1964,	
highlighted	in	dark	gray.	B)	Magnified	view	of	the	highlighted	area	in	A)	showing	the	local	structural	
change	around	the	SNP	position	(orange).	C)	Displayed	is	the	secondary	structure	for	the	second	
exon	of	human	NkxUS	in	a	planar	graphic	with	wildtype	on	the	left	and	mutant	on	the	right.	The	
colored	region	highlights	the	local	structural	change	around	the	SNP	and	the	arrows	indicate	the	
position	of	the	SNP.	
	
	
2.6.3 Haplotype	analysis	of	rs6882776	in	Europeans	identified	five	linked	SNPs	
GWAS	studies	are	usually	run	on	commercial	SNParrays,	which	use	only	one	SNP	per	haplotype	
(region	in	linkage	disequilibrium	(LD)),	termed	lead	SNP.	Therefore,	they	may	not	identify	the	causal	
variant,	as	any	SNP	in	high	LD	with	the	lead	SNP	could	be	the	disease-causing	SNP,	and	additional	
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studies	are	generally	required	to	identify	the	causal	variant.	Since	the	NKXUS	SNP	was	identified	in	
a	study	of	individuals	with	mostly	European	ancestry,	we	performed	a	haplotype	analysis	in	
Europeans	using	LDlink	(https://ldlink.nci.nih.gov/)	[224].	SNPs	with	a	squared	coefficient	of	
correlation	(r2)	threshold	of	0.8	qualify	as	linked,	meaning	that	during	meiotic	recombination,	these	
SNPs	are	almost	never	separated	and	most	likely	inherited	together.	Five	SNPs,	all	within	a	~16kb	
radius	of	NKXUS,	were	identified	to	be	in	high	LD	with	rs6882776	and	therefore	linked	(Figure	22A	
and	B).	Three	of	the	five	SNP’s	lie	within	NkxUS’s	first	exon,	one	lies	in	an	intergenic	region	and	one	
in	the	NKX2-5	coding	region	(Figure	22A).	Looking	at	heart	RNA	Sequencing	data	as	well	as	histone	
marks,	no	expression	or	methylation	marks	were	found	at	the	position	of	the	intergenic	SNP,	
suggesting	that	the	chance	of	this	being	the	causative	SNP	is	very	low.	The	NKX2-5	SNP,	rs2277923,	
sits	at	amino	acid	position	21	of	NKX2-5,	the	last	amino	acid	of	the	tinman	domain,	which	is	one	of	
the	six	domains	conserved	between	members	of	the	NK2	family	of	proteins	[225].	However,	the	
SNP	does	not	cause	a	change	in	the	amino	acid	(GAA	->	GAG),	thus	is	a	synonymous	SNP.	Further,	
the	codon	usage	changed	only	slightly	from	a	value	of	0.4	to	0.58,	suggesting	that	this	SNP	most	
likely	does	not	affect	NKX2-5	function.	However,	previous	studies	showed	synonymous	mutations	
can	still	affect	protein	function	by	affecting	miRNA	or	transcription	factor	binding	sites,	changing	
the	secondary	structure	of	mRNAs	or	disrupting	splicing,	which	we	did	not	further	follow	up	on	
[226].	The	SNPs	within	the	first	exon	of	NkxUS	do	not	overlap	any	of	the	structural	conserved	
alignments	thus	questioning	their	relevance.	
Interestingly,	another	recent	GWAS	study	of	>	1.000.000	Europeans	associated	one	of	these	
linked	SNPs	(rs6891790-G)	with	atrial	fibrillation	(P-value	=	1	x	10-14,	OR=	1.07)		[227];	thus,	in	total,	
three	independent	GWAS	studies	associated	NkxUS	with	atrial	fibrillation.	
In	Europeans,	there	are	three	possible	haplotypes	an	individual	can	carry	in	the	LD	region	of	
the	NKXUS	SNP	with	the	most	common	having	a	frequency	of	about	70%	(Figure	22C),	which	closely	
matches	the	EAF	of	the	initial	GWAS	study.	
In	summary,	the	likelihood	of	rs6882776	being	the	causal	variant	is	quite	high	since	we	
identified	that	it	lies	within	and	is	predicted	to	totally	disrupt	the	conserved	RNA	structure	of	
NkxUS,	whereas	the	other	linked	SNPs	are	not	within	conserved	alignments,	are	synonymous	
mutations	or	lie	in	regions	with	seemingly	no	cardiac	expression.		
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Figure	22	Haplotype	analysis	of	rs6882776	in	Europeans.	A)	Genomic	location	of	the	SNPs	in	LD	
with	rs6882776.	B)	Table	of	linked	SNPs	showing	their	distance	in	bp	to	rs6882776,	the	r2	value,	
functional	class	and	gene	location.	C)	European	specific	haplotype	frequencies	of	all	haplotypes	
observed	for	the	linked	SNPs.	
	
	
2.7 Functional	analysis	of	NkxUS	in	vitro	
Based	on	the	association	with	the	GWAS	SNP,	as	well	as	the	conserved	structure,	we	henceforth	
concentrated	on	analysing	NkxUS.	To	identify	its	function,	a	series	of	functional	assessments	were	
performed	to	determine	the	effect	of	partial	loss	of	NkxUS	at	the	level	of	the	transcriptome.	
Further	to	this,	NkxUS	DNA-binding	targets	were	investigated,	as	well	as	protein	interacting	
partners.	All	three	experiments	were	performed	using	HL-1	cells.	
	
	
2.7.1 Knockdown	of	NkxUS	in	HL-1	cells	results	in	mostly	upregulated	genes	
To	generate	a	general	hypothesis	about	NkxUS	function,	we	conducted	a	knockdown	experiment	in	
HL-1	cells	followed	by	RNA	sequencing	to	analyse	changes	upon	downregulation	of	NkxUS.	We	
targeted	the	transcript	using	locked	nucleotide	acid	(LNA)	GapmeR	antisense	oligonucleotides	
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(ASO)	(Qiagen).	LNA	GapmeRs	are	single	stranded	ASOs	consisting	of	LNA	oligonucleotides	in	the	
flanking	region	and	DNA	oligonucleotides,	free	from	LNAs,	in	the	middle	[228].	LNA	
oligonucleotides	are	“locked”	by	a	methylene	bridge	in	the	ideal	conformation	for	binding	resulting	
in	a	higher	binding	affinity,	increased	target	specificity	and	increased	stability	of	the	formed	
RNA:DNA	complex	[228].	Upon	binding	to	the	target,	the	LNA-free	DNA	center	activates	RNAseH,	
which	in	turn	cleaves	the	RNA	resulting	in	degradation	of	the	transcript	[228].	LNA	GapmeR	ASOs	
were	designed	using	Exiqon’s	GapmeR	Design	Algorithm	to	identify	the	most	potent	and	target	
specific	ASOs	with	minimal	off-target	effects.	Initially,	three	different	ASOs	(ASO1-3)	targeting	
NkxUS	at	different	positions	and	one	control	ASO	(Control,	Qiagen),	which	is	a	commercially	
available	and	validated	negative	control,	were	purchased	in	order	to	perform	the	experiment	once	
with	the	three	different	ASOs	resembling	biological	replicates.	However,	ASO3	was	excluded	during	
the	optimisation	process	due	to	insufficient	NkxUS	knockdown.	To	increase	specificity	of	the	
experiment,	we	chose	to	knockdown	NkxUS	with	the	two	remaining	ASOs	(ASO1	and	ASO2)	(Figure	
23A),	which	then	allowed	us	to	analyse	for	targets	which	are	deregulated	with	both	ASOs	to	
diminish	potential	off-target	effects	specific	to	one	set	of	ASO.	
HL-1	cells	were	transfected	with	either	ASO1,	ASO2	or	Control.	One	day	after	transfection,	
the	cells	were	harvested	and	tested	for	knockdown	efficiency	via	RT-PCR.	The	most	successful	
knockdown	achieved	was	a	~80%	reduced	NkxUS	expression	with	ASO1	and	ASO2	when	analysed	
relative	to	cells	grown	in	transfection	medium	(Lipofectamine)	only	(Figure	23A).	Therefore,	
biological	replicates	showing	each	~70-80%	knockdown	of	NkxUS	were	sequenced	using	the	
Illumina	HiSeq	2500	platform	and	analysed	for	differentially	expressed	genes	using	DESeq2	(Figure	
23A)	[229].	In	order	to	identify	dysregulated	genes	in	common	between	ASO1	and	ASO2,	we	tested	
for	differentially	expressed	genes	by	evaluating	ASO1	and	ASO2	combined	against	Control.		
Clustering	of	the	three	conditions	and	replicates	was	visualised	on	a	principal	component	
analysis	(PCA)	plot	(Figure	23B).	The	technical	replicates	clustered	together	and	ASO	and	Control	
samples	were	separated	on	the	first	component	axis	(Figure	23B),	indicating	that	the	highest	
variance	is	observed	between	the	two	conditions	(ASOs	versus	Control)	rather	than	between	the	
biological	replicates.	ASO1	and	ASO2	are	separated	on	the	second	component	axis,	indicating	
variance,	potentially	from	off-target	effects	of	the	individual	ASOs	(Figure	23B).	However,	since	we	
analyse	the	combined	effect	of	both	ASOs	against	Control,	noise	from	off-targets	should	be	filtered	
out	in	the	differentially	expressed	gene	list,	since	only	targets	showing	a	similar	fold	change	
direction	(up-	or	downregulated)	in	both	ASOs	are	expected	to	reach	significance.	
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Differential	gene	expression	analysis	using	DESeq2	with	a	false	discovery	rate	(FDR)	<0.05	
cut-off	resulted	in	1226	upregulated	and	570	downregulated	genes	in	ASO1	and	ASO2	samples	
when	computed	against	Control	(Figure	23C).	A	heatmap	further	illustrates	that	comparatively	
more	genes	are	upregulated	for	both	ASO1	and	ASO2	(red)	(Figure	23D).	In	the	heatmap,	genes	are	
grouped	together	based	on	their	expression	pattern.	A	dendrogram	is	added	to	the	left	side	and	the	
top	according	to	cluster	analysis,	highlighting	that	both	ASOs	behave	similarly	and	are	distinct	from	
the	Control	(Figure	23D).	Furthermore,	several	clusters	are	observed	in	the	heatmap,	as	seen	from	
the	dendrogram	on	the	left	side,	suggesting	that	several	different	pathways	or	processes	are	
affected	by	the	knockdown	of	NkxUS	(Figure	23D).		
The	gene	list	generated	using	DESeq2	with	a	FDR	<0.05	and	log2-fold	change	(logFC)	cut-off	
of	±0.5	included	538	genes	of	which	432	are	upregulated	and	106	are	downregulated.	This	list	is	
given	in	Appendix	II	and	was	used	for	further	analysis.	The	relative	changes	in	transcript	expression	
levels	were	relatively	low,	ranging	from	a	logFC	of	-1.974	for	NkxUS	to	a	logFC	of	+2.452	for	Rnf31	
(Ring	Finger	Protein	31).	
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Figure	23	Knockdown	of	NkxUS	followed	by	RNA	sequencing	results	in	mostly	upregulated	genes.	
A)	ASO1	and	ASO2	target	the	second	exon	of	NkxUS.	RT-PCR	showing	~80%	knockdown	of	NkxUS	
using	ASO1	and	ASO2	relative	to	cells	with	Lipofectamine	only.	ASO	Control	did	not	have	an	effect	
on	NkxUS	expression.	Data	presented	as	mean	±	SD,	n=3,	*P<0.05,	unpaired	two-tailed	t-test.	B)	
PCA	plot	showing	that	ASO1	and	ASO2	separate	from	ASO	Control	on	the	first	principal	component	
axis.	C)	Differential	expression	analysis	resulted	in	mostly	upregulated	transcripts.	Here	showing	a	
scatter	plot	of	log2	fold	changes	(on	the	y-axis)	versus	the	mean	of	normalised	counts	(on	the	x-
axis).	Significant	differentially	expressed	transcripts	are	indicated	with	red	dots.	D)	Heatmap	
showing	the	global	differences	between	ASOs	and	Control	identified	using	DeSeq2.	The	scaled	
expression	of	each	transcript,	denoted	as	the	row	Z-score,	is	plotted	with	red	representing	higher	
expression	and	blue	representing	lower	expression.	a,	b	and	c	denote	biological	replicates.	
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2.7.1.1 Transcripts	involved	in	cardiac	contraction	are	deregulated	upon	reduced	
expression	of	NkxUS	
In	order	to	interpret	the	gene	expression	data	and	determine	functional	association	of	the	
differentially	expressed	genes,	a	gene	set	enrichment	analysis	was	performed	using	both	network	
analysis	and	gene	ontology	(GO)	tools	[230].	This	enrichment	analysis	is	based	on	the	function	of	
annotated	genes	and	is	a	useful	tool	to	investigate	if	the	differentially	expressed	genes	are	
associated	with	a	common	biological	process	or	pathway.	In	our	analysis,	a	background	list	
consisting	of	all	the	genes	expressed	in	the	Control	dataset	was	used.	Using	the	GO	consortium	tool	
to	search	for	enriched	biological	processes	(BP)	did	not	reveal	any	significantly	enriched	terms	for	
the	whole	dataset,	nor	when	split	into	down-	and	upregulated	genes	[231].	Therefore,	we	searched	
for	networks	within	the	differentially	expressed	genes	using	protein-protein	association	
connections	obtained	from	the	STRING	data-base	(STRINGdb)	[232],	after	filtering	for	high	
confidence	connections.	We	used	the	STRINGdb	R	package	to	retrieve	the	network	connections,	
which	were	used	to	search	for	enriched	GO	terms	[232].	Running	STRINGdb	with	the	538	genes	
significantly	differentially	expressed	(logFC	>	±0.5,	FDR	<	0.05)	between	both	ASOs	and	Control	
resulted	in	a	total	of	125	connected	genes,	of	which	102	genes	were	upregulated	and	23	
downregulated.	The	complete	list	of	all	differentially	expressed	genes	included	in	the	STRINGdb	
network	is	given	in	Appendix	III.		
The	upregulated	STRING	network	genes	were	enriched	for	several	GO	BP	terms	involved	in	
cardiac	contraction	and	conduction	(Figure	24A).	The	most	significant	terms	(FDR	<0.05)	included	
regulation	of	transport,	signaling,	cell	communication	and	regulation	of	localisation,	followed	by	
more	specific	terms	like	action	potential,	regulation	of	vesicle-mediated	transport	and	neuron	
differentiation	and,	interestingly,	regulation	of	cardiac	action	potential	and	cardiac	muscle	
contraction	(Figure	24A).		
The	downregulated	STRING	network	genes	were	significantly	(FDR	<	0.05)	enriched	for	
terms	involved	in	cell	communication	and	signaling,	as	well	as	regulation	of	developmental	
processes,	more	specifically	blood	vessel	and	glomerulus	development	as	well	as	cardiac	cell	fate	
commitment	(Figure	24B).	Genes	included	in	the	cardiac	cell	fate	term	are	Tbx3	(T-box	transcription	
factor	TBX3),	which	is	involved	in	valve	and	sinoatrial	node	development,	and	Wt1	(Wilms	tumor	
protein	homolog),	which	is	involved	in	epicardial	development	[17,	233,	234].	
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Based	on	the	GWAS	SNP	being	linked	to	increased	heart	rate	and	higher	risk	of	atrial	
fibrillation,	we	focused	on	the	cardiac	conduction	and	contraction	related	terms.	Genes	included	in	
these	terms	were	mostly	ion	channels	including	potassium	(Kcnj3,	Kcnj5,	Hcn4)	and	calcium	
(Cacna1c,	Cacna1d,	Ryr2)	channels	as	well	as	regulators	of	signal	transduction	(Table	5),	all	of	which	
also	contributed	to	the	most	significant	term,	regulation	of	transport.		
Analysis	for	enriched	Kyoto	Encyclopedia	of	Genes	and	Genomes	(KEGG)	pathways	did	not	
result	in	any	enriched	terms	for	either	down-	or	up-regulated	STRING	network	gene	list.		
To	validate	the	RNA	sequencing	results,	we	used	ASO1,	ASO2	and	a	new	Control	ASO	
(Control-2).	Control-2	was	used	to	rule	out	possible	off-target	effects	caused	by	a	single	Control	
ASO.	We	performed	independent	knockdown	experiments	and	analysed	a	subset	of	deregulated	
genes	involved	in	heart	development	and	cardiac	conduction	using	RT-PCR.	Analysis	of	Nkx2-5,	
NkxDS,	NkxUS,	Cacna1c,	Cacna1d,	Hcn4,	Ryr2,	Pde3a,	Pde5b,	Kcnj3	and	Notch1	resulted	in	an	
upregulation	of	all	transcripts,	verifying	the	transcriptome	data	(Figure	24C).		
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Figure	24	Knockdown	of	NkxUS	results	in	upregulation	of	genes	involved	in	cardiac	contraction.	A-
B)	Summary	of	the	top	20	most	significant	GO	terms	for	BP	for	the	upregulated	(A)	and	
downregulated	(B)	STRINGdb	identified	genes	showing	associated	FDRs	in	a	–log10	scale.	C)	RT-PCR	
on	selected	differentially	expressed	transcripts	with	ASO1	and	ASO2	and	a	new	ASO	Control	
(Control-2)	confirmed	the	RNA	sequencing	results.	Data	presented	as	mean	±	SD,	*P<0.05,	unpaired	
two-tailed	t-test,	n=4.	
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Table	5	Genes	included	in	cardiac	conduction	and	contraction	terms	(logFC	>	±0.5,	FDR	<	0.05)	
Symbol	 logFC	 FDR	 Description	
Pde5a	 1.62	 5.67E-19	 Phosphodiesterase	5A	
Kcnj3	 1.17	 5.14E-15	 G	protein-activated	inward	rectifier	potassium	channel	
Dmd	 0.54	 4.55E-07	 Dystrophin	
Cacna1c	 0.79	 2.39E-06	 Voltage-dependent	L-type	calcium	channel	subunit	alpha-1C	
Cav1	 0.57	 6.19E-06	 Caveolin	1	
Ryr2	 0.76	 5.55E-05	 Ryanodine	receptor	2	
Cacna1d	 0.59	 1.07E-04	 Voltage-dependent	L-type	calcium	channel	subunit	alpha-1D	
Kcnj5	 0.31	 1.11E-02	 G	protein-activated	inward	rectifier	potassium	channel	4	
Hcn4	 0.39	 4.98E-02	 Hyperpolarization	Activated	Cyclic	Nucleotide	Gated	Potassium	
Channel	4	
	
	
2.7.1.2 Discovery	of	a	novel	alternative	first	exon	of	mouse	NkxUS	
Looking	at	the	RNA	sequencing	data	with	the	Integrative	genome	browser	(IGV),	we	observed	a	
possible	splice	junction	to	a	further	upstream	exon	from	the	second	exon	of	mouse	NkxUS	(Figure	
25A).	Subsequently,	we	performed	a	PCR	on	mouse	heart	cDNA	across	the	junction	using	a	forward	
primer	located	within	the	approximate	location	of	the	potential	exon	and	the	reverse	primer	within	
the	start	of	the	second	exon	(Figure	25B).	The	results	revealed	that	there	is	indeed	an	alternative	
first	exon	spliced	to	the	second	exon	of	NkxUS	(Figure	25B).	Further,	5’RACE	using	mouse	heart	
cDNA	identified	the	same	splice	junction	and	the	potential	start	of	this	exon,	indicating	that	NkxUS	
has	two	alternative	first	exons	(Figure	25C).	Therefore,	we	termed	NkxUS	containing	the	earlier	
identified	shorter	exon	NkxUS-1	and	NkxUS	containing	the	further	upstream	first	exon	NkxUS-2.	
From	the	ENCODE	heart	RNA	sequencing	data,	the	first	exon	of	NkxUS-1	was	observed	to	be	more	
lowly	expressed	compared	to	the	one	of	NkxUS-2,	suggesting	that	NkxUS-2	is	the	predominant	
isoform	(Figure	25C).	
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Figure	25	Identification	of	an	additional	further	upstream	first	exon	of	mouse	NkxUS.	A)	IGV	
image	of	the	ASO	Control	RNA	sequencing	results	showing	the	mapped	reads	to	the	NkxUS	and	
Nkx2-5	region	showing	in	purple	reads	belonging	to	the	plus	strand	and	in	red	reads	mapping	to	the	
minus	strand.	B)	PCR	using	mouse	heart	cDNA	across	the	potential	junction	with	the	reverse	primer	
(R,	red	arrow)	close	to	the	start	of	the	second	exon	and	the	forward	primer	(F,	red	arrow)	~4kb	
upstream	showed	that	NkxUS	has	an	additionally	first	exon	which	is	spliced	directly	to	the	second	
exon;	n=4.C)	5’RACE	on	mouse	heart	RNA	with	a	gene	specific	reverse	primer	(R,	red	arrow)	close	to	
the	start	of	the	second	exon	also	identified	the	further	upstream	first	exon	of	NkxUS.	Here	showing	
the	results	of	DNA	sequencing	of	the	5’RACE	product;	n=4.	
	
	
2.7.2 Identification	of	DNA	and	protein	interacting	partner	of	NkxUS	
RNA	can	interact	with	DNA,	RNA	or	proteins.	To	analyse	if	NkxUS	binds	to	certain	chromatin	regions	
genome-wide	or	interacts	with	a	specific	set	of	proteins,	which	would	in	turn	give	additional	insight	
into	its	related	function,	we	performed	chromatin	isolation	by	RNA	purification	(ChIRP)	[235].	A	
method	established	by	the	Howard	Chang	group	utilising	tiling	antisense	oligonucleotides	(oligos)	
to	capture	the	target	RNA	along	with	its	bound	DNA,	RNA	or	protein	partners	[235,	236].	The	
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approach	uses	48	biotinylated	complementary	oligos,	which	are	approximately	20	nucleotides	long	
and	cover	the	entire	RNA,	excluding	repetitive	regions	and	regions	which	are	complementary	to	
other	parts	of	the	genome	(Figure	26A).	The	tiling	approach	makes	the	method	feasible	for	any	RNA	
without	prior	knowledge	of	the	secondary	structure.	To	improve	signal	accuracy,	the	oligos	were	
ranked	according	to	their	location	along	NkxUS	and	then	divided	into	two	pools.	All	the	even	
numbered	oligos	were	grouped	together	as	the	“EVEN”	probe	set	and	the	odd	numbered	oligos	as	
the	“ODD”	probe	set	(Figure	26A).	As	a	control	for	unspecific	binding	to	oligos	and	beads,	oligos	
against	LacZ	mRNA,	which	is	not	expressed	in	mammalian	cells,	were	used.	The	key	to	specificity	is	
the	split	of	the	oligo	probe	sets.	If	a	signal	is	NkxUS	specific,	it	should	appear	in	EVEN	and	ODD,	but	
not	in	the	LacZ	samples.		
The	efficiency	and	specificity	of	NkxUS	capture	can	be	measured	after	pull-down	by	RT-PCR,	
where	EVEN	and	ODD	samples	should	be	enriched	specifically	for	NkxUS	and	no	other	transcripts.	
In	Figure	26B,	a	gel	of	the	RT-PCR	products	is	illustrated	showing	in	the	ODD	and	EVEN	samples	
enrichment	for	NkxUS	and	no	enrichment	for	other	highly	expressed	genes	such	as	beta-Actin	and	
Nkx2-5,	suggesting	that	the	probes	are	specific	and	captured	NkxUS	efficiently.	In	contrast,	the	
negative	controls,	LacZ	and	NTC	(non-template	control),	showed	no	strong	expression	for	any	of	the	
analysed	transcripts	(Figure	26B).	Additionally,	the	positive	controls,	input	and	mouse	heart	cDNA,	
showed	high	levels	of	expression	of	all	tested	transcripts	(NkxUS,	beta-Actin,	Nkx2-5)	(Figure	26B).	
Some	minor	unspecific	bands	were	observed	in	the	gel,	which	most	likely	are	due	to	unspecific	
amplification	seen	after	40	cycles	of	RT-PCR.	
In	order	to	identify	possible	chromatin	interactions,	DNA	sequencing	is	performed	after	
successful	enrichment	of	the	RNA.	RNA	sequencing	is	performed	to	identify	RNA	targets	and	mass	
spectrometry	to	identify	protein	interacting	partner.	In	our	study,	we	were	interested	in	discovering	
potential	DNA-binding	sites	and	protein	interacting	partners	of	NkxUS.	
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Figure	26	ChIRP	successfully	captures	NkxUS.	A)	Location	of	the	EVEN	(green)	and	ODD	(blue)	
probes	tiling	along	NkxUS	not	overlapping	repeat	regions.	B)	Gel	following	RT-PCR	after	NkxUS	pull-
down	of	one	replicate	showing	specific	enrichment	for	NkxUS	with	EVEN	and	ODD	probes	but	not	
Nkx2-5	or	beta-Actin.	LacZ	and	NTC	(non	template	control)	do	not	show	specific	retrieval	of	any	of	
the	tested	transcripts,	whereas	input	and	heart	cDNA	showed	expression	of	all	three	transcripts.	
	
	
2.7.3 NkxUS	shows	limited	association	with	genomic	DNA	
Several	nuclear	lncRNAs	were	shown	to	associate	with	chromatin	and	influence	chromatin	state	
and	thus	transcriptional	activity	through	association	with	chromatin	modulating	factors	[112,	177,	
237-239].	
Initially,	the	DNA	ChIRP	was	performed	with	five	biological	replicates,	which	all	showed	
enrichment	for	NkxUS	after	capture.	NkxUS	ChIRP	enriched	DNA	samples	were	sequenced	on	the	
Illumina	Hi-Seq	2500	and	peak	enrichment	analysis	using	the	software	MACS	was	performed	by	
Thomas	Kavanagh	(Garvan	medical	institute,	Australia)	[240].	Three	replicates	had	to	be	excluded	
either	due	to	low	DNA	library	yield	or	low	read/peak	counts	after	DNA	sequencing.	Altogether,	we	
analysed	two	DNA	ChIRP	replicates	(EVEN2/ODD2	and	EVEN3/ODD3)	which	showed	10-20%	yield	
for	NkxUS	following	capture	(Figure	27A).	Yield	is	defined	as	the	amount	of	NkxUS	retrieved	using	
ChIRP	compared	to	an	input	sample,	which	was	taken	before	probe	hybridisation.	The	input	sample	
was	further	used	as	a	background	to	compute	peak	enrichment	over	background.	When	looking	at	
the	shared	peaks	between	EVEN	and	ODD,	excluding	peaks	detected	by	LacZ	probes,	of	individual	
replicates,	59	and	23	high	confidence	DNA-binding	targets	for	EVEN2/ODD2	and	EVEN3/ODD3,	
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respectively,	were	identified	(Figure	27B).	Overlapping	these	two	replicates,	resulted	in	11	shared	
peaks	(Figure	27B).	Nine	out	of	those	11	peaks	mapped	the	NkxUS	locus	(Figure	27C),	one	to	Ptprk	
(protein	tyrosine	phosphatase,	receptor	type	K)	(Figure	27D)	and	one	to	Grm8	(glutamate	
metabotropic	receptor	8)	(Figure	27E).		
Ptprk	is	involved	in	regulating	cell	adhesion	as	well	as	cell	contact	and	is	a	negative	regulator	
of	the	epidermal	growth	factor	receptor	(EGFR)	signaling	pathway.	GO	terms	for	biological	process	
associated	with	Ptprk	include	cell	adhesion,	cell	migration,	negative	regulation	of	cell	cycle	and	
transcription,	neuron	projection	development,	protein	dephosphorylation	and	cellular	response	to	
reactive	oxygen	species.	
Grm8	is	a	G	protein-coupled	receptor	for	glutamate	and	its	signaling	is	known	to	inhibit	
adenylate	cyclase	activity.	Associated	GO	terms	for	biological	process	include	regulation	of	neuron	
transmitter	secretion,	synaptic	transmission	(glutamatergic)	and	adenylate	cyclase-inhibiting	G	
protein	coupled	receptor	signaling	pathway.		
Therefore,	using	the	EVEN	and	ODD	strategy,	we	did	not	see	compelling	enrichment	across	
the	two	biological	replicates	and	probe	sets	and	we	further	investigated	the	EVEN	and	ODD	overlap	
of	individual	replicates.	
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Figure	27	NkxUS	pull-down	followed	by	DNA	sequencing	identified	two	DNA	binding	regions.	A)	
Results	for	NkxUS	yield	calculated	from	the	RT-PCR	results.	B)	Venn	Diagram	of	overlapping	peaks	
identified	using	the	MACS	package.	C-E)	Peak	enrichment	at	the	NkxUS	locus	(C),	Ptprk	locus	(D)	and	
Grm8	locus	(E).	
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2.7.3.1 Analysis	of	individual	experiments	
Due	to	a	lack	of	enrichment	of	possible	DNA	targets	when	using	the	overlap	of	biological	replicates,	
we	also	investigated	the	chromatin	targets	within	the	EVEN	and	ODD	overlap	of	individual	
replicates.	Looking	at	the	overlap	of	experiment	2	revealed,	among	several	predicted	genes,	one	
additional	candidate,	Osr1	(Protein	odd-skipped-related	1).	Osr1	is	a	transcription	factor	that	is	
involved	in	the	regulation	of	embryonic	heart	and	urogenital	development	[241].	Osr1	was	shown	
to	regulate	atrial	septum	formation	in	the	heart	[241].	Studies	in	mice	have	shown	that	loss	of	
Osr1	expression	is	embryonic	lethal	due	to	deformed	atrioventricular	junctions	and	hypoplastic	
venous	valves	[242].	Associated	GO	terms	for	biological	function	include	regulation	of	transcription,	
heart	and	kidney	development	and	cell	differentiation.	
Experiment	3	revealed,	again,	many	predicted	genes	with	no	known	function,	as	well	as	16	
known	genes	listed	in	Table	6.	Analysis	of	the	biological	function	of	these	genes,	revealed	four	
genes	that	are	involved	in	G	protein-coupled	receptor	signaling	pathway,	while	others	are	involved	
in	cell	adhesion,	cell	cycle,	transcription	and	circadian	rhythm	(Table	6).	However,	further	studies	
have	to	be	conducted	to	validate	if	these	genes	are	specific	targets	of	NkxUS.	
	
	
Table	6	DNA	target	results	from	replicate	3		
Gene	 Description	 BP	
Aida	 Axin	interactor,	dorsalization-associated	protein	 Determination	of	ventral	identity	
Ank1	 Ankyrin-1	 Cytoskeleton	organisation	
Cadm2	 Cell	adhesion	molecule	2	 Cell	adhesion	
Cdc73	 Parafibromin	 Cell	cycle,	transcription	
Ercc6	 DNA	excision	repair	protein	 Transcription	
Erdr1	 Erdr1	protein	 Cell	proliferation	
Ghr	 Growth	hormone	receptor	 Endocytosis	
Kctd16	 BTB/POZ	domain-containing	protein	KCTD16	
G	protein-coupled	receptor	signaling	
pathway	
Nampt	 Nicotinamide	phosphoribosyltransferase	 Circadian	rhythm	
Npr3	 Atrial	natriuretic	peptide	receptor	3	
G	protein-coupled	receptor	signaling	
pathway	
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Olfr211	 Olfactory	receptor	
G	protein-coupled	receptor	signaling	
pathway	
Opcml	 Opioid-binding	protein/cell	adhesion	molecule	 Cell	adhesion	
Rgs6	 Regulator	of	G	protein	signaling	6	
G	protein-coupled	receptor	signaling	
pathway	
Sfi1	 Protein	SFI1	homolog	 Cell	cycle	
Tnik	 TRAF2	and	NCK-interacting	protein	kinase	 Wnt	signaling	pathway	
Tspan9	 Tetraspanin-9	 Cell	surface	receptor	signaling	
	
	
2.7.3.2 Four	DNA	targets	are	deregulated	upon	NkxUS	knockdown	
Binding	of	NkxUS	to	these	DNA	targets	may	lead	to	the	activation	or	inhibition	of	their	transcription	
for	example	by	recruiting	chromatin	modifying	complexes	to	these	specific	genomic	loci	as	shown	
for	many	well-characterised	lncRNAs	[101,	112].	The	lncRNA	HOTAIR	was	shown	to	associate	with	
PRC2	to	silence	distant	loci,	whereas	the	lncRNA	HOTTIP	binds	to	TrxG/MLL	to	activate	transcription	
of	target	genes	[141,	243].	
Therefore,	the	list	of	DNA	targets	of	each	replicate	was	overlapped	with	the	list	of	significant	
(FDR	<0.05)	deregulated	transcripts	following	NkxUS	knockdown.	The	intersection	revealed	four	
genes	(Figure	28),	which	are	listed	in	Table	7	with	their	corresponding	logFC	after	NkxUS	
knockdown	and	their	associated	function.	All	four	genes	are	upregulated	indicating	that	NkxUS	
may,	upon	binding,	repress	transcription.	Aida	and	Tnik	are	both	involved	in	embryonic	
development,	Sfi1	is	involved	in	the	regulation	of	cell	cycle	as	well	as	organelle	biogenesis	and	
maintenance	and	Rgs6	is	known	to	modulate	cardiovascular	activity.	Rgs6	is	a	regulator	of	
parasympathetic	activation	in	the	heart,	functioning	as	a	negative	regulator	of	G	protein	activation	
of	β-adrenergic	receptors	[244,	245].	
Altogether,	the	DNA	ChIRP	with	two	biological	replicates	identified	only	a	limited	amount	of	
targets,	Ptprk	and	Grm8,	when	looking	for	the	overlap	between	EVEN	and	ODD,	excluding	LacZ,	and	
between	the	biological	replicates.	Investigating	the	overlap	between	individual	replicates	resulted	
in	17	additional	candidates.	Some	of	which	share	a	common	biological	function	with	Ptprk	and	
Grm8	(Table	6).	However,	further	follow	up	experiments	have	to	be	performed	to	evaluate	specific	
NkxUS	interaction.	
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Table	7	Annotation	of	DNA	ChIRP	targets	that	are	deregulated	upon	NkxUS	knockdown	showing	
the	gene	name,	the	logFC	as	seen	from	the	NkxUS	knockdown	RNA	sequencing	results	and	
associated	gene	function	
Gene	 Description	 logFC	 Function	
Aida	
Axin	interactor,	dorsalization-
associated	protein	
0.22	
Acts	as	a	ventralizing	factor	during	
embryogenesis.	
Rgs6	
Regulator	of	G	protein	
signaling	6	
0.52	
Regulates	G	protein-coupled	receptor	
signaling	cascades.	Inhibits	signal	transduction	
by	increasing	the	GTPase	activity.	
Sfi1	 Protein	SFI1	homolog	 0.67	
Plays	a	role	in	the	dynamic	structure	of	
centrosome-associated	contractile	fibers.	
Tnik	
TRAF2	and	NCK-interacting	
protein	kinase	
0.18	
Serine/threonine	kinase	that	acts	as	an	
essential	activator	of	the	Wnt	signaling	
pathway.	It	is	recruited	to	promoters	of	Wnt	
target	genes	and	required	to	activate	their	
expression.	
	
	
	
Figure	28	Overlap	of	NkxUS	knockdown	and	DNA	ChIRP	results.	Venn	diagram	intersecting	the	
deregulated	transcripts	with	a	FDR	<	0.05	following	NkxUS	knockdown	and	the	DNA	ChIRP	
identified	targets.	
	
	
2.7.4 Identification	of	protein	interacting	partners	of	NkxUS		
To	identify	the	protein	interacting	partners	of	NkxUS,	we	performed	ChIRP	followed	by	mass	
spectrometry	(MS).	After	NkxUS	capture,	proteins	were	precipitated	and	separated	on	a	gel,	which	
was	then	cut	into	at	least	four	fragments	per	lane.	Proteins	were	eluted	from	individual	gel	slices	
DNA ChIRP targets Deregulated transcripts
(FDR <0.05)
415 1789
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and	then	analysed	using	a	QExactive	Plus	Orbitrap	mass	spectrometer	by	Dr.	Ben	Crosset	
(University	of	Sydney,	Australia).	For	ChIRP-MS,	several	parameters	had	to	be	optimised,	including	
input	HL-1	cell	number,	cell	harvesting	method,	crosslinking	condition,	fragmentation	method	and	
reverse	crosslinking	time	(Table	8).	Efficiency	of	reverse	crosslinking	can	be	determined	by	
intersecting	the	proteins	identified	in	the	individual	gel	pieces.	Ideally,	after	breaking	the	crosslink,	
proteins	should	separate	in	the	gel	according	to	its	molecular	weight	and	individual	gel	pieces	
should	not	show	many	shared	proteins.	Therefore,	if	after	protein	digestion	and	peptide	extraction,	
peptides	are	still	crosslinked	to	other	proteins	or	RNA,	they	will	not	match	any	protein	in	the	
database	as	the	tolerances	for	detection	are	very	tight	(less	than	0.01Da).	Thus,	in	our	analysis	we	
rely	on	the	non-crosslinked	peptides	and	might	loose	a	large	amount	of	peptides	if	the	reverse	
crosslinking	step	was	not	efficient.		
As	for	the	DNA-ChIRP,	we	determined	the	number	of	proteins	shared	between	EVEN	and	
ODD,	which	were	not	present	in	LacZ,	for	each	replicate	(Table	8).	Unfortunately,	no	replicates	
were	done	for	any	one	method	and	therefore	difficulties	were	experienced	in	the	data	analysis.		
	
	
Table	8	Optimisation	parameters	for	ChIRP-MS.	Listed	are	the	number	of	cells	used,	whether	cells	
were	harvested	by	scraping	or	trypsin	digestion,	whether	whole	or	nuclear	enriched	cell	lysates	
were	used,	the	formaldehyde	concentration	used	for	crosslinking,	if	the	samples	were	fragmented	
using	a	probe	or	water	bath	sonicator	as	well	as	the	time	for	reverse	crosslinking	and	resulting	
protein	number	after	MS	identification.	
#	
~	Million	
cells	
Cell	
harvest	
Cell	
lysate	
Formaldehyde	
concentration	
Sonication	
method	
Reverse	
crosslinking	
#	
proteins	
	1	 100	 scrape	 whole	 3%	
probe	
sonicator	
30min	 1	
2	 100	 trypsin	
nuclear	
enriched	
3%	
water	
bath	
30min	 6	
3	 100	 trypsin	 whole	 0.5%	
water	
bath	
30min	 46	
4	 400	 trypsin	 whole	 0.5%	
water	
bath	
90min	 168	
5	 400	 scrape	 whole	 0.5%	
water	
bath	
90min	 20	
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2.7.4.1 Analysis	of	proteins	shared	between	experiments	
Since	no	biological	replicates	were	performed,	an	initial	analysis	was	focused	on	looking	at	the	most	
enriched	proteins	from	all	experiments	with	the	idea	that	true	interacting	partners	should	be	
consistently	represented	above	noise.	The	unique	EVEN/ODD	specific	proteins	of	each	replicate	
were	intersected	to	search	for	common	proteins	from	several	independent	experiments.	The	first	
experiment	was	excluded	as	it	only	identified	one	protein,	which	was	not	shared	with	any	other	
experiments.	Intersection	of	experiments	2-5	did	not	reveal	any	proteins	shared	between	all	
experiments	(Figure	29).	An	overlap	was	only	observed	between	two	experiments	at	a	time,	with	in	
total	17	shared	proteins	(Figure	29).	As	a	different	approach	we	analysed	the	overlap	of	all	the	
EVEN	and	ODD	experiments	taken	individually.	Both	approaches	revealed	the	same	proteins	with	
only	one	additional	one,	HNRNPAB,	using	the	second	approach.	Listed	in	Table	9	are	the	proteins	
shared	between	the	experiments	and	ranked	based	on	the	number	of	times	observed	in	any	EVEN	
or	ODD	experiment.	
	
	
Figure	29	Venn	Diagram	showing	the	intersection	of	proteins	identified	from	the	individual	
replicates.	Shown	are	the	proteins	shared	between	EVEN	and	ODD,	excluding	proteins	found	in	
LacZ.	Number	of	proteins	shared	between	individual	replicates	are	indicated	in	the	overlap.	
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Table	9	Proteins	ranked	based	on	the	number	of	times	observed	in	any	EVEN	or	ODD	sample	
Protein	 Description	 #	observed		
DLAT	
Dihydrolipoyllysine-residue	acetyltransferase	component	of	pyruvate	
dehydrogenase	complex	
5	
PRDX3	 Thioredoxin-dependent	peroxide	reductase	 5	
ACOT13	 Acyl-coenzyme	A	thioesterase	13	 4	
ATP5H	 ATP	synthase	subunit	e	 4	
CYCS	 Cytochrome	c	 4	
FH	 Fumarate	hydratase	 4	
GOT2	 Aspartate	aminotransferase	 4	
GSTP1	 Glutathione	S-transferase	P	1	 4	
HINT2	 Histidine	triad	nucleotide-binding	protein	2	 4	
HNRNPAB	 Heterogeneous	nuclear	ribonucleoprotein	A/B	 4	
HSPD1	 60	kDa	heat	shock	protein	 4	
LDHA	 L-lactate	dehydrogenase	A	chain	 4	
OXCT1	 Succinyl-CoA:3-ketoacid	coenzyme	A	transferase	1	 4	
PCBP1	 Poly(rC)-binding	protein	1	 4	
PDHA1	 Pyruvate	dehydrogenase	E1	component	subunit	alpha	 4	
UQCRC1	 Cytochrome	b-c1	complex	subunit	1	 4	
NDUFV1	 NADH	dehydrogenase	[ubiquinone]	flavoprotein	1	 4	
SOD2	 Superoxide	dismutase	 4	
	
	
2.7.4.2 Highest	NkxUS	enrichment	was	achieved	with	Experiment	4	
Given	that	only	a	limited	number	of	proteins	were	identified	to	overlap	between	experiments,	we	
performed	a	more	detailed	analysis	of	Experiment	4.	Experiment	4	worked	best	in	terms	of	visual	
inspection	of	the	gel,	reverse	crosslinking	efficiency	and	subsequent	protein	identification	as	well	as	
highest	NkxUS	retrieval	(~40%)	(Figure	30A).	Two	sharp	bands	were	detected	in	EVEN	and	ODD	and	
not	LacZ	when	running	the	gel	after	reverse	crosslinking	(Figure	30B).	The	lanes	were	sliced	into	six	
pieces	in	order	to	identify	the	specific	proteins	in	these	bands	via	MS	(Figure	30C).		
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Figure	30	ChIRP	successfully	enriched	for	NkxUS.	A)	~40%	of	NkxUS	was	retrieved	with	EVEN	and	
ODD	probes,	whereas	no	enrichment	was	observed	with	LacZ	probes.	B)	Two	clear	bands	were	
detected	(indicated	by	arrows)	for	EVEN	and	ODD,	which	were	absent	in	LacZ.	C)	Each	lane	was	cut	
into	6	fragments,	which	were	analysed	individually	using	MS.	
	
	
2.7.4.3 Analysis	of	the	NkxUS	specific	bands	of	the	protein	gel	
Experiment	4	showed	clear	visualisation	of	two	sharp	bands	in	EVEN	and	ODD	lanes	(Figure	30B),	
suggesting	that	these	might	be	specific	NkxUS	interacting	proteins	as	no	bands	of	that	size	were	
observed	in	the	LacZ	lane.	MS	of	these	gel	fragments,	however,	did	not	identify	any	high	confidence	
targets	for	the	upper	band.	The	most	abundant	proteins	in	this	slice	were	also	present	in	LacZ	and	
no	protein	matched	the	expected	size,	potentially	due	to	incomplete	reverse	crosslinking	and	thus	
the	band	could	represent	a	protein	complex	or	a	still	crosslinked	protein,	which	we	were	unable	to	
identify.		
For	the	lower	band,	the	trifunctional	enzyme	subunit	alpha	(HADHA)	was	the	only	protein	
identified	within	the	particular	gel	slice	that	was	not	shared	with	LacZ.	Interestingly,	HADHA	was	
also	identified	in	the	EVEN	probe	set	of	Experiment	3.	The	absence	of	HADHA	in	LacZ	and	its	
substantial	enrichment	in	the	gel	suggests	that	it	may	be	specific.	
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2.7.4.4 NkxUS	interacting	proteins	are	involved	in	metabolic	processes		
When	overlapping	the	proteins	identified	per	lane	from	each	sample	in	Experiment	4,	168	proteins	
were	shared	between	EVEN	and	ODD	and	absent	in	LacZ	(Figure	31A).	Looking	at	the	most	
significant	GO	terms	for	biological	process	revealed	largely	metabolism	related	terms	but	also	some	
non-metabolic	terms,	including	ion	transport,	cell	communication,	transcription	and	muscle	
contraction	(Figure	31B).	The	vast	majority	and	most	enriched	captured	proteins	have	a	
mitochondrial	associated	function	(Table	10).		
Taken	together,	the	majority	of	proteins	shared	between	experiments,	detected	in	
individual	experiments	and	even	in	the	prominent	gel	band	have	annotated	mitochondrial	
functions.	It	remains	to	be	evaluated	if	these	interact	specifically	with	NkxUS	or	represent	
experimental	noise.	
	
	
	
Figure	31	Results	for	NkxUS	interacting	proteins	from	Experiment	4.	A)	Overlap	of	all	three	
samples	resulted	in	168	proteins	shared	between	EVEN	and	ODD	but	not	LacZ.	B)	Most	significant	
GO	term	for	biological	process	for	the	shared	proteins.	Scale	in	–log10(FDR).	
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Table	10	Top	20	most	enriched	ChIRP-MS	identified	proteins	of	Experiment	4	showing	the	unique	
peptide	count	for	the	EVEN	and	ODD	probes.	
Protein	 Description	 EVEN	 ODD	
ACO2	 Aconitate	hydratase	 29	 28	
HSPD1	 60	kDa	heat	shock	protein	 24	 22	
PCCB	 Propionyl-CoA	carboxylase	beta	chain	 22	 22	
TUFM	 Elongation	factor	Tu	 20	 18	
ACAA2	 3-ketoacyl-CoA	thiolase	 18	 18	
LRPPRC	 Leucine-rich	PPR	motif-containing	protein	 19	 16	
HADHA	 Trifunctional	enzyme	subunit	alpha	 15	 17	
ALDH2	 Aldehyde	dehydrogenase	 16	 15	
LONP1	 Lon	protease	homolog	 14	 15	
ACADM	 Medium-chain	specific	acyl-CoA	dehydrogenase	 14	 14	
PDHA1	 Pyruvate	dehydrogenase	E1	component	subunit	alpha	 13	 14	
ALDH18A1	 Delta-1-pyrroline-5-carboxylate	synthase	 11	 16	
OAT	 Ornithine	aminotransferase	 13	 13	
TRAP1	 Heat	shock	protein	75	kDa	 12	 14	
SUCLG2	 Succinate--CoA	ligase	[GDP-forming]	subunit	beta	 14	 11	
ETFB	 Electron	transfer	flavoprotein	subunit	beta	 12	 12	
FH	 Fumarate	hydratase	 12	 12	
TUBB5	 Tubulin	beta-5	chain	 12	 12	
ACAT1	 Acetyl-CoA	acetyltransferase	 12	 11	
ACADL	 Long-chain	specific	acyl-CoA	dehydrogenase	 11	 12	
	
	
2.8 The	mouse	model	to	study	the	function	of	NkxUS	in	vivo	
Functional	experiments	have	so	far	been	performed	in	vitro	using	an	immortalised	cell	line.	
However,	as	these	cells	can	have	substantial	abnormal	functions,	we	expanded	our	analysis	of	
NkxUS	function	in	vivo	using	a	mouse	model.	
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2.8.1 Generation	of	a	mouse	model	to	study	the	conserved	RNA	structure		
Since	we	identified	an	RNA	structure	conserved	between	mouse	and	human	NkxUS	and	
since	conservation	often	implies	function,	we	intended	to	generate	a	mouse	model	by	altering	this	
domain.	In	our	approach,	we	wanted	to	target	part	of	the	conserved	structure	of	NkxUS.	Initially,	
we	intended	to	insert	three	polyadenylation	signals	using	clustered	regularly	interspaced	short	
palindromic	repeats/CRISPR-associated	protein	9	(CRISPR-Cas9)	in	order	to	terminate	NkxUS	
transcription	early,	which	in	turn	would	lead	to	reduced	or	no	NkxUS	expression.	However,	at	that	
time	insertion	of	the	polyadenylation	signals	was	unsuccessful	and	we	decided	to	study	the	effect	
of	a	partial	deletion	of	the	conserved	structure.	
For	NkxUS,	a	single	guide	RNA	(sgRNA)	targeting	the	conserved	structure	was	used.	In	
mouse,	the	conserved	structure	lies	at	the	start	of	the	second	exon	not	overlapping	any	of	the	
known	Nkx2-5	enhancers	(Figure	32A)	[84-88].	Histone	marks	also	do	not	show	any	evidence	of	
enhancer	marks,	as	seen	from	the	absence	of	H3K4me1	marks	(Figure	32A).	One	limitation	is	that	
the	entire	conserved	structural	region	overlaps	a	transcript	antisense	to	NkxUS,	as	seen	from	the	
ENCODE	heart	RNA	sequencing	data	(Figure	32A).	Thus,	by	deleted	this	region	we	may	also	alter	the	
antisense	transcript	and	potentially	abort	its	transcription	(Figure	33A).	However,	as	we	believe	
that	this	RNA	structure	has	functional	relevance	we	decided	to	pursue	this	approach.	
A	region	of	286-289bp	was	successfully	deleted	and	two	homozygous	female	founders	were	
generated	(Figure	32).	The	line	was	termed	NkxUS∆	and	the	two	founder	females	were	named	
NkxUS∆-F5	and	NkxUS∆-F10.	NkxUS∆-F5	harbors	a	286bp	deletion	(Figure	32B)	and	NkxUS∆-F10	a	
289bp	deletion	and	1bp	insertion	(Figure	32C).	
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Figure	32	Deletion	of	part	of	the	conserved	structure	using	CRISPR.	A)	Depiction	of	the	Nkx2-5	and	
NkxUS	locus	highlighting	the	deleted	(yellow)	and	the	conserved	(red	rectangle)	region	in	NkxUS.	
Nkx2-5	enhancers	are	shown	in	green	(cardiac)	and	yellow	(non-cardiac)	and	inhibitory	regions	are	
shown	in	black.	Mouse	heart	RNA	sequencing	data	from	ENCODE	is	shown	in	red,	also	showing	the	
short	NkxUS	antisense	transcript	on	the	plus	strand.	Histone	marks	from	adult	and	embryonic	
hearts	are	shown	in	the	grey	tracks.	Along	with	CAGE	counts	and	mammalian	sequence	
conservation	in	the	lower	two	tracks.	B)	NkxUS∆-F5	harbors	a	286bp	deletion	C)	NkxUS∆-F10	
harbors	a	289bp	deletion	and	an	1bp	insert.	Legend:	CAPITALS	=	Exon	2	of	NkxUS,	Red	=	start	of	the	
exon	prior	to	conserved	region;	Blue	=	conserved	region;	Green	=	sgRNA	sites;	Wild-type	sequence	
is	illustrated	on	the	top.		
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2.8.2 No	abnormal	phenotype	was	observed	in	NKXUS∆-/-	mice	
NKXUS∆-/-	mice	appeared	normal.	Crossing	of	NKXUS∆+/-	mice	resulted	in	average	litter	sizes	of	4-6	
mice	with	normal	Mendelian	ratios.	NKXUS∆-/-	mice	are	viable,	fertile	and	show	no	obvious	
abnormal	phenotype	or	change	in	body	weights	(Figure	33).	
	
	
Figure	33	Body	weights	are	unchanged	in	adult	NKXUS∆-/-	mice.	Body	weight	measurements	of	
NKXUS∆-/-	and	NKXUS∆+/+	mice	did	not	reveal	any	differences.	Data	presented	as	mean	±	SD,	n=20.		
	
	
2.8.3 NkxUS	RNA	levels	are	unchanged	in	NkxUS∆-/-	hearts	
To	analyse	if	deletion	of	part	of	the	conserved	region	affected	the	RNA	levels	of	NkxUS	we	checked	
expression	levels	in	whole	hearts	from	adult	NkxUS∆-/-	and	NkxUS∆+/+	mice.	RT-PCR	showed	that	the	
RNA	levels	of	NkxUS,	NkxDS,	Nkx2-5	and	the	NkxUS	antisense	transcript	(NkxUSas)	were	not	
changed,	indicating	that	the	deletion	did	not	affect	the	transcript	levels	of	NkxUS,	nor	had	any	
affect	on	NkxDS,	Nkx2-5	or	NkxUSas	expression	(Figure	34).	
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Figure	34	NkxUS	RNA	levels	are	unchanged	in	NkxUS∆-/-	hearts.	RT-PCR	showed	no	change	in	the	
expression	levels	of	Nkx2-5,	NkxDS,	NkxUS	and	NkxUSas	in	NKXUS∆-/-	hearts	when	normalised	to	
four	housekeeping	genes	and	relative	to	NKXUS∆+/+.	Data	presented	as	mean	±	SD,	n=4.	
	
	
2.8.4 NKX2-5	protein	levels	are	not	altered	in	NkxUS∆-/-	hearts	
Nkx2-5	RNA	levels	were	unchanged	in	NKXUS∆-/-	mice,	however,	since	mRNA	levels	may	not	
necessarily	reflect	protein	levels,	western	blot	analysis	was	performed	for	NKX2-5	on	NKXUS∆-/-		and	
NKXUS∆+/+	adult	hearts.	Western	blot	analysis	with	an	antibody	against	NKX2-5	(NKX2-5	N19,	Santa	
Cruz)	and	Vinculin	(H300,	Santa	Cruz)	as	a	control	revealed	no	significant	changes	between	
NKXUS∆+/+	and	NKXUS∆-/-	mice	(Figure	35A	and	B),	suggesting	that	the	conserved	RNA	structure	
affects	neither	Nkx2-5	protein	nor	RNA	levels.	However,	whether	potential	Nkx2-5	and	NkxUS	
interactions	are	affected	by	this	deletion	remains	to	be	elucidated.	  
	
Figure	35	NKX2-5	protein	levels	are	unchanged	in	NkxUS∆	adult	hearts.	A)	Protein	extracts	from	
NKXUS∆+/+	and	NKXUS∆-/-	hearts	were	analysed	by	western	blot	using	Vinculin	as	a	control	and	
NKX2-5;	n=5.	B)	Analysis	of	western	blot	band	intensity,	normalised	to	Vinculin	and	relative	to	
NKXUS∆+/+,	revealed	no	significant	changes	on	protein	level	for	NKX2-5.	Data	presented	as	mean	±	
SD,	n=5.	The	complete	western	blot	can	be	found	in	Appendix	IV.	
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2.8.5 No	heart	defects	were	detected	in	NKXUS∆-/-	embryos	
Hearts	of	E17.5	embryos	were	collected	to	analyse	for	cardiac	morphological	defects	using	optical	
projection	tomography	(OPT).	The	OPT	creates	high	resolution	three-dimensional	(3D)	images	by	
taking	images	every	few	seconds	and	rotating	the	samples	360	degrees.	Biological	samples	up	to	
15mm	thick	can	be	imaged	[246].	Following	reconstruction	and	compilation	of	images,	the	software	
Amira	allows	researches	to	scroll	through	the	heart,	rotate	and	flip	it	in	any	direction	to	analyse	for	
heart	defects.	The	samples	were	analysed	for	defects	in	the	size	and	morphology	of	the	ventricles	
and	atria,	as	well	for	any	septal	and	valve	defects.	Four	NkxUS∆-/-	and	NKXUS∆+/+	embryos	were	
analysed	and	no	defects	were	identified.	
	
	
2.8.6 NkxUS∆-/-	adult	mice	exhibit	normal	atrial	septal	development		
In	humans,	NKX2-5	is	commonly	associated	with	several	congenital	heart	abnormalities	including	
atrial	septal	defects	(ASD).	ASD	is	a	relatively	common	congenital	heart	defect	and	occurs	during	
heart	development	when	the	atrial	septum	fails	to	close	completely	resulting	in	a	permanent	
opening	between	both	atria.	The	atrial	septum	is	therefore	arguably	the	most	vulnerable	structure	
to	developmental	perturbations	affecting	the	heart.	The	main	pathological	consequence	is	cardiac	
shunt,	meaning	a	deviation	of	normal	blood	flow	[247].	After	birth,	the	pressure	in	the	left	atrium	is	
higher	than	in	the	right	atrium.	An	ASD	allows	blood	flow	from	the	left	into	the	right	atrium,	which	
will	ultimately	lead	to	an	increase	in	right	atrial	pressure	and	hence	progressive	enlargement	and	
myocardial	thickening	[247].	
In	Nkx2-5	heterozygous	mice,	ASD	was	rarely	observed	[75].	Instead,	these	mice	were	
shown	to	have	an	increased	prevalence	of	patent	foramen	ovale	(PFO)	[75].	PFO	is	generally	a	
benign	condition.	It	is	evident	after	birth,	when	the	foramen	ovale	fails	to	close.	The	foramen	ovale	
is	a	small	opening	in	the	septum	secundum	(Figure	37A),	one	of	the	two	distinct	walls	(septum	
primum	and	secundum)	which	form	the	interatrial	septum	[248].	Before	birth,	the	lungs	are	not	yet	
functional	and	oxygen	rich	blood	is	received	from	the	mother’s	placenta.	The	foramen	ovale	
therefore	allows	blood	to	bypass	the	lungs	and	facilitates	the	passage	of	oxygenated	blood	to	the	
left	atrium.	After	birth,	pressure	in	the	left	atrium	rises,	forcing	the	septum	secundum	against	the	
septum	primum,	permanently	closing	the	opening	[248].	In	individuals	with	PFO,	a	small	amount	of	
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blood	may	leak	from	the	right	atrium	to	the	left,	which,	for	the	vast	majority,	is	asymptomatic.	
Clinically,	an	ASD	can	be	described	as	a	large	PFO.	Studies	suggested	that	the	occurrence	of	PFO	in	
mice	might	be	linked	genetically	to	the	causation	of	ASD	in	humans	[75].	
Hearts	of	adult	(6-8	weeks	old)	NKXUS∆-/-	and	NKXUS∆+/+	mice	were	dissected	and	
anatomically	analysed	by	Dr.	Edwin	Kirk	(University	of	New	South	Wales,	Australia)	for	ASD	and	PFO	
as	well	as	differences	in	atrial	septal	morphology,	more	specifically	crescent	width	(CRW),	foramen	
ovale	width	(FOW)	and	flap	valve	length	(FVL)	(Figure	36A).	Previously,	mean	flap	valve	length	was	
measured	and	shown	to	be	negatively	correlated	with	the	incidence	of	PFO,	whereas	the	foramen	
ovale	and	crescent	width	were	positively	correlated	[75].	These	quantitative	parameters	have	been	
previously	demonstrated	to	be	highly	correlated	with	prevalence	for	PFO	[75,	249].	
20	animals	of	each	genotype	were	analysed	but	no	significant	differences	were	found	in	any	
of	the	septal	quantitative	measurements	(Figure	36B).	In	total,	one	ASD	as	well	as	five	PFOs	were	
identified	in	NKXUS∆-/-	mice,	whereas,	no	ASD,	but	6	PFOs	were	found	in	NKXUS∆+/+	mice,	indicating	
that	deletion	of	part	of	the	conserved	region	did	not	affect	atrial	septal	development,	as	was	seen	
for	Nkx2-5	heterozygous	mice.	Based	on	gross	morphology	and	quantitative	assessment	of	atrial	
septal	parameters,	we	conclude	that	the	region	deleted	in	NKXUS∆	has	no	impact	on	heart	
development.	
	
	
Figure	36	Atrial	morphology	analysis	of	NKXUS∆-/-	and	NKXUS∆+/+	mice.	A)	Light	micrograph	of	
atrial	septal	details	as	seen	from	the	left	aspect	after	removal	of	the	left	atrial	appendage.	The	
A      
B
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annulus	of	the	mitral	valve	is	toward	the	lower	left	of	this	panel.	Septal	landmarks	and	quantitative	
septal	measurements	used	in	this	study	are	highlighted	(taken	from	[249]).	B)	No	significant	
differences	between	genotypes	were	detected	for	any	of	the	quantitative	measurements.	CRW=	
crescent	width.	Data	presented	as	mean	±	SD,	n=20.	
	
	
2.8.7 Functional	analysis	of	NkxUS∆-/-	mice	in	a	model	of	left	ventricle	hypertrophy		
Often	phenotypes	develop	under	stress.	Several	models	to	stress	the	heart	are	well	established	and	
are	important	tools	to	gain	further	insight	into	the	potential	function	of	genes	in	the	heart.	Based	
on	the	possible	association	of	human	NKXUS	with	an	increased	heart	rate,	we	decided	to	use	a	
model	of	pressure	overload	to	study	the	consequences	of	overload	induced	hypertrophy	on	cardiac	
function	and	contractility.	Pressure	overload	of	the	left	ventricle	(LV)	leads	to	an	increased	
stretching	force	on	the	myocardium,	which	in	turn	results	in	hypertrophy	and	an	altered	contractile	
function	of	the	myocardium	[250].		
We	performed	transverse	aortic	constriction	(TAC)	surgery	on	male	NKXUS∆-/-	and	
NKXUS∆+/+	mice.	TAC	is	a	commonly	used	method	to	induce	LV	hypertrophy	and	heart	failure	in	
mice	[251].	It	is	designed	to	increase	the	resistance	of	pumping	for	the	LV,	which	leads	to	an	
elevated	energy	demand	and	eventually	to	disturbed	cardiac	contraction	and	heart	failure.	As	the	
name	suggests,	the	inside	diameter	of	the	aorta	close	to	the	right	ventricle	will	be	constricted.	
Banding	of	the	aorta	leads	to	left	ventricular	overload	and	hypertrophy	as	it	has	to	work	harder	to	
eject	the	normal	amount	of	blood.	Over	time,	the	heart	cannot	adjust	adequately	anymore	to	the	
chronic	pressure	overload,	resulting	in	cardiac	dilatation	and	heart	failure	[251].		
We	performed	TAC	on	10-11	male	adult	mice	of	each	genotype	and	sham	surgery	(placebo	
surgery)	on	9	mice	of	each	genotype.	In	sham	surgery,	the	chest	was	opened	but	no	banding	was	
performed.	At	21	days	post-surgery,	echocardiography	as	well	as	left	ventricle	micromanometry	
were	performed.	Echocardiography	is	a	non-invasive	ultrasound	method	used	to	study	cardiac	
structure	and	function	in	anaesthetised	mice.	LV	micromanometry	was	used	to	determine	the	
development	of	LV	pressure	over	time	in	each	contractile	cycle	to	analyse	ventricular	systolic	and	
diastolic	function.		
After	completion	of	left	ventricle	micromanometry,	mice	were	sacrificed.	The	hearts	and	tibia	were	
collected	to	measure	heart	weight,	left	ventricular	weight	and	left	atrial	weight	relative	to	tibia	
length.	The	surgery	and	LV	micromanometry	were	performed	by	Jianxin	Wu	and	the	
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echocardiography	by	Scott	Kesteven	(both	of	the	Victor	Chang	Cardiac	Research	Institute,	
Australia).	
We	decided	to	complete	the	study	at	day	21	to	achieve	a	model	of	left	ventricle	
hypertrophy.	Heart	failure	develops	at	later	timepoints	as	the	chronic	overload	worsens	cardiac	
function.	
	
	
2.8.7.1 Tissue	collection	data	showed	that	LV	hypertrophy	was	successfully	induced	
Tissues	were	collected	and	weighted.	To	account	for	variations	in	mouse	size,	the	body	and	heart	
weight	parameters	were	corrected	for	tibia	length.	The	results	showed	no	significant	difference	in	
body	weight	between	the	genotypes	nor	TAC	and	sham	animals	(Figure	37).	LV	hypertrophy	was	
successfully	induced	as	seen	from	the	increased	whole	heart	and	LV	weight	in	TAC	compared	to	
sham	mice	(Figure	37).	However,	no	significant	changes	between	NKXUS∆-/-	and	NKXUS∆+/+	TAC	
mice	regarding	the	hypertrophic	response	were	detected.	The	left	atrial	weight	did	not	increase	
significantly,	indicating	that	no	atrial	dilation	occurred,	which	would	be	expected	at	later	time	
points	when	the	mice	proceed	into	heart	failure	(Figure	37).		
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Figure	37	Body	weight	and	tissue	collection	data.	Body	weights	of	NKXUS∆+/+	and	NKXUS∆-/-		mice	
did	not	change	during	the	experiment	and	are	not	different	between	the	groups.	The	tissue	
collection	data	showed	a	significant	increase	in	whole	heart	and	LV	weight	in	TAC	animals	in	both	
groups.	No	differences	between	NKXUS∆-/-	TAC	and	NKXUS∆+/+	TAC	mice	were	observed.	All	
parameters	were	corrected	for	tibia	length.	Data	presented	as	mean	±	SD,	n=9-11,	*P<0.05,	
unpaired	two-tailed	t-test.	
	
	
2.8.7.2 Echocardiography	results	revealed	an	impairment	in	LV	relaxation		
Echocardiography	was	performed	on	anaesthetised	mice	to	analyse	cardiac	function.	No	difference	
in	heart	rate	under	anaesthesia	was	identified	between	the	groups	or	genotypes	(Figure	38).	TAC	
animals	in	both	groups	had	a	heart	rate	of	~470bpm	and	sham	animals	one	of	~505bpm	(Figure	38).	
In	line	with	the	left	atrial	weight,	the	diameter	did	not	change	significantly	(Figure	38).	As	expected,	
the	wall	thickness	was	increased	in	TAC	mice	compared	to	sham	animals	as	the	muscle	undergoes	
hypertrophy	in	response	to	the	pressure	overload,	further	confirming	the	tissue	collection	data	
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(Figure	38).	However,	again,	no	difference	in	the	response	to	hypertrophy	was	observed	between	
the	genotypes	(Figure	38).	
While	all	parameters	for	ejection	fraction	(measurement	of	the	fraction	of	blood	ejected	
from	the	ventricle	per	heartbeat),	stroke	volume	(volume	of	blood	pumped	from	the	left	ventricle	
per	beat)	and	cardiac	output	(volume	of	blood	pumped	from	the	ventricles	per	minute)	showed	a	
trend	for	worsening	cardiac	function	in	NKXUS∆-/-	TAC	mice	compared	to	NKXUS∆+/+	TAC	mice,	none	
of	these	parameters	reached	significance	due	to	the	increased	variance	in	the	response	in			
NKXUS∆-/-	TAC	animals	(Figure	38).	
However,	when	looking	at	the	blood	flow	velocity	through	the	mitral	valve	(E/A),	measured	
as	the	ratio	of	the	early	(E)	to	late	(A)	filling	phase	of	the	LV,	NKXUS∆-/-	sham	animals	had	a	
significant	lower	value	than	NKXUS∆+/+	sham	animals	(Figure	38).	This	difference	was	attenuated	in	
TAC	animals.	The	mitral	valve	lies	between	the	left	atrium	and	LV	and	the	mitral	flow	signal	is	used	
to	assess	diastolic	function.	The	LV	has	two	filling	phases,	the	early	(passive)	phase,	and	the	late	
(active)	phase.	During	diastole	(ventricular	relaxation),	the	mitral	valve	opens	as	soon	as	the	
pressure	in	the	left	atrium	exceeds	the	pressure	of	the	LV.	Once	opened,	blood	flows	rapidly	into	
the	LV	due	to	the	high-pressure	gradient.	This	early,	passive	filling	accounts	for	about	70%	of	LV	
filling.	In	the	late	phase,	blood	is	actively	pumped	into	the	LV	during	atrial	contraction,	accounting	
for	30%	of	total	filling.	Therefore,	under	normal	conditions,	the	E-wave	is	higher	than	the	A-wave.	
The	difference	detected	in	our	study	is	driven	by	a	significant	difference	in	the	early	phase	of	filling,	
the	E-wave,	whereas	no	significant	change	was	observed	for	the	A-wave	(Figure	38).	The	E-wave	in	
NKXUS∆+/+	sham	animals	had	an	averaged	value	of	900cm/s	and	in	NKXUS∆-/-	sham	mice	one	of	
750cm/s.	The	A-wave	had	a	value	of	about	555-565cm/s;	as	such,	the	E-wave	is	still	higher	than	the	
A-wave	in	NKXUS∆-/-	sham	mice,	suggesting	a	mild	diastolic	dysfunction.	Diastolic	dysfunction	could	
either	be	due	to	disturbed	LV	relaxation	or	differences	in	left	atrial	pressure.	However,	the	E/e’	
value	(e’	measured	at	mitral	annulus,	a	fibrous	ring	at	the	mitral	valve),	which	is	a	measure	of	atrial	
pressure,	was	not	different	between	the	groups,	suggesting	that	NKXUS∆-/-	mice	have	a	mild	
impairment	in	LV	relaxation	when	unchallenged	(Figure	38).		
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Figure	38	Echocardiography	data	revealing	a	mild	diastolic	dysfunction	in	NKXUS∆-/-	sham	
animals.	Heart	rates	were	unchanged	between	the	groups.	As	expected	LV	wall	mass	was	
significantly	increased	in	TAC	animals	compared	to	sham	animals,	but	similar	between	TAC	animals.	
Left	atrial	diameter,	ejection	fraction,	cardiac	output	and	stroke	volume	were	not	significantly	
Heart rate
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changed.	Measuring	the	blood	flow	velocity	at	the	mitral	valve	(E/A)	identified	a	significant	
difference	between	NKXUS∆+/+	and	NKXUS∆-/-	sham	animals,	which	is	attenuate	in	TAC	animals.	This	
difference	is	driven	by	the	E-wave	as	the	A-wave	was	not	changed.	The	atrial	pressure	(E/e’)	did	not	
show	any	significant	differences,	indicating	that	NKXUS∆-/-	animals	have	a	dysfunction	in	LV	
relaxation.	Data	presented	as	mean	±	SD,	n=9-11,	*P<0.05,	unpaired	two-tailed	t-test.	
	
	
2.8.7.3 Left	ventricular	pressure	results	showed	no	difference	in	LV	relaxation	
To	determine	if	TAC	resulted	in	differences	in	pressure	between	NKXUS∆-/-	and	NKXUS∆+/+	mice,	a	
catheter	was	inserted	into	the	LV	to	measure	the	pressure	continuously	for	a	few	minutes.	
The	end-systolic	pressure	was	significantly	increased	in	TAC	animals	as	expected	due	to	the	
increased	resistance	to	pumping	as	we	constricted	the	aorta	(Figure	39).	However,	again	no	
difference	between	NKXUS∆+/+	and	NKXUS∆-/-	TAC	mice	was	detected	(Figure	39).	The	end	–diastolic	
pressure	was	not	changed	indicating	that	the	left	ventricular	filling	pressure	is	unaffected	(Figure	
39).	dp/dt	max,	which	is	the	derivative	of	pressure	over	time	and	measurement	of	contractility,	is	
not	changed,	indicating	that	cardiac	contraction	is	unaffected	by	the	induced	hypertrophy	and	
similar	between	genotypes.	dp/dt	min,	which	is	the	minimal	rate	of	change	of	ventricular	pressure	
and	a	measure	for	relaxation,	was	also	not	changed,	indicating	that	the	dysfunction	in	LV	relaxation	
seen	from	the	echocardiography	data	is	mild.	
In	summary,	the	pressure	data	confirmed	the	successful	induction	of	LV	hypertrophy.	
Despite	this,	as	in	the	tissue	collection	and	echocardiography,	no	differences	between	the	groups	
were	observed	regarding	the	response	to	hypertrophy.	However,	a	mild	but	significant	reduction	of	
the	E-wave	velocity	with	normal	atrial	(E/e’)	and	LV	(dp/dt	min)	pressures	was	detected	in			
NKXUS∆-/-	sham	compared	to	NKXUS∆+/+	sham	animals,	indicating	that	NKXUS∆-/-	mice	have	a	mild	
diastolic	dysfunction,	potentially	due	to	a	stiffer	ventricle,	which	is	attenuated	in	hypertrophy,	
when	the	ventricles	become	stiffer	in	both	groups	due	to	thickening	of	the	LV	wall.	
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Figure	39	LV	pressure	data	did	not	show	differences	in	LV	relaxation.	TAC	induced	as	expected	a	
rise	in	LV	end-systolic	pressure	as	the	constriction	of	the	aorta	hindered	the	ejection	of	blood	from	
the	LV,	indicating	that	the	model	worked.	No	significant	change	was	observed	for	the	end-diastolic	
pressure	nor	in	the	maximal	(dp/dt	max)	and	minimal	(dp/dt	min)	rate	of	pressure	change.	Data	
presented	as	mean	±	SD,	n=9-11,	*P<0.05,	unpaired	two-tailed	t-test.	
	
	
2.8.8 Heart	rate	analysis	in	conscious	mice	
Since	the	determination	of	the	precise	heart	rate	of	NKXUS∆-/-	and	NKXUS∆+/+	mice	is	crucial	for	this	
study	and	since	the	TAC	study	only	analysed	anaesthetised	animals,	we	next	performed	a	telemetry	
study	to	monitor	the	heart	rate	in	conscious,	freely	moving	mice.			
The	electrocardiogram	(ECG)	is	the	gold	standard	when	it	comes	to	heart	rate	and	cardiac	
rhythm	measurements	under	normal	conditions.	Therefore,	we	recorded	the	ECG	in	conscious	
animals	using	a	telemetry	device.	Telemetry	studies	involve	the	implantation	of	a	small	transmitter	
into	the	subcutaneous	space	of	a	mouse	for	the	long-term	recording	of	physiological	parameters.	
9-11	adult	male	animals	of	each	genotype,	aged	10-12	week	old,	were	implanted	with	an	
ECG	telemetry	device	by	Jianxin	Wu	(Victor	Chang	Cardiac	Research	Institute).	Four	days	after	
implantation,	ECG	parameters	were	recorded	for	24hrs,	while	the	animals	were	undisturbed	in	
SH
AM
 N
kx
US
!
+/+
TA
C 
Nk
xU
S!
+/+
SH
AM
 N
kx
US
!
-/-
TA
C 
Nk
xU
S!
-/-
0
50
100
150
200
250
m
m
H
g
LV end-systolic pressure
SH
AM
 N
kx
US
!
+/+
TA
C 
Nk
xU
S!
+/+
SH
AM
 N
kx
US
!
-/-
TA
C 
Nk
xU
S!
-/-
0
5
10
15
m
m
H
g
LV end-diastolic pressure
SH
AM
 N
kx
US
!
+/+
TA
C 
Nk
xU
S!
+/+
SH
AM
 N
kx
US
!
-/-
TA
C 
Nk
xU
S!
-/-
0
5000
10000
15000
20000
m
m
H
g/
s
dP/dt max
-20000
-15000
-10000
-5000
0
m
m
H
g/
s
dP/dt min
TA
C 
Nk
xU
SΔ
-/-
SH
AM
 N
kx
US
Δ
-/-
+/
+
TA
C 
Nk
xU
SΔ
SH
AM
 N
kx
US
Δ
+/
+
dP/dt min
* *
Results	
	 86	
their	normal	cage	environment.	The	data	was	analysed	using	the	ECG	analysis	tool	ECG	Pro	(Data	
Sciences	International).		
	
	
2.8.8.1 NKXUS∆-/-	mice	exhibit	an	increased	resting	heart	rate	
Mice	rest	during	the	day	and	are	active	during	the	night,	therefore,	the	data	was	divided	into	the	
light	(7am-7pm)	and	dark	(7pm-7am)	period	of	the	day.	The	results	showed	a	significant	increased	
resting	heart	rate	for	NKXUS∆-/-	mice,	whereas	no	difference	was	observed	in	the	active	period	of	
the	day	(Figure	40).	The	heart	rates	at	rest	differed	by	19.07	±	7.1bpm	with	NKXUS∆-/-	mice	having	
on	average	a	heart	rate	of	~570bpm.	When	active,	NKXUS∆+/+	mice	had	on	average	a	heart	rate	of	
617.5	±	8.5bpm	and	NKXUS∆-/-	mice	one	of	624	±		5.5bpm.	Furthermore,	when	looking	at	the	24h	
dataset	and	searching	for	the	lowest	heart	rate	of	each	animal,	NKXUS∆-/-	animals	had	on	average	a	
significantly	higher	heart	rate	(444.3	±		3.4bpm	versus	428.1	±	5.5bpm)	(Figure	40).		
	
	
Figure	40	Telemetry	data	identified	an	increased	resting	heart	rate	in	NKXUS∆-/-	mice.	A	telemetry	
study	monitoring	the	heart	rate	in	conscious,	freely	moving	mice	revealed	that	during	the	light	
(7am	-	7pm)	period	of	the	day	when	the	mice	are	at	rest,	NKXUS∆-/-	mice	have	a	significantly	
increased	heart	rate	compared	to	NKXUS∆+/+	mice.	This	difference	is	attenuated	in	the	dark	(7pm	–	
7am),	active	phase	of	the	day.	The	overall	lowest	heart	rates	of	the	whole	24h	dataset	per	mouse	
were	also	significantly	higher	in	NKXUS∆-/-	mice.	Data	presented	as	mean	±	SD,	n=9-10,	*P<0.05,	
unpaired	two-tailed	t-test.	
	
	
2.8.8.2 Impulse	transmission	is	not	altered	in	NKXUS∆-/-	mice	
Changes	in	heart	rate	may	reflect	disturbed	electrophysiological	properties	in	other	compartments	
of	the	heart,	which	can	be	analysed	using	ECG.	A	normal	mouse	cardiac	rhythm	in	an	ECG	shows	
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five	electrical	events,	the	P-,	Q-,	R-,	S-	and	T-wave.	The	P-wave	reflects	electrical	activity	triggering	
atrial	contraction,	the	QRS-complex	represents	ventricular	depolarisation	and	the	T-wave	
ventricular	repolarisation.	The	duration	between	these	complexes	gives	insight	into	
electrophysiological	properties,	with	the	PR-interval	indicating	atrial	and	atrioventricular	nodal	
conduction,	the	QRS-duration	showing	activation	of	the	ventricles,	QT-interval	displaying	the	
duration	for	myocardial	repolarisation	and	ST-interval	illustrating	the	period	between	
depolarisation	and	repolarisation	of	the	ventricles.	However,	no	difference	was	observed	in	any	of	
the	intervals,	indicating	that	impulse	propagation	throughout	the	heart	is	not	altered	(Figure	41).		
	
	
Figure	41	Propagation	of	action	potentials	throughout	the	heart	is	not	affected.	ST-,	PR-,	QRS-	or	
QT-interval	were	not	changed	between	animal	groups.	Data	presented	as	mean	±	SD,	n=9-10.	
	
	
2.8.8.3 Sinus	pauses	occurred	at	a	similar	rate	in	both	genotypes	
The	data	was	additionally	analysed	for	arrhythmias,	more	specifically	the	occurrences	of	sinus	
pauses.	A	sinus	pause	is	described	as	a	period	where	no	heart	beat	is	initiated	from	the	sinoatrial	
node	and	was	defined	as	a	section	on	the	ECG	with	an	R-wave	to	R-wave	interval	greater	or	equal	
to	400ms.	A	few	sinus	pauses	were	observed	in	the	24-hour	dataset,	but	with	no	significant	
differences	between	NKXUS∆-/-	and	NKXUS∆+/+	mice	(Figure	42).	Dividing	the	dataset	into	light	and	
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dark	phase	of	the	day	also	did	not	reveal	any	differences	(Figure	42),	indicating	that	no	
spontaneous	arrhythmias	occurred.	
	
	
Figure	42	Analysing	the	telemetry	data	for	the	occurrences	of	sinus	pauses	revealed	no	significant	
differences	between	the	groups	when	looking	at	the	whole	dataset	nor	when	dividing	it	into	day	
and	night	time.	Data	presented	as	mean	±	SD,	n=9-10.	
	
	
2.8.8.4 Circadian	rhythm	and	heart	rate	variability	are	not	changed	in	NKXUS∆-/-	
mice	
An	increased	heart	rate	could	be	due	to	a	disturbed	circadian	rhythm	or/and	heart	rate	fluctuation,	
alternating	between	tachycardia	and	bradycardia.	Therefore,	the	telemetry	data	was	divided	into	
one-hour	sections	and	plotted	on	a	graph.	On	average,	mice	of	both	genotypes	did	not	show	
differences	in	heart	rate	variability	and	showed	a	similar	24-hour	cycle	pattern	(Figure	43),	
indicating	that	the	increased	resting	heart	rate	is	not	due	to	a	disturbed	circadian	rhythm	nor	heart	
rate	fluctuations.	
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Figure	43	Heart	rates	of	NKXUS∆-/-	and	NKXUS∆+/+	animals	showed	a	similar	pattern	over	24hrs.	
Plotting	of	the	average	heart	rate	per	hour	did	not	show	any	signs	of	heart	rate	variability	in	
NKXUS∆-/-	mice	compared	to	NKXUS∆+/+	mice.	NKXUS∆-/-	mice	showed	the	same	heart	rate	pattern	
as	NKXUS∆+/+	mice.	Data	presented	as	mean	±	SD,	n=9-10.	
	
	
2.8.8.5 Increased	resting	heart	is	not	due	to	higher	activity	or	elevated	body	
temperature	
Higher	heart	rates	in	the	resting	period	of	the	day	could	result	from	NKXUS∆-/-	mice	being	more	
active.	Looking	at	the	activity	data	recorded	by	the	telemetry	device,	did	not,	however,	show	any	
significant	differences	in	mouse	activity,	nor	body	temperature,	during	day	or	night	time	(Figure	
44).		
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Figure	44	Activity	and	body	temperature	are	not	changed.	Mouse	activity	and	body	temperature	
were	not	significantly	changed	during	the	day	or	night	time	between	NKXUS∆-/-	and	NKXUS∆+/+	
mice.	Data	presented	as	mean	±	SD,	n=9-10.	
	
In	summary,	no	difference	in	any	of	the	ECG	parameter	intervals	was	detected,	indicating	
that	the	propagation	of	the	electrical	signal	from	the	sinoatrial	node	throughout	the	heart	is	not	
altered.	Heart	rates	of	NKXUS∆-/-	mice	did	not	seem	to	vary	considerably	more	than	NKXUS∆+/+	mice	
over	24hrs,	indicating	that	the	averaged	increased	heart	rates	are	not	due	to	alternating	high	and	
low	heart	rates.	Furthermore,	circadian	rhythm	did	not	seem	to	be	affected,	as	heart	rates	were	
lower	during	the	day	and	higher	during	the	night	time,	as	was	expected.	Neither	higher	activity	nor	
higher	body	temperature	could	explain	the	increased	resting	heart	rate.	Therefore,	there	are	two	
possible	causes.	An	altered	heart	rate	can	reflect	a	disturbed	function	of	the	sinoatrial	node	(SAN)	
or	the	autonomic	nervous	system.	Within	the	autonomic	nervous	system,	the	sympathetic	nervous	
system	activates	the	“fight	or	flight”	response,	thus	increases	the	heart	rate.	However,	since	the	
sympathetic	is	less	active	while	the	mice	are	at	rest,	we	suspect	that	the	heart	rate	difference	is	due	
to	a	dysfunction	in	the	SAN.	
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2.8.9 Pacemaker	activity	analysis	
The	telemetry	study	identified	that	NKXUS∆-/-	mice	have	an	increased	resting	heart	rate	compared	
to	NKXUS∆+/+	mice,	which	might	be	due	to	an	increased	firing	rate	of	the	SAN.	The	SAN	is	the	
pacemaker	of	the	heart,	where	the	heart	beat	is	initiated	and	coordinated.	To	analyse	for	
differences	in	SAN	beating	rate,	we	dissected	the	SAN	regions	from	NKXUS∆+/+	and	NKXUS∆-/-	mice	
for	calcium	imaging	(Figure	46A).		
	
	
2.8.9.1 SAN’s	of	NKXUS∆-/-	mice	exhibit	a	higher	beating	frequency	
Calcium	imaging	was	performed	on	dissected	SAN	preparations	of	male	NKXUS∆-/-	and	NKXUS∆+/+	
mice,	aged	10-12	weeks	old.	The	SANs	were	dissected	with	the	right	atrium	and	part	of	the	
interatrial	septum	as	well	as	inferior	and	superior	vena	cava	still	attached	(Figure	45A).	To	detect	
intracellular	calcium	mobilisation,	a	calcium	sensitive	dye,	Cal-520	(AAT	Biosystem),	was	added	to	
the	tissue	preparation.	Cal-520	can	cross	the	cell	membrane	and,	upon	binding	to	calcium	inside	
the	cell,	its	fluorescence	is	greatly	increased	(Figure	45A).	The	tissue	samples	were	imaged	while	
perfused	with	Tyrode	solution	at	37°C.	
Calcium	imaging	of	SAN	preparation	at	37°C	revealed	a	significant	increased	beating	rate	in	
NKXUS∆-/-	(388	±	10.4bpm)	compared	to	NKXUS∆+/+	SANs	(340	±	14.8bpm)	(Figure	45B).	To	analyse	
for	any	differences	in	the	response	to	heart	rate	lowering	and	increasing	drugs,	two	drugs	were	
administered.	First,	we	applied	Ivabradine	(IVA),	which	specifically	blocks	the	pacemaker	HCN	
channels,	thereby	decreasing	the	heart	rate.	Second,	we	applied	Isoproterenol	(ISO),	which	is	a	β-
adrenoreceptor	agonists	that	functions	by	binding	to	β-adrenoceptors,	thereby	increasing	the	heart	
rate	by	mimicking	the	actions	of	sympathetic	adrenergic	stimulation.	Perfusion	with	3µM	IVA	
showed	the	expected	decrease	in	heart	rate;	however,	no	significant	differences	were	observed	in	
the	response	to	the	drug	(Figure	45B	and	C).	The	heart	rate	decreased	in	NKXUS∆+/+	SANs	by	~15%	
and	NKXUS∆-/-	SANs	by	~20%	(Figure	45C).	Upon	β-adrenergic	stimulation	(1µM	ISO)	the	heart	rate	
increased	to	~490bpm	in	both,	NKXUS∆+/+	and	NKXUS∆-/-,	preparations	(Figure	45B)	with	a	
significant	difference	in	the	mean	change	before	and	after	ISO	treatment	(Figure	45D).	NKXUS∆+/+	
SANs	showed	a	greater	response	to	ISO	with	a	heart	rate	increase	by	~45%	whereas	NKXUS∆-/-	SANs	
were	less	responsive	(~25%	increase)	(Figure	45D).	
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Furthermore,	to	identify	any	disturbances	in	impulse	formation,	the	tissues	were	paced	for	
20s	at	50V	to	measure	the	sinoatrial	node	recovery	time	(SANRT).	The	SANRT	is	defined	as	the	
interval	between	the	last	paced	beat	and	the	first	spontaneous	one.	The	SANRT	was	corrected	
(cSANRT)	for	the	cycle	length	measured	immediately	prior	to	pacing.	The	cSANRT	was	slightly	
prolonged	in	NKXUS∆+/+	preparations,	however	did	not	reach	significance	(Figure	45E),	indicating	
that	the	recovery	of	normal	beat	pattern	is	not	altered.		
In	summary,	we	identified	an	increased	beating	rate	in	NKXUS∆-/-	SAN	preparations,	which	
showed	a	normal	response	to	IVA	and	normal	impulse	formation,	however	are	less	responsive	to	
ISO	treatment.	
	
	
Figure	45	Increased	beating	rate	in	isolated	SAN	preparation	of	NKXUS∆-/-	mice.	A)	SAN	
preparation	during	calcium	imaging.	RA=	right	atrium;	IVC=	inferior	vena	cava;	SVC=	superior	vena	
cava.	B)	Beating	rate	of	NKXUS∆-/-	SAN	preparations	was	significantly	increased	under	control	
conditions	(start)	but	not	after	perfusion	with	IVA	(3µM)	and	ISO	(1µM).	C-D)	The	change	in	heart	
rate	before	and	after	drug	treatment	showed	no	difference	for	IVA	(C),	but	a	significant	change	in	
the	response	to	ISO	(D).	E)	The	cSANRT	is	slightly	changed	but	not	significant.	Data	presented	as	
mean	±	SD,	n=9-10,	*P<0.05,	unpaired	two-tailed	t-test.	
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Cardiovascular	disease	is	a	global	problem	and	especially	affects	the	elderly	population	(<65	years)	
[252,	253].	Worldwide	the	average	life	span	is	increasing	leading	to	an	increased	incidence	of	CVD,	
which	will	place	a	major	burden	on	health	care	systems	[252].	Despite	decades	of	research	to	
better	understand	the	mechanisms	driving	CVD,	the	molecular	and	genetic	basis	of	CVD	
development	remains	largely	unknown.	Heart	development	and	function	are	regulated	by	a	
network	of	transcription	factors	and	disruption	of	this	network	has	catastrophic	outcomes	for	the	
cardiovascular	system.	Though	many	of	these	transcriptional	regulators	are	known	and	well	
studied,	the	complete	picture	remains	unresolved.		
The	recent	discovery	of	lncRNAs	as	a	new	class	or	regulators	reveals	an	additional	layer	of	
regulation	of	gene	regulatory	networks.	LncRNAs	play	major	roles	in	many	biological	processes,	
including	development,	cell	cycle	regulation,	response	to	stress	and	regulation	of	transcription,	and	
are	associated	with	numerous	human	diseases	[101,	254,	255].	To	date,	thousands	of	lncRNAs	have	
been	identified,	but	their	precise	function	in	vivo	has	only	been	determined	for	a	small	fraction,	
leaving	the	in	vivo	function	for	most	lncRNAs	less	understood	[255].	So	far,	most	studies	have	
focused	on	global	expression	or	potential	function	of	lncRNAs,	by	analysing	healthy	versus	disease	
tissue	or	comparison	of	different	tissues	or	developmental	stages,	and	only	a	limited	amount	of	
lncRNAs	have	been	investigated	in	detail.	While	a	number	of	lncRNAs	have	been	identified	to	play	
central	roles	in	cardiac	development	and	disease,	still	thousands	remain	uncharacterised	[101,	151,	
152].	Studies	have	shown	that	at	least	100	are	specifically	expressed	in	the	heart,	highlighting	the	
abundant	opportunities	for	novel	discoveries	of	yet	uncharacterised	cardiac	lncRNAs	[156-159].	
Interestingly,	GWAS	studies	have	identified	that	a	large	proportion	(>90%)	of	trait-	and	disease	
associated	SNPs	lie	within	non-coding	regions	of	the	genome,	of	which	~85%	lie	within	haploblocks	
expressing	non-coding	transcripts,	raising	the	possibility	that	the	GWAS	phenotype	could	be	due	to	
disruption	of	non-coding	transcripts	[161,	163,	256,	257].	Indeed,	many	lncRNAs	have	been	
identified	to	contain	genetic	risk	factors	and	have	already	contributed	to	a	better	understanding	of	
the	genetics	of	human	diseases	[108,	160].	Thus,	functional	characterisation	of	novel	non-coding	
transcripts	harboring	disease	associated	SNPs	remains	a	crucial	goal	to	understand	how	these	
transcripts	contribute	to	disease	and	will	thus	lead	to	advancements	in	precision	medicine	and	
human	health.		
Regarding	the	heart,	NKX2-5	is	one	of	the	key	regulators	of	heart	development	and	thus	
essential	for	survival	of	mouse	embryos	[258,	259].	Numerous	mutations	within	NKX2-5	have	been	
associated	with	congenital	heart	disease	[258,	260].	However,	even	though	Nkx2-5	has	been	the	
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focus	of	many	studies	in	the	last	two	decades,	the	exact	molecular	mechanism	of	its	function	and	
regulation	remains	still	largely	unknown.	By	scanning	the	transcriptional	landscape	of	the	Nkx2-5	
locus,	we	detected	previously	unrecognised	cardiac	RNA	expression	downstream	and	upstream	of	
Nkx2-5.	For	this	reason,	the	potential	involvement	of	these	transcripts	(NkxDS	and	NkxUS)	in	the	
regulation	of	Nkx2-5	or	other	genes	important	for	heart	development	and/or	function	was	
investigated.		
This	discussion	is	divided	into	two	parts.	The	first	part	will	describe	the	identification	and	
characterisation	of	NkxDS	(downstream	transcript)	and	its	relationship	to	Nkx2-5.	The	second	part	
will	first	describe	the	localisation	and	expression	of	NkxUS	(upstream	transcript),	followed	by	the	
functional	characterisation	of	NkxUS	in	vitro	as	well	as	in	vivo.	
	
	
3.1 Discovery	of	a	novel	isoform	of	Nkx2-5	
Detailed	structural	analysis	showed	that	mouse	NkxDS	is	a	long,	polyadenlyated	transcript	that	can	
be	continuous	with	and	contains	the	coding	region	of	Nkx2-5,	suggesting	that	NkxDS	represents	a	
novel	transcript	isoform	of	Nkx2-5	generated	by	differential	termination	and	polyadenylation	
(Figure	8).	A	similar	transcript	was	identified	in	humans	(Figure	15),	although	continuity	has	not	
been	confirmed	yet.	Interestingly,	Nkx2-5	and	NkxDS	shared	a	similar	expression	pattern	in	mouse	
tissues	being	cardiac	enriched,	more	precisely	in	the	myocardium,	but	also	showing	expression,	
although	at	much	lower	levels,	in	adult	spleen	and	tongue,	which	has	been	previously	described	for	
Nkx2-5	(Figure	9)	[187].	Moreover,	NkxDS	followed	the	expression	dynamics	of	Nkx2-5	in	mouse	
and	human	differentiating	cardiomyocytes	(Figure	10	and	18),	although	NkxDS	was	more	lowly	
expressed,	suggesting	that	both	transcripts	are	co-regulated	and	may	function	at	similar	
timepoints.	As	many	lncRNAs	were	identified	to	be	cell-type	specific,	it	would	be	of	interest	to	
investigate	whether	NkxDS,	as	for	Nkx2-5,	is	also	expressed	in	other	cardiac	cell-types,	or	if	it	is	
cardiomyocyte-specific	[261].	In	contrast,	even	though	NkxDS	contains	the	Nkx2-5	protein-coding	
region,	its	cellular	localisation	and	polysome	association	was	quite	different.	NkxDS	was	detected	
almost	exclusively	in	the	nucleus	whereas	Nkx2-5	was	enriched	in	the	cytoplasm	(Figure	12),	as	
expected	for	an	mRNA.	Consistent	with	its	subcellular	localisation,	NkxDS	showed	no	or	minimal	
association	with	polysomes	(Figure	13),	whereas	Nkx2-5	was	clearly	polysome-associated	as	
expected	for	a	well	translated	mRNA.	This	suggests	that,	when	the	extended	3’UTR	NkxDS	tail	is	
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attached,	the	transcript	is	retained	in	the	nucleus	and	thus	may	not	be	accessible	for	translation.	In	
fact,	several	recent	studies	have	identified	genes	producing	protein-coding	and	non-coding	
isoforms	[262-265].	These	bifunctional	RNAs	were	found	to	be	generated	by	various	post-
transcriptional	mechanisms	including	alternative	splicing,	intron	retention,	RNA	modifications	as	
well	as,	similar	to	our	case,	differential	polyadenylation	[262,	263].	Their	coding	and	non-coding	
isoforms	were	shown	to	have	distinct	functions	and	can	be	separated	either	temporally	with	
expression	and	function	at	different	developmental	stages,	or	spatially	in	different	cellular	or	
subcellular	compartments	[263].	Since	NkxDS	and	Nkx2-5	showed	a	similar	expression	pattern,	but	
different	cellular	localisations,	they	could	have	distinct	functions	within	these	different	
compartments.	However,	since	NKX2-5	is	as	a	transcription	factor	and	thus	expressed	in	the	
nucleus,	NKX2-5	and	NkxDS	may	be	involved	in	similar	nuclear	processes.	The	mechanism	of	how	
differential	polyadenylation	is	regulated	and	how	NkxDS	is	retained	in	the	nucleus	remains	
unknown	and	would	be	of	great	interest	for	future	studies.	Elements	residing	within	the	long	NkxDS	
tail	could	determine	non-coding	versus	coding	or	nuclear	versus	cytoplasmic	localisation	as	was	
identified	for	several	bifunctional	RNAs	[264,	266].	In	several	cases,	differential	polyadenylation	was	
shown	to	be	regulated	by	proteins.	In	the	case	of	NEAT1,	HNRNPK	was	identified	to	inhibit	
polyadenylation	of	the	shorter	transcript,	NEAT1_1,	which	then	resulted	in	the	production	of	the	
long	isoform,	NEAT1_2	[267].	Using	online	prediction	tools,	a	few	HNRNPK	sites	have	been	found	
around	the	Nkx2-5	polyadenylation	site	(data	not	shown);	however,	association	of	HNRNPK	to	any	
of	these	sites	has	yet	to	be	investigated.		
Analysis	of	the	known	bifunctional	transcripts	revealed	diverse	functions	as	observed	for	
lncRNAs	[262,	263,	265,	268].	NkxDS	and	NKX2-5	could	act	antagonistically	to	regulate	each	other,	
crosstalk,	or	the	long	non-coding	NkxDS	tail	could	harbor	miRNA	or	protein	binding	sites	and	
thereby	act	as	a	miRNA	sponge	or	competing	RNA.	It	is	noteworthy	that	previous	Nkx2-5	knockout	
mouse	models	targeted	the	coding	region	of	Nkx2-5,	thus	would	have	also	disrupted	NkxDS	[74,	75,	
269].	To	determine	the	specific	functions	of	Nkx2-5	and	NkxDS,	systematic	analyses	of	mutants	in	
which	specifically	NkxDS	is	disrupted	versus	those	that	affect	the	protein-coding	capacity	of	Nkx2-5	
have	to	be	performed.	One	Nkx2-5	mouse	model	exists,	which	expresses	nuclear-localising	Cre	
Recombinase	protein	from	the	3'UTR	of	Nkx2-5,	thus	does	not	affect	the	Nkx2-5	coding	region	[71].	
In	contrast	to	Nkx2-5	null	mutations,	these	mice	are	viable	as	homozygous,	but	interestingly	
express	only	~50%	of	the	normal	NKX2-5	protein	levels	[71].	However,	since	the	insertion	might	
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have	altered	miRNA	or	protein	binding	sites	within	the	3'UTR	of	Nkx2-5,	this	mouse	model	is	not	
suitable	to	determine	a	specific	NkxDS	function	[71].	
In	conclusion,	the	essential	cardiac	transcription	factor	Nkx2-5	may	have	a	coding	and	non-
coding	function	and	analysis	of	the	specific	function	of	NkxDS	has	the	potential	to	reveal	a	new	
regulatory	mechanism	of	Nkx2-5	and/or	of	heart	development.		
 
	
3.2 NkxUS	is	a	cardiac	specific	lncRNA	involved	in	the	regulation	of	cardiac	
conduction	
3.2.1 	NkxUS	is	retained	in	the	nucleus	
This	work	identified	NkxUS	as	a	novel,	polyadenylated	lncRNA	(Figure	8).	NkxUS	is	expressed	in	
cardiac	tissues	throughout	mouse	development	with	nuclear-enriched	expression	but	no	specific	
sub-nuclear	localisation	(Figure	49D4	and	12),	suggesting	that	it	functions	within	the	nucleus	but	not	
in	a	particular	sub-nuclear	organelle.	Nuclear	expression	was	observed	for	the	majority	of	lncRNAs,	
which	were	shown	to	be	involved	in	chromatin	organisation	and	regulation	of	transcriptional	and	
post-transcriptional	gene	expression	[101,	112,	270].	Consistent	with	its	exclusive	nuclear	
expression,	no	or	minimal	association	with	polysomes	and	no	coding	potential	was	identified	
(Figure	13	and	14),	suggesting	that	NkxUS	is	truly	non-coding.	However,	there	is	still	the	possibility	
that	NkxUS	encodes	a	micropeptide,	although	analysis	using	PhyloCSF	makes	this	possibility	unlikely	
(Figure	14)	and	was	not	further	investigated.		
Taken	together,	nuclear	with	no	sub-nuclear	expression	of	NkxUS	narrows	down	the	list	of	the	
potential	functions	and	suggests	that	NkxUS	may	play	a	role	in	epigenetic,	transcriptional	and/or	
posttranscriptional	control	or	chromatin	remodeling.	
	
	
3.2.2 Mouse	NkxUS	is	tissue	specific	in	adult	mice	
Expression	analysis	revealed	that	NkxUS	is	in	adults	specifically	expressed	in	cardiac	tissues	(Figure	
9A).	In	situ	hybridisation	showed	that	early	in	development	NkxUS	is	also	expressed	in	lung	and	
neural	tube	(Figure	9G),	however	no	expression	in	these	tissues	was	observed	in	later	stages,	and	
the	function	of	NkxUS	in	these	tissues	was	not	further	explored.	During	differentiation	of	mouse	
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embryonic	stem	cells	into	embryoid	bodies	enriched	for	cardiomyocytes,	NkxUS	was	lowly	
expressed	at	day	0	to	4	(Figure	10A),	suggesting	that	it	does	not	play	a	role	in	maintaining	
pluripotency	or	early	differentiation	of	germ	layers.	In	the	time	course	analysis,	Nkx2-5	and	NkxUS	
showed	a	similar	dynamic	expression	pattern	(Figure	10A),	suggesting	that	they	may	function	at	
similar	timepoints	and/or	through	related	pathways.	The	expression	was	highest	at	day	7	during	
cardiomyocyte	enriched	differentiation	(Figure	10A),	which	approximately	resembles	the	cardiac	
crescent	stage	when	cardiac	mesodermal	tissues	start	to	develop,	suggesting	that	NkxUS	may	be	
important	for	cardiomyocyte	differentiation,	similar	to	what	was	shown	for	Nkx2-5	[180,	271,	272].	
However,	NkxUS	was	much	more	lowly	expressed	compared	to	Nkx2-5	(Figure	10B).		
Interestingly,	the	in	situ	hybridisation	showed	some	distinct	differences	between	both	
transcripts.	NkxUS	showed	a	predominately	endocardial	expression	whereas	Nkx2-5	was	expressed	
mostly	in	the	myocardium	(Figure	9D-H),	although	Nkx2-5	is	also	known	to	be	expressed	in	the	
endocardium	of	the	forming	heart	tube	[71,	261].	Nevertheless,	low-level	NkxUS	expression	was	
also	observed	in	the	myocardium	early	in	development	(Figure	9D)	and	also	in	isolated	and	
differentiating	cardiomyocytes	(Figure	9B,	10	and	11).	However,	NkxUS	expression	in	endocardial	
cells	may	be	higher,	which	remains	to	be	analysed,	since	no	endocardial	cell	line	was	available.	
Moreover,	NkxUS	showed	a	strong	in	situ	expression	in	the	valve	leaflets	before	and	after	birth,	
whereas	no	expression	was	observed	for	Nkx2-5	nor	NkxDS	in	this	tissue	before	birth	(Figure	9F,	
49E3	and	F3).	The	endocardium	is	crucial	for	valve	development	and	since	NkxUS	is	predominately	
expressed	in	endocardial	cells,	NkxUS	could	be	important	for	the	function	or	development	of	the	
valves,	which	could	be	analysed	using	a	full	NkxUS	knockout	mouse	[273].	Furthermore,	although	
the	mESC	differentiation	time	course	was	enriched	for	cardiomyocytes,	there	was	also	
differentiation	of	other	cell-types	such	as	endothelial	cells.	Therefore,	the	much	lower	expression	of	
NkxUS	relative	to	Nkx2-5	could	also	mean	that	NkxUS	is	not	critical	for	cardiomyocyte	
differentiation	but	rather	for	the	differentiation	of	the	minor	cell	types,	most	likely	endothelial	
cells,	since	NkxUS	is	at	later	stages	predominately	expressed	in	this	cell	type.		
Taken	together,	NkxUS	and	Nkx2-5	share	many	characteristics,	both	are	predominately	cardiac	
expressed,	expressed	in	cardiomyocytes	and	at	the	same	timepoints	during	mESC	differentiation	
and	mouse	heart	development,	suggesting	co-regulation	and	a	potential	role	for	NkxUS	in	pathways	
and	time	points	related	to	those	involving	Nkx2-5.	
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3.2.3 Human	NkxUS	is	associated	with	an	increased	heart	rate	
Evolutionary	conservation	is	considered	a	powerful	resource	to	identify	functionally	important	
genomic	regions.	Despite	the	lack	of	sequence	conservation	of	most	lncRNAs,	many	to	date	have	
been	identified	or	predicted	to	contain	conserved	RNA	secondary	structures,	which	are	currently	
used	to	propose	functional	relevance	and	interrogated	to	understand	their	broader	roles	[128-130].	
Structural	studies	of	the	lncRNA	Braveheart	identified	a	short	G-rich	secondary	structure,	which	
upon	genetic	perturbation	prevented	cardiomyocyte	differentiation	[274]. 	
For	NkxUS,	a	similar	heart	specific	transcript	was	detected	in	humans	(Figure	15),	although	
the	relative	proximity	to	the	transcriptional	start	site	of	Nkx2-5	and	orientation	was	different.	
Expression	of	NkxUS	was	confirmed	in	human	cardiac	tissues	(Figure	17)	and	showed	similar	
expression	dynamics	to	Nkx2-5	in	pluripotent	stem	cell-derived	cardiac	tissue	(Figure	18).	This	
supports	functional	conservation	of	NkxUS	between	mouse	and	human	and	further	suggests	that,	
as	in	mouse,	human	NkxUS	is	not	involved	in	maintaining	pluripotency	and	may	function	at	time	
points	and	processes	similar	to	those	of	Nkx2-5.	Sequence	conservation	between	species	is	low,	
consistent	with	the	idea	that	lncRNAs	evolved	only	recently.	However,	three	conserved	RNA	
structures	were	identified	within	human	NkxUS	which	map	to	the	start	of	the	second	exon	of	
mouse	NkxUS	(Figure	16),	implying	that	these	might	be	important	for	the	biological	function	of	
NkxUS.	Intriguingly,	a	GWAS	SNP	associated	with	an	increased	resting	heart	rate	and	increased	risk	
for	atrial	fibrillation	lies	within	and	is	predicted	to	totally	disrupt	one	of	these	conserved	structures	
of	human	NkxUS	(Figure	20	and	21),	supporting	functional	relevance	[217].	The	magnitude	of	the	
SNP	effect	was	shown	to	be	small	(0.301bpm),	however,	in	combination	with	other	heart	rate	
increasing	SNPs	the	effect	size	reached	clinical	relevance	with	an	increase	in	resting	heart	rate	of	up	
to	4bpm	in	adults	[217].	Moreover,	the	GWAS	SNP	was	part	of	a	common	haplotype	and	it	is	
possible	that	the	NKXUS	SNP	is	not	the	causal	variant.	Haplotype	analysis	revealed	five	SNPs	in	high	
LD	with	the	NKXUS	SNP	(Figure	22);	three	of	them	map	to	the	first	exon	of	NKXUS	not	overlapping	
any	of	the	conserved	structures,	one	maps	to	an	intergenic	region	and	one	is	a	synonymous	
mutation	within	NKX2-5.	While	NKX2-5	protein	is	likely	not	affected	by	this	SNP,	the	SNP	could	still	
affect	binding	sites	for	interacting	partners	or	splicing	of	the	mRNA,	which	we	did	not	test	[226].	
However,	since	the	NKXUS	SNP	lies	within	the	conserved	structure	of	a	cardiac	specific	transcript	
and	is	predicted	to	alter	this	structure,	we	proposed	that	the	NKXUS	SNP	is	the	causal	variant	and	
further	explored	the	potential	function	of	NkxUS.	
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3.2.4 NkxUS	knockdown	in	HL-1	cells	affects	genes	involved	in	cardiac	contraction	
LncRNAs	employ	a	variety	of	gene	regulatory	mechanisms	[112,	139,	142].	They	are	able	to	directly	
bind	to	target	genes,	act	as	decoys,	guides,	signals	or	as	scaffolds	for	transcription	factors	and	
histone	modifiers	to	activate	or	inhibit	the	expression	of	target	genes	[112,	142].	To	explore	the	
function	of	NkxUS,	we	intended	to	first	identify	the	biological	processes	and	pathways	NkxUS	is	
influencing	
Downregulation	of	NkxUS	in	HL-1	cells	resulted	in	predominately	an	upregulation	of	
transcripts	(Figure	23),	suggesting	that	NkxUS	has	an	inhibitory	role	either	directly	for	example	by	
associating	with	histone	modifying	proteins	or	indirectly	for	example	through	the	act	of	its	
transcription	or	genome	organisation,	as	shown	for	many	lncRNAs	[104,	144,	145].	Of	note,	Nkx2-5	
mRNA	and	NkxDS	were	not	altered	upon	NkxUS	knockdown,	indicating	that	NkxUS	does	not	affect	
their	gene	expression.	However,	whether	Nkx2-5	is	altered	at	the	protein	level	following	
knockdown	has	not	been	investigated.	
GO	terms	associated	with	the	upregulated	transcripts	were	enriched	for	regulation	of	
transport,	signaling	and	cell	communication,	as	well	as	cardiac	conduction	and	contraction	
associated	terms	(Figure	24).	Since	the	GWAS	SNP	in	NKXUS	is	associated	with	an	altered	heart	rate	
and	since	NKXUS∆-/-	mice	exhibit	an	increased	resting	heart	rate	(Figure	40),	we	focused	on	the	
cardiac	contraction	and	conduction	associated	terms	(Figure	24).	The	transcripts	within	these	terms	
were	also	included	in	the	most	significant	terms,	regulation	of	transport,	signaling	and	cell	
communication.	Most	of	these	transcripts	were	ion	channels,	regulators	of	ion	channels	as	well	as	
genes	involved	in	cAMP	production	(Figure	24	and	46).		
cAMP	is	an	important	secondary	messenger,	which	in	the	heart	triggers	the	activation	of	ion	
channels	and	is	therefore	critical	for	cardiac	contraction.	Stimulation	of	cardiomyocyte	G	protein-
coupled	β-adrenergic	receptors	(β-AR)	by	epinephrine	or	norepinephrine,	leads	to	the	activation	of	
an	associated	stimulating	G	protein	(Gs),	which	in	turn	activates	adenylate	cyclases	to	form	cAMP	
from	ATP	(Figure	46).	The	resulting	cAMP	interacts	with	and	regulates	cyclic	nucleotide-gated	ion	
channels,	such	as	HCN	channels,	as	well	as	protein	kinase	A	(PKA)	(Figure	46).	PKA	enhances	
contractility	and	calcium	transients	by	phosphorylating	a	range	of	proteins,	including	the	L-	and	T-
Type	calcium	channels,	HCN	channels,	G	protein-coupled	inwardly-rectifying	potassium	channels	
(GIRKs),	the	ryanodine	receptor	(RYR)	and	phospholamban	(PLB)	(Figure	46).	Upon	phosphorylation,	
PLB	detaches	from	SERCA,	which	is	then	activated.	SERCA	is	an	ATPase	which,	at	the	cost	of	ATP,	
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transfers	calcium	back	into	the	SR	during	diastole.	Additionally,	parasympathetic	triggered	release	
of	acetylcholine	activates	cholinergic	receptors,	which	are	also	GPCRs	and	can	either	activate	an	
inhibitory	G	protein	(Gi)	subunit,	which	inhibits	adenylate	cyclases,	or	an	activating	β-G	protein	(Gβ)	
subunit	which	activates	GIRKs	(Figure	46)	[26].	Parasympathetic	activation	can	be	modulated	by	
RGS6,	which	inhibits	Gβ	as	well	as	Gi	(Figure	46)	[245,	275].	Interestingly,	GIRKS	are	also	activated	
upon	sympathetic	induced	β-adrenergic	stimulation	through	PKA	(Figure	46)	[276].	
All	of	these	proteins	mentioned	and	illustrated	in	Figure	46	(except	β-adrenergic	receptors,	
PKA	and	T-Type	calcium	channels)	are	upregulated	at	the	mRNA	level	in	our	dataset,	indicating	that	
NkxUS	may	play	a	role	in	regulating	gene	expression	of	cardiac	cAMP	signaling	components.	
Interestingly,	Rgs6	was	also	identified	in	the	DNA	ChIRP	(Table	7),	indicating	that	NkxUS	may	under	
normal	circumstances	bind	to	Rgs6	to	negatively	influence	its	transcription.	However,	Rgs6	was	
only	identified	in	one	ChIRP	replicate	and	chromatin	association	has	not	been	verified	yet.	
	
Figure	46.	Several	upregulated	genes	are	involved	in	cardiac	cAMP	signaling.	Schematic	of	
components	involved	in	regulation	of	cardiac	contraction	via	cAMP	signaling.	Ach=	Acetylcholine;	
Epi=	Epinephrine;	NE=	Norepinephrine;	GPCR=	G	protein-coupled	receptor;	Gi=	inhibitory	G	protein;	
Ga=	activating	G	protein;	Gβ=	activating	β-G	protein;	PKA=	Protein	kinase	A;	Girk=	G	protein-coupled	
inwardly-rectifying	potassium	channels;	PLB=	Phospholamban;	RYR=	ryanodine	receptor;	SR=	
Sarcoplasmic	reticulum;	SERCA=	Sarcoplasmic/endoplasmic	reticulum	calcium	ATPase	2a;	HCN=	
Hyperpolarisation-activated	cyclic	nucleotide–gated	channel;	RGS6=	Regulator	of	G	protein	
signaling	6.	
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3.2.5 NkxUS	may	bind	to	genes	involved	in	the	regulation	of	transcription	and/or	G	
protein-coupled	receptor	signaling	
Many	lncRNAs	reside	in	the	nucleus	and	target	specific	genomic	loci	directly	to	regulate	gene	
expression	[112,	139].	Analysis	of	DNA	binding	region	of	NkxUS	using	DNA	ChIRP	revealed	a	limited	
number	of	candidates	(Figure	27).	Using	the	EVEN	and	ODD	strategy	and	comparing	biological	
replicates,	we	did	not	see	compelling	enrichment	across	the	two	replicates	and	probe	sets	and	only	
identified	two	targets	(Grm8	and	Ptprk),	which	could	have	been	due	to	several	factors.	It	could	
either	be	that	1)	NkxUS	does	not	bind	DNA,	2)	we	did	not	enrich	for	NkxUS	efficiently	or	3)	NkxUS	
only	binds	at	these	few	sites.	However,	2)	seems	less	likely	since	we	observed	peak	enrichment	at	
the	NkxUS	locus	(9	out	of	the	11	shared	peaks)	(Figure	27),	which	is	a	positive	control	for	the	
technical	part	of	the	experiment	as	it	represents	nascent	transcription	of	NkxUS.	In	our	experiment	
we	retrieved	10-20%	of	NkxUS	(Figure	27).	However,	higher	NkxUS	yields	might	improve	the	signal-
to-noise	ratio	and	thus	potentially	identify	additional	targets	and/or	result	in	an	improved	overlap	
between	replicates	if	NkxUS	indeed	binds	to	chromatin.	In	comparison,	the	original	ChIRP	
publication	retrieved	88-95%	of	their	lncRNAs	of	interest	[239].	However,	these	were	quite	
abundant	lncRNAs	and	hence	lead	to	more	efficient	pull-down.	Nevertheless,	with	the	peak	
enrichment	detected	at	the	NkxUS	locus	and	the	observed	specific	NkxUS	yield	(Figure	27),	we	can	
be	confident	that	NkxUS	was	successfully	captured.	Therefore,	it	could	either	be	that	NkxUS	does	
not	bind	DNA	or	only	to	these	few	locations.	
Looking	at	the	overlap	between	biological	replicates	revealed	two	genes,	Grm8	and	Ptprk	
(Figure	27).	We	could	have	lost	a	lot	of	shared	peaks	due	to	differences	in	NkxUS	yield	between	the	
two	biological	replicates,	EVEN3/ODD3	retrieved	more	NkxUS	RNA	than	EVEN2/ODD2	(Figure	27A)	
and	four	times	more	shared	peaks,	which	could	explain	the	limited	number	of	overlap	between	the	
two	biological	replicates.	Therefore,	we	thought	it	is	reasonable	to	also	investigate	the	12	and	48	
peaks	shared	between	EVEN2/ODD2	and	EVEN3/ODD3,	respectively,	and	analyse	whether	these	
have	a	related	function	to	Grm8	and	Ptprk	(Figure	27B).	When	intersecting	the	individual	
experiments,	several	additional	potential	DNA	targets	with	similar	function	to	Grm8	and	Ptprk	were	
identified	(Table	6).	
Grm8	is	a	G	protein-coupled	receptor	for	glutamate	and	its	signaling	is	known	to	inhibit	
adenylate	cyclase	activity.	Interestingly,	altogether	five	genes	detected	by	DNA	ChIRP	(Grm8,	Npr3,	
Rgs6,	Kctd16	and	Olfr211)	were	identified	to	be	involved	in	G	protein-coupled	receptor	signaling	
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and,	all	except	Rgs6,	were	shown	to	inhibit	adenylate	cyclase	activity,	thus	preventing	the	
formation	of	cAMP	[277,	278].	The	observation	that	several	of	the	ChIRP	identified	genes	inhibit	
adenylate	cyclases	is	intriguing	and	consistent	with	the	RNA	sequencing	results,	in	which	adenylate	
cyclases	and	its	downstream	targets	such	as	calcium	and	HCN	channels	were	upregulated.	
Potentially,	NkxUS	binding	to	these	genomic	loci	under	normal	circumstances	enhances	gene	
expression	and	therefore	inhibits	adenylate	cyclases,	which	are	important	to	regulate	cardiac	
contraction.	Although,	apart	from	Rgs6,	for	none	of	the	other	genes	a	cardiac	role	has	been	
described	to	date,	even	though	they	are	expressed	in	cardiac	tissue.	Grm8	is	known	to	function	in	
the	neurotransmission	of	glutamate	and	it	is	associated	with	several	neuropathological	conditions	
including	schizophrenia	and	depression	[279,	280].	Its	function	in	the	heart	is	unexplored.	However,	
a	GWAS	study	associated	Grm8	with	PR	interval,	supporting	a	role	in	cardiac	conduction,	although	
the	study	did	not	indicated	whether	the	PR	interval	increased	or	decreased	[281].	Another	recent	
study	analysed	brain	tissues	from	patients	with	sudden	unexpected	death	in	epilepsy,	which	
proposed	that	among	others,	cardiac	dysfunction	has	a	causal	link	to	epilepsy	[282].	The	study	
identified	several	variants	in	genes	associated	with	cardiac	arrhythmia	as	well	as	Grm8,	further	
supporting	a	cardiac	role	[282].	This	is	consistent	with	several	ion	channels,	among	other	for	
example	Kcnh2,	which	are	associated	with	long	QT	syndrome	and	epilepsy	as	most	ion	channels	are	
expressed	in	excitable	cells	of	the	heart	and	brain	[283].	Additionally,	as	previously	mentioned,	
Rgs6	was	also	upregulated	upon	NkxUS	knockdown	in	cardiac	cells,	making	it	a	valuable	candidate	
for	follow	up	studies	as	its	function	in	regulating	cardiac	contraction	is	well	described	(Figure	46)	
[245].	Rgs6	is	a	negative	regulator	of	parasympathetic	regulation	of	heart	rate	and	mice	lacking	
RGS6	exhibit	bradycardia,	therefore	an	upregulation	of	Rgs6	would	result	in	an	increased	heart	rate	
(Figure	46)	[245,	275,	284].	
The	second	gene	identified	through	ChIRP,	Ptprk,	is	involved	in	the	regulation	of	cell	
adhesion,	cell	cycle	and	transcription	as	are	Cadm2,	Cdc73,	Ercc6,	Opcml,	Tnik	and	Sfi1.	The	role	of	
Ptprk	in	tumor	suppression	and	in	the	nervous	system	is	well	studied,	but	although	expressed	in	the	
heart,	a	specific	cardiac	function	has	not	yet	been	determined	[285,	286].	Mechanisms	of	tumor	
suppression	involve	regulation	of	β-catenin,	which	is	a	multifunctional	protein	playing	major	roles	
in	cell-cell	adhesion	and	Wnt	signal	transduction	[285,	287].	Wnt/β-catenin	signaling	plays	an	
important	role	during	heart	development	and	is	activated	in	response	to	cardiac	injury	[288,	289].	
Interestingly,	a	recent	study	identified	active	Wnt/β-catenin	signaling	in	developing	SAN	cells	and	
functional	analysis	revealed	that	this	signaling	regulates	the	parasympathetic	control	of	pacemaker	
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activity	and	thereby	heart	rate	[290].	However,	it	remains	unclear	if	Ptprk	plays	a	similar	role	in	the	
heart	to	regulate	β-catenin.	Intriguingly,	three	additional	ChIRP	identified	genes	were	shown	to	
interact	with	β-catenin.	Cdc73,	which	is	a	component	of	the	RNA	polymerase	II	associated	protein	
complex	(PAF),	was	shown	to	positively	regulate	Wnt	signaling	by	directly	binding	to	β-catenin	upon	
dephosphorylation	and	to	be	important	for	cardiomyocyte	specification	and	elongation	of	the	heart	
tube	[291-294].	The	PAF	complex	has	been	shown	to	regulate	a	number	of	transcription-related	
processes	including	3’end	formation	of	polyadenylated	and	nonpolyadenylated	RNA	Polymerase	II	
transcripts,	histone	modification	and	gene	transcription	[295,	296].	Opcml	is	another	cell	adhesion	
protein	and	tumor	suppressor.	Knockdown	in	mice	resulted	in	cell	cycle	arrest	and	an	upregulation	
of	β-catenin	[297].	Moreover,	a	GWAS	study	associated	a	mutation	in	Opcml	with	increased	heart	
rate	variability	[298].	Tnik	is	a	serine/threonine	kinase	that	acts	as	an	essential	activator	of	the	Wnt	
signaling	pathway	and	was	shown	to	directly	interact	with	β-catenin	[299].	It	is	recruited	to	target	
genes	in	a	β-catenin	dependent	manner	to	activate	gene	expression	[299].	Moreover,	it	was	also	
slightly	upregulated	upon	NkxUS	knockdown	(Table	7),	indicating	that	NkxUS	may	negatively	
regulate	Tnik	gene	expression.	Although	all	of	these	genes	are	expressed	in	the	heart,	a	cardiac	
function,	except	for	Cdc73,	has	not	been	determined	to	date	and	studies	mainly	focused	on	their	
role	in	cancer	and	the	nervous	system.		
Moreover,	the	downregulated	transcripts,	Tbx3	and	Wt1,	which	are	involved	in	cardiac	cell	
fate	commitment	are	also	associated	with	Wnt/β-catenin	signaling	(Figure	24).	Wt1	is	a	positive	
upstream	regulator	of	the	Wnt/β-catenin	signaling	pathway.	Loss	of	Wt1	resulted	in	a	
downregulation	of	Ctnnb1	(β-catenin)	and	other	components	of	the	signaling	pathway	[300].	Tbx3	
is	a	transcription	factor	and	plays	a	major	role	in	cardiac	development	and	the	formation	of	the	
sinoatrial	node	[301].	Tbx3	lies	downstream	of	the	β-catenin	signaling	pathway	and	was	in	cancer	
studies	shown	to	be	directly	and	positively	transcriptionally	regulated	by	β-catenin	[302,	303].	
In	summary,	since	the	DNA	ChIRP	identified	several	genes	with	similar	functions	to	Grm8	
and	Ptprk	and	to	transcripts	deregulated	in	the	NkxUS	knockdown	experiment,	NkxUS	may	indeed	
bind	to	those	genomic	locations	and	function	in	the	negative	regulation	of	adenylate	cyclases	or	in	
Wnt/β-catenin	signaling.	However,	similar	to	ChIP-sequencing	results,	not	all	binding	sites	are	often	
functional	and	additional	follow	up	experiments	using	independent	ChIRP	experiments	followed	by	
RT-PCRs	are	required	to	validate	NkxUS	binding	to	these	regions.		
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3.2.6 NkxUS	potentially	associates	with	proteins	that	can	localise	to	the	nucleus	
and	mitochondrion	
Cardiac	contraction	and	relaxation	is	a	highly	energy	demanding	process,	relying	on	the	production	
and	consumption	of	an	immense	amount	of	ATP	every	day,	which	matches	roughly	our	body	weight	
[304].	~90%	of	ATP	is	produced	by	mitochondrial	oxidative	phosphorylation	in	the	inner	
mitochondrial	membrane,	thus	mitochondria	play	an	essential	role	in	controlling	cardiac	
contraction	[305].	To	meet	the	hearts	energy	requirement	for	contraction	and	relaxation,	
cardiomyocytes	have	a	high	mitochondrial	content	and	rely	heavily	upon	its	energy	supply.	In	
cardiomyocytes,	ATP	is	needed	to	release	actin	from	myosin	during	cardiac	contraction,	to	restore	
SR	calcium	load	via	the	sarcoplasmic/endoplasmic	reticulum	calcium	ATPase	(SERCA)	during	
relaxation	and	for	the	synthesis	of	cAMP	via	adenylate	cyclases	[305].	Most	mitochondrial	proteins	
are	encoded	in	the	nucleus,	thus	communication	between	these	compartments	is	critical	in	order	
for	the	nucleus	to	respond	to	metabolic	changes	within	the	mitochondria	[306].		
ChIRP	followed	by	MS	to	identify	protein	interacting	partners	of	NkxUS	resulted	in	
enrichment	of	numerous	mitochondrial	proteins	(Figure	31).	Based	on	the	nuclear	localisation	of	
NkxUS	and	higher	mitochondrial	content	in	cardiomyocytes,	we	were	unsure	about	the	accuracy	
and	specificity	of	the	results.	However,	recent	studies	discovered	that	the	nucleus	harbors	several	
mitochondrial	proteins,	with	some	involved	in	the	direct	mitochondria-to-nucleus	communication,	
indicating	that	these	might	directly	link	mitochondrial	metabolism	to	gene	expression	[307-310].	
These	mitochondrial	proteins	were	found	to	exert	their	canonical	functions	within	the	nucleus	as	
well	as	nuclear	specific	functions	including	regulation	of	transcription,	DNA	repair	and	kinase	
activity	[309].	Based	on	the	nuclear	localisation	of	NkxUS	we	first	focused	on	proteins	with	an	
annotated	nuclear	localisation.	Several	mitochondrial	proteins	identified	in	our	work	are	indeed	
also	described	to	localise	to	the	nucleus.	Among	the	most	enriched	ChIRP	detected	mitochondrial	
and	nuclear	proteins	is	the	pyruvate	dehydrogenase	complex	(PDC)	(Table	9),	which	converts	
pyruvate	into	acetyl-CoA	that	contributes	to	oxidative	phosphorylation	and	consists	of	three	
enzymes	[311].	Two	subunits	of	the	first	enzyme,	Pyruvate	dehydrogenase	(PDHA1	and	PDHB),	as	
well	as	the	second	enzyme,	Dihydrolipoyl	transacetylase	(DLAT)	(Table	9),	were	captured	following	
NkxUS	pull-down.	Moreover,	DLAT	was	one	of	the	two	most	enriched	proteins	identified.	PDC	was	
shown	to	translocate	from	the	mitochondria	to	the	nucleus	in	response	to	growth	signals	and	
disrupted	oxidative	phosphorylation	[311].	Within	the	nucleus	it	exerts	its	normal	function	by	
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producing	acetyl-CoA,	which	can	normally	not	cross	the	mitochondrial	membrane	and	is	necessary	
as	a	cofactor	for	histone	acylation	[311].	Histone	acylation	alters	chromatin	accessibility	and	
subsequently	regulates	gene	transcription,	DNA	replication	and	DNA	repair	[312].	Another	protein	
identified	in	our	study,	fumarate	hydratase	(FH)	(Table	9	and	10),	has	emerged	as	a	mitochondrial	
and	nuclear	localised	protein	[313,	314].	Within	the	mitochondrion	it	participates	in	the	
tricarboxylic	acid	(TCA)	cycle	and	within	the	nucleus	in	DNA	repair	by	inhibiting	histone	
demethylation	[313,	315].	Interestingly,	it	was	shown	that	two	groups	of	Fh	mRNAs	are	generated	
by	the	same	gene,	one	group	containing	the	mitochondrial	targeting	sequence,	while	the	other	
lacks	it	and	localises	to	the	cytoplasm	[313].	Upon	DNA	damage,	FH	translocates	to	the	nucleus,	
produces	fumarate,	which	in	turn	is	required	for	the	DNA	damage	response	[313].	Additional	
examples	of	nuclear	localised	proteins	found	in	this	work	are	listed	in	Table	11.	
Altogether,	it	becomes	evident	that	numerous	mitochondrial	enzymes	also	reside	in	the	
nucleus	and	potential	nuclear	roles	for	mitochondrial	proteins	have	to	be	considered	in	the	future	
until	shown	that	they	exclusively	localise	to	mitochondria	[307].	How	many	more	of	the	proteins	
identified	in	this	work	localise	to	the	nucleus	or	may	represent	noise	or	indirect	interacting	partners	
is	difficult	to	determine	and	requires	follow	up	studies.	No	other	ChIRP	study	to	date	has	used	a	
muscle	cell	line,	which	would	have	been	helpful	to	compare	whether	they	also	identified	many	
mitochondrial	proteins.		
Of	the	identified	proteins	with	to	date	no	annotated	nuclear	localisation,	many	are	involved	
in	oxidative	phosphorylation,	which	fuels	the	synthesis	of	ATP	(Figure	32).	The	protein	identified	
within	one	of	the	visible	bands	in	the	gel,	HADHA,	is	part	of	the	fatty	acid	metabolism	pathway	
which	leads	to	the	generation	of	acetyl-CoA,	which	is	then	oxidised	for	energy	production	via	
oxidative	phosphorylation.	ATP	is	essential	for	cardiac	contraction	and	needed	for	the	basal	beating	
of	the	SAN	in	the	absence	of	β-adrenergic	receptor	stimulation.	The	more	ATP	available,	the	more	
can	be	used	for	actin-myosin	contraction,	by	adenylate	cyclases	to	produce	cAMP	and	by	SERCA	to	
pump	calcium	back	into	the	sarcoplasmic	reticulum	to	prime	the	cell	for	the	next	depolarisation.	
ATP	consumption	within	the	SAN	is	tightly	linked	to	ATP	production	within	mitochondria.	It	was	
shown	that	reducing	ATP	consumption	through	inhibition	of	adenylate	cyclases	in	the	SAN	resulted	
in	a	reduced	mitochondrial	ATP	synthesis	[316].		
Furthermore,	ChIRP-MS	would	benefit	from	additional	optimisation	especially	in	the	
crosslink/reverse-crosslink	and	washing	conditions.	We	discovered	that	the	reverse-crosslinking	
was	still	incomplete	after	several	optimisation	attempts.	We	might	achieve	a	better	overlap	
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between	replicates	once	this	step	is	optimised.	Additionally,	ChIRP	might	benefit	from	more	
stringent	washing	conditions	to	enable	the	efficient	removal	of	unspecific	bound	proteins.	A	recent	
paper	established	a	new	method	to	identify	RNA-Protein	interactions	by	targeting	the	RNA	using	
antisense	probes	consisting	of	a	mix	of	LNA	and	DNA	nucleotides	[317].	The	incorporation	of	LNA	
nucleotides	increases	the	melting	temperature	of	the	oligonucleotides	allowing	more	stringent	
washing	condition.	If	the	mitochondrial	proteins	non-specifically	bind	to	the	probes	or	beads,	they	
might	be	removed	using	these	more	stringent	washing	steps.	
In	summary,	even	though	we	did	not	fully	optimise	the	ChIRP	method	and	did	not	perform	
biological	replicates,	we	identified	several	proteins	over	several	experiments	which	exert	a	nuclear	
function.	Based	on	the	nuclear	function	of	these	proteins	NkxUS	might	play	a	role	in	regulating	
transcription	and/or	histone	modification	to	control	cell	cycle	progression,	cell	proliferation	or	gene	
expression	of	nuclear	genes	and	potentially	mitochondrial	genes	in	response	to	mitochondrial	
stress	or	higher	metabolic	demand	(Table	11).	Additionally,	if	the	DNA	and	protein	ChIRP	targets	
are	indeed	specific,	NkxUS	could	recruit	some	these	proteins	to	the	DNA	targets	to	regulate	
transcription.	However,	validation	of	interaction	has	not	been	performed	and	could	be	verified	
using	immunoprecipitation	of	the	protein	of	interest	followed	by	RT-PCR	to	check	for	NkxUS	
expression.		
	
	
Table	11	Nuclear	function	of	proteins	enriched	in	NkxUS	ChIRP	
Protein	 Description	 Nuclear	function	 Reference	
PDC	 Pyruvate	dehydrogenase	complex	
acetyl-CoA	for	histone	
acetylation	
[307,	311]	
OXCT1	
Succinyl-CoA:3-ketoacid	coenzyme	
A	transferase	1	
acetyl-CoA	for	histone	
acetylation	
[318]	
LDH	 L-lactate	dehydrogenase	
lacatate	and	NAD+	for	
histone	acetylation;	DNA	
replication/repair;	
Transcription	
[309,	319,	
320]	
PCBP1	 Poly(rC)-binding	protein	1	
regulation	of	transcription	
and	splicing	
[321]	
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FH	 Fumarate	hydratase	
DNA	replication/repair;	
fumarate	for	inhibition	of	
histone/DNA	demethylation	
[313-315]	
HNRNPAB	
Heterogeneous	nuclear	
ribonucleoprotein	A/B	
mRNA	processing	and	
transport	
[322]	
MYH6	 Myosin	6	
enhanced	RNA	Polymerase	II	
dependent	transcription	
[323]	
ACO2	 Aconitase	2	 unknown	 [324]	
CRAT	 Carnitine	O-acetyltransferase	
acetyl-CoA	for	histone	
acetylation	
[325]	
PGK	 Phosphoglycerate	kinase	 DNA	replication/repair	 [326]	
PGM	 Phosphoglycerate	mutase	 unknown	
[327]	
	
SDH	 Succinate	dehydrogenase	
fumarate	for	inhibition	of		
Histone/DNA	demethylation	
[309,	328]	
	
	
3.2.7 The	conserved	RNA	structure	is	not	essential	for	development	
As	conservation	is	assumed	to	indicate	function,	we	interrogated	using	a	mouse	model	the	
potential	function	of	the	conserved	structure.	Deletion	of	part	of	the	conserved	structure	including	
the	SNP	homolog	did	not	affect	the	transcript	levels	of	NkxUS	nor	NkxUSas	in	isolated	hearts	(Figure	
34),	indicating	that	it	is	not	essential	for	the	stability	or	production	of	these	RNAs.	Moreover,			
Nkx2-5	is	not	altered	on	RNA	or	protein	level	in	NKXUS∆-/-	hearts	(Figure	34	and	35),	indicating	that	
this	structure	is	not	involved	in	the	regulation	of	Nkx2-5	expression.	This	is	consistent	with	the	
knockdown	experiment,	in	which	Nkx2-5	was	also	not	deregulated.	However,	it	is	still	possible	that	
NkxUS	acts	downstream	of	Nkx2-5,	which	has	not	been	tested	yet.		
Since	heart	morphology	was	normal	in	NKXUS∆-/-	embryos	and	NKXUS∆-/-	adult	mice	did	not	
show	any	defects	in	atrial	septal	development	(Figure	36),	which	is	the	most	prone	structure	for	
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developmental	defects,	we	conclude	that	the	conserved	RNA	structure	is	not	crucial	for	heart	
development.	
	
	
3.2.8 Left	ventricular	relaxation	is	impaired	in	NKXUS∆-/-	mice		
To	gain	insights	into	the	potential	function	of	the	conserved	region	in	cardiac	contraction,	we	
challenged	NKXUS∆-/-	and	NKXUS∆+/+	mice	using	a	model	of	LV	hypertrophy.	Under	anaesthesia	the	
heart	rates	showed	no	difference	between	the	groups	(Figure	38).	Although,	LV	hypertrophy	was	
successfully	induced	(Figure	37),	no	difference	was	observed	between	the	genotypes	regarding	the	
response	(Figure	37,	38	and	39).	Both	groups	behaved	similarly,	showing	an	increase	in	left	
ventricular	wall	mass	and	systolic	pressure	and	no	significant	difference	in	cardiac	output,	ejection	
fraction,	stroke	volume	nor	contractility	(Figure	37	and	38).	Although,	NKXUS∆-/-	mice	showed	a	
slight	worse	(non-significant)	cardiac	output,	ejection	fraction	and	stroke	volume,	it	would	be	
interesting	to	study	if	these	terms	reach	significance	at	later	timepoints	of	the	study	when	the	mice	
proceed	into	heart	failure.		
However,	a	significant	difference	between	the	genotypes	was	observed	in	the	flow	velocity	
at	the	mitral	valve	during	the	passive	filling	phase	of	the	LV	in	sham	mice	(Figure	37),	indicating	that	
NKXUS∆-/-	mice	have	a	disturbed	left	ventricular	relaxation,	potentially	due	to	a	stiffer	ventricle.	
This	difference	was	not	observed	in	TAC	animals	(Figure	37),	as	induced	hypertrophy	and	thus	
growth	of	the	LV	is	known	to	decrease	ventricular	compliance	and	LV	diastolic	filling,	likely	masking	
the	effect	seen	in	sham	NKXUS∆-/-	mice	[329].		
In	summary,	under	control	condition	NKXUS∆-/-	mice	have	a	mild	diastolic	dysfunction	due	
to	altered	LV	relaxation,	which	could	be	due	to	a	stiffer	ventricle	and	has	not	been	further	
investigated.		
	
	
3.2.9 NKXUS∆-/-	mice	exhibit	an	increased	resting	heart	rate		
As	a	GWAS	SNP	in	human	NKXUS	was	associated	with	an	increased	resting	heart	rate	and	the	LV	
hypertrophy	study	only	measured	the	heart	rate	in	anaesthetised	mice	(Figure	38),	we	analysed	the	
heart	rates	in	conscious,	freely	moving	mice.	
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Monitoring	of	the	heart	rate	over	24hrs	showed	that	NKXUS∆-/-	mice	have	an	increased	
resting	heart	rate	(Figure	40),	as	observed	for	the	GWAS	SNP	in	humans.	Conduction	of	excitation	
throughout	the	heart	was	not	affected	as	no	difference	in	the	PR-,	QT-	or	QRS-intervals	were	
observed	(Figure	41).	This	is	consistent	with	the	RNA	sequencing	results	of	the	NkxUS	knockdown	in	
HL-1	cells	where	gap	junction	transcripts	were	not	deregulated.	Gap	junctions	are	essential	for	
signal	transmission	as	they	connect	the	cytoplasm	of	neighbouring	cells	to	provide	cell-cell	
communication	[11].	Thus,	changes	in	gap	junction	composition	lead	to	an	altered	transmission	of	
the	electrical	excitation	between	neighbouring	cells,	which	would	be	detected	while	interpreting	
the	ECG	data.	Furthermore,	the	increased	heart	rate	was	not	due	to	increased	mouse	activity	
(Figure	44),	altered	circadian	rhythm	or	heart	rate	fluctuations	(Figure	43),	which	are	partly	
regulated	by	the	autonomic	nervous	system.	Since	the	heart	rate	difference	was	detected	during	
the	day	when	mice	are	at	rest	and	since	NkxUS	expression	was	also	detected	in	the	SAN	(Figure	9G),	
we	investigated	if	the	increase	is	due	to	an	elevated	pacemaker	activity.	
The	analysis	of	spontaneous	beating	frequency	and	the	corresponding	calcium	transients	of	
dissected	SAN	preparation	of	NKXUS∆-/-	and	NKXUS∆+/+	mice	revealed	a	significant	faster	beating	in	
NKXUS∆-/-	SANs	(Figure	45),	indicating	that	the	phenotype	observed	in	vivo	is	due	to	an	increased	
intrinsic	SAN	firing	rate.	NKXUS∆+/+	SANs	showed	a	similar	beating	frequency	as	reported	by	other	
studies	using	the	same	buffer	temperature	(Figure	45)	[49,	330].	Beating	rates	were	lower	in	
dissected	tissues	compared	to	the	in	vivo	results	for	both	genotypes	(Figure	40	and	45),	consistent	
with	previous	studies	and	is	most	likely	attributable	to	the	absence	of	sympathetic	tone	as	well	as	
other	signaling	molecules	such	as	peptides	and	hormones,	which	also	modulate	cardiac	and	
neuronal	activity	[331].	The	observed	statistical	difference	between	genotypes	was	higher	in	
dissected	SAN	tissues	compared	to	in	vivo	(Figure	40	and	45),	potentially	due	to	experimental	
factors,	such	as	the	physiological	buffer	system,	perfusion	rate	and/or	temperature.		
Collectively,	we	identified	a	dysfunction	in	the	SAN	network.	However,	this	impairment	
could	be	caused	by	enhanced	intrinsic	properties	of	single	pacemaker	cells.	The	next	step	would	be	
to	dissociate	the	SAN	tissue	into	single	cells	and	then	analyse	the	firing	rate	using	calcium	imaging	
experiments.	If	single	SAN	cells	of	NKXUS∆-/-	mice	still	beat	faster	than	NKXUS∆+/+	SAN	cells,	then	
the	increased	heart	rate	is	due	to	a	cell	autonomous	disturbance	in	single	SAN	cells,	which	can	arise	
from	heightened	basal	ion	channel	activity	in	the	absence	of	β-stimulation.	If	the	results	show	no	
difference,	then	the	faster	beating	is	due	to	enhanced	properties	of	the	SAN	cellular	network	itself,	
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which	also	contains	fibroblasts,	fat	and	nervous	cells,	and	which	could	result	from	an	altered	
structure	or	cell	composition	of	the	network	or	enhanced	conduction	[15,	332].		
To	investigate	the	mechanism	initiating	spontaneous	pacemaker	action	potentials,	we	
challenged	the	SAN	tissues	with	two	drugs. Blocking	of	the	HCN	channels	using	IVA	showed	the	
expected	decrease	in	beating	rate	(Figure	45).	For	both	genotypes,	the	firing	rate	decreased	by	the	
same	relative	amount	(Figure	45),	indicating	that	the	HCN	channels	are	most	likely	not	the	source	of	
the	increased	beating	frequency	in	NKXUS∆-/-	mice.	Changes	in	the	overall	rate	of	calcium	transients	
after	IVA	perfusion	was	consistent	with	results	of	other	studies	(Figure	45)	[49].	A	concentration	of	
3µM	IVA	was	chosen	as	it	equals	the	half	maximal	inhibitory	concentration	(IC50),	hence	the	
concentration	which	leads	to	about	50%	inhibition	of	the	pacemaker	current.	However,	although	
we	specifically	blocked	the	HCN	channels,	pacemaker	automaticity	is	complex	and	multiple	
pathways	evolved	to	compensate	for	the	loss	of	one	component	[29].	Here,	we	specifically	inhibited	
HCN	channels,	which	are	part	of	the	membrane	clock,	thus	the	calcium	clock	is	not	affected	and	
remains	sufficient	to	depolarise	the	cells.	Therefore,	we	did	not	see	a	50%	decrease	in	beating	rate.	
Inhibition	using	IVA	was	shown	to	be	dose-dependent,	however	in	this	study	we	have	not	
investigated	whether	higher	IVA	doses	might	lead	to	an	altered	response	between	the	genotypes.	
In	contrast,	the	second	drug,	ISO,	was	used	to	activate	the	cAMP	signaling	pathway	via	
activation	of	β-adrenoreceptors,	which	are	essential	regulators	of	SAN	pacemaker	activity.	β-
adrenergic	stimulation	with	ISO	lead	to	the	expected	strong	increase	in	beating	frequency	(Figure	
45).	However,	NKXUS∆-/-	SANs	were	less	responsive	to	ISO	treatment	than	NKXUS∆+/+	SANs	(Figure	
45).	ISO	treatment	resulted	in	a	~25%	increase	in	beating	for	NKXUS∆-/-	SANs	and	a	~45%	increase	
for	NKXUS∆+/+	SANs	(Figure	45).	The	reduced	responsiveness	of	NKXUS∆-/-	SANs	to	ISO	may	indicate	
that	downstream	targets	of	β-adrenoreceptor	signaling	are	potentially	already	more	active.	
Consistent	with	the	results	of	the	telemetry	study	for	the	active	period	of	the	day	when	
sympathetic	stimulation	is	elevated	(Figure	40),	NKXUS∆-/-	and	NKXUS∆+/+	SANs	reached	similar	
heart	rates	after	ISO	treatment	(Figure	45).		
As	mentioned	previously,	the	mechanism	of	SAN	automaticity	is	facilitated	by	two	
oscillators.	Therefore,	it	would	be	of	interest	to	investigate	whether	the	increased	heart	rate	is	due	
to	a	dysfunction	in	the	membrane	or	calcium	clock,	or	potentially	both.	Transcripts	of	both	clocks	
are	upregulated	in	the	knockdown	experiment,	suggesting	that	both	clocks	may	be	altered.	
However,	whether	the	conserved	structure	affects	both	clocks	is	unknown.	As	previously	
mentioned	NkxUS	transcript	levels	were	unchanged	in	NKXUS∆-/-	hearts,	however	since	the	
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phenotype	of	NKXUS∆-/-	mice	is	consistent	with	the	results	of	the	knockdown	of	the	entire	NkxUS	
transcript,	the	conserved	structure	potentially	may	affect	the	main	function	of	NkxUS.	
To	distinguish	between	the	two	clocks,	an	SAN	experiment	analysing	the	effect	of	ISO	in	
presence	of	IVA	could	give	further	insight.	Previously,	we	analysed	ISO	and	IVA	separately	(Figure	
45),	therefore	the	effect	we	observed	with	ISO	was	solely	from	this	drug.	If	the	heart	rate	difference	
is	due	to	the	membrane	clock,	a	similar	result	to	the	one	we	measured	with	ISO	alone	is	expected	
(Figure	45).	The	idea	is	that	if	the	membrane	clock	is	already	dysfunctional,	blocking	it	using	IVA	
should	not	alter	the	outcome	much	more	and	therefore	show	a	similar	outcome	as	with	ISO	alone,	
whereas	if	the	membrane	clock	was	functional	then	blocking	it	in	the	presence	of	ISO	should	results	
in	a	much	smaller	increase	in	beating	rate.		
Taken	together,	this	work	discovered	a	role	for	the	conserved	RNA	structure	in	the	
regulation	of	cardiac	contraction.	The	presence	of	an	increased	heart	rate	in	NKXUS∆-/-	mice	at	the	
in	vivo	and	in	vitro	level,	indicates	a	dysfunction	at	the	level	of	the	SAN	network	rather	than	the	
autonomic	nervous	system.	It	is	unclear	if	this	is	caused	by	an	intrinsic	problem	of	individual	cells	or	
within	the	SAN	network.	An	increased	beating	rate	may	have	arisen	as	a	consequence	of	higher	
protein	abundance	or	activity	of	β-adrenoreceptors	or	downstream	components,	which	requires	
further	analysis.	As	a	next	step,	studies	to	dissect	which	specific	components	of	the	network	are	
altered	and	responsible	for	the	increased	heart	rate	will	be	of	great	interest	and	help	to	decipher	a	
more	detailed	function	of	the	conserved	NkxUS	RNA	structure	in	the	regulation	of	heart	rate.	
  
 
3.2.9.1 Insights	into	mechanisms	of	NkxUS	function	
Analysis	of	the	NkxUS	transcript	in	HL-1	cells	identified	a	connection	of	NkxUS	to	the	negative	
regulation	of	gene	expression	of	cardiac	contraction	associated	genes.	Moreover,	NkxUS	may	
interact	with	proteins	involved	in	transcription,	histone	modification	and	possibly	nuclear-to-
mitochondrial	communication	and	ATP	synthesis.	On	the	DNA	level	NkxUS	may	bind	to	genes	
involved	in	G	protein	coupled	receptor	signaling	to	inhibit	adenylate	cyclase	activity	and	Wnt	
signaling.	Analysis	of	the	conserved	RNA	structure	resulted	in	the	association	with	an	altered	heart	
rate	due	to	enhanced	intrinsic	pacemaker	activity,	which	aligns	with	the	results	of	the	knockdown	
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experiment	in	HL-1	cells,	indicating	that	the	conserved	structure	may	be	an	essential	domain	for	
NkxUS	function.	
Considering	the	association	of	the	GWAS	SNP	with	heart	rate,	the	phenotype	of	the	mouse	
and	the	results	of	NkxUS	knockdown,	we	suspect	that	an	impairment	in	the	cAMP	signaling	
pathway	may	cause	the	increased	resting	heart	rate.	cAMP	is	an	important	secondary	messenger	
and	plays	an	essential	role	in	the	regulation	of	several	ion	channels	important	for	pacemaker	
activity.	Numerous	genes	involved	in	this	pathway	are	upregulated	upon	NkxUS	knockdown	(Figure	
46),	suggesting	that	perhaps	a	subset	of	these	genes	are	also	altered	in	NKXUS∆-/-	mice.	
Upregulated	genes	included	downstream	targets	of	cAMP	signaling,	such	as	adenylate	cyclases,	
calcium	channels,	including	L-type	calcium	channels	and	the	ryanoide	receptor,	ATPases	and	the	
pacemaker	specific	sodium	channel	Hcn4	(Figure	46).	β-adrenoreceptors	which	activate	adenylate	
cyclases	were	not	altered.	An	increased	influx	of	sodium	and	calcium	ions	depolarises	the	cell	more	
rapidly	and	together	with	increased	uptake	of	calcium	back	into	the	SR	via	SERCA	as	well	as	
potassium	efflux,	which	facilitate	repolarisation,	results	in	increased	contractility	and	thus	heart	
rate.		
However,	it	has	not	been	tested	yet	whether	these	genes	are	also	deregulated	in	NKXUS∆-/-	
SANs	and	RT-PCRs	as	well	as	western	blots	on	SANs	have	to	be	performed.	If	the	results	show	no	
difference	in	expression,	the	channels	may	be	more	active	but	not	more	abundant,	which	could	be	
caused	by	elevated	cAMP	levels	which	then	activate	PKA,	which	in	turn	activates	the	previously	
mentioned	channels	(Figure	46).	This	can	be	investigated	by	using	drugs	to	specifically	inhibit	
individual	channels	as	we	have	done	for	the	HCN	channels	and	then	analyse	for	the	differences	in	
calcium	transients	between	both	genotypes.		
Knockout	mouse	models	of	several	components	required	for	SAN	automaticity	exist.	Loss	of	
function	was	demonstrated	to	results	as	expected	in	SAN	dysfunction,	including	bradycardia	(HCN1,	
HCN4,	RYR2,	SERCA2a)	and	tachycardia-bradycardia	syndrome	(NCX,	CACNA1D)	[22,	49,	331,	333-
335].	Accordingly,	overexpression	of,	for	example,	HCN4	and	SERCA2a	resulted	in	enhanced	
contractility	[336,	337].	Elevated	heart	rate	induced	by	SERCA2a	overexpression	resulted	from	an	
increased	calcium	uptake	into	the	SR,	thus	increased	calcium	load	within	the	SR,	which	can	then	be	
used	in	the	next	cycle	to	depolarise	the	cells	[337].	On	the	other	hand,	gain-of-function	mutations	
within	RYR2	lead	to	higher	intracellular	calcium	concentrations,	but	did	not	accelerate	the	heart	
rate.	On	the	contrary,	it	resulted	in	spontaneous	calcium	release	without	being	in	synchrony	with	
the	membrane	or	calcium	clock,	which	in	turn	lead	to	cardiac	arrhythmia	[338].	This	suggests	that	in	
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our	model	both	clocks	still	work	in	concert	and	that	potentially	several	clock	components	are	
deregulated.	As	we	do	not	see	sinus	dysrhythmia,	components	facilitating	depolarisation	as	well	as	
repolarisation	are	functional	and	likely	more	active,	which	is	consistent	with	the	RNA	sequencing	
results	as	we	also	discovered	upregulated	GIRK	potassium	channels	(Kcnj3,	Kcnj5)	and	Serca2a,	
which	facilitate	repolarisation.	Furthermore,	this	is	consistent	with	the	observation	that	action	
potential	duration	is	rate	dependent	and	shortens	during	higher	heart	rates	to	ensure	regular	
pacing	[339].	This	is	facilitated	through	heightened	sympathetic	signaling	at	higher	heart	rates,	
which	activates	β-adrenoreceptors	and	thereby	also	its	downstream	targets	including	potassium	
channels	(Figure	46).		
Taken	together,	the	mechanism	underlying	sinoatrial	node	automaticity	is	clearly	
complicated	and	does	not	rely	on	a	single	component.	Given	that	we	identified	an	increased	but	
regular	resting	heart	rate,	we	suggest	that	several	components	facilitating	pacemaker	
depolarisation	as	well	as	repolarisation	are	altered.	Either	gene	expression	of	cAMP	signaling	
components	is	upregulated	as	in	the	HL-1	knockdown	experiment,	or	intracellular	cAMP	or	ATP	
levels	are	higher	in	NKXUS∆-/-	SANs,	which	in	turn	activate	important	contraction	and	relaxation	
mediating	proteins,	or	both.	Additionally,	the	protein	ChIRP	identified	several	proteins	with	both	
mitochondrial	and	nuclear	function	(Table	11).	Mitochondria	are	the	main	ATP	source	and	many	of	
the	identified	proteins	are	involved	in	ATP	synthesis,	thus	perhaps	the	crosstalk	between	NkxUS	
and	the	dual-localised	proteins	could	play	a	role	in	controlling	ATP	production	within	mitochondria	
via	nuclear-to-mitochondrial	signaling	and	disruption	of	NkxUS	could	lead	to	enhanced	ATP	
production.	Most	mitochondrial	proteins	are	encoded	in	the	nucleus	and	mitochondrial	
communication	with	the	nucleus	is	well	described	and	essential	for	homeostasis	[340].	However,	
we	still	have	to	verify	these	interactions.	Similarly,	the	DNA	ChIRP	results	support	a	function	of	
NkxUS	in	G	protein-coupled	receptor	signaling	which	regulates	cAMP	signaling.	The	functions	of	
these	candidates	were	mostly	studied	in	excitable	neurons,	in	which	they	played	a	role	in	the	
negative	regulation	of	adenylate	cyclases.	This	is	consistent	with	our	phenotype	as	a	disrupted	
NkxUS	function	leads	to	an	increased	heart	rate,	potentially	due	to	reduced	inhibition	of	genes	
involved	in	the	cAMP	signaling	pathway.	However,	initial	results	require	validation. 
Altogether,	follow	up	experiments	to	validate	the	ChIRP	results	and	explore	whether	ion	
channels	of	the	calcium	and/or	membrane	clock	are	altered	and	whether	the	cAMP/ATP	levels	are	
elevated	in	NKXUS∆-/-	SANs	would	provide	a	detailed	understanding	of	the	underlying	mechanism	of	
the	phenotype.	Moreover,	it	would	be	of	interest	to	analyse	whether	NKXUS∆-/-	mice	are	more	
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prone	to	develop	atrial	fibrillation,	since	three	independent	GWAS	studies	associated	rs6882776	
with	atrial	fibrillation.	Preliminary	data	of	pacing	induced	atrial	fibrillation	on	NKXUS∆-/-	and	
NKXUS∆+/+	mice	suggests	a	sensitivity	of	NKXUS∆-/-	mice	to	develop	atrial	fibrillation,	however	so	far	
this	has	not	been	statistically	significant.		
In	conclusion,	we	identified	a	novel	nuclear	and	cardiac	specific	lncRNA,	just	upstream	of	one	
of	the	most	important	genes	for	heart	development.	Our	hypothesis	that	NkxUS	might	regulate	
Nkx2-5	and/or	heart	development	was	not	confirmed.	However,	NkxUS	is	important	for	proper	
heart	function	as	it	seems	to	regulate	the	expression	of	genes	involved	in	cardiac	contraction.	Most	
significantly,	we	identified	a	GWAS	SNP	associated	with	an	increased	resting	heart	rate	within	the	
conserved	RNA	structure	of	NkxUS	and	by	deleting	this	region	in	the	mouse,	even	though	the	
genomic	location	and	orientation	of	the	mouse	transcript	is	different,	we	recapitulated	the	same	
phenotype	as	the	GWAS	SNP.	We	pinpointed	the	phenotype	to	be	originating	from	the	SAN,	most	
likely	due	to	altered	gene	expression,	increased	activity	of	cAMP	signaling	components	or	elevated	
ATP/cAMP	levels.	
Importantly,	from	our	understanding	this	is	the	first	study	achieving	such	a	connection	in	vivo.	
Since	the	majority	of	GWAS	SNPs	map	to	non-coding	regions,	many	more	are	likely	to	affect	
lncRNAs	and	potentially	lie	within	conserved	RNA	structures.	This	study	could	lead	the	way	to	
motivate	other	researchers	to	investigate	GWAS	SNPs	within	lncRNAs	and/or	conserved	RNA	
structures	using	animal	models,	which	ultimately	will	lead	to	a	better	understanding	of	underlying	
causes	of	diseases	and	advancements	in	precision	medicine.	
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4.1 Molecular	Biology	and	Microbiology	
4.1.1 	Polymerase	Chain	reaction	(PCR)		
KAPA	HiFi	DNA	Polymerase	(KAPABiosystems)	was	used	for	PCR	reactions	as	follows:	
	
5X	KAPA	HiFi	Buffer	(Fidelity)		 5µl	
10mM	KAPA	dNTP	Mix	 	 0.75µl	
10	μM	Forward	Primer		 	 0.75µl		
10	μM	Reverse	Primer		 	 0.75µl		
Template	DNA		 	 	 1µg	
KAPA	HiFi	DNA	Polymerase		 	 1µl	
PCR-grade	water		 	 	 Up	to	25µl		
	
PCRs	was	performed	with	the	following	cycling	protocol:	
Step	 Temperature	 Duration	 Cycles	
Initial	
denaturation	 95°C	 3min	 1	
Denaturation	 98°C	 20	s	
30	Annealing	 60°C	 15	s	
Extension	 72°C	 1min	
Final	extension	 72°C	 3min	 1	
	
A	complete	list	of	used	primers	can	be	found	in	Appendix	V.	
	
	
4.1.2 	Agarose	gel	electrophorese	
DNA	fragments	were	separated	based	on	size	using	agarose	gel	electrophoresis.	The	gels	were	
prepared	using	1%	agarose	(Sigma-Aldrich)	dissolved	in	1x	TAE	buffer	(40mM	Tris,	1mM	EDTA,	pH	
8)	containing	1ug/ml	ethidiumbromide	(Sigma-Aldrich).	A	1	kilobase	(kb)	or	100	basepair	(bp)	DNA	
marker	(Promega)	was	used	for	size	determination.	Prior	to	loading	the	gels,	the	DNA	samples	were	
mixed	with	6x	loading	buffer	(Promega).	The	samples	were	run	at	120V	for	30-60min	and	the	DNA	
was	visualized	using	an	UV-transilluminator	(BioRad).	 
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4.1.3 	Isolation	of	DNA	fragments	from	agarose	gels		
Bands	of	interest	were	excised	using	scalpels	under	UV	light	(UV	transilluminator,	Thermo	Fisher	
Scientific)	and	the	DNA	was	extracted	using	the	Wizard	SV	Gel	and	PCR	Clean-Up	System	(Promega)	
following	the	manufacturer’s	protocol.	
	
	
4.1.4 	Bacterial	transformation	
PCR	fragments	were	A-tailed	using	Taq-Polymerase	(Roche)	for	15min	at	75°C	as	follows:	
	
T4	DNA	Ligase	Buffer	 	 5µl	
pGEM-T	Easy	Vector	 	 1µl	
PCR	Fragment		 	 3µl	
T4	DNA	Ligase		 	 1µl	
Total	 	 	 	 10µl	
	
Afterwards,	the	fragments	were	cloned	into	the	pGEM-T	Easy	Vector	Systems	(Promega).	The	
ligation	was	set	up	as	follows:	
	
T4	DNA	Ligase	Buffer	 	 5µl	
pGEM-T	Easy	Vector	 	 1µl	
PCR	Fragment		 	 3µl	
T4	DNA	Ligase		 	 1µl	
Total	 	 	 	 10µl	
	
The	reaction	was	incubated	for	one	hour	at	room	temperature	(RT).	Afterwards,	the	plasmids,	
which	carry	an	ampicillin	resistance	cassette,	were	transformed	into	chemically	competent	10-beta	
Escherichia	coli	cells	(NEB).	The	competent	cells	were	first	thawed	on	ice.	2µl	of	plasmid	was	added	
to	50µl	of	competent	cells,	carefully	mixed	and	then	incubated	on	ice	for	20min.	This	was	followed	
by	a	heat	shock	at	42°C	for	40	sec	and	an	incubation	on	ice	for	5min.	200µl	of	stable	outgrowth	
medium	(NEB)	was	added	to	the	mixture	and	incubated	for	one	hour	at	37°C.	Afterwards,	cells	
were	transferred	on	Luria-Bertani	(LB)	agar	plates	with	ampicillin	(Sigma-Aldrich,	final	
concentration:	100μg/μl)	and	incubated	overnight	at	37°C.	LB	agar	plates	were	examined	for	colony	
formation	on	the	following	day.	
Material	&	Methods	
	 119	
4.1.5 	Preparation	of	plasmid	DNA	from	bacterial	cultures	
Single	colonies	were	picked	and	inoculated	in	5ml	LB	medium	supplemented	with	ampicillin	(final	
concentration:	100μg/μl)	overnight	at	37°C	with	shaking	at	180	RPM.	Plasmid	DNA	was	isolated	
using	the	Wizard	Plus	SV	Minipreps	Start-Up	Kit	(Promega)	following	the	manufacturer’s	protocol.	
Afterwards,	DNA	concentrations	were	determined	using	a	NanoDrop2000	(Thermo	Fisher	
Scientific).	
	
	
4.1.6 	DNA	sequencing	
The	plasmid	inserts	were	sequenced	at	an	external	facility	(Garvan	Molecular	Genetics,	Garvan	
Institute	of	Medical	Research,	Sydney,	Australia).	A	sequencing	reaction	mix	of	40ng	plasmid	and	2	
pmol	of	primer	was	prepared	for	Sanger	sequencing.	A	list	of	all	used	primers	can	be	found	in	
Appendix	V.	
	
	
4.1.7 Digestion	of	DNA	
Plasmids	were	digested	using	restriction	digestion	enzymes	from	NEB.	Reaction	were	set	up	as	
follows:	
	
NEB	Buffer		 	 	 1.5µl	
Plasmid	DNA	 	 	 1µg	
Enzyme	 	 	 1µl	
PCR-grade	water		 	 Up	to	15µl		
	
After	an	one	hour	incubation	at	37°C	,	the	linearised	plasmids	were	separated	on	a	1%	agarose	gel	
in	1x	TAE	Buffer	and	extracted	from	the	gel	using	Wizard	SV	Gel	and	PCR	Clean-Up	System	
(Promega)	following	the	manufacturer’s	protocol.		
The	following	enzymes	were	used:	SpeI,	NcoI,	AfeI.	
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4.1.8 	Rapid	amplification	of	cDNA	ends	(RACE)	
RACE	was	performed	on	heart	RNA	from	C57BL/6J	mice.	The	experiment	was	performed	using	the	
FirstChoice	RLM-RACE	Kit	(Thermo	Fisher	Scientific)	following	the	manufacturer’s	protocol.	All	
reagents	detailed	in	this	section	were	provided	with	the	kit.	10µg	of	total	RNA	was	used	for	3’	and	
5’RACE.	Gene	specific	primers	used	for	the	nested	PCRs	are	listed	in	Table	12.	The	PCRs	was	run	as	
follows:	
	
Step	 Temperature	 Duration	 Cycles	
Initial	
denaturation	 94°C	 3min	 1	
Amplification	
94°C	 30	s	
35	60°C	 30	s	
72°C	 30	s	
Final	extension	 72°C	 7min	 1	
	
The	PCR	products	were	run	on	a	2%	agarose	gel	containing	1µg/µl	of	ethidiumbromide.	Bands	were	
isolated	from	the	gel,	purified,	cloned	into	the	pGEM-T	Easy	vector	and	the	inserts	were	sequenced	
using	m13	forward	and	reverse	primer	(Appendix	V).	DNA	sequences	were	visualized	using	the	
University	of	California	Santa	Cruz	(UCSC)	genome	browser	(https://genome.ucsc.edu/)[175].	
	
	
Table	12	List	of	gene	specific	primers	used	for	the	nested	RACE	PCR	in	5’-3’	direction	
Gene	specific	primer	 Sequence	(5’-3'	direction)	
NkxUS	5’Outer	 CGACCACTTACAACCTGATTCATGC	
NkxUS	5’Inner	-1	 GCAGTGACTCTTGGACTCTGACCAC	
NkxUS	5’Inner-2	 CTTTAATCCCTGAGCCATCTCTCCA	
NkxUS	5’Inner-3	 CTGTAGCGCTGTAGCGGTTT	
NkxUS	3’Outer	 GGAATCTGTTAGTAAAATCGCAGCA	
NkxUS	3’Inner	 GCAGCCTGTATATTCTCCAGCTCTT	
NkxDS	3’Outer	 GTGAGGGTGAAGGAGAA	
NkxDS	3’Inner	 GGTCTCAGAATGGACAAGCA		
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4.2 Gene	expression	analysis	
4.2.1 	RNA	extraction	
RNA	was	extracted	using	Trizol	(Life	Technologies)	following	the	manufacturer’s	protocol.	Briefly,	
1mL	Trizol	was	added	to	the	samples,	vortexed	for	10s	and	incubated	for	5min	at	RT.	Afterwards,	
200μl	chloroform	(Sigma-Aldrich)	was	added,	the	tube	was	shaken	for	15	s,	incubated	for	2-3min	at	
RT	and	then	centrifuged	for	15min	at	4°C	at	12,000	g.	The	aqueous,	upper	phase	was	transferred	
into	a	new	tube	and	500μl	isopropanol	(Sigma-Aldrich)	was	added,	the	tubes	were	mixed	by	shaking	
for	15s	and	incubated	at	RT	for	10min.	Following	centrifugation	at	12,000g	for	10min	at	4°C,	the	
supernatant	was	removed	and	the	pellet	was	washed	with	1ml	of	75%	ethanol.	The	tubes	were	
inverted	several	times	to	mix	and	then	centrifuged	for	5min	at	7,500g	at	4°C.	The	supernatant	was	
removed,	the	pellet	was	left	to	air-dry	and	then	resuspended	in	30μl	of	nuclease-free	water	(Life	
Technologies).	The	samples	were	stored	at	-80°C	or	used	directly	for	DNaseI	treatment.	
	
	
4.2.2 	DNase	treatment	
RNA	was	either	treated	with	DNaseI	from	NEB	or	Promega.	The	reactions	were	set	up	as	follows	
using	either	DNaseI:	
	
RNA	 	 	 1µg	
10x	DNase	buffer	 1µl	
DNaseI	(1U/µl)		 1µl	
water	 	 	 up	to	10µl	
	
The	samples	mixed	carefully	by	pipetting	and	incubated	for	10min	at	37°C.	Afterwards,	the	samples	
were	cleaned	up	using	the	RNA	Clean	&	Concentrator	kit	from	Zymo	Research.	
	
4.2.3 	RNA	clean	up	and	concentration	
RNA	was	cleaned	up	and	concentrated	using	the	RNA	Clean	&	Concentrator-	5	kit	(Zymo	Research)	
following	the	manufacturer’s	protocol.	Briefly,	nuclease-free	water	was	added	to	the	samples	up	to	
50µl.	100µl	of	RNA	binding	buffer	was	added,	the	samples	were	vortexed	and	centrifuged	briefly.	
Then	an	equal	amount	of	100%	ethanol	(150µl)	was	added	to	the	samples.	After	vortexing	and	a	
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brief	spin.	The	samples	were	spin	through	the	columns	for	30s	at	16,000	g.	The	flow-through	was	
discarded	and	400µl	of	RNA	Prep	buffer	was	added	to	the	columns.	The	samples	were	centrifuged	
again	for	30	s,	the	flow-through	was	discarded	and	700µl	of	RNA	Wash	buffer	was	added	to	the	
columns.	After	another	centrifugation	for	30s	the	samples	were	washed	again	with	400µl	RNA	
Wash	buffer	and	centrifuged	for	2min.	The	columns	were	transferred	into	new	collection	tubes,	
15µl	of	nuclease	free	water	was	added	and	the	columns	were	centrifuged	for	30	s.	Eluted	RNA	was	
quantified	using	a	Nanodrop2000	(Thermo	Fisher	Scientific)	and	then	stored	at	-80°C	or	used	
directly	for	downstream	experiments.	
	
	
4.2.4 	cDNA	synthesis	and	real-time	PCR	(RT-PCR)	
cDNA	was	synthesised	using	the	SuperScript	III	First-Strand	Synthesis	SuperMix	(Thermo	Fisher	
Scientific)	for	real-time	PCR	(RT-PCR).	The	reaction	was	set	up	as	follows:	
	
RT	Reaction	Mix	 10μl	 	
RNA	 	 	 up	to	1μg	
RT	Enzyme	Mix	 2μl	
DEPC-treated	water	 up	to	20μl	
	
The	reaction	mix	was	incubated	at	25°C	for	10min,	then	50°C	for	30min	and	then	terminated	at	
85°C	at	5min.	The	mix	was	chilled	on	ice	and	then	used	for	RT-PCR.	RT-PCR	was	performed	using	the	
SYBR	green	Master	Mix	(Roche).	The	reaction	was	set	up	in	15µl	and	in	384	well	plates	(BioRad)	as	
follows:	
	
cDNA	 	 	 	 	 1μl	
SYBR	green	Master	Mix	 	 7.5μl	 	
DEPC-treated	water	 	 	 5.3μl	
10	µM	Forward	primer	(FW)	 	 0.6μl	
10	µM	Reverse	primer	(RV)	 	 0.6μl	
Total	 	 	 	 	 15µl	
	
	The	samples	were	run	on	the	BioRad	CFX384	with	the	following	cycle	conditions:	
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Step	 Temperature	 Duration	 Cycles	
Pre-incubation	 95°C	 7min	 1	
Amplification	
95°C	 20	s	
40	60°C	 15	s	
72°C	 1min	
Melting	curve	
95°C	 5	s	
1	65°C	 1min	
97°C	 continuous	
Cooling	 40°C	 10	s	 1	
	
Primers	used	for	gene	expression	analysis	in	mouse	and	human	samples	are	listed	in	Table	13	and	
14.	Levels	of	gene	expression	were	normalised	against	a	combination	of	two	to	three	housekeeping	
genes	listed	in	Table	15.	Calculations	were	performed	by	comparative	method	(2−∆∆CT).		
	
Table	13	List	of	RT-PCR	primers	for	mouse	transcripts	in	5’-3’	direction	
Symbol	 Transcript	name	 Sequence	
Cacna1c	 Calcium	Voltage-Gated	Channel	Subunit	Alpha1	C	
FW:	TCCCGAGCACATCCCTACTC	
RV:	ACTGACGGTAGAGATGGTTGC	
Hcn1	
Potassium/Sodium	
Hyperpolarization-Activated	
Cyclic	Nucleotide-Gated	Channel	
1	
FW:	CAAATTCTCCCTCCGCATGTT	
RV:	TGAAGAACGTGATTCCAACTGG	
Kcnj3	 Potassium	Voltage-Gated	Channel	Subfamily	J	Member	3	
FW:	GGGGACGATTACCAGGTAGTG	
RV:	CGCTGCCGTTTCTTCTTGG	
Kcnj5	 Potassium	Voltage-Gated	Channel	Subfamily	J	Member	5	
FW:	AAAACCTTAGCGGCTTTGTATCT	
RV:	AAGGCATTAACAATCGAGCCC	
Cacna1d	 Calcium	Voltage-Gated	Channel	Subunit	Alpha1	D	
FW:	GCTTACGTTAGGAATGGATGGAA	
RV:	GAAGTGGTCTTAACACTCGGAAG	
Hcn4	
Potassium/sodium	
hyperpolarization-activated	cyclic	
nucleotide-gated	channel	4	
FW:	GCATGATGCTTCTGCTGTGT	
RV:	CCAGCTTTCGGCAGTTAAAG	
Nt5m	 5',3'-Nucleotidase	
FW:	GAGCAGATTGTGTTGACCAGA	
RV:	CAGGTGGTAGTTGTGGCAGG	
Ptprs	 Protein	Tyrosine	Phosphatase,	Receptor	Type	S	
FW:	GGTGAACAACATACCCCCGAC	
RV:	TCCCACCTCTGTGTAAGCCA	
Ryr2	 Ryanodine	receptor	2	
FW:	AAAAGTGCGTGTTGGAGATGA	
RV:	CACCGCCAATGAGATAGCCT	
Nkx2-5	 NK2	Homeobox	5	 FW:	CCCAAGTGCTCTCCTGCTTTC	
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RV:	TCCAGCTCCACTGCCTTCTG	
NkxDS	 Nkx2-5	Downstream	
FW:	GGAATGTGTGAGGCTCTGCT	
RV:	TGAATTGACACCCAGAACACA	
NkxUS	 Nkx2-5	Upstream	
FW:	CACTCTGACCCAGCACCTTT	
RV:	GGCATAGCGAACCTTGTCTC	
NkxUSas	 NkxUS	antisense	
FW:	CCCGCACATTCTGCTATTTGAG	
RV:	GTCCCCGTTAGTCAGTCCAG	
Pde3b	 Phosphodiesterase	3B	
FW:	AGTATCAGTAGCTTGATGGGTGC	
RV:	CCCTTGTGAAGTTTTCGATCTCC	
Pde5a	 Phosphodiesterase	5a	
FW:	CGGCCTACCTGGCATTCTG	
RV:	GCAAGGTCAAGTAACACCTGATT	
	
Table	14	List	of	RT-PCR	primers	for	human	transcripts	in	5’-3’	direction	
Symbol	 Transcript	name	 Sequence	
Nkx2-5	 NK2	Homeobox	5	
FW:	CTATCCACGTGCCTACAGCGAC	
RV:	GCACAGCTCTTTCTTTTCGGC	
NkxDS	 Nkx2-5	Downstream	
FW:	CTGGCACAAAGTAAGCACCA	
RV:	CCAGTGGTGAGCAGTGAAGA	
NkxUS	 Nkx2-5	Upstream	
FW:	CTCCTCTCTCCTGCAACACC	
RV:	GTCAGTCCTGTGGGTCAGGT	
	
Table	15	List	of	primer	sequences	for	house	keeping	genes	in	5’-3’	direction	
Symbol	 Transcript	Name	 Sequence	
Eef1e1	 Eukaryotic	Translation	Elongation	Factor	1	Epsilon	1	
FW:	TCCAGTAAAGAAGACACCCAGA	
RV:	GACAAAACCAGCGAGACACA	
Hprt1	 Hypoxanthine	Phosphoribosyltransferase	1	
FW:	GCTTGCTGGTGAAAAGGACCTCTCGAAG	
RV:	CCCTGAAGTACTCATTATAGTCAAGGGCAT	
Rpl4	 Ribosomal	Protein	L4	
FW:	GCCGCTGGTGGTTGAAGATAA	
RV:	CGTCGGTTTCTCATTTTGCCC	
Tbp	 TATA-Box	Binding	Protein	
FW:	TATGACCCCTATCACTCCTG	
RV:	TTCTTCACTCTTGGCTCCTGT	
Actb	 Actin	Beta	
FW:	GGCTGTATTCCCCTCCATCG	
RV:	CCAGTTGGTAACAATGCCATGT	
Gapdh	 Glycerinaldehyd-3-phosphat-Dehydrogenase	
FW:	GGTCCTCAGTGTAGCCCAAG	
RV:	AATGTGTCCGTCGTGGATCT	
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4.3 Northern	blot	analysis	
4.3.1 	Probe	synthesis	
For	DIG-labeled	RNA	probes,	specific	regions	of	Nkx2-5,	NkxUS	and	NkxDS	were	amplified	from	
mouse	cDNA	using	primers	listed	in	Table	16	and	cloned	into	the	pBlueScriptII	SK	vector.	1µg	of	
plasmid,	linearised	using	SpeI	(NEB),	was	used	for	in	vitro	transcription	reactions	with	digoxigenin-
11-UTP	labelling	mixture	(Roche)	as	follows:		
	
Lineraised	plasmid	 1µg	
10x	transcription	buffer	(NEB)	 1.5µl	
10x	DIG	reaction	mix	(Roche)	 1.5µl	
0.1M	DTT	(Sigma)	 1.5µl	
rRNasin	(Promega)	 0.75µl	
T7	Polymerase	(NEB)	 0.5µl	
water	 up	to	15µl	
	
The	samples	were	incubated	at	37°C	for	2hrs	and	then	treated	with	1µl	of	DNaseI	(NEB).	
Afterwards,	the	samples	were	purified	through	G-50	columns	(GE	Healthcare)	according	to	
manufactures’	instructions.	Aliquots	of	probes	were	stored	at	-80°C.	
	
Table	16	List	of	primers	used	to	generate	northern	probes	in	5’-3’	direction	
Transcript	 Sequence	 Probe	length	
NkxDS	
FW:	CAGCTTTCTCCCAGGTCAAG	
1025	bp	RV:	ATTGTCCCAGAAGCCAACAC	
Nkx2-5	
FW:	CTACGGCGTGGGTCTCAAT	
601	bp	RV:	CTCTTCCCATTAAAGTGAGTGCG	
NkxUS	
FW:	CACTCTGACCCAGCACCTTT	
719	bp	RV:	GACGTGGCTAGGTGGACTGT	
	
	
4.3.2 	Northern	blot	run	
Northern	Blots	were	performed	as	outlined	in	the	NorthernMax	Procedure	(Ambion)	and	the	DIG	
Northern	Starter	Kit	(Roche)	with	a	few	modifications.	Briefly,	total	RNA	was	extracted	from	wild-
type	adult	mouse	heart	(C57BL/6J)	using	Trizol,	DNase	treated	and	quantified	on	the	Nanodrop	
2000	(Thermo	Fisher	Scientific).	10µg	of	RNA	in	a	volume	of	6µl	was	prepared	in	20µl	of	loading	
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buffer	containing	2µl	10x	MOPS	(200mM	MOPS	(Sigma-Aldrich),	50mM	Sodium	Acetate,	10mM	
EDTA),	10µl	formamide	and	2µl	37%	formaldehyde,	heated	at	65°C	for	15min	and	chilled	on	ice.	3µl	
6x	loading	dye	(Promega)	and	0.5µl	EtBr	(10µg/ul)	were	added	and	the	samples	were	loaded	onto	a	
1.2%	agarose	gel	made	with	1x	MOPS	buffer	and	containing	2%	formaldehyde.	5µl	of	denatured	
ssRNA	ladder	(NEB)	was	also	loaded.		The	gel	was	run	in	1x	MOPS	buffer	at	105V	(5	volts/cm)	for	
3hrs	and	visualized	for	RNA	integrity	and	size	on	a	UV	transilluminator.	The	gel	was	blotted	
overnight	by	capillary	transfer	using	20x	SSC	onto	a	positively	charged	Nylon	membrane	
(Amersham).	The	membrane	was	cross-linked	for	15s	and	pre-hybridised	in	7ml	pre-warmed	
NorthernMax	ULTRAhyb	Buffer	(Life	Technologies)	at	68°C	for	1	h.	100ng/ml	Dig-labeled	probe	was	
added	to	the	ULTRAhyb	buffer	and	incubated	overnight	at	68°C	with	rolling.	The	membrane	was	
washed	twice	for	5min	each	with	Low	Stringency	Wash	Buffer	(2x	SSC,	0.1%	SDS)	at	RT	and	then	
twice	for	15min	washes	in	High	Stringency	Wash	Buffer	(0.1%	SSC,	0.1%	SDS)	at	68°C.	The	
membrane	was	rinsed	briefly	in	MAB	Buffer	pH7.5	(0.1M	Maleic	Acid,	0.15M	NaCl)	and	blocked	for	
30min	at	RT	in	Blocking	Solution	(Roche).	DIG	anti-AP	(1:10.000)	in	blocking	solution	was	added	to	
the	membrane,	incubated	for	30min	at	RT	and	then	washed	three	times	for	10min	in	MABT	(MAB	+	
0.3%	Tween	20).	The	membrane	was	equilibrated	for	3min	in	Detection	Buffer	(0.1M	Tris	pH	9.5,	
0.1M	NaCl)	and	probes	were	detected	with	Amersham	Hyperfilm	ECL	(GE	Healthcare	Life	Sciences)	
using	CSPD	(1:100	in	detection	buffer).	
	
	
4.4 Western	Blot	
For	western-blotting,	mouse	heart	tissues	were	homogenized	using	a	homogenizer	in	using	RIPA	
buffer	(20mM	Tris-HCl	pH	8.0,	150mM	NaCl,	1%	NP-40,	0.5%	sodium	deoxycholate,	0.1%	SDS,	1	
protease	inhibitor	(cOmplete™	Mini	EDTA-free	Protease	Inhibitor	Cocktail,	Sigma	Aldrich)).	Proteins	
were	measured	using	the	Pierce	BCA	Protein	Assay	Kit	(Thermo	Fisher	Scientific)	using	the	
manufacturer’s	protocol.	30µg	of	protein	was	prepared	for	SDS-	polyacrylamide	gel	electrophoresis	
(SDS-PAGE)	by	adding	4x	LDS	sample	buffer	(Thermo	Fisher	Scientific)	with	100mM	DTT	to	the	
samples,	followed	by	an	incubation	at	70°C	for	10min.	Proteins	were	separated	on	a	4-12%	Bis-Tris	
gel	(Thermo	Fisher	Scientific)	in	1x	MOPS	buffer	(Thermo	Fisher	Scientific),	which	was	run	at	200V	
for	40min.	Afterwards,	the	gel	was	blotted	onto	a	PVDF	membrane	(BioRad).	Proteins	were	
transferred	onto	the	PVDF	membrane	at	30V	for	1	h.	After	transfer,	the	membrane	was	cut	into	at	
Material	&	Methods	
	 127	
~60kDa.	The	two	membrane	pieces	were	incubated	in	5%	milk	powder	in	TBST	(0.1%	Tween20,	
Sigma	Aldrich)	for	at	least	1h	at	RT.	Incubation	with	primary	antibodies	(Table	17)	was	performed	
over	night	at	4°C	in	5%	milk	powder	in	TBST.	The	next	day,	the	membranes	were	washed	three	
times	with	TBST	before	incubating	with	the	respective	fluorescently	labelled	secondary	antibody	
(Table	17)	in	5%	milk	powder	in	TBST	for	1h	at	RT.	The	membranes	were	washed	three	times	with	
TBST	and	once	with	TBS,	before	signals	were	detected	using	the	Pierce	ECL	Western	Blotting	
Substrate	(Thermo	Fisher	Scientific)	and	documented	using	the	ChemiDoc	(BioRad).	Signal	
intensities	were	quantified	using	the	Image	Lab	software	(BioRad).		
	
Table	17	List	of	antibodies	used	for	western	blotting	
Antibody	 Concentration	 Species	 Company	
Primary	 	 	 	
Nkx2-5	N19	 1:1000	 Goat	 Santa	Cruz	
Vinculin	H300	 1:1000	 Rabbit	 Santa	Cruz	
Secondary	 	 	 	
anti	goat	 1:8000	 Donkey	 Thermo	Fisher	Scientific	
anti	rabbit	 1:8000	 Rat	 Sigma	Aldrich	
	
	
4.5 Cell	culture	techniques	
4.5.1 	Cell	lines	
The	HL-1	cell	line	was	donated	by	Prof	W	C	Claycomb	(Department	of	Biochemistry	and	Molecular	
Biology,	Louisiana	State	University,	New	Orleans,	LA,	USA)	[179].	
HL-1	cells	were	cultured	in	Claycomb	Medium	(Sigma-Aldrich)	supplemented	with	10%	heat	
inactivated	fetal	bovine	serum	(FBS;	SAFC),	2mM	L-glutamine	(Life	Technologies)	and	0.1mM	
Norepinephrine	(Sigma-Aldrich)	at	37°C	in	5%	CO2.	Cells	were	seeded	in	60-180cm
2	dishes	(Corning)	
and	split	when	confluent.		
Mouse	muscle	C2C12	cells	(ATCC)	were	cultured	in	high	Glucose	DMEM	(Sigma-Aldrich)	
supplemented	with	10%	FBS	(SAFC)	and	1%	sodium	pyruvate	(Sigma-Aldrich)	at	37°C	in	5%	CO2.	
Cells	were	seeded	in	60-180cm2	dishes	and	split	when	reached	about	80%	confluence.		
Mouse	embryonic	fibroblasts	(MEF,	ATCC)	were	cultured	in	high	glucose	DMEM,	10%	FBS	and	5ml	
Material	&	Methods	
	 128	
Glutamax	(life	Technologies)	at	37°C	in	5%	CO2.	Cells	were	cultured	in	6-well	culture	plates	
(Corning)	and	split	when	about	80%	confluent.		
	
	
4.5.2 	Mouse	embryonic	stem	cell	differentiation	into	embryoid	bodies		
Embryonic	stem	cells	(ESC)	were	maintained	on	irradiated	MEFs	in	ESC	medium	(Knockout-DMEM	
(Life	Technologies)	supplemented	with	20%	Knockout	Serum	Replacement	(Life	Technologies),	
0.1mM	MEM	minimum	essential	amino	acids	solution	(Life	Technologies),	1mM	sodium-pyruvate	
(Sigma-Aldrich),	0.1mM	β-mercaptoethanol	(Sigma-Aldrich),	100U/ml	Penicillin/Streptomycin	
(Sigma-Aldrich),	and	1000U/ml	Leukemia	Inhibitory	Factor	(LIF,	Sigma-Aldrich)).		
For	direct	cardiomyocyte	differentiation,	800	ESCs	were	cultured	for	2	days	in	20µl	of	ESC	medium	
that	contained	10−4M	ascorbic	acid	(Sigma-Aldrich)	in	hanging	drops	to	produce	embryoid	bodies	
(EBs).	Subsequently,	EBs	were	cultured	as	suspensions	in	bacterial	dishes	for	5	additional	days.	On	
Day	7,	EBs	were	plated	separately	in	1%	gelatin-coated	wells	of	a	24-well	tissue	culture	plate	for	an	
additional	23	days	to	allow	adherence	and	development	of	beating	cardiomyocytes.		
	
	
4.5.3 	Differentiation	of	hiPSCs	into	Cardiomyocytes		
The	experiment	was	started	with	hiPSCs	cultured	on	irradiated	MEF	cells	in	a	1:3	ratio	which	are	
approximately	70-80%	confluent.	Any	differentiated	colonies	were	removed	using	the	
stereomicroscope.	0.5ml	Dissociation	Solution	(DS;	10ml	0.05%	Trypsin	(Life	Technologies),	4ml	
Knockout	Serum	Replacement	(Life	Technologies),	1ml	Collagenase	type	IV	(1mg/ml)	(ScimaR),	5ml	
Knockout-DMEM	(Life	Technologies)	and	20µl	1M	CaCl2)	was	added	to	the	cells	and	incubate	for	
0.5–1min	until	MEF	cells	were	dissociated	and	the	edges	of	hiPSCs	colonies	became	clear.	DS	was	
removed	and	0.75ml	collagenase	type	IV	(1mg/ml)	was	added.	The	cells	were	incubated	for	5-
15min	at	37°C	and	checked	under	the	microscope	during	the	incubation	period.	When	the	colonies	
started	to	lift	off	and	detach,	the	solution	was	removed	and	1.5ml	hES	medium	(390ml	Knockout-
DMEM,	100ml	Knockout	Serum	Replacement,	5ml	Glutamax	(Life	Technologies),	5ml	MEM	
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minimum	essential	amino	acids	solution	(Life	Technologies)	and	0.5ml	β-Mercaptoethanol	(Sigma-
Aldrich))	was	added.	Using	a	p1000	pipette,	the	colonies	were	gently	detached	as	a	whole,	taking	
care	not	to	separate	the	cells.	The	cells	were	transferred	into	a	15ml	tube	using	a	5ml	pipette.	The	
well	was	washed	with	1ml	hES	medium,	which	was	afterwards	added	to	the	same	tube.	The	tube	
was	left	to	stand	for	5min	until	all	colonies	sediment.	Medium	was	removed	and	replaced	with	2ml	
hES	medium	supplemented	with	100ng/ml	basic	fibroblast	growth	factor	(bFGF;	Life	Technologies).	
The	cells	were	transferred	into	an	ultra-low	attachment	plate	using	a	5ml	pipette	(1ml	into	each	
well	of	a	24-well	plate	and	3ml	into	each	well	of	a	6-well	plate)	and	incubated	at	37°C/5%	CO2	for	at	
least	6	hr.	During	this	time,	the	required	number	of	plates	were	coated	with	laminin	(Life	
Technologies)	and	incubated	for	1h	at	37°C.	After	6	hrs,	the	colony	aggregates	were	transferred	
into	a	15ml	tube	using	5ml	pipette,	the	plate	was	washed	with	RB	medium	(390ml	RPMI	1640	(Life	
Technologies),	10ml	B27	minus	insulin	(Life	Technologies),	5ml	Glutamax,	5ml	MEM	minimum	
essential	amino	acids	solution,	5ml	Penicillin/Streptomycin	(Sigma-Aldrich)	and	0.5ml	β-
Mercaptoethanol)	to	collect	any	remaining	aggregates	and	the	medium	was	added	to	the	same	
15ml	tube	(0.5ml	per	well	for	24-well	and	1ml	per	well	for	6-well	plates).	The	aggregates	were	left	
standing	for	5min	and	then	the	medium	was	carefully	aspirated.	2ml	RB	medium	supplemented	
with	12µM	CHIR99021	(WNT	activator)	(Miltenyi	Biotec	Australia)	was	added	to	the	aggregates	and	
carefully	transferred	with	a	5ml	pipette	to	laminin	coated	wells.	After	24	hrs,	the	medium	was	
carefully	removed	in	each	well	and	1ml	RB	medium	was	added.	
After	another	24	hrs,	the	medium	was	carefully	removed	and	exchanged	with	RB	medium	
supplemented	with	IWP2	(inhibitor	of	Wnt	ligand	production),	Purmorphamine	(activator	of	the	
Hedgehog	pathway)	and	SB431542	(inhibitor	of	the	TGF-beta/Activin/Nodal	pathway)	(5µM	each,	
all	from	Miltenyi	Biotec	Australia).	The	medium	was	changed	every	second	day	for	four	days	and	
then	every	3-4	days	with	RB	medium.	
	
	
4.5.4 	Cell	fractionation	
HL-1	cell	fractionation	was	performed	according	to	the	protocol	described	by	Weil	et	al.	[341].	HL-1	
cells	were	grown	as	monolayers	in	10	cm	dishes	until	80%	confluent.	Cells	were	trypsinised	and	
transferred	into	1ml	of	1x	PBS	pH	7.4.	100µl	was	removed	as	“total	cell	extract”	and	added	to	1ml	
of	Trizol.	Remaining	cells	were	spun	at	3000rpm	for	3min	and	carefully	resuspended	in	200µl	
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Dautry	Buffer	(10mM	Tris	pH7.8,	140	nM	NaCl,	1.5mM	MgCl2,	10mM	EDTA,	0.5%	NP-40	(Sigma-
Aldrich),	100U/ml	RNaseOUT	(Life	Technologies)),	incubated	on	ice	for	5min	and	then	centrifuged	
at	4°C	for	5min	at	3000	RPM.	The	supernatant	was	transferred	to	a	new	tube	and	the	pellet	was	
kept.	The	supernatant	was	centrifuged	again	at	full	speed	for	one	minute	to	eliminate	any	potential	
nuclei	and	transferred	to	a	new	tube	together	with	1ml	of	Trizol	for	the	“Cytoplasmic	Fraction”.	The	
first	pellet,	was	washed	once	with	500µl	Dautry	Buffer,	mixed	by	pipetting	and	centrifuged	at	4°C,	
3000rpm	for	5min.	The	supernatant	was	eliminated	and	the	pellet	kept	and	resuspended	in	1ml	of	
Trizol	for	the	“Nuclear	Fraction”.	RNA	was	extracted,	DNase	digested	and	500ng	RNA	per	fraction	
was	used	in	cDNA	reactions.	Cellular	localisation	was	checked	via	RT-	PCR.	
	
	
4.5.5 	Polysome	gradient	profiling	
HL-1	cells	were	grown	as	described	in	[179].	10μl	of	cycloheximide	(CHX,	100mg/ml,	Sigma-Aldrich)	
or	puromycin	(10mg/ml,	Thermo	Fisher	Scientific)	was	added	to	the	cells.	After	an	incubation	of	
10min	at	37°C,	the	media	was	removed,	the	cells	washed	and	harvested.	Cytoplasmic	lysates	were	
prepared	and	polysomes	were	extracted	by	adding	1ml	of	polysome	extraction	buffer	(20mM	Tris,	
pH	7.5,	100mM	KCl,	5mM	MgCL2,	0.5%	NP-40,	supplemented	with	Protease-Inhibitor	(PI,	50x	stock,	
Roche),	100U/ml	RNaseOUT	and	100μg/ml	CHX	or	puromycin)	to	the	cell	pellet.	The	samples	were	
incubated	on	ice	for	10min	and	then	centrifuged	for	12,000g	for	10min	at	4°C	to	pellet	nuclei	and	
debris.	The	supernatant	was	transferred	to	a	new	tube	and	RNA	concentrations	were	measured	
using	the	Nanodrop2000.	Equal	amounts	of	cytoplasmic	lysate	were	loaded	onto	10%–50%	linear	
sucrose	gradients	and	centrifuged	at	36,000rpm	for	1h	and	45min	at	8°C	in	a	SW41	rotor	(Beckman	
Coulter).	Twelve	fractions	were	collected	from	the	top	of	the	gradient	using	a	piston	gradient	
fractionator	(BioComp	Instruments).	The	absorbance	at	254	nm	was	measured	with	a	UV-M	II	
monitor	(Bio-Rad).	
Following	fractionation,	110μl	of	10%	SDS	and	12μl	of	proteinase	K	(20mg/mL;	Invitrogen)	were	
added	to	each	fraction	and	incubated	with	shaking	at	1000rpm	for	30min	at	42°C	to	digest	protein	
debris	and	to	inactivate	nucleases.	Polysomal	RNA	was	extracted	using	Trizol	(Thermo	Fisher	
Scientific)	following	the	manufacturer’s	protocol.	RNA	quality	was	assessed	on	the	Bioanalyzer	2100	
(Agilent),	cDNA	was	synthesised	and	used	for	RT-PCR.	
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4.5.6 		RNA	Fluorescence	in	situ	hybridisation	(RNA	FISH)	
Custom	Stellaris	FISH	Probes	were	designed	towards	the	non-repetitive	regions	of	mouse	NkxUS	
and	NkxDS,	using	the	Stellaris	RNA	FISH	Probe	Designer	(Biosearch	Technologies)	available	online	at	
www.biosearchtech.com/	stellaris	designer.	48x	20mer	oligonucleotides	were	designed	per	target	
transcript	and	conjugated	to	Quasar670	flurophores	(Table	18).		A	NEAT1	probe	set	(Cat	#:	SMF-
3010-1),	conjugated	to	Quasar	570	fluorophore,	was	used	as	a	predesigned	control.	Staining	was	
carried	out	following	the	manufacturer’s	protocol	for	adherent	mammalian	cells.	NkxDS,	NkxUS	and	
NEAT1	probe	sets	were	used	at	200	nM	with	hybridisation	overnight	at	37°C.	Briefly,	HL-1	and	
C2C12	cells	were	grown	on	coated	13mM	glass	coverslips	(Menzel	Glaeser)	in	24	well	plates	and	
grown	for	2-3	days	prior	to	staining.	Cells	were	washed	once	in	1x	PBS	and	fixed	for	10min	at	RT	in	
fixation	solution	(10	mL:	1ml	37%	formaldehyde	solution	(Sigma-Aldrich),	1ml	10X	RNase-free	PBS	
(Life	Technologies),	and	8ml	RNase-free	water).	The	fixation	solution	was	removed	and	cells	were	
washed	twice	with	1x	PBS	before	permeabilization	with	70%	ethanol	at	4°C	for	at	least	one	hour.	
Ethanol	was	then	aspirated	and	cells	were	incubated	for	5min	in	wash	buffer	(50	mL:	5ml	20x	SSC,	
5ml	deionized	formamide	(Sigma	Aldrich),	40ml	RNase-free	water).	Coverslips	were	removed	from	
the	wells	and	inverted	onto	a	40µl	drop	of	probe	(200	nM)	in	hybridisation	buffer	(5	mL:	0.5g	
dextran	sulfate	(Fisher	BioReagents),	0.5ml	20x	SSC,	0.5ml	deionized	formamide,	4ml	RNase-free	
water)	on	a	clean	parafilm	surface,	and	placed	at	37°C	in	a	dark	humidified	chamber	overnight.	The	
next	day,	coverslips	were	carefully	transferred	to	a	new	24	well	plate,	cell	side	up,	containing	0.5ml	
wash	buffer,	and	incubated	in	the	dark	at	37°C	for	30min	with	shaking.	The	wash	buffer	was	
replaced	with	wash	buffer	containing	Hoechst	(Life	Technologies,	1:20.000),	and	cells	were	
incubated	again	in	the	dark	at	37°C	for	30min	with	shaking.	Hoechst	solution	was	replaced	with	2x	
SSC	and	incubated	for	5min	at	RT.	The	coverslips	were	mounted	on	glass	microscope	slides	in	one	
drop	of	Prolong	gold	antifade	mountant	(Life	Technologies)	and	sealed	with	nail	polish.	Slides	were	
imaged	using	a	Zeiss	LSM	700	Upright	confocal	microscope	(Zeiss)	with	the	manufacturer	provided	
ZEN	imaging	software.		
	
Table	18	RNA-FISH	probe	sequences	for	NkxUS	and	NkxDS	
Final	probe	name	 Probe	(5'->	3')	 Final	probe	name	 Probe	(5'->	3')	
NkxUS_1	 ggttcctatatttcaccgaa	 NkxDS_1	 cttttatgagtgcaggttct	
NkxUS_2	 gcggaagatgtacttcttca	 NkxDS_2	 cccagcaacagtgaatcaag	
NkxUS_3	 cggagcccggagaaataaaa	 NkxDS_3	 cccagcaacagtgaatcaag	
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NkxUS_4	 tttatgctgtagcgctgtag	 NkxDS_4	 gtcaaattactgccataccg	
NkxUS_5	 attatcaccttctgagacgc	 NkxDS_5	 cagagcgattatgttggtca	
NkxUS_6	 ctcaatctgagctctcaagc	 NkxDS_6	 aaacttgggacacccagtaa	
NkxUS_7	 accacttacaacctgattca	 NkxDS_7	 agcagctgagctgaatacat	
NkxUS_8	 taccggttcacaatcctctc	 NkxDS_8	 cattagtttagtcccaggaa	
NkxUS_9	 cgcttttcaccaattcgtgc	 NkxDS_9	 gattggtagaggagtgctac	
NkxUS_10	 gtgacattgtgttcctctag	 NkxDS_10	 acgttgagaatgtggtggtt	
NkxUS_11	 atgtgcaccttgaaagcttg	 NkxDS_11	 cctgaaagagaggagttgca	
NkxUS_12	 gttcacactaattggtgtgc	 NkxDS_12	 gctctttcttcagtaggtaa	
NkxUS_13	 tgcactccggaattgtgaac	 NkxDS_13	 gactactttgactctgggac	
NkxUS_14	 ataccagagcagatttggtg	 NkxDS_14	 ttgcctttgtcattgttaga	
NkxUS_15	 ttggctgttccttgtgtttg	 NkxDS_15	 cttccactaccactattttt	
NkxUS_16	 ctctgatcaggttgtcttag	 NkxDS_16	 gaagtgttccaatctggcaa	
NkxUS_17	 gtattgcagccaagaagtga	 NkxDS_17	 ttccatagtgtatggtgaca	
NkxUS_18	 ctcagcagtttgagtaatcc	 NkxDS_18	 gctgtttggctaaattctgg	
NkxUS_19	 ccctgataaatgacaaggga	 NkxDS_19	 aagcagtcagttcactgttt	
NkxUS_20	 ggagaaggctgatctaaaga	 NkxDS_20	 ctctttcagagggctcaaag	
NkxUS_21	 gaatcagcttcagttagggc	 NkxDS_21	 caccaactgggagctaattt	
NkxUS_22	 atcaaccttttgctattgcc	 NkxDS_22	 ggggatgggggaataaggaa	
NkxUS_23	 cactgagttgttcggtttgc	 NkxDS_23	 tcttgtgttactaccttcac	
NkxUS_24	 tgttagagggaaagacaccc	 NkxDS_24	 tctaaatggcgctggatcta	
NkxUS_25	 aaccaggcactatagcttcc	 NkxDS_25	 gattcaaacctgagtgacct	
NkxUS_26	 ctagttttcgggtcaagagt	 NkxDS_26	 ttgacttctgggtcaaagca	
NkxUS_27	 gtcaagaatgctcaacctgg	 NkxDS_27	 ggaaatgggttgctcagatc	
NkxUS_28	 ccatttgataggcagacaga	 NkxDS_28	 gtgtagaagcctgtaacagt	
NkxUS_29	 tatctgaagcatcacctacc	 NkxDS_29	 taggtgcttgtactagtctg	
NkxUS_30	 tctctaggtgtccagataac	 NkxDS_30	 gcacttcaggattacatgga	
NkxUS_31	 taagccattggagatagctc	 NkxDS_31	 ggttaactctgggatgtgac	
NkxUS_32	 agagatagacaggcaccttg	 NkxDS_32	 ggctctgtgtcttatggaaa	
NkxUS_33	 tcagagtgggagacattgtg	 NkxDS_33	 tttccaacattatccctaga	
NkxUS_34	 gacgagaagattgctcagct	 NkxDS_34	 caccaggactgtgtatagat	
NkxUS_35	 ttaggattgagagacgtggc	 NkxDS_35	 actgagcaaagtgatcctca	
NkxUS_36	 agaagcatgaagacagctga	 NkxDS_36	 cacagtgatggctacattca	
NkxUS_37	 ttgtcctgtggacttaacac	 NkxDS_37	 aagccctgaggattactctg	
NkxUS_38	 ttccaatctgtgcagaagtc	 NkxDS_38	 gcagttcattgacagtgctg	
NkxUS_39	 aagcaaggatcttgcatgct	 NkxDS_39	 actggagtttctggagacag	
NkxUS_40	 ctgtaccccagaaaaacagt	 NkxDS_40	 acatcattttgtacctgact	
NkxUS_41	 ctttccatttgataggcaga	 NkxDS_41	 tctgagggtggttaatgtga	
NkxUS_42	 tcatcctggagttagggaaa	 NkxDS_42	 ggtcctttgtaactgcagat	
NkxUS_43	 tgagtgggcagtagagagaa	 NkxDS_43	 tgactgtgagtgctcactgc	
NkxUS_44	 gttccattcgatggatcatt	 NkxDS_44	 gtgacagtgtctatgtgctg	
NkxUS_45	 gatgtccaggatggaaatgc	 NkxDS_45	 atgggaccatgtgcattaag	
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NkxUS_46	 aggcccaggtaaaagaactc	 NkxDS_46	 ctgcatgtgttccatattta	
NkxUS_47	 ctcttttcccactcaattac	 NkxDS_47	 aggaaacctataggtcgcat	
NkxUS_48	 cctaaagcaagggtcaagga	 NkxDS_48	 tttggctgatgcgtttagag	
	
	
4.5.7 Cell	transfection	
Two	locked	nucleotide	acid	(LNA)	GapmeR	antisense	oligonucleotides	(ASOs)	(Exiqon)	were	custom	
designed	for	NkxUS,	named	ASO1	and	ASO2	as	well	as	a	ready	to	use	control	LNA	GapmeR.	The	
target	sequences	are	listed	in	Table	19.	Lipofectamine	2000	(Life	Technologies)	was	used	as	a	
transfection	reagent	and	the	transfection	was	set	up	in	a	24-well	format.	40	nM	of	ASO	was	mixed	
with	50µl	of	OPTI-MEM	(Thermo	Fisher	Scientific)	directly	in	the	well	and	incubated	for	5min	at	RT.	
4µl	of	Lipofectamine	2000	was	used	per	well	and	mixed	with	50µl	of	OPTI-MEM.	After	5min,	the	
Lipofectamine	mixture	was	added	to	the	ASO	solution,	mixed	well	and	incubated	for	20min	at	RT.	
Meanwhile,	the	cells	were	harvested	using	Trypsin	(Life	Technologies)	as	previously	described.	
2x105	cells	in	1ml	of	HL-1	medium	were	used	per	well	and	directly	added	to	the	transfection	mix	
and	incubated	at	37°C	for	24	hrs.	The	following	day	the	cells	were	washed	twice	with	1x	PBS	before	
harvesting	in	700µl	of	Trizol.	The	samples	were	stored	at	–80°C	until	further	use.	
RNA	was	extracted	following	the	Trizol	protocol.	The	RNA	was	treated	with	1µl	DNAseI	for	10min	at	
37°C.	RNA	samples	were	quantified	using	the	NanoDrop2000	(Thermo	Fisher	Scientific)	and	
knockdown	efficiency	was	determined	using	RT-PCR.	
	
Table	19	ASO	target	sequences	
	 Target	sequence	
ASO1	 CACGTCTCTCAATC	
ASO2	 GTCTATCTCTTTTGTC	
	
	
4.5.7.1 RNA	sequencing	after	cell	transfection	
High	quality	RNA	with	an	RNA	integrity	number	(RIN)	of	>	9,	extracted	from	three	biological	
replicates	for	ASO1,	ASO2	and	control	ASO,	were	used	to	prepare	in	total	twelve	libraries	using	the	
TruSeq	Stranded	mRNA	Library	Prep	kit	from	illumina	following	the	standard	protocol.	The	library	
preparation	was	performed	by	Dominik	Kaczorowski	(Garvan	Institute	of	Medical	Research,	Sydney,	
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Australia).	The	RNA-sequencing	libraries	were	sequenced	on	the	Illumina	HiSeq2500	v4	platform	in	
high	output	mode	at	the	Kinghorn	Centre	for	Clinical	Genomics	(Garvan	Institute	of	Medical	
Research,	Sydney,	Australia).	For	all	samples,	over	20	million	125	nucleotide	paired-end	reads	were	
generated.	
	
	
4.6 Chromatin	isolation	by	RNA	immunoprecipitation	(ChIRP)	
4.6.1 	Design	of	ChIRP	probes	
Antisense	DNA	tiling	probes	for	selective	retrieval	of	NkxUS	were	designed	using	the	online	probe	
designer	at	singlemoleculefish.com	as	recommended	by	the	original	ChIRP	paper	[235].		
40	biotintylated	probes	were	designed,	labelled	according	to	their	position	along	NkxUS	and	then	
divided	into	two	pools,	“EVEN”	(all	even	numbered	probes)	and	“ODD”	(all	odd	numbered	probes)	
(Table	20).	Additionally,	LacZ	probes	were	used	as	a	negative	control	as	LacZ	is	not	present	in	
mammalian	cells	(Table	20).	The	oligos	with	standard	desalting	purification	were	produced	by	
Sigma-Aldrich.	The	probes	were	diluted	to	100	μM	concentration	and	stored	at	-20°C.	All	ChIRP	
experiments	were	done	with	the	three	probe	pools.		
	
Table	20	NkxUS	and	LacZ	ChIRP	probes		
Final	probe	
name	 Probe	(5'->	3')	 Final	probe	name	 Probe	(5'->	3')	
NkxUS_Probe	1	 ggttcctatatttcaccgaa	 LacZ_Probe	1	 ccagtgaatccgtaatcatg	
NkxUS_Probe	2	 gcggaagatgtacttcttca	 LacZ_Probe	3	 attaagttgggtaacgccag	
NkxUS_Probe	3	 cggagcccggagaaataaaa	 LacZ_Probe	5	 aatgtgagcgagtaacaacc	
NkxUS_Probe	4	 tttatgctgtagcgctgtag	 LacZ_Probe	7	 aataattcgcgtctggcctt	
NkxUS_Probe	5	 attatcaccttctgagacgc	 LacZ_Probe	9	 aattcagacggcaaacgact	
NkxUS_Probe	6	 ctcaatctgagctctcaagc	 LacZ_Probe	11	 atcttccagataactgccgt	
NkxUS_Probe	7	 accacttacaacctgattca	 LacZ_Probe	13	 gctgatttgtgtagtcggtt	
NkxUS_Probe	8	 taccggttcacaatcctctc	 LacZ_Probe	15	 aactgttacccgtaggtagt	
NkxUS_Probe	9	 cgcttttcaccaattcgtgc	 LacZ_Probe	17	 tttcgacgttcagacgtagt	
NkxUS_Probe	10	 gtgacattgtgttcctctag	 LacZ_Probe	19	 accattttcaatccgcacct	
NkxUS_Probe	11	 atgtgcaccttgaaagcttg	 LacZ_Probe	21	 ttcatcagcaggatatcctg	
NkxUS_Probe	12	 gttcacactaattggtgtgc	 LacZ_Probe	23	 tggttcggataatgcgaaca	
NkxUS_Probe	13	 tgcactccggaattgtgaac	 LacZ_Probe	25	 agacgattcattggcaccat	
NkxUS_Probe	14	 ataccagagcagatttggtg	 LacZ_Probe	27	 atttgatccagcgatacagc	
NkxUS_Probe	15	 ttggctgttccttgtgtttg	 LacZ_Probe	29	 tttgatggaccatttcggca	
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NkxUS_Probe	16	 ctctgatcaggttgtcttag	 LacZ_Probe	31	 aaacggggatactgacgaaa	
NkxUS_Probe	17	 gtattgcagccaagaagtga	 LacZ_Probe	33	 atacagaactggcgatcgtt	
NkxUS_Probe	18	 ctcagcagtttgagtaatcc	 LacZ_Probe	35	 tattcgctggtcacttcgat	
NkxUS_Probe	19	 ccctgataaatgacaaggga	 LacZ_Probe	37	 tttaccttgtggagcgacat	
NkxUS_Probe	20	 ggagaaggctgatctaaaga	 LacZ_Probe	39	 aaatccatttcgctggtggt	
NkxUS_Probe	21	 gaatcagcttcagttagggc	 	 	
NkxUS_Probe	22	 atcaaccttttgctattgcc	 	 	
NkxUS_Probe	23	 cactgagttgttcggtttgc	 	 	
NkxUS_Probe	24	 tgttagagggaaagacaccc	 	 	
NkxUS_Probe	25	 aaccaggcactatagcttcc	 	 	
NkxUS_Probe	26	 ctagttttcgggtcaagagt	 	 	
NkxUS_Probe	27	 gtcaagaatgctcaacctgg	 	 	
NkxUS_Probe	28	 ccatttgataggcagacaga	 	 	
NkxUS_Probe	29	 tatctgaagcatcacctacc	 	 	
NkxUS_Probe	30	 tctctaggtgtccagataac	 	 	
NkxUS_Probe	31	 taagccattggagatagctc	 	 	
NkxUS_Probe	32	 agagatagacaggcaccttg	 	 	
NkxUS_Probe	33	 tcagagtgggagacattgtg	 	 	
NkxUS_Probe	34	 gacgagaagattgctcagct	 	 	
NkxUS_Probe	35	 ttaggattgagagacgtggc	 	 	
NkxUS_Probe	36	 agaagcatgaagacagctga	 	 	
NkxUS_Probe	37	 ttgtcctgtggacttaacac	 	 	
NkxUS_Probe	38	 ttccaatctgtgcagaagtc	 	 	
NkxUS_Probe	39	 aagcaaggatcttgcatgct	 	 	
NkxUS_Probe	40	 ctgtaccccagaaaaacagt	 	 	
	
	
4.6.2 	ChIRP	followed	by	mass	spectrometry	
The	protein	ChIRP	was	performed	following	a	published	protocol	[236].	100-500	million	HL-1	cells	
were	harvested	and	crosslinked	with	0.5%	or	3%	Formaldehyde	for	10min	followed	by	quenching	
with	1.25M	Glycine	(Sigma-Aldrich)	for	5min.	After	spinning,	the	pellet	was	washed	with	cold	1x	
phosphate	buffered	saline	(PBS)	and	spin	again.	The	pellet	was	resuspended	in	1ml	of	cold	1x	PBS,	
transferred	to	a	1.5ml	tube	and	spin	again	at	4°C.	Afterwards,	the	pellet	was	flash	frozen	and	stored	
at	-80°C.	
Pellets	were	thawed	at	RT	and	weighed.	Per	100mg	of	pellet,	1ml	of	lysis	buffer	(50mM	Tris-Cl	
pH7.0,	10mM	EDTA,	1%	SDS)	supplemented	with	Protease-Inhibitor	(PI,	50x	stock,	Roche),	
Superase-IN	(200x	stock,	Ambion)	and	Phenylmethylsulfonyl	fluoride	(PMSF,	100x	stock,	Sigma-
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Aldrich)	was	added	and	resuspended.	The	chromatin	was	placed	on	ice	and	sonicated	at	4°C	using	
the	Bioruptor	Pico	(Diagenode)	until	the	fragments	were	under	500bp	long.	After	sonication	the	
chromatin	was	centrifuged	at	16,000	RCF	for	10min,	the	supernatant	was	transferred	to	a	new	
tube,	flash	frozen	and	stored	at	-80°C.	
Chromatin	of	100-500	million	cells	were	thawed	at	RT	and	pooled.	Per	ml	of	lysate,	30µl	of	C-1	
magnetic	beads	(Invitrogen)	were	washed	three	times	with	unsupplemented	lysis	buffer	and	
resuspended	in	original	volume	of	lysis	buffer	supplemented	with	PI,	Superase-IN	and	PMSF.	The	
beads	were	added	to	the	lysate	and	incubated	for	30min,	shaking	at	37°C.	Afterwards,	the	beads	
were	removed	twice	from	the	lysate	using	a	magnetic	stand.	Per	1ml	of	lysate,	10µl	was	removed	
to	serve	as	RNA	input	and	50µl	to	serve	as	protein	input.	The	input	samples	were	kept	on	ice	until	
further	use.	In	the	meanwhile,	2ml	of	hybridisation	buffer	(750mM	NaCl,	1%	SDS,	50mM	Trsi-Cl	
pH7.0,	1mM	EDTA,	15%	formamide	(Sigma-Aldrich))	supplemented	with	fresh	PI,	Superase-IN	and	
PMSF	was	prepared	per	1ml	of	lysate.	The	lysate	was	divided	equally	into	three	15ml	Falcon	tubes,	
one	for	EVEN,	one	for	ODD	and	one	for	LacZ.	2ml	of	Hybridisation	buffer	and	1µl	of	100µmol	of	
probe	pool	was	added	per	1ml	of	lysate	and	incubated	overnight	at	37°C	shaking.		
The	next	day,	100µl	of	beads	per	100	pmol	of	probe	were	prepared	as	the	day	before	and	added	to	
the	samples.	After	30min	at	37°C,	the	beads	were	collected	using	a	magnetic	stand	and	washed	five	
times	with	wash	buffer	(2x	NaCL	and	socium	citrate,	0.5%	SDS)	freshly	supplemented	before	each	
wash	with	PMSF.	The	samples	were	washed	each	time	for	5min	at	37°C	shaking.	At	the	last	wash,	
100µl	per	1ml	of	lysate	was	removed	for	RNA	isolation	and	the	rest	was	used	for	protein	isolation.		
For	the	RNA	isolation,	85µl	and	95µl	of	Proteinase	K	buffer	(100mM	NaCl,	10mM	Tris-Cl	pH8,	1mM	
EDTA,	0.5%	SDS)	was	added	to	the	RNA	input	and	bead	sample,	respectively,	as	well	as	5µl	
Proteinase	K	(20mg/ml,	Ambion)	each.	The	samples	were	incubated	at	50°C	for	45min,	briefly	spin	
down	and	incubated	for	10min	at	95°C.	The	samples	were	chilled	on	ice	and	500µl	Trizol	(Thermo	
Fisher	Scientific)	was	added.	After	vortexing	the	samples	were	incubated	for	10min	at	RT	and	then	
either	stored	at	-80°C	or	further	processed	directly.	100µl	of	chloroform	(Sigma-Aldrich)	was	added	
to	each	sample,	the	samples	were	vortexed	and	then	spin	at	16,000	RCF	for	15min	at	4°C.	The	
aqueous	phase	was	transferred	to	a	new	tube	and	1.5	volume	of	100%	ethanol	was	added.	The	
samples	were	vortexed	and	the	spin	through	miRNeasy	mini	columns	(Qiagen)	following	the	
manufacturer’s	protocol.	An	on-column	DNAseI	(Qiagen)	digest	was	performed	and	the	RNA	was	
eluted	in	30µl	of	nuclease-free	water.	8µl	of	each	sample	was	used	for	cDNA	synthesis	using	
Superscript	III	Supermix.	The	cDNA	was	diluted	1:3	and	used	for	RT-PCR	to	check	for	NkxUS	
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enrichment.	Primers	for	Nkx2-5,	Gapdh	and	Actb	(Table	13	and	15)	were	used	to	check	for	specific	
enrichment.		
For	protein	elution,	the	beads	of	the	protein	fraction	were	collected	and	resuspended	in	50µl	biotin	
elution	buffer	(12.5mM	biotin	(Invitrogen),	7.5mM	HEPES	pH	7.5,	75mM	NaCl,	1.5mM	EDTA,	0.15%	
SDS,	0.075%	sarkosyl	(Sigma-Aldrich),	and	0.02%	Na-Deoxycholate	(Sigma-Aldrich)).	50µl	of	biotin	
elution	buffer	was	also	added	to	the	protein	input.	The	samples	were	mixed	at	RT	for	20min	
followed	by	10min	at	65°C.	The	elution	was	repeated	once	more	with	fresh	biotin	elution	buffer.	
The	two	eluents	were	pooled,	leading	to	in	total	100µl	of	sample.	Residual	beads	were	removed	
again	and	25%	total	volume	of	Trichlorotic	acid	(Sigma-Aldrich)	was	added	to	the	samples.	After	
vortexing,	the	samples	were	rotated	overnight	at	4°C	for	protein	precipitation.	The	following	day,	
the	samples	were	centrifuged	at	16,000	RCF	for	60min	at	4°C.	The	supernatant	was	removed	and	
the	pellets	were	washed	with	cold	acetone	(Sigma-Aldrich).	After	another	spin	for	5min	at	4°C	the	
acetone	was	removed	completely	and	the	pellet	was	air-dried.	The	pellet	was	the	resuspended	in	
7.5µl	of	nuclease-free	water	and	2.5µl	of	4x	LDS	sample	buffer	(Thermo	Fisher	Scientific).	The	
samples	were	boiled	for	30min	at	95°C	for	reverse	crosslinking	and	then	loaded	onto	a	6%	Bis-Tris	
gel	(Thermo	Fisher	Scientific).	The	gel	was	run	for	50min	at	200V	and	afterwards	stained	with	
Coomassie	Brilliant	Blue	G250	(Thermo	Fisher	Scientific)	as	follows.	A	dye	stock	solution	was	
prepared	consisting	of	0.1%	Coomassie	Brilliant	Blue	G250,	2%	ortho-phopshotic	acid	(Sigma-
Aldrich)	and	10%	ammonium	sulphate	(Sigma-Aldrich).	The	gel	was	fixed	with	40%	ethanol,	10%	
acetic	acid	for	one	hour.	Afterwards,	the	gel	was	washed	twice	in	water	for	10min.	The	gel	was	
stained	with	Coomassie	Brilliant	Blue	G250	working	solution	(80%	stock	solution,	20%	methanol)	
overnight	at	RT.	The	next	day	the	gel	was	destained	with	1%	acetic	acid	for	three	hours,	changing	
the	solution	several	times.	
The	lanes	of	the	stained	gel	were	cut	into	at	least	4	pieces	each.	The	samples	were	prepared	and	
analysed	using	mass	spectrometry	by	Dr.	Ben	Crosset	(University	of	Sydney)	as	follows.	
The	excised	gel	fragments	were	destained	in	a	60:40	solution	of	40mM	NH4HCO3	(pH	7.8)/100%	
acetonitrile	(MeCN)	for	1	h.	Gel	pieces	were	vacuum-dried	and	the	rehydrated	with	a	12ng/µL	
trypsin	(Promega)	solution	at	4°C	for	one	hour.	Excess	trypsin	was	removed	and	gel	pieces	covered	
with	40mM	NH4HCO3	and	incubated	overnight	at	37°C.		Peptides	were	concentrated	and	desalted	
using	C18	Zip-	Tips	(Millipore)	as	per	the	manufactures	instructions.	Peptides	were	resuspended	in	
25µl	3%	(v/v)	acetonitrile/0.1%	(v/v)	formic	acid,	and	briefly	sonicated.	Samples	were	separated	by	
nano-LC	using	an	Ultimate	3000	HPLC	and	autosampler	system	(Thermo	Fisher	Scientific)	coupled	
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to	an	in-house	fritless	nano	75µm	×	40cm	column	packed	with	ReproSil	Pur	120	C18	stationary	
phase	(1.9µm,	Dr,	Maisch	GmbH,	Germany).	LC	mobile	phase	buffers	were	comprised	of	A:	0.1%	
(v/v)	formic	acid	and	B:	80%	(v/v)	acetonitrile/0.1%	(v/v)	formic	acid.	Peptides	were	eluted	using	a	
linear	gradient	of	5%	B	to	40%	B	over	60min	and	then	95%	B	wash	over	1min	at	a	flow	rate	of	
250nL/min.	The	LC	was	coupled	to	a	QExactive	Plus	Orbitrap	mass	spectrometer	(Thermo	Fisher	
Scientific).	Column	voltage	was	2300V	and	the	heated	capillary	set	to	275°C.	Positive	ions	were	
generated	by	electrospray	and	the	Orbitrap	operated	in	data-dependent	acquisition	mode.	A	survey	
scan	of	350-1550m/z	was	acquired	(resolution	=	70,000,	with	an	accumulation	target	value	of	
1,000,000	ions)	with	lockmass	enabled.		Up	to	10	of	the	most	abundant	ions	(>1.7e5	ions),	with	
charge	states	≥	+2	were	sequentially	isolated	and	fragmented	and	target	value	of	100,000	ions	
collected.	Ions	selected	for	MS/MS	were	dynamically	excluded	for	20s.		The	data	were	analysed	
using	Proteome	Discoverer	vr	2.1	(Thermo	Fisher	Scientific)	and	Mascot	vr	2.4	(Matrix	Science).	The	
search	parameters	included	the	following	variable	modifications:	oxidized	methionine	and	
carbamidomethyl	cysteine.	The	enzyme	was	set	to	trypsin,	precursor	mass	tolerance	was	10ppm	
while	the	fragment	tolerance	was	0.1Da.		The	database	was	the	SwissProt	database	restricted	to	
Mus	musculus	taxonomy.	
	
	
4.6.3 	ChIRP	followed	by	DNA	Sequencing	
The	DNA	ChIRP	was	performed	following	the	methods	paper	[235].	The	method	is	similar	to	the	one	
used	for	the	protein	ChIRP	except	that	1%	glutaraldehyde	(Sigma-Aldrich)	was	used	for	crosslinking	
and	about	100	million	cells	per	experiment	were	used.	Otherwise,	the	method	was	followed	as	
described	for	the	protein	ChIRP	until	the	protein	elution	step.	Instead	of	protein	elution,	DNA	was	
isolated	as	follows.	Each	bead	sample	was	resuspended	in	150µl	DNA	elution	buffer	(50mM	sodium	
bicarbonate	(Sigma-Aldrich),	1%	SDS),	10µl	RNaseA	(10mg/ml,	Sigma-Aldrich)	and	10µl	RNaseH	
(10U/µl,	Life	Technologies).	The	samples	were	incubated	at	37°C	for	30min	with	shaking.	
Afterwards,	beads	and	supernatant	were	separated	using	a	magnetic	stand.	The	supernatant	was	
transferred	to	a	new	1.5ml	tube.	This	step	of	DNA	elution	was	repeated	once	more.	The	
supernatants	were	pooled,	yielding	in	total	300µl	of	sample.	15µl	of	Proteinase	K	(Sigma-Aldrich)	
was	added	to	each	sample,	mixed	and	incubated	at	45°C	for	50min	with	shaking.	The	DNA	samples	
were	transferred	into	yellow	phase	lock	gel	tubes.	300µl	of	Phenol:Chloroform:Isoamyl	(Sigma-
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Aldrich)	was	added	per	sample	and	incubated	for	10min	with	vigorous	shaking.	The	samples	were	
spin	down	for	5min	at	full	speed	at	4°C	and	the	aqueous	phase	was	transferred	into	a	new	tube.	3µl	
GlycoBlue	(Ambion),	30µl	sodium	acetate	(Sigma-Aldrich)	and	900µl	100%	ethanol	were	added,	the	
samples	were	vortexed	and	then	stored	overnight	at	-20°C.	The	next	day	the	samples	were	spin	
down	for	30min	at	4°C	at	full	speed.	The	supernatant	was	removed	and	1ml	70%	ethanol	was	
added	to	the	samples.	After	vortexing,	the	samples	were	centrifuged	at	full	speed	for	5min.	The	
supernatant	was	removed	and	the	pellet	was	left	to	air	dry	for	1min.	The	pellet	was	resuspended	in	
30µl	elution	buffer	(Qiagen)	and	the	samples	were	stored	at	–	20°C	until	library	preparation.	
Efficient	enrichment	of	NkxUS	was	determined	by	RT-PCR	as	described	for	the	protein	ChIRP.	DNA	
from	five	biological	replicates	for	EVEN,	ODD,	LacZ	and	DNA	input	were	assessed	for	quantity	and	
quality	using	a	NanoDrop2000	(Thermo	Fisher	Scientific)	and	the	Bioanalyser2100	(Agilent)	using	
the	high	sensitivity	DNA	chip	as	per	the	manufacturer's	protocol.	Samples	were	end-repaired	using	
Klenow	DNA	polymerase	(NEB)	and	T4	DNA	polymerase	(NEB).	Briefly,	Klenow	DNA	polymerase	was	
diluted	1:5	to	1U/μl	and	added	to	the	reaction	mix	(Table	21).	The	sample	mix	was	incubated	at	
20°C	for	30min	and	then	the	DNA	was	purified	using	90μl	of	AMPure	XP	beads	and	resuspended	in	
8.75µl	of	resuspension	buffer.	End-repaired	samples	were	then	used	in	the	Illumina	TruSeq	
stranded	mRNA	kits	from	the	3’	adenylation	step	using	half-reactions.	The	library	preparation	was	
performed	by	Dominik	Kaczorowski	(Garvan	Institute	of	Medical	Research,	Sydney,	Australia).	The	
samples	were	sequenced	over	two	lanes	using	125bp	paired-end	and	the	Illumina	HiSeq2500	v4	
platform	in	high	output	mode	at	the	Kinghorn	Centre	for	Clinical	Genomics	(Garvan	Institute	of	
Medical	Research,	Sydney,	Australia)	
	
Table	21	Reaction	mixture	for	DNA	end	repair	
ChIRP		DNA	 30μl	
Nuclease-free	water	 10μl	
10x	T4	DNA	Polymerase	buffer	 5μl	
dNTP	mix	 2μl	
T4	DNA	Polymerase	(10U/μl)	 1μl	
Klenow	DNA	Polymerase	(5U/μl)	 1μl	
T4	PNK	(10U/μl)	 1μl	
Total	 50μl	
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4.7 Animal	experimentation	
Animal	experimentation	was	performed	with	approval	of	the	Garvan	Institute/St	Vincent's	Hospital	
Animal	Ethics	Committee	(Project	numbers	16/03	and	16/10).	All	mice	were	kept	on	a	full	C57BL/6J	
background	and	housed	at	the	BioCore	facilities	in	the	Victor	Chang	Cardiac	Research	Institute.	
Mice	were	sacrificed	by	CO2	inhalation.		
	
	
4.7.1 	Experimental	mouse	model	
For	the	investigation	of	the	conserved	region	in	NkxUS,	mice	lacking	part	of	this	region	were	
generated	using	CRISPR/Cas9	(Figure	33).	This	mouse	line	was	termed	NkxUS∆	and	is	on	a	C57BL/6J	
background.	Genome	editing	using	CRISPR	may	have	off-target	mutation	sites	[342,	343].	Typically,	
mice	are	backcrossed	for	several	generations	to	remove	off-targets.	However,	in	the	interest	of	
time	we	crossed	the	founder	females	with	C57BL/6J	mice	to	expand	the	colonies	and	then	crossed	
heterozygous	offspring	of	NkxUS∆_F5	to	the	ones	of	NkxUS∆_F10	to	limit	the	chance	of	off-target	
effects.	In	the	meantime,	NkxUS∆-F5	and	NkxUS∆-F10	lines	were	continued	to	backcross	until	the	
10th	generation	to	C57BL/6J	mice	to	ensure	removal	of	off-target	sites.		For	all	experiments	
described	in	this	thesis,	animals	generated	from	intercrossing	NkxUS∆-F5	and	NkxUS∆-F10	were	
used	and	are	referred	to	as	NkxUS∆.	NkxUS∆	homozygous	(NKXUS∆-/-)	and	NkxUS∆	wildtype	
(NKXUS∆+/+)	mice	were	analysed	in	the	following	experiments.	
	
	
4.7.2 	Mouse	genotyping	
For	genotyping,	genomic	DNA	was	extracted	from	tail	clips	using	Extract-N-AmpTM	Tissue	PCR	Kit	
(Sigma-Aldrich)	following	manufacturer’s	protocol.	PCR	was	performed	on	tail	clip	DNA	using	two	
different	primer	pairs	(USD1	and	USD2)	listed	in	Table	22,	which	span	the	deletion.	The	REDExtract-
N-Amp	PCR	ReadyMix	(Sigma-Aldrich)	was	used	for	the	PCR	and	set	up	as	follows:		
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REDExtract-N-Amp	PCR	ReadyMix	 5µl								
DNA																																																																																																																												 1µl							
10µM	Forward	primer																		 1µl							
10µM	Reverse	primer																								 1µl								
nuclease-free	water																																																				 2µl	
Total		 10	µl	
	
The	samples	were	run	with	the	following	PCR	conditions:	
	
Temperature	 Duration	 Cycles	
94°C	 3min	 1	
95°C	 15	s	
34x	63°C	 1min	
72°C	 1min	
72°C	 10min	 1	
	
Table	22	Genotyping	primers	(FW=forward;	RV=	reverse)	
USD1	
FW:	AGATTCCCAGCAGTCCGTAG	
RV:	GCAGTGCCAGTAACAAGGTC	
USD2	
FW:	TAAGGGCTGTAAAGCACGG	
RV:	CCAGTAACAAGGTCCTCCAC	
	
	
4.7.3 	In	situ	hybridisation	
In	situ	hybridisation	was	performed	on	C57BL/6J	mice	using	the	same	RNA	probes	as	for	the	
Northern	blot	(Table	16)	and	based	on	a	protocol	described	previously	[344].	Tissues	were	collected	
and	fixed	overnight	in	4%	paraformaldehyde	(PFA)	in	1x	PBS	by	rocking	4°C.	Tissues	were	
dehydrated	in	a	graded	ethanol	series,	embedded	in	paraffin	and	sectioned.	Sectioned	tissues	were	
deparaffinised	and	rehydrated,	followed	by	proteinase	K	treatment	(20µg/mL,	Roche)	in	1x	PBS	for	
10min	at	37°C.	Slides	were	washed	two	times	5min	with	1x	PBS,	post-fixed	in	4%	PFA	for	5min	at	RT	
and	washed	once	with	1x	PBS	fro	5min.	The	tissues	were	permeabilised	with	0.07M	HCl	for	15min	
at	RT.	Afterwards,	the	slides	were	washed	washed	two	times	5min	with	1x	PBS	and	incubated	with	
0.25%	acetic	acid	in	0.1M	triethanolamine	(pH8,	Sigma	Aldrich)	for	10min	at	RT	to	block	non-
specific	probe	binding.	The	slides	were	washed	once	for	5min	with	1x	PBS	and	once	with	nuclease-
free	water.	The	slides	were	incubated	in	hybridisation	buffer	(50%	formamide,	5	×	SSC,	1%	block	
solution	(Roche),	5mM	EDTA,	0.1%	Tween-20,	0.1%	Chaps	(Sigma-Aldrich),	0.1mg/ml	heparin	
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(Becton-Dickinson),	and	1mg/ml	yeast	total	RNA	(Roche))	without	probe	for	2hrs	at	70°C	in	a	
humidified	chamber	and	then	with	probe	(1ng/µl)	overnight	at	70°C.	The	next	day,	the	slides	were	
briefly	rinsed	in	2x	SSC	and	washed	three	times	for	30min	in	50%	formamide	in	2x	SSC	at	65°C,	
followed	by	three	times	5min	washed	with	PBST.	Probe	bound	to	the	section	was	immunologically	
detected	using	sheep	anti-digoxigenin	Fab	fragment	covalently	coupled	to	alkaline	phosphatase	
(Sigma-Aldrich)	overnight	at	4°C,	according	to	the	manufacturer's	protocol.		
The	next	day,	slides	were	washed	twice	for	10min	with	MABT	at	RT,	then	three	times	for	1h	at	RT.	
BM	purple	(Sigma-Aldrich)	was	to	the	slides	and	incubated	until	staining	developed.	The	slides	were	
washed	two	times	for	5min	in	1x	PBS,	then	incubated	in	4%	PFA	at	RT	for	20min	and	washed	again	
in	1x	PBS	for	5min.	The	slides	were	dehydrated	using	a	graded	ethanol	series	and	mounted	using	
DPX	(Sigma-Aldrich).	Images	were	taken	using	a	Leica	microscope.	
	
	
4.7.4 	RNA	extraction	from	mouse	tissues	
Tissues	were	collected	from	mice	and	flash	frozen.	Tissues	were	homogenized	in	1ml	Trizol	for	30-
50s	until	the	samples	were	completely	homogenized.	Total	RNA	was	extracted	as	described	in	2.2.1.	
The	extracted	RNA	was	treated	with	DNAseI	and	subsequently	cleaned	up	using	the	RNA	Clean	and	
Concentrator	kit	as	described	in	2.2.2	and	2.2.3.	RNA	was	eluted	in	10-15µl.	After	measuring	the	
RNA	concentration	using	the	NanoDrop2000,	the	RNA	was	stored	at	-80°C.		
	
	
4.7.5 	Optical	projection	tomography	(OPT)	
Embryonic	day	(E)	17.5	old	NkxUS∆-/-	and	NkxUS∆+/+	mouse	embryos	were	analysed	by	OPT	for	
heart	defects.	Heart	were	dissected	in	1x	PBS	containing	40mM	potassium	chloride	(KCl)	and	1mM	
Heparin	(Clifford	Hallam	Healthcare).	Following	dissection,	the	hearts	were	incubated	in	3%	
glutaraldehyde	(Sigma-Aldrich)	for	at	least	one	hour	at	RT.	Afterwards,	the	hearts	were	transferred	
to	70%	methanol	(MeOH),	followed	by	85%	and	two	times	100%,	each	for	at	least	one	hour,	before	
placing	in	fresh	100%	MeOH	overnight.	The	next	day	the	hearts	were	optically	cleared	using	a	1:2	
mixture	of	benzyl	alcohol	and	benzyl	benzoate	(BA:BB)	for	at	least	one	hour.	The	BA:BB	was	
replaced	with	fresh	one	and	the	hearts	were	left	to	clear	overnight.	The	next	day,	the	samples	were	
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analysed	using	the	OPT	scanner	by	placing	a	single	heart	in	the	tip	of	a	cut-off	and	sealed	glass	
pipette,	which	was	then	fixed	to	the	mounting	post	of	the	OPT.	OPT	scanning	was	performed	using	
the	FITC	channel	and	a	custom	microscope	controlled	by	the	software	OPTimum	(James	Springfield,	
Institute	for	Molecular	Biosciences,	University	of	Queensland,	Australia).	About	800	images	were	
obtained	per	heart.	The	images	were	reconstructed	using	the	software	Nrecon	(Bruker	microCT)	
and	heart	morphology	analysed	using	the	software	AMIRA	(version	5.5.0,	FEI	Visualization	Services	
Group).		
	
	
4.7.6 	Atrial	septal	morphology	analysis	
Twenty	6-8	week	old	NkxUS∆-/-	and	NkxUS∆+/+	mice	were	anatomically	dissected	by	Dr.	Edwin	Kirk	
(University	of	New	South	Wales,	Sydney)	to	analyse	the	atrial	septal	morphology	following	his	
published	article	[249].	Briefly,	the	mouse	body	weight	was	measured	before	the	mice	were	
euthanized	using	CO2	chambers.	The	mouse	chest	was	opened	and	the	heart	was	removed	and	
placed	into	a	petridish	containing	1x	PBS.	The	left	atrium	(LA)	was	opened	to	analyse	for	atrial	
septal	defects	(ASD),	patent	foramen	ovale	(PFO),	crescent	width	(CRW),	flap	valve	length	(FLV),	
foramen	ovale	width	(FOW).	CRW,	FLV	and	FOW	were	measured	using	an	eyepiece	graticule.	To	
determine	whether	a	PFO	was	present,	the	right	atrium	(RA)	was	pressurised.	If	remaining	blood	
contained	within	the	RA	would	pass	across	the	septum	into	the	LA,	then	a	PFO	was	present.	To	
measure	the	atrial	septal	anatomy,	the	cut	edges	of	the	LA	were	hold	by	dissection	forceps	to	
expose	the	atrial	septum	and	quantitative	parameters	were	measured	using	an	eyepiece	graticule	
as	in	Figure	47.	Care	was	taken	to	maintain	a	consistent	amount	of	stretch	for	all	the	animals.	Dr.	
Edwin	Kirk	was	kept	blinded	to	the	genotype	throughout	the	whole	experiment.	
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Figure	47	Atrial	septal	morphology	analysis.	Measurements	of	quantitative	parameters	are	shown	
for	CRW,	FVL	ad	FOW.	
	
	
4.7.7 	Thoracic	Aortic	Constriction	surgery	(TAC)	
TAC	is	a	surgery	in	which	one	of	the	major	arteries	leading	from	the	heart,	the	aorta,	is	constricted.	
Constriction	causes	an	increase	in	the	resistance	to	pumping	for	the	left	ventricle	(LV)	leading	to	LV	
hypertrophy	(growth).	In	this	model,	the	inside	diameter	of	the	aorta	close	to	the	LV	was	reduced	
by	tying	a	suture	around	it.		
	 10-12	week	old	male	NkxUS∆-/-	and	NkxUS∆+/+	mice	were	used	for	this	study.	The	surgery	
was	performed	by	Jianxin	Wu	(Victor	Chang	Cardiac	Research	Institute),	an	experienced	small	
animal	surgeon.	Anaesthesia	was	induced	via	an	intraperitoneal	injection	of	xylazine	and	ketamine	
mixed	in	the	same	syringe	(mice:		ketamine	80-100mg/kg,	xylazine	10-20mg/kg	and	atropine	0.02-
0.05mg/kg;	Troy	Laboratories).	Xylazine	is	a	muscle	relaxant	and	was	used	to	ensure	safe	
intubation.	Atropine	is	an	anticholinergic	agent,	not	an	anaesthetic	agent,	and	is	used	in	mice	to	
counteract	ketamine-xylazine-induced	bradycardia	(slow	heart	rates).	Following	induction,	the	mice	
were	shaved	on	the	belly	side	and	intubated	using	a	20G	cannula	(Insyte	BD).	After	intubation,	the	
animal	was	transferred	to	the	warming	pad	and	a	ventilator	is	connected	to	the	intubation	cannula.	
Anaesthesia	was	maintained	throughout	the	surgical	procedure	by	1-2%	of	isoflurane.	Once	an	
adequate	plane	of	anaesthesia	was	reached	a	1-2cm	horizontal	skin	incision	was	made	over	the	
suprasternal	notch.	The	thyroid	was	retracted	and	a	small	incision	was	made	into	the	muscles	
overlying	the	sternum.	A	longitudinal	cut	(approximately	2mm)	was	then	made	through	the	
proximal	sternum.	The	ribs	were	retracted	to	allow	visualisation	of	the	thoracic	organs	under	low	
power	magnification.	The	aorta	was	separated	between	the	right	and	left	carotid	arteries	and	
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isolated	from	the	surrounding	tissues.	Once	the	vessel	was	isolated,	forceps	are	passed	underneath	
to	capture	a	ligature,	which	is	then	pulled	back.	A	25-gauge	shortened	and	blunted	needle	was	
placed	on	top	of	the	artery	and	the	silk	suture	was	then	tied	firmly	around	the	needle	and	the	
artery.	The	needle	was	subsequently	removed	as	quickly	as	possible	to	leave	the	internal	diameter	
of	the	vessel	the	size	of	the	needle.	The	thoracic	muscles	was	closed	in	one	layer	by	horizontal	
mattress	pattern	using	Prolene	suture	material	as	appropriate	to	the	size	of	the	animal.	Air	was	
evacuated	from	the	chest	by	briefly	over-inflating	the	lungs	by	occluding	the	gas-out	arm	of	the	
ventilation	circuit.	The	skin	was	closed	with	one	cruciate	suture	in	Prolene	as	appropriate	to	the	size	
of	the	animal.	At	this	point	all	surgical	interventions	were	complete.	A	sham	procedure	is	exactly	
the	same	except	that	no	ligature	was	tied	around	the	aorta.	Following	surgery,	the	mice	were	
placed	in	a	recovery	cage	overnight.	The	next	day,	the	mice	were	transferred	back	into	their	home	
cage.	The	mice	were	housed	singly	for	the	whole	experiment	and	were	monitored	until	completion	
of	the	experiment.	21	days	after	surgery	cardiac	function,	heart	size	and	blood	flow	were	analysed	
in	real	time	using	echocardiography.	Following	echocardiography,	chamber	pressure	was	measured	
using	LV	micromanometry.	After	completion,	the	mice	were	sacrificed	and	the	hearts	and	tibias	
were	collected.	After	the	whole	hearts	were	weighted,	the	LV	and	LA	were	dissected	and	weighted.	
The	tibia	length	was	determined	using	a	Vernier	caliper	(RS	pro).	Jianxin	Wu	was	kept	blinded	to	the	
genotype	for	the	whole	experiment.	
	
	
4.7.8 	Echocardiography	
Echocardiography	is	the	non-invasive	method	for	imaging	the	heart	in	real	time	using	ultrasound.	
We	used	a	high	frequency	probe	operating	at	a	central	frequency	of	30MHz	(MX	400,	FujiFilm	
Visualsonics).	To	induce	anaesthesia,	the	mouse	was	placed	in	an	induction	chamber	with	3-4%	
isoflurane	and	when	unconscious	was	transferred	to	a	warmed	platform	with	integrated	ECG	
amplifier.	Anaesthesia	was	maintained	by	1-2%	isoflurane	inhalation	via	a	nose	cone.	The	animal	
was	positioned	on	its	back	with	each	foot	held	by	tape	above	each	ECG	electrode	which	were	then	
connected	electrically	individually	with	ultrasound	gel,	which	is	conductive.	The	chest	was	shaved	
and	washed	with	water	to	minimise	hair	and	ultrasound	gel	applied	to	enable	transmission	of	the	
ultrasound	beam.	The	echo	probe	is	brought	into	contact	with	the	gel	and	echo	images	were	
obtained	and	recorded.		
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The	warming	platform	is	on	a	moveable	table	in	the	horizontal	plane	(X	and	Y	axes)	
controlled	by	micrometre	mechanisms	(rack	and	pinion).	The	probe	is	held	above	the	animal	in	a	
circular	clamp	on	an	armature	that	is	independent	of	the	table	and	can	be	adjusted	vertically.	The	
circular	clamp	allows	the	probe	to	rotate	about	its	central	vertical	axis.	
The	first	image	acquired	was	the	2D	B-mode	image	of	the	parasternal	long	axis	(LAX)	and	was	
achieved	with	the	probe	beam	aligned	with	the	Y	axis	of	the	table	and	the	mouses	heart	aligned	
with	the	beam,	with	the	aortic	valve	and	the	apical	dimple	in	view	and	orthogonal	to	the	beam.	
Next	the	short	axis	B-mode	image	was	acquired	by	rotating	the	probe	in	its	circular	clamp	90°	and	
adjusting	the	table	in	the	Y	axis	to	observe	the	mid-papillary	plane	of	the	LV.	By	moving	the	table	so	
the	probe	moves	toward	the	head	of	the	mouse	the	pulmonary	artery	(PA)	bifurcation	was	
observed	just	beyond	the	aortic	annulus	and	the	pulse	wave	Doppler	(PW)	voxel	is	located	proximal	
to	the	bifurcation	to	limit	turbulence.	The	LA	was	imaged	in	B-mode	from	a	modified	LAX	
orientation	with	the	beam	set	orthogonal	to	the	posterior	wall	of	the	LA	where	it	aligns	with	the	
aortic	valve.	Aortic	PW	data	was	obtained	from	a	supra-sternal	view	with	the	voxel	located	above	
the	aortic	valve	in	line	with	the	crossing	of	the	PA.	Mitral	valve	(MV)	PW	and	MV	annulus	tissue	
Doppler	(TD)	was	observed	from	a	sub-costal	4-chamber	view.	
LV	mass	and	volumes	were	derived	using	a	modified	bullet	formula	(V	=	5	x	LAX	length	x	SAX	
area	/	6)	where	SAX	area	was	obtained	by	planimetry	of	the	border	and	LAX	length	taken	from	the	
inferior	point	of	the	valve	leaflet	co-optation	to	the	apical	dimple.	The	conservation	of	mass	rule	(LV	
mass	at	diastole	=	LV	mass	at	systole)	was	applied	when	determining	LV	mass	and	was	determined	
first	providing	an	internal	control	to	the	chamber	volume	estimates.	Papillary	muscles	were	
excluded	from	the	internal	chamber	border	planimetry	estimates.	Echocardiography	was	
performed	by	Scott	Kesteven	(Victor	Chang	Cardiac	Research	Institute)	who	was	kept	blinded	for	
the	whole	study.	
	
	
4.7.9 LV	Micromanometry	
Micromanometry	uses	a	transducer	tipped	catheter	which	is	inserted	into	the	LV	to	measure	the	
chamber	pressure	in	anaesthetized	mice	allowing	the	determination	of	ventricular	systolic	and	
diastolic	function.	LV	micromanometry	was	performed	by	Jianxin	Wu.	Anaesthesia	was	induced	and	
maintained	as	for	Echocardiography.	Once	the	mouse	was	anaesthetized,	a	midline	incision	was	
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made	in	the	ventral	neck	and	the	submandibular	glands	are	gently	separated.	The	right	carotid	
artery	was	isolated	and	retracted	using	two	sutures	placed	proximally	and	distal	around	the	artery.	
A	second	proximal	ligature	was	looped	around	the	vessel	between	the	other	two	sutures.	The	loop	
and	two	free	ends	were	tight	together	with	a	loose	knot.	The	artery	was	elevated	and	ligated	with	a	
distal	suture.	Gentle	tension	was	applied	to	the	first	proximal	suture	to	occlude	blood	flow.	Using	a	
bent-tipped	25-gauge	syringe	needle	as	a	catheter	introducer,	the	carotid	artery	was	punctured	
close	to	the	distal	suture	and	the	catheter	was	inserted	to	a	point	beyond	the	second	proximal	
suture.	A	knot	was	firmed	tightly	around	the	vessel	and	catheter	to	minimize	blood	flow.	The	first	
proximal	ligature	was	released	and	the	catheter	tip	advanced	into	the	vessel	and	progressed	into	
the	LV.	LV	pressure	was	recorded	for	several	minutes.	After	completion,	mice	were	euthanized	
while	still	under	deep	anaesthesia.	
	
	
4.7.10 			Telemetry	
A	small	transmitter	was	implanted	by	Jianxin	Wu	into	the	subcutaneous	space	of	male	NkxUS∆-/-	
and	NkxUS∆+/+	mice	(10-12	weeks	of	age)	for	the	long	term	recording	of	physiological	parameters.	
For	the	implantation,	anesthesia	was	induced	and	maintained	by	isoflurane	inhalation	as	per	LV	
micromanometry.	
We	used	the	PhysioTel	ETA-F10	transmitter	(Data	Sciences	International,	DSI),	which	is	currently	the	
smallest	of	the	single	channel	bipotential	transmitter	series	available.	The	device	was	placed	
subcutaneously	on	the	left	flank	of	the	mice	between	the	fore	and	hind	limb.	The	ETA-F10	is	fitted	
with	flexible	leads	that	extend	from	the	transmitter	body.	Two	incisions	were	made	for	the	leads.	
The	positive	one	was	be	located	on	the	lower	left	of	chest	wall	and	made	big	enough	to	enable	
insertion	of	the	transmitter.	The	negative	lead	incision	was	made	on	the	upper	right	side	of	the	
chest.	After	inserting	the	transmitter,	the	leads	were	tunneled	subcutaneously	to	their	incision	site	
and	secured	to	the	skeletal	muscle	to	serve	as	sensing	electrodes	across	the	heart	on	the	chest	wall.	
All	incisions	were	closed	and	the	animal	was	placed	overnight	in	a	recovery	cage.	
After	surgery,	the	mice	were	housed	singly	for	3	days	to	recover	from	the	surgery.	At	day	4	post-
surgery	the	ECG	was	recorded	for	24	hrs.	While	recording,	the	mice	were	in	their	normal	home	
cage.	A	receiving	plate	was	placed	under	the	cage	of	each	implanted	mouse,	the	transmitter	was	
activated	using	a	magnet	and	recording	was	started	using	the	Ponemah	software	(DSI).	
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After	completion	of	recording,	mice	were	sacrificed	using	CO2	chambers.	Transmitters	were	
recovered	from	euthanised	animals	and	prepared	for	reuse	following	the	manufacturer’s	
recommendation.	Briefly,	the	transmitters	were	cleaned	from	as	much	tissue	as	possible	and	were	
soaked	overnight	in	an	enzymatic	cleaner	(Edwards	group	holdings).	The	next	day,	the	implants	
were	gently	cleaned	using	a	soft	brush,	rinsed	in	water	and	then	soaked	again	if	any	remaining	
tissue	was	attached.	After	removal	of	all	tissue,	the	transmitters	were	sterilized	in	Actril	(OnBoard	
Solutions)	overnight,	then	rinsed	in	water	and	stored	in	sterile	packaging	until	further	use.	
Telemetry	data	was	analysed	using	the	Ponemah	ECG	pro	and	Data	Insights	softwares	(DSI).		
	
	
4.7.11 			Dissection	of	the	sinoatrial	node	(SAN)	
Mice	were	sacrificed	using	CO2	chambers.	The	hearts	along	with	lungs	and	thymus	were	dissected	
from	the	mouse’s	chest	and	washed	in	warmed	Tyrode	solution	(140mM	NaCl,	5.4mM	KCl,	5mM	
Hepes	(Life	Technologies),	5.5mM	glucose,	1mM	MgCl2,	1.8mM	CaCl2,	pH7.4).	The	tissue	was	
transferred	to	a	with	silicon	(Dow	Corning)	coated	dish	containing	warmed	Tyrode	solution.	The	
heart	was	oriented	so	that	the	posterior	vessels	were	facing	up,	with	the	animals’	RA	on	the	right	
and	immobilised	by	pinning	through	the	ventricles,	lungs	and	thymus	(Figure	48A).	The	vessels	were	
separated	so	that	the	inferior	vena	cava	(IVC)	and	superior	vena	cava	(SVC)	are	clearly	visible	
(Figure	48B).	Both	vessels	were	cleaned	from	fat	tissue	as	best	as	possible	(Figure	48B).	Then	the	
ventricles,	lungs,	thymus	and	left	atrium	were	removed.	The	tissue	was	re-pinned	through	the	IVC,	
SVC	and	RA.	Any	remaining	ventricular	tissue	was	removed.	The	anterior	wall	of	the	RA	and	vena	
cava	was	opened	using	dissection	scissors.	The	pins	were	repositioned	to	stretch	the	tissue	gently	
revealing	the	sinoatrial	node	region,	which	lies	in	between	the	interatrial	septum,	RA,	IVC	and	SVC	
(Figure	48C).		
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Figure	48	Dissection	of	the	mouse	SAN.	A)	After	dissecting	the	heart	from	the	mouse’s	chest,	it	was	
pinned	to	a	siliconised	dish,	through	the	lungs,	ventricle	and	thymus.	B)	Vessels	were	separated,	
cleaned	from	fat	and	stretched	apart	to	free	the	SVC	and	IVC.	C)	The	RA	along	with	SVC,	IVC	and	
part	of	the	IAS	were	dissected	from	the	heart,	cut	open	and	spread	open	to	reveal	the	SAN	region.	
RA=	right	atrium,	LA=	left	atrium,	SVC=	superior	vena	cava,	IVC=	inferior	vena	cava,	IAS=	interatrial	
septum.	
	
	
4.7.11.1 Calcium	imaging	of	the	SAN	
The	SAN’s	were	dissected	as	described	in	4.8.11.	Dissected	tissues	were	transferred	to	a	with	~2mM	
silicon	(Dow	Corning)	coated	petri	dish	and	warmed	Tyrode	solution.	The	tissue	was	pinned	to	the	
new	dish	with	the	endocardial	surface	facing	down.	To	stain	the	tissue,	10µM	Cal-520	dye	(AAT	
Bioquest)	in	2ml	Tyrode	solution	was	added	and	the	tissue	was	incubated	for	one	hour	shaking	
gently	at	RT	in	the	dark.	Afterwards,	the	tissue	was	washed	three	times	with	dye	free	warmed	
Tyrode	and	then	incubated	for	30min	in	2ml	of	warm	Tyrode	with	5µM	Blebbistatin	(Sigma-Aldrich).	
The	tissue	was	imaged	on	the	Eclipse	Ti2	inverted	microscope	(Nikon),	while	perfused	at	a	rate	of	8	
ml/min	with	warmed	Tyrode	containing	5µM	Blebbisstatin.	The	Tyrode	solution	was	either	kept	at	
37°C.	During	the	whole	experiment,	perfusion	was	never	stopped.	Before	capturing	the	first	video	
to	measure	the	heart	rate,	the	tissue	was	allowed	to	adjust	to	the	perfusion	for	15min.	Videos	were	
taken	for	5s,	unless	otherwise	stated,	with	8x8	binning,	5ms	exposure	time	and	100-120	frames	per	
second	(fps).	First,	a	video	was	taken	at	a	2x	magnification	visualizing	the	entire	tissue	preparation.	
After,	identifying	the	SAN	region,	an	additional	video	was	taken	at	10x	magnification.	The	heart	rate	
was	determined	by	counting	the	calcium	spikes	within	the	5s	video	and	multiplying	by	12	to	
determine	the	heart	rate	in	beats	per	minute	(bpm).	
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4.7.11.2 SAN	tissue	pacing	
Following	identification	of	the	SAN	region,	the	SAN	tissue	was	paced	while	imaging	to	determine	
the	SAN	recovery	time	(SANRT).	Two	silver	wires	attached	to	two	electrodes	were	placed	on	
opposite	sides	of	the	SAN	tissue,	one	close	to	the	inferior	and	one	close	to	the	superior	vena	cava.	
The	tissue	was	paced	for	20s	at	50V	with	a	width	of	0.2ms	and	at	an	interval	of	0.1ms.	A	video	was	
taken	for	30s	with	the	pacing	starting	after	5	s.	The	SANRT	was	calculated	as	the	time	interval	
between	the	last	stimulation	spike	and	the	first	spontaneous	one.	Corrected	SNRT	(cSNRT)	was	
calculated	as	the	difference	between	the	SNRT	and	the	cycle	length	immediately	before	pacing.	
	
	
4.7.11.3 SAN	drug	administration	
The	effects	of	two	drugs	were	tested,	Ivabradine	(IVA,	Sigma-Aldrich)	and	Isoproterenol	(ISO,	
Sigma-Aldrich).	IVA	was	used	at	a	concentration	of	3µM	and	ISO	at	a	concentration	of	1µM.	IVA	is	a	
selective	inhibitor	of	the	pacemaker	specific	HCN	channels	and	is	thus	a	heart	rate	reducing	agent.	
ISO	is	a	ß-adrenergic	receptor	agonist	and	thus	a	heart	rate	increasing	agent.	The	drugs	were	added	
to	the	perfusion	and	after	10min	for	IVA	and	2min	for	ISO	a	video	was	taken	to	measure	the	heart	
rate	changes	due	to	the	drugs.	The	tissue	was	washed	with	fresh	Tyrode	solution	for	at	least	1h	
following	the	first	drug	treatment.	
	
	
4.8 Bioinformatics	analyses	
4.8.1 Structure	alignment	with	Foldalign	
FoldAlign	was	run	with	the	parameters	-plot_score -max_length 500 -no_backtrack	to	align	
human	and	mouse	NkxUS	[212].	Local	non-overlapping	hits	were	identified	with	locateHits.	
Afterwards,	FoldAlign	was	run	with	parameters	-plot_score -max_length 500 -
no_backtrack	to	align	human	TCONS_00010558	and	1,000	di-nucleotide	mouse	NkxUS	sequences,	
and	to	estimate	kappa	and	lambda	of	an	extreme	value	distribution	describing	the	alignment	score	
distribution.	Based	on	this	distribution,	p-values	were	calculated	for	the	real	alignments.		
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RNAfold	with	the	parameters	–p	–d2	was	run	for	the	identified	structural	human	alignments	to	
analyse	for	common	domains	between	the	conserved	structures	and	thermodynamic	structures.		
	
	
4.8.2 	Impact	of	SNP	prediction	
RNAsnp	version	1.1	was	run	in	global	mode	(parameters	-m 1 -M 1 -w 100)	on	the	second	exon	of	
human	NkxUS	containing	the	rs6882776	SNP	[223].	
	
	
4.8.3 	RNA	sequencing	analysis		
500ng	of	RNA	was	used	per	sample.	The	libraries	were	prepared	using	the	TruSeq	Library	Prep	kit	
(Illumina)	and	were	sequenced	on	the	Illumina	HiSeq	on	two	lanes.	
After	sequencing,	reads	from	the	two	lanes	were	merged.	FastQC	(version	0.11.3)	was	used	to	
assess	the	initial	quality	of	the	collated	read	files.	Adapters	sequences,	over-represented	reads,	
5’GC	bias	and	low-quality	reads	were	trimmed	using	trimmomatic	(version	0.32)	and	quality	was	
checked	again	using	fastqc	[345].	Reads	were	then	aligned	to	the	mouse	genome	(mm10)using	
STAR	(version	2.5.1a)	[346].	Bam	files	were	indexed	and	sorted	using	samtools	(version	1.2.5)	[347].	
Read	counts	from	the	indexed	bam	files	were	quantified	using	RSEM	(version	1.3.0)	[348].	Post	
alignment	mapped	files	were	quality	checked	with	RSeQC	(version	2.6.1),	which	collects	multiple	
statistics	including	gene	body	coverage,	read	distributions,	quality	and	error	rates,	duplication	
rates,	deletion	rates,	insertion	rates,	junction	coverage	and	saturation.	[349].	The	read	counts	
results	from	RSEM	were	collated	and	were	analysed	using	DESeq2	for	differential	expression	in	R-
Studio	(version	1.1.419)	[229].		
	
	
4.8.4 		DNA	ChIRP	analysis	
The	analysis	of	the	DNA	sequencing	of	the	ChIRP	samples	was	performed	by	Thomas	Kavanagh	
(Garvan	Institute	of	Medical	Research,	Sydney,	Australia).	Short	reads	were	checked	for	quality	and	
trimmed	as	described	in	section	2.4.1.	The	reads	were	then	ma
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using	STAR	as	detailed	in	section	2.4.1.	Read	distribution	was	assessed	with	RSeQC	v2.6.1	using	the	
read_distribution.py	script.	Peaks	were	called	using	MACS	v2.0.10.	[350].	BAM	files	were	used	as	
input	with	an	EVEN	or	ODD	pool	as	the	test	dataset	and	the	corresponding	replicates	LacZ	pool	as	
the	control	data.	Separately	all	sample	peaks	were	called	with	MACS	without	using	LacZ	as	the	
background.	Peak	files	were	intersected	between	the	EVEN	and	ODD	pool	and	then	to	the	LacZ	for	
each	replicate	using	bedtools	v2.22.0	(bedtools	window	function).	Any	peaks	within	2kb	of	each	
other,	in	both	the	EVEN	and	ODD	pool,	were	considered	as	true	peaks	if	they	didn’t	intersect	a	peak	
in	the	LacZ	controls.			
	
	
4.9 Statistics	
GraphPad	Prism	software	(Version	7)	was	used	for	all	statistical	analyses.	For	all	comparisons	of	
means,	unpaired	student	t-test	was	performed	and	standard	deviation	was	used	as	the	measure	of	
spread.	
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Appendix	
I. Detailed	in	situ	hybridisation	results		
	
Figure	49	NkxUS	and	NkxDS	are	expressed	in	the	heart	throughout	mouse	development.	(A-F3)	
Nkx2-5	(left	panels),	NkxDS	(middle	panels)	and	NkxUS	(right	panels)	expression	pattern	by	in	situ	
hybridisation	on	sections	from	embryos	at	E8.5	(A),	E9.5	(B),	E10.5	(C-C1),	E17.0	(D-D5),	postnatal	
day	10	(P10,	E-E3)	and	Adult	(F-F3).	(C-C1)	whole	heart	view	on	C	and	higher	magnification	of	left	
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ventricle	in	C1.	(D-D5)	whole	heart	view	on	D	and	higher	magnification	of	left	ventricle	in	D1,	right	
atria	in	D2,	atrioventricular	valves	in	D3,	an	even	higher	magnification	to	show	the	nuclear	pattern	
of	NkxDS	(middle	panels)	and	NkxUS	(right	panels)	compared	to	Nkx2-5	(left	panels),	and	
extracardiac	tissue	expression	in	D5.	Note	the	expression	of	NkxUS	in	the	sinoatrial	node	(D5	right	
panel	and	inset.	(E-F3)	atrioventricular	bundle	region	in	E	and	F,	ventricular	wall	in	E1	and	E1,	right	
atrium	in	E2	and	F2,	and	aortic	valve	region	in	E3	and	atrioventricular	valve	region	in	F3.	Heart	(h),	
endocardium	(endo),	myocardium	(myo),	atrium	(a),	atrioventricular	canal	(avc),	outflow	tract	(oft),	
left	ventricle	(lv),	right	atrium	(ra),	left	atrium	(la),	right	ventricle	(rv),	left	ventricle	(lv),	
atrioventricular	valve	(avv),	neural	tube	(nt),	lungs	(l),	sinoatrial	node	(san),	atrioventricular	bundle	
(avb),	aortic	valve	(Aov).	
	
	
II. List	of	deregulated	genes	(logFC	±	0.5,	FDR	<0.05)	
Table	23	List	of	transcripts	differentially	expressed	genes	in	NkxUS	knockdown	analysis	
Symbol	 logFC	 FDR	
NkxUS	 -1.974120864	 4.83E-76	
Orai2	 -1.358030924	 2.26E-23	
Galnt17	 -1.142136706	 2.86E-05	
Hsd3b1	 -1.1391927	 8.63E-05	
Wt1	 -1.044732138	 0.012887285	
Arhgap22	 -1.042908738	 0.010303458	
Zic1	 -0.991837961	 0.001156969	
Garem2	 -0.988354033	 0.046252393	
Tek	 -0.961422159	 0.028702617	
Ttbk1	 -0.945494118	 0.00280253	
Gm17029	 -0.918114041	 0.047170694	
Sh3tc1	 -0.918051543	 0.005886205	
Dpf1	 -0.909428954	 8.66E-05	
Amz1	 -0.901187128	 0.008631171	
Ctgf	 -0.89283263	 9.25E-06	
Duox1	 -0.885210452	 0.00487689	
Bmp4	 -0.87870426	 0.012146739	
Nt5m	 -0.870866497	 3.82E-09	
Hrct1	 -0.850166189	 0.035334764	
Rasgrp3	 -0.845104358	 1.49E-06	
Cdk20	 -0.814884167	 0.014995941	
Fam46b	 -0.804781011	 0.015568907	
Epcam	 -0.800247888	 0.011516789	
Tcaf2	 -0.799217157	 0.008566907	
Mmp17	 -0.798339406	 0.019364483	
Gm29609	 -0.795553395	 0.013390264	
Chd3os	 -0.789430301	 7.19E-08	
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Phf19	 -0.787422347	 1.72E-07	
Dntt	 -0.786920478	 0.017698186	
Prkch	 -0.779099094	 0.004637747	
Susd1	 -0.771568002	 0.011108799	
Opn3	 -0.763264894	 0.032874208	
Tmem159	 -0.750499567	 0.002487276	
Dennd3	 -0.742928808	 0.047431366	
Abca12	 -0.733934015	 0.001664799	
Hck	 -0.733261244	 0.000307319	
Cers1	 -0.716820235	 0.018988133	
Sema3g	 -0.715471494	 6.45E-05	
Fbxo40	 -0.712666213	 0.01757791	
Emilin2	 -0.710599656	 0.008277044	
Slco4a1	 -0.698823044	 0.000235644	
Fmnl3	 -0.691947318	 0.000173049	
Baz1b	 -0.691402299	 1.78E-07	
Akna	 -0.685616395	 0.002673338	
Tns4	 -0.664274406	 0.00035394	
Asb12	 -0.656043982	 0.000369566	
Inhba	 -0.655015689	 0.00755748	
9930012K11Rik	 -0.652789877	 0.027121793	
Gss	 -0.649898677	 1.35E-05	
Dmtn	 -0.649632325	 0.015420245	
Cntf	 -0.640660575	 0.042304777	
Naaa	 -0.640296594	 0.007387519	
Abi3	 -0.63896704	 1.03E-05	
Mfsd13a	 -0.636936562	 5.25E-06	
Sh3rf2	 -0.632570798	 0.00244589	
Tnfrsf12a	 -0.630222012	 2.04E-15	
Scn10a	 -0.62570447	 0.002558532	
Dirc2	 -0.622655724	 0.001704271	
Prdm11	 -0.620934399	 3.72E-06	
Dusp27	 -0.6178745	 0.027183558	
Gm42715	 -0.617461245	 0.024709964	
Rhof	 -0.609771671	 0.030067997	
Pus10	 -0.608911512	 0.001514664	
Bdh2	 -0.608259038	 0.016611478	
H2-T10	 -0.605524147	 0.011889929	
Rapsn	 -0.604888349	 0.001476135	
Abca4	 -0.60387815	 0.006279814	
Txnrd3	 -0.60199785	 0.018739361	
Zfp934	 -0.599500423	 0.028828946	
Appendix	
	 xvii	
Rab26os	 -0.598247136	 0.011873459	
Fgf13	 -0.596593599	 0.012511453	
Gm10727	 -0.595685445	 0.004324999	
Syt11	 -0.591461561	 4.45E-09	
Osbp2	 -0.587857224	 0.000147848	
Pip5k1b	 -0.580387125	 0.006026636	
Hexim1	 -0.576472023	 9.25E-08	
1190005I06Rik	 -0.571983422	 0.001337162	
9130401M01Rik	 -0.57079895	 3.50E-06	
Gm26795	 -0.569022661	 0.000373498	
Mphosph9	 -0.56361739	 1.79E-20	
Pemt	 -0.55882414	 0.005967815	
AI480526	 -0.55224819	 0.043304742	
Cyp2j6	 -0.552037802	 0.02145807	
Hnf1a	 -0.550384482	 0.047916817	
Lrp8	 -0.548957107	 0.004380918	
Sipa1	 -0.547728263	 2.71E-07	
Gm11627	 -0.544808807	 0.010240512	
Daglb	 -0.540520694	 4.38E-06	
Kcnn1	 -0.538779222	 0.016952221	
Tbx3	 -0.538229121	 0.04776858	
Gpr161	 -0.537681086	 0.026166133	
Kcnv2	 -0.529044451	 0.015568907	
Relt	 -0.528812455	 0.009994584	
Nap1l5	 -0.528003196	 0.003410031	
Mtfp1	 -0.527058187	 0.006438329	
1600002K03Rik	 -0.526205958	 0.008435839	
Ccdc102a	 -0.525428873	 0.006099038	
Dera	 -0.521578791	 0.000764776	
Zfp419	 -0.519509066	 0.011355676	
Sh3rf1	 -0.5190187	 0.000221983	
Nhlrc1	 -0.516713669	 0.012479401	
Palm	 -0.513597271	 2.41E-06	
Mum1l1	 -0.512543556	 0.033236274	
Plppr2	 -0.506104652	 0.007795673	
Gsap	 -0.500435447	 0.026435263	
Hcn4	 0.397426257	 0.046584237	
Sspn	 0.501801135	 0.000824463	
Npdc1	 0.502437247	 1.88E-05	
Chmp6	 0.503852053	 4.47E-07	
Adamts7	 0.504625179	 0.0342827	
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Pura	 0.505611783	 1.05E-13	
Dpy19l1	 0.505834352	 2.00E-06	
Ddx6	 0.50589409	 2.75E-17	
Abcc1	 0.506004758	 0.005537315	
Cux1	 0.506742156	 1.56E-13	
Mapk8ip3	 0.50792203	 4.51E-19	
Tcta	 0.508283018	 0.005679737	
AW011738	 0.508365956	 0.048172239	
Tyk2	 0.509032269	 0.000255444	
Usp34	 0.509841633	 1.12E-11	
Ppm1e	 0.510621454	 0.000157195	
Gm45062	 0.511197284	 0.015063349	
Slc12a2	 0.511976066	 8.89E-07	
Nus1	 0.512180525	 2.67E-12	
Phip	 0.513149522	 7.05E-12	
Fgf12	 0.513270679	 0.003314299	
Gm37818	 0.515581966	 0.034370631	
Prune2	 0.516341181	 0.043304742	
Nrbp2	 0.51682098	 0.012398843	
Nav3	 0.51754893	 3.16E-08	
Myzap	 0.517977396	 0.000540505	
Hnrnpc	 0.518813664	 1.28E-10	
march5	 0.51949675	 7.55E-09	
Rpe	 0.52084458	 8.60E-12	
R3hcc1l	 0.523083878	 1.73E-10	
Mapkapk2	 0.523295878	 2.01E-16	
Sema5a	 0.524738507	 1.09E-05	
Nav2	 0.525051437	 6.37E-07	
Fuz	 0.526092069	 0.047431366	
Atf2	 0.526998364	 4.29E-05	
Pakap	 0.527452152	 1.12E-06	
Il6st	 0.528484938	 3.74E-07	
Vopp1	 0.528593892	 1.37E-10	
A730056A06Rik	 0.528954433	 0.035728039	
Tmtc3	 0.529249651	 1.30E-13	
Cep57	 0.529400396	 8.97E-18	
Gm14325	 0.529799193	 0.000323006	
Clip1	 0.529800242	 2.78E-11	
Rnf19b	 0.529954652	 1.44E-07	
Rgs6	 0.529955596	 0.002044157	
Chd1l	 0.530222541	 1.88E-09	
Kazn	 0.530763191	 0.000428627	
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Cpeb2	 0.531190342	 5.00E-10	
Utp4	 0.53134533	 4.43E-07	
Slc9a5	 0.531470307	 0.030928354	
Tcf12	 0.531911994	 6.14E-15	
Zfp277	 0.532132546	 0.002723471	
Large1	 0.53296516	 0.007082902	
Kpna4	 0.534854635	 2.74E-05	
Setd1b	 0.536568031	 9.67E-07	
Rexo5	 0.537821452	 0.000149665	
Dhx57	 0.538750723	 8.62E-06	
Gatb	 0.539952603	 1.27E-07	
Commd1	 0.541087667	 3.85E-05	
Tmem87b	 0.541937865	 1.38E-06	
2500002B13Rik	 0.542438059	 0.003287568	
Ccdc112	 0.542883757	 1.29E-05	
Tbc1d1	 0.542954547	 7.26E-12	
Snx25	 0.546545874	 2.94E-10	
Dmd	 0.546563094	 3.98E-10	
Me1	 0.546837818	 1.50E-14	
Senp6	 0.547356758	 1.10E-17	
1110019D14Rik	 0.547571272	 0.015689074	
Arhgef4	 0.548109672	 0.000127129	
Kmt5b	 0.549174703	 1.15E-15	
Zfp704	 0.549670662	 1.25E-06	
Arfip2	 0.549850206	 5.99E-06	
Nrip3	 0.55151955	 0.002040463	
Tmeff2	 0.552835601	 0.018493203	
Bpnt1	 0.55308232	 5.19E-07	
Adcy5	 0.555507168	 7.41E-06	
Lrif1	 0.556436868	 6.21E-14	
Mib1	 0.556748903	 8.49E-18	
Zfp871	 0.557767529	 1.82E-15	
Sec24a	 0.557957438	 1.06E-07	
Rmnd5a	 0.559539247	 2.92E-15	
Brd8	 0.560030725	 1.49E-10	
Mettl8	 0.561932514	 0.030172976	
H19	 0.562941168	 0.030153482	
Setd2	 0.563203514	 9.89E-30	
Gm37084	 0.563278478	 0.000181552	
Stradb	 0.56427769	 2.90E-05	
Slc7a2	 0.565127204	 0.000176515	
Pde3b	 0.565342965	 9.21E-16	
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Gramd3	 0.565988262	 8.90E-05	
Fnbp1l	 0.566566378	 1.36E-16	
Vps41	 0.567246071	 1.34E-09	
Prkce	 0.570118206	 8.18E-07	
Cav1	 0.570762127	 1.26E-06	
Rabgap1l	 0.571462943	 4.56E-09	
Tom1l2	 0.572772831	 2.23E-08	
BC017158	 0.572836785	 2.46E-06	
Ide	 0.572947421	 4.87E-08	
Ankrd13d	 0.574197447	 0.02779753	
Kin	 0.574554711	 0.000163459	
Gls	 0.577421023	 4.48E-16	
Dennd4a	 0.578185141	 2.90E-05	
Cand1	 0.578643729	 1.60E-23	
Zfp949	 0.581209955	 0.000116973	
Acbd5	 0.581514126	 2.61E-14	
Alcam	 0.581564102	 0.00680135	
Zrsr2	 0.582207815	 3.94E-17	
Map4k3	 0.583444323	 1.11E-10	
Ptpn23	 0.583722172	 4.51E-19	
Ube3a	 0.584849368	 6.46E-07	
Atxn1	 0.58488787	 0.006322855	
NA	 0.58499627	 1.37E-10	
1700020I14Rik	 0.586459405	 4.88E-13	
Mbd5	 0.587169706	 5.72E-05	
Cnot2	 0.587919612	 4.93E-13	
Tmem127	 0.588944877	 7.62E-17	
Ankrd12	 0.590186323	 3.92E-17	
Dock11	 0.594059186	 0.007165546	
Tbc1d16	 0.595842717	 1.31E-08	
Invs	 0.596943788	 1.54E-07	
Spred2	 0.596960772	 1.04E-06	
Aven	 0.597104724	 0.000315525	
Cacna1d	 0.598310831	 1.24E-05	
Phf8	 0.598714955	 9.03E-06	
Gatad1	 0.599555264	 3.60E-20	
Pitpnc1	 0.600109816	 3.55E-05	
Mgea5	 0.600751364	 2.23E-27	
Ints6	 0.601442739	 5.62E-15	
Katna1	 0.601523409	 1.61E-07	
Tmem209	 0.601535858	 0.000227056	
Wdpcp	 0.602165708	 0.001007041	
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Unc13c	 0.603094078	 2.56E-05	
Gm12696	 0.60811408	 0.020581817	
Trim23	 0.608181719	 1.46E-06	
Ccdc28a	 0.608319098	 0.02655378	
Notch3	 0.608344593	 0.010403402	
Zxdb	 0.608586333	 9.33E-08	
Krit1	 0.608955524	 1.29E-09	
Ppm1l	 0.611489803	 0.011108799	
Hells	 0.612268477	 1.32E-17	
Proser1	 0.614188373	 2.36E-13	
Brca2	 0.61643117	 0.005523516	
Gm11400	 0.616958306	 0.033840457	
Gm19721	 0.617080025	 0.038564556	
Coq3	 0.617722667	 4.39E-08	
Scfd2	 0.622439704	 0.006311148	
Atp11a	 0.623051758	 1.28E-05	
Acer3	 0.623472077	 2.34E-07	
Tln1	 0.624502243	 3.70E-32	
Uaca	 0.625530149	 1.72E-14	
Adar	 0.625626238	 0.004592875	
Lrrc28	 0.626923263	 4.28E-05	
Nfxl1	 0.630175758	 2.98E-06	
Appl2	 0.630377497	 7.90E-06	
Twsg1	 0.630749626	 1.02E-10	
Dock7	 0.632620114	 0.001670481	
Gstt1	 0.633627435	 9.27E-12	
Zhx1	 0.637172725	 6.82E-05	
Zcchc6	 0.638577895	 1.00E-20	
Ranbp17	 0.641403053	 4.42E-06	
Exoc4	 0.646239528	 6.52E-17	
Hectd1	 0.646463317	 5.41E-41	
Tcp11l2	 0.647596538	 0.018807535	
Pros1	 0.650085667	 0.000701967	
Sash1	 0.653207925	 1.05E-13	
Gm10138	 0.654359701	 0.00315873	
Gm20186	 0.655118433	 0.002437542	
Zcchc7	 0.655858547	 3.11E-09	
Scaper	 0.656149729	 7.72E-05	
Kdm7a	 0.658062996	 5.13E-05	
Pard3	 0.661161082	 1.90E-12	
Jmy	 0.66416667	 2.80E-20	
Ptpn4	 0.665616873	 2.13E-18	
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Nono	 0.667361205	 6.79E-46	
Frem1	 0.669151326	 5.12E-08	
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Megf9	 0.679555358	 7.49E-20	
Yaf2	 0.680245147	 4.70E-09	
Plp1	 0.682005854	 0.033946157	
Gfpt2	 0.690296785	 5.49E-05	
Palm2	 0.691099186	 1.32E-12	
Vps8	 0.697325358	 8.25E-12	
Pla2r1	 0.700059435	 0.021447671	
F8	 0.701598051	 0.003168731	
Glcci1	 0.701951686	 0.013652924	
Lonrf3	 0.702254498	 1.79E-05	
Serpinb6a	 0.702583827	 4.39E-17	
2210408I21Rik	 0.70286362	 0.000710338	
Ankrd13b	 0.703652105	 4.35E-14	
Fdx1l	 0.704588671	 4.50E-08	
Ahi1	 0.704924864	 0.000157429	
Lamp2	 0.705691487	 2.67E-09	
Lpp	 0.708295246	 2.65E-09	
Neat1	 0.708640702	 0.000544882	
Ttc19	 0.709521297	 5.22E-12	
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Efr3a	 0.715691404	 5.26E-08	
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Plscr3	 0.725890602	 5.79E-14	
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Stag2	 0.796719066	 2.62E-10	
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2010111I01Rik	 0.821211733	 3.70E-16	
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Klf7	 0.835147476	 2.95E-29	
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Zfp280d	 0.84777949	 6.12E-06	
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Gm21738	 0.858337926	 0.02269822	
Dph6	 0.859119008	 3.48E-11	
Atl1	 0.85968985	 1.27E-05	
Mturn	 0.861343771	 0.012408788	
Fsd1l	 0.862961087	 2.82E-08	
Mdn1	 0.864996515	 1.76E-31	
Efcab11	 0.869911374	 0.004539079	
Polk	 0.870864066	 1.49E-07	
Ranbp3	 0.874128478	 2.49E-20	
Klhl12	 0.876060297	 7.40E-22	
2810030D12Rik	 0.881016264	 0.044930397	
Lrrc1	 0.883777332	 9.04E-24	
Gm6211	 0.885905429	 0.030144114	
Pank2	 0.887642874	 8.70E-20	
Pogz	 0.889415948	 3.64E-40	
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Fip1l1	 0.890805727	 5.89E-48	
Galm	 0.892466241	 1.70E-09	
Ttc27	 0.893911468	 5.78E-24	
Usp38	 0.895785367	 8.23E-32	
Gm38257	 0.89978993	 0.011713787	
Spag9	 0.902290666	 6.20E-15	
Otud7b	 0.9062282	 2.73E-44	
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Gbf1	 0.924548294	 1.34E-34	
Nup160	 0.933912121	 8.40E-17	
Exoc2	 0.944597562	 3.99E-34	
D5Ertd579e	 0.947063427	 3.30E-59	
Lama3	 0.947761612	 0.003001571	
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Dnah7c	 0.975654896	 0.034247481	
Crtc3	 0.978736202	 4.72E-33	
Pikfyve	 0.980039817	 1.10E-20	
Notch1	 0.985748153	 1.06E-10	
Cep83	 0.985879816	 2.37E-24	
Plscr4	 0.986962635	 3.86E-08	
Usp43	 0.998638933	 1.74E-06	
Gm45713	 0.999455427	 0.00117145	
Slc1a4	 1.00584915	 1.23E-05	
Bcas3	 1.007973009	 1.77E-10	
Rexo4	 1.008591696	 1.26E-21	
Tomm70a	 1.011800009	 1.12E-56	
Zmynd11	 1.012099687	 1.14E-47	
A930001C03Rik	 1.016514492	 7.96E-05	
Klf12	 1.022369059	 0.020156313	
Mecp2	 1.024677799	 7.55E-06	
Tanc2	 1.02565436	 2.93E-44	
Rbm6	 1.027756735	 2.78E-28	
Ccdc122	 1.038380126	 0.003171914	
Arap2	 1.040471516	 1.73E-10	
Taf1b	 1.044940973	 5.29E-13	
Asah2	 1.047584254	 8.37E-18	
Hsd17b12	 1.049501486	 2.71E-07	
Mindy2	 1.052860391	 4.11E-29	
Mlip	 1.063695444	 4.24E-21	
Deptor	 1.064103883	 0.018493203	
Arih1	 1.067754088	 9.30E-51	
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Prickle2	 1.069925711	 1.24E-08	
Gmds	 1.07701884	 5.21E-05	
Rbms3	 1.081159534	 4.20E-11	
Shprh	 1.086341543	 3.21E-42	
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Rptor	 1.138106071	 4.44E-33	
Arl5b	 1.140183653	 1.14E-34	
Nup210l	 1.15878975	 0.006740568	
Rbm27	 1.173521588	 2.86E-40	
Kcnj3	 1.176381386	 6.14E-15	
Slc9a7	 1.180037521	 3.66E-07	
Rbm41	 1.183252039	 1.54E-22	
Rsrc1	 1.19079515	 1.52E-25	
Poc1b	 1.197340753	 1.63E-11	
Nek6	 1.207437204	 1.60E-15	
Lgr4	 1.214235525	 8.20E-21	
Fbln7	 1.226007467	 8.63E-05	
Diaph3	 1.227761172	 6.98E-28	
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Fgfr1op	 1.27675076	 4.95E-36	
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Taok3	 1.351487243	 3.98E-14	
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Ica1	 1.415767746	 4.03E-12	
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Btbd10	 1.417721409	 7.85E-61	
Ankrd55	 1.437333604	 0.009640606	
Acsl4	 1.440635066	 1.08E-48	
Mycbp2	 1.444967474	 7.01E-57	
Ctnnd1	 1.457593256	 3.35E-33	
Vamp7	 1.463083131	 5.36E-31	
Pcx	 1.465196651	 3.68E-31	
Exoc6b	 1.467586371	 1.47E-55	
Palmd	 1.495769816	 3.96E-34	
Gm42892	 1.520106767	 9.64E-05	
Gm26510	 1.529337167	 8.78E-05	
Per3	 1.539654047	 3.91E-29	
Tbck	 1.576580385	 1.29E-31	
Cryl1	 1.589409112	 3.63E-29	
Fam35a	 1.607338974	 3.42E-10	
Pde5a	 1.620509551	 3.87E-21	
Ust	 1.622070458	 4.20E-09	
Ctnnbl1	 1.636089019	 3.65E-28	
Ccdc138	 1.644964727	 4.57E-13	
4833413G10Rik	 1.653830449	 1.41E-06	
Fuca2	 1.65942174	 2.92E-94	
Pyurf	 1.678505383	 3.41E-80	
Cltc	 1.682190321	 2.81E-86	
Scfd1	 1.692893302	 1.36E-56	
Lnpk	 1.697797393	 9.12E-55	
Elavl1	 1.705111947	 1.01E-102	
Alpk1	 1.710183771	 3.91E-67	
Tsc22d2	 1.714227811	 4.68E-60	
Cblb	 1.717717725	 2.93E-83	
Nr6a1	 1.721387563	 2.63E-06	
Reps1	 1.742766854	 4.61E-77	
Gigyf1	 1.787123727	 6.43E-64	
Fam122b	 1.796381138	 1.54E-57	
Corin	 1.799794852	 1.82E-24	
Gm42876	 1.901459785	 7.51E-05	
Lyrm7	 1.910861429	 1.25E-11	
Mthfd1l	 1.91562277	 3.98E-32	
Gm37397	 1.974947315	 2.62E-21	
Canx	 1.984053386	 7.29E-69	
Zfp185	 1.988845677	 4.62E-08	
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Wwc2	 2.037375076	 1.76E-73	
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Ptprs	 2.038800689	 9.57E-118	
Trip12	 2.116709008	 1.01E-65	
Slf1	 2.14751243	 6.29E-58	
Arl13b	 2.213658877	 2.25E-54	
Slc4a1ap	 2.34550361	 1.55E-76	
Gm38374	 2.42382019	 8.92E-08	
Rnf31	 2.452224203	 9.34E-78	
Gm9403	 2.623884742	 1.86E-07	
	
	
III. List	of	genes	identified	using	StringDB	
Table	24	List	of	StringDB	genes	
Symbol	 logFC	 FDR	
Orai2	 -1.36	 2.26E-23	
Wt1	 -1.04	 1.29E-02	
Arhgap22	 -1.04	 1.03E-02	
Zic1	 -0.99	 1.16E-03	
Tek	 -0.96	 2.87E-02	
Ctgf	 -0.89	 9.25E-06	
Bmp4	 -0.88	 1.21E-02	
Nt5m	 -0.87	 3.82E-09	
Rasgrp3	 -0.85	 1.49E-06	
Prkch	 -0.78	 4.64E-03	
Hck	 -0.73	 3.07E-04	
Baz1b	 -0.69	 1.78E-07	
Gss	 -0.65	 1.35E-05	
Cntf	 -0.64	 4.23E-02	
Abi3	 -0.64	 1.03E-05	
Scn10a	 -0.63	 2.56E-03	
Rhof	 -0.61	 3.01E-02	
Rapsn	 -0.60	 1.48E-03	
Fgf13	 -0.60	 1.25E-02	
Pip5k1b	 -0.58	 6.03E-03	
Lrp8	 -0.55	 4.38E-03	
Sipa1	 -0.55	 2.71E-07	
Kcnn1	 -0.54	 1.70E-02	
Tbx3	 -0.54	 4.78E-02	
Gpr161	 -0.54	 2.62E-02	
Kcnv2	 -0.53	 1.56E-02	
Hcn4	 0.40	 4.66E-02	
Sspn	 0.50	 8.24E-04	
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Chmp6	 0.50	 4.47E-07	
Ddx6	 0.51	 2.75E-17	
Abcc1	 0.51	 5.54E-03	
Cux1	 0.51	 1.56E-13	
Tyk2	 0.51	 2.55E-04	
Fgf12	 0.51	 3.31E-03	
Prune2	 0.52	 4.33E-02	
Nav3	 0.52	 3.16E-08	
Sema5a	 0.52	 1.09E-05	
Nav2	 0.53	 6.37E-07	
Atf2	 0.53	 4.29E-05	
Il6st	 0.53	 3.74E-07	
Cep57	 0.53	 8.97E-18	
Clip1	 0.53	 2.78E-11	
Rgs6	 0.53	 2.04E-03	
Chd1l	 0.53	 1.88E-09	
Tcf12	 0.53	 6.14E-15	
Kpna4	 0.53	 2.74E-05	
Tmem87b	 0.54	 1.38E-06	
Tbc1d1	 0.54	 7.26E-12	
Dmd	 0.55	 3.98E-10	
Me1	 0.55	 1.50E-14	
Arhgef4	 0.55	 1.27E-04	
Adcy5	 0.56	 7.41E-06	
Mib1	 0.56	 8.49E-18	
Sec24a	 0.56	 1.06E-07	
Mettl8	 0.56	 3.02E-02	
H19	 0.56	 3.02E-02	
Pde3b	 0.57	 9.21E-16	
Vps41	 0.57	 1.34E-09	
Prkce	 0.57	 8.18E-07	
Cav1	 0.57	 1.26E-06	
Gls	 0.58	 4.48E-16	
Cacna1d	 0.60	 1.24E-05	
Notch3	 0.61	 1.04E-02	
Acer3	 0.62	 2.34E-07	
Tln1	 0.62	 3.70E-32	
Twsg1	 0.63	 1.02E-10	
Gstt1	 0.63	 9.27E-12	
Exoc4	 0.65	 6.52E-17	
Pros1	 0.65	 7.02E-04	
Pard3	 0.66	 1.90E-12	
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Ago3	 0.67	 1.23E-08	
Nono	 0.67	 6.79E-46	
Stxbp3	 0.67	 1.72E-11	
Sfi1	 0.68	 7.26E-12	
Gfpt2	 0.69	 5.49E-05	
Vps8	 0.70	 8.25E-12	
F8	 0.70	 3.17E-03	
Neat1	 0.71	 5.45E-04	
Chmp7	 0.71	 6.25E-13	
Cdk17	 0.72	 3.73E-11	
Api5	 0.72	 9.25E-25	
Gab2	 0.73	 3.78E-06	
Rapgef1	 0.73	 1.38E-12	
Stx7	 0.76	 2.71E-14	
Lnpep	 0.76	 2.26E-10	
Kat2b	 0.76	 2.59E-36	
Gnaq	 0.76	 9.25E-10	
Ryr2	 0.77	 1.38E-04	
Nrp1	 0.77	 6.69E-27	
Gng12	 0.78	 1.23E-25	
Mcf2l	 0.78	 1.81E-05	
Tiam1	 0.78	 1.65E-15	
Tsc1	 0.78	 7.21E-15	
Cacna1c	 0.79	 8.56E-06	
Stag2	 0.80	 2.62E-10	
Ago4	 0.80	 5.70E-07	
Agfg1	 0.80	 7.54E-40	
Lamc1	 0.82	 6.52E-17	
Mocs1	 0.82	 2.80E-05	
Pdcd4	 0.83	 1.09E-03	
Sgcb	 0.85	 9.52E-38	
Cdc14b	 0.85	 4.99E-12	
Dtna	 0.85	 5.99E-12	
Tfcp2	 0.85	 3.42E-05	
Ranbp3	 0.87	 2.49E-20	
Spag9	 0.90	 6.20E-15	
Nup160	 0.93	 8.40E-17	
Exoc2	 0.94	 3.99E-34	
Lama3	 0.95	 3.00E-03	
Pikfyve	 0.98	 1.10E-20	
Notch1	 0.99	 1.06E-10	
Arap2	 1.04	 1.73E-10	
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Taf1b	 1.04	 5.29E-13	
Asah2	 1.05	 8.37E-18	
Deptor	 1.06	 1.85E-02	
Gmds	 1.08	 5.21E-05	
Rapgef4	 1.13	 8.34E-03	
Rptor	 1.14	 4.44E-33	
Kcnj3	 1.18	 6.14E-15	
Nek6	 1.21	 1.60E-15	
Fgfr1op	 1.28	 4.95E-36	
Ammecr1	 1.29	 2.72E-58	
Tbc1d4	 1.37	 3.96E-34	
Acsl4	 1.44	 1.08E-48	
Vamp7	 1.46	 5.36E-31	
Pcx	 1.47	 3.68E-31	
Exoc6b	 1.47	 1.47E-55	
Pde5a	 1.62	 3.87E-21	
Elavl1	 1.71	 1.01E-102	
Cblb	 1.72	 2.93E-83	
Mthfd1l	 1.92	 3.98E-32	
Canx	 1.98	 7.29E-69	
Ptprs	 2.04	 9.57E-118	
Trip12	 2.12	 1.01E-65	
Atp2a2	 0.28	 4.72E-02	
	
	
IV. Complete	western	blot	
	
Figure	50	Complete	western	blot	of	Figure	35.	Complete	western	blot	from	five	NkxUS∆-/-	and	
NkxUS∆+/+	mice	with	antibodies	against	Vinculin	and	NKX2-5.	The	indicated	region	(dashed	
rectangle)	was	used	for	Figure	35.	The	protein	sizes	are	indicated	on	the	right	in	kDa.	M=	Marker.	
	
Vinculin
N
kx-2-5
62
198
98
49
38
28
17
14
kDa NKXUS∆
+/+
NKXUS∆  -/-MM
Appendix	
	 xxxii	
V. List	of	primers	
Table	25	List	of	PCR	primers	
Nkx2-5/DS	junction	1	 FW	 CCAATGGCAGGCTGAATCC	
Nkx2-5/DS	junction	2	 FW	 GGAACGACTCCCACCTTTAG	
Nkx2-5/DS	junction	3	 FW	 ATGTTCCCCAGCCCTGGG	
Nkx2-5/DS	junction	4	 FW	 CCCAAGTGCTCTCCTGCTTTC	
Nkx2-5/DS	junction	5	 FW	 GAGCTGGACAAAGCCGAGGAC	
Nkx2-5/DS	junction	6	 FW	 CTACGGCGTGGGTCTCAAT	
Nkx2-5/DS	junction	1	 RV	 CTCTTCCCATTAAA	GTGAGTGCG	
Nkx2-5/DS	junction	2	 RV	 GGATTTCTGAGCGAGCGCAGAGG	
Nkx2-5/DS	junction	3	 RV	 CATCCTCAGGCCAACTTGAT	
human	NkxUS	junction	
FW	 AGACCCCACACTTCAGGGAG	
RV	 GGACTCGCCTCATTCAGGT	
mNkxUS	upstream	first	exon	
FW	 GGGTGTTTGCGC	TTTTTGCT	
RV	 CTGTAGCGCTGTAGCGGTTT	
m13	
FW	 CGCCAGGGTTTTCCCAGTCACGAC	
RV	 TCACACAGGAAACAGCTATGAC	
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